U.S. patent application number 12/939998 was filed with the patent office on 2011-05-12 for compounds and methods for kinase modulation, and indications therefor.
This patent application is currently assigned to Plexxikon, Inc.. Invention is credited to Ryan Bremer, Hanna Cho, Prabha N. Ibrahim, Wayne Spevak, Jiazhong Zhang.
Application Number | 20110112127 12/939998 |
Document ID | / |
Family ID | 43970340 |
Filed Date | 2011-05-12 |
United States Patent
Application |
20110112127 |
Kind Code |
A1 |
Zhang; Jiazhong ; et
al. |
May 12, 2011 |
COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS
THEREFOR
Abstract
Compounds and salts thereof, formulations thereof, conjugates
thereof, derivatives thereof, forms thereof and uses thereof are
described. In certain aspects and embodiments, the described
compounds or salts thereof, formulations thereof, conjugates
thereof, derivatives thereof, or forms thereof are active on Fms
protein kinase, or on Fms and Kit protein kinase, or on Fms and
Flt-3 protein kinase. Also described are methods of use thereof to
treat diseases and conditions, including diseases and conditions
associated with activity of Fms protein kinase, Kit protein kinase,
or Flt-3 protein kinase including rheumatoid arthritis,
osteoarthritis, multiple sclerosis, Alzheimer's disease,
Parkinson's disease, glomerulonephritis, interstitial nephritis,
Lupus nephritis, tubular necrosis, diabetic nephropathy, renal
hypertrophy, acute myeloid leukemia, melanoma, multiple myeloma,
metastatic breast cancer, prostate cancer, pancreatic cancer,
neurofibromatosis, brain metastases, and gastrointestinal stromal
tumors.
Inventors: |
Zhang; Jiazhong; (Foster
City, CA) ; Ibrahim; Prabha N.; (Mountain View,
CA) ; Bremer; Ryan; (Oakland, CA) ; Spevak;
Wayne; (Berkeley, CA) ; Cho; Hanna; (Oakland,
CA) |
Assignee: |
Plexxikon, Inc.
|
Family ID: |
43970340 |
Appl. No.: |
12/939998 |
Filed: |
November 4, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61259093 |
Nov 6, 2009 |
|
|
|
Current U.S.
Class: |
514/275 ;
514/300; 544/333; 546/122 |
Current CPC
Class: |
A61P 29/00 20180101;
A61P 25/28 20180101; A61P 19/02 20180101; A61P 13/12 20180101; A61P
19/00 20180101; A61P 25/00 20180101; A61P 25/16 20180101; A61P
37/02 20180101; A61P 35/04 20180101; A61K 31/437 20130101; A61P
43/00 20180101; C07D 471/04 20130101; C07D 401/14 20130101; A61P
35/00 20180101; A61K 31/506 20130101; A61P 37/00 20180101; A61P
35/02 20180101; A61P 19/08 20180101; A61P 9/10 20180101; A61K
31/4427 20130101; C07D 401/04 20130101 |
Class at
Publication: |
514/275 ;
546/122; 544/333; 514/300 |
International
Class: |
A61K 31/506 20060101
A61K031/506; C07D 471/04 20060101 C07D471/04; C07D 401/14 20060101
C07D401/14; A61K 31/437 20060101 A61K031/437; A61P 35/02 20060101
A61P035/02; A61P 19/02 20060101 A61P019/02; A61P 37/00 20060101
A61P037/00 |
Claims
1. A compound having the chemical structure of Formula I',
##STR01557## or a salt, a prodrug, a tautomer or a stereoisomer
thereof, wherein: Ar is selected from the group consisting of:
##STR01558## wherein ##STR01559## indicates the point of attachment
of Ar to --CH.sub.2-- of Formula I and wherein ##STR01560##
indicates the point of attachment of Ar to --NH-- of Formula I;
R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently
selected from the group consisting of --H, halogen, lower alkyl,
halogen substituted lower alkyl, halogen substituted lower alkoxy,
alkoxy substituted lower alkyl, cycloalkylamino, --CN,
--O--R.sup.40, --S(O).sub.2--R.sup.41,
--S(O).sub.2--N(H)--R.sup.42, --N(H)--R.sup.42,
--N(R.sup.42).sub.2, and --N(H)--S(O).sub.2--R.sup.43, provided
that at least two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are --H
and one of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is other than
hydrogen, wherein: R.sup.40 is lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, or cycloalkyl:
R.sup.41, R.sup.42 and R.sup.43 are lower alkyl; R.sup.5 is
selected from the group consisting of --H, --F, --Cl, --Br, lower
alkyl, halogen substituted alkyl, lower alkenyl, lower alkynyl,
cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.10,
--C(O)--N(H)--R.sup.11, --C(O)--O--R.sup.11,
--S(O).sub.2--R.sup.12, --S(O).sub.2--N(H)--R.sup.11,
--N(H)--C(O)--R.sup.12, and --N(H)--S(O).sub.2--R.sup.12, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl; R.sup.6 is selected from the group consisting of
H, halogen, lower alkyl, halogen substituted alkyl, lower alkenyl,
lower alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.13,
--C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.14, --S(O).sub.2--R.sup.15,
--S(O).sub.2--N(H)--R.sup.14, --N(H)--C(O)--R.sup.15, and
--N(H)--S(O).sub.2--R.sup.15, wherein pyrazolyl is optionally
substituted with lower alkyl or heterocycloalkyl; R.sup.7 is H,
halogen or lower alkyl; R.sup.8 is H, halogen or lower alkoxy;
R.sup.9 is H or halogen; R.sup.10 and R.sup.13 are independently
--H, lower alkyl, lower alkyl substituted with --O--CH.sub.3, lower
alkyl substituted with di-alklylamine, or lower alkyl substituted
with heterocycloalkyl; R.sup.11 and R.sup.14 are independently
hydrogen or lower alkyl; and R.sup.12 and R.sup.15 are each
independently lower alkyl. with the proviso that the compound is
other than those set forth in Table 1.
2. The compound of claim 1, wherein Ar is ##STR01561##
3. The compound of claim 1, wherein Ar is ##STR01562##
4. The compound of claim 1, wherein Ar is ##STR01563##
5. The compound of claim 1, wherein Ar is ##STR01564##
6. The compound of claim 1, wherein Ar is ##STR01565##
7. The compound of claim 1, wherein: i) R.sup.1, R.sup.3 and
R.sup.4 are H and R.sup.2 is halogen; or ii) R.sup.1, R.sup.2 and
R.sup.3 are --H and R.sup.4 is halo substituted lower alkyl; or
iii) R.sup.1 and R.sup.4 are --H and R.sup.2 is lower alkoxy; or
iv) R.sup.3 is halogen; or v) R.sup.2 and R.sup.4 are --H, R' is
lower alkoxy and R.sup.3 is halogen.
8. The compound of claim 7, wherein i) R.sup.1, R.sup.2 and R.sup.3
are --H and R.sup.4 is CF.sub.3; or ii) R.sup.1 and R.sup.4 are --H
and R.sup.2 is --OCH.sub.3; or iii) R.sup.3 is F; or iv) R.sup.2
and R.sup.4 are --H, R.sup.1 is OCH.sub.3 and R.sup.3 is F.
9. The compound of claim 1, wherein R.sup.5 is --H, --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, lower alkenyl,
lower alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.10,
--C(O)--N(H)--R.sup.11, --C(O)--O--R.sup.11,
--S(O).sub.2--R.sup.12, --S(O).sub.2--N(H)--R.sup.11,
--N(H)--C(O)--R.sup.12, and --N(H)--S(O).sub.2--R.sup.12, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl
10. The compound of claim 1, wherein R.sup.6 is selected from the
group consisting of H, halo, lower alkyl, fluoro substituted lower
alkyl, lower alkenyl, lower alkenyl, cycloalkyl, phenyl, pyrazolyl,
--CN, --O--R.sup.13, --C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl.
11. The compound of claim 10, wherein R.sup.6 is halo, lower alkyl
or fluoro substituted lower alkyl.
12. The compound of claim 1, wherein R.sup.7 is H, halogen or lower
alkyl.
13. The compound of claim 12, wherein R.sup.7 is H, --F, --Cl, Br
or --CH.sub.3.
14. The compound of claim 1, wherein R.sup.8 is H, halogen or lower
alkoxy.
15. The compound of claim 14, wherein R.sup.8 is H, --F, Br or
--OCH.sub.3.
16. The compound of claim 1, wherein R.sup.9 is H or halogen.
17. The compound of claim 16, wherein R.sup.9 is --H or --Cl
18. The compound of claim 1, wherein: R.sup.1, R.sup.3 and R.sup.4
are --H, and R.sup.2 is --F, --Cl or --Br; or R.sup.1, R.sup.2 and
R.sup.3 are --H and R.sup.4 is --CF.sub.3; or R.sup.1 and R.sup.4
are --H, R.sup.2 is --O--CH.sub.3, and R.sup.3 is --F; or R.sup.2
and R.sup.4 are --H, R.sup.1 is --O--CH.sub.3, and R.sup.3 is --F;
R.sup.5 is selected from the group consisting of --H, --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, lower alkenyl,
lower alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.10,
--C(O)--N(H)--R.sup.11, --C(O)--O--R.sup.11,
--S(O).sub.2--R.sup.12, --S(O).sub.2--N(H)--R.sup.11,
--N(H)--C(O)--R.sup.12, and --N(H)--S(O).sub.2--R.sup.12, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl: R.sup.6 is selected from the group consisting of
--H, --F, --Cl, --Br, lower alkyl, fluoro substituted lower alkyl,
lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN,
--O--R.sup.13, --C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl; R.sup.7 is --F, --Cl, or --CH.sub.3; R.sup.8 is
--H, --F, --CH.sub.3, or --O--CH.sub.3; R.sup.9 is --H or --Cl;
R.sup.10 and R.sup.13 are independently --H, lower alkyl, lower
alkyl substituted with --O--CH.sub.3, lower alkyl substituted with
di-alklylamine, or lower alkyl substituted with heterocycloalkyl;
R.sup.11 and R.sup.14 are independently hydrogen or lower alkyl;
and R.sup.12 and R.sup.15 are each independently lower alkyl.
19. The compound of claim 1, having Formula II': ##STR01566## or a
salt, a prodrug, a tautomer or a stereoisomer thereof., wherein:
R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are each independently
selected from the group consisting of H, halogen, lower alkyl,
lower alkoxy, halo substituted lower alkyl, alkoxy substituted
lower alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --S(O).sub.2--N(H)--R.sup.22,
--N(H)--R.sup.22, --N(R.sup.22).sub.2, and
--N(H)--S(O).sub.2--R.sup.23, provided that at least two of
R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are --H; R.sup.20 is
lower alkyl, fluoro substituted lower alkyl, methoxy substituted
lower alkyl, or cycloalkyl; R.sup.21 is lower alkyl: R.sup.22 is
lower alkyl: and R.sup.22 is lower alkyl.
20. The compound of claim 19, wherein R.sup.6 is selected from the
group consisting of halogen, lower alkyl, fluoro substituted lower
alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl,
--CN, --C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl.
21. The compound of claim 20, wherein R.sup.6 is F, Cl, Br, lower
alkyl, fluoro substituted lower alkyl, lower alkenyl, --CN,
--C(O)--N(H)--R.sup.14, --N(H)--C(O)--R.sup.15.
--C(O)--O--R.sup.14, --S(O).sub.2--R.sup.15,
--S(O).sub.2--N(H)--R.sup.14 or --N(H)--S(O).sub.2--R.sup.15.
22. The compound of claim 19, having Formula II: ##STR01567##
23. The compound of claim 19, wherein R.sup.16, R.sup.17, R.sup.18
and R.sup.19 are each independently selected from the group
consisting of --H, --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.20, --S(O).sub.2--R.sup.21,
--S(O).sub.2--N(H)--R.sup.22, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, and --N(H)--S(O).sub.2--R.sup.23.
24. The compound of claim 23, wherein R.sup.16, R.sup.17, R.sup.18
and R.sup.19 are each independently selected from H, halogen, lower
alkyl, lower alkoxy, halo substituted lower alkyl, --OR.sup.20, or
alkoxy substituted lower alkyl.
25. The compound of claim 19, having Formula IIa: ##STR01568##
26. The compound of claim 25, wherein R.sup.16, R.sup.18 and
R.sup.19 are each independently selected from the group consisting
of --F, --Cl, --13r, lower alkyl, fluoro substituted lower alkyl,
methoxy substituted lower alkyl, cycloalkylamino, --CN,
--O--R.sup.20, --S(O).sub.2--R.sup.21,
--S(O).sub.2--N(H)--R.sup.22, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, and --N(H)--S(O).sub.2--R.sup.23.
27. The compound of claim 26, wherein R.sup.16, R.sup.17, R.sup.18
and R.sup.19 are each independently selected from H, halogen, lower
alkyl, lower alkoxy, halo substituted lower alkyl, --OR.sup.20, or
alkoxy substituted lower alkyl.
28. The compound of claim 1, having Formula III': ##STR01569## or a
salt, a prodrug, a tautomer or a stereoisomer thereof, wherein:
R.sup.24, R.sup.25, R.sup.26 and R.sup.27 are each independently
selected from the group consisting of --H, halogen, lower alkyl,
lower alkoxy, halo substituted lower alkyl, lower alkoxy, alkoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.28,
--S(O).sub.2--R.sup.29, --S(O).sub.2--N(H)--R.sup.30,
--N(H)--R.sup.30, --N(R.sup.+).sub.2, and
--N(H)--S(O).sub.2--R.sup.34, provided that at least two of
R.sup.24, R.sup.25, R.sup.26 and R.sup.27 are --H: R.sup.28 is
lower alkyl, fluoro substituted lower alkyl, methoxy substituted
lower alkyl, or cycloalkyl: R.sup.29 is lower alkyl; R.sup.30 is
lower alkyl; and R.sup.31 is lower alkyl.
29. The compound of claim 28, wherein R.sup.6 is selected from the
group consisting of halogen, lower alkyl, fluoro substituted lower
alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl,
--CN, --O--R.sup.13, --C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl.
30. The compound of claim 29, wherein R.sup.6 is F, Cl, Br, lower
alkyl, fluoro substituted lower alkyl, lower alkenyl, --CN,
--C(O)--N(H)--R.sup.14, --N(H)--C(O)--R.sup.15,
--C(O)--O--R.sup.14, --S(O).sub.2--R.sup.15,
--S(O).sub.2--N(H)--R.sup.14 or --N(H)--S(O).sub.2--R.sup.15.
31. The compound of claim 28, having Formula III: ##STR01570##
32. The compound of claim 28, wherein R.sup.24, R.sup.25, R.sup.26
and R.sup.27 are each independently selected from the group
consisting of --H, --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, lower alkoxy, methoxy substituted lower alkyl,
cycloalkylamino, --CN, --O--R.sup.20, --S(O).sub.2--R.sup.21,
--S(O).sub.2--N(H)--R.sup.22, --N(H)--R.sup.22,
--N(H)R.sup.22).sub.2, and --N(H)--S(O).sub.2--R.sup.23.
33. The compound of claim 32, wherein R.sup.24, R.sup.25, R.sup.26
and R.sup.27 are each independently selected from H, halogen, lower
alkyl, lower alkoxy, halo substituted lower alkyl, --OR.sup.20, or
alkoxy substituted lower alkyl.
34. A compound selected from the group consisting of:
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)pyridin-2-yl]-(2,6-dimet-
hoxy-pyridin-3-ylmethyl)-amine (P-1496),
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-1622),
N-(3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin--
3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1669),
N-(3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-fluoro-pyridin-3-ylmethyl-
}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide (P-1679),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-2001),
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(5-fluoro-pyridin-3-ylmethyl)-amine (P-2028),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-2029),
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-2030),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-meth-
oxy-pyridin-3-ylmethyl)-amine (P-2038),
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(2-methoxy-pyridin-3-ylmethyl)-amine (P-2043),
[6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-2045),
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2048),
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2049),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-2052),
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2057),
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2061),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2062),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2063),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-2-methoxy-pyridin-3-ylmethyl)-amine (P-2064),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methyl-pyridin-4-ylmethyl)-amine (P-2067),
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2070),
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2071),
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2073),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(2-methyl-pyridin-4-ylmethyl)-amine (P-2075),
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2078),
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2088),
(2,6-Dimethoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b-
]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2097),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-fluoro-pyridin-3-ylmethyl)-amine (P-2103),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-fluoro-pyridin-4-ylmethyl)-amine (P-2118),
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2139),
3-{[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-ylamino]-
-methyl}-5-fluoro-1-methyl-1H-pyridin-2-one (P-2157),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-2165),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-pyridin-3-ylmethyl)-amine (P-2176),
3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2193),
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-fluoro-6-
-methoxy-3-pyridyl)methyl]pyridin-2-amine (P-2203),
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204),
6-chloro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine (P-2205),
6-fluoro-N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-5-[[5-(trifluoromethyl)-
-1H-pyrrolo[2,3-b]pyridin-3-yl]methyl]pyridin-2-amine (P-2206) and
a salt, prodrug, tautomer, or stereoisomer thereof.
35. A compound selected from the group consisting of:
(6-Methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1554),
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-1562),
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2003),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-fluoro-
-pyridin-3-ylmethyl)-amine (P-2004),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3,4-di-
fluoro-benzyl)-amine (P-2008),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-meth-
yl-benzyl)-amine (P-2013),
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2019),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2031),
(4-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2032),
(4-Chloro-benzyl)-[6-fluoro-5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2037),
(6-Methyl-pyridin-2-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2079),
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-morp-
holin-4-yl-pyridin-2-ylmethyl)-amine (P-2081),
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-pyrr-
olidin-1-yl-pyridin-2-ylmethyl)-amine (P-2082),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-methyl-pyridin-2-ylmethyl)-amine (P-2131),
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2146),
[3-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2147),
(2-Cyclopentyloxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2148),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-3-ylmethyl)-amine (P-2154),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-2-ylmethyl)-amine (P-2163),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3-fluoro-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2172),
Ethanesulfonic
acid(2-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridi-
n-2-ylamino]-methyl}-phenyl)-amide (P-2198), Ethanesulfonic
acid(3-fluoro-5-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-ylamino]-methyl}-phenyl)-amide (P-2202), and any salt,
prodrug, tautomer, or stereoisomer thereof.
36. A compound selected from the group consisting of:
(6-Trifluoromethyl-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1644),
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-
-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1646),
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-t-
rifluoromethyl-pyridin-3-ylmethyl)-amine (P-1667),
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2003),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-fluoro-
-pyridin-3-ylmethyl)-amine (P-2004),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluo-
ro-5-trifluoromethyl-benzyl)-amine (P-2009),
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2019),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-2029),
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-2030),
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2031),
(4-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2032),
(2-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2034),
(4-Chloro-benzyl)-[6-fluoro-5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2037),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-meth-
oxy-pyridin-3-ylmethyl)-amine (P-2038),
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2040),
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2041),
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2044),
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2047),
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2048),
(4-Chloro-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyridin-2-yl]-amine (P-2050),
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2057),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-2165), and any
salt, prodrug, tautomer, or stereoisomer thereof.
37. A composition comprising a compound of claim 1 and a
pharmaceutically acceptable excipient or carrier.
38. A kit comprising a compound of claim 1.
39. A compound of claim 1 for use as a medicament.
40. A method for treating a subject suffering from or at risk of a
disease or condition, said method comprising administering to the
subject in need thereof an effective amount of a compound of claim
1, wherein the disease or condition is selected from the group
consisting of multiple sclerosis, glioblastoma, Alzheimer's
disease. Parkinson's disease, rheumatoid arthritis, osteoarthritis,
atherosclerosis, systemic lupus erythematosus, glomerulonephritis,
interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic
nephropathy, and renal hypertrophy, metastatic breast cancer,
prostate cancer, multiple myeloma, melanoma, acute myeloid
leukemia, brain metastases, neurolibromatosis, gastrointestinal
stromal tumors and acute myeloid leukemia.
41. The method of claim 40, wherein the disease or condition is
selected from the group consisting of multiple sclerosis,
glioblastoma, Alzheimer's disease, Parkinson's disease, rheumatoid
arthritis, osteoarthritis, atherosclerosis, systemic lupus
erythematosus, glomerulonephritis, interstitial nephritis, Lupus
nephritis, tubular necrosis, diabetic nephropathy, and renal
hypertrophy.
42. The method of claim 40, wherein the disease or condition is
selected from the group consisting of metastatic breast cancer,
prostate cancer, multiple myeloma, melanoma, acute myeloid
leukemia, brain metastases, neurofibromatosis, gastrointestinal
stromal tumors, rheumatoid arthritis, and multiple sclerosis.
43. The method of claim 40, wherein the disease or condition is
acute myeloid leukemia.
44. A method for treating a subject suffering from or at risk of a
disease or condition, said method comprising administering to the
subject in need thereof an effective amount of a compound of claim
34, wherein the disease or condition is selected from the group
consisting of multiple sclerosis, glioblastoma, Alzheimer's
disease, Parkinson's disease, rheumatoid arthritis, osteoarthritis,
atherosclerosis, systemic lupus erythematosus, glomerulonephritis,
interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic
nephropathy, and renal hypertrophy.
45. A method of for treating a subject suffering from or at risk of
a disease or condition, said method comprising administering to the
subject in need thereof an effective amount of a compound of claim
35, wherein the disease or condition is selected from the group
consisting of metastatic breast cancer, prostate cancer, multiple
myeloma, melanoma, acute myeloid leukemia, brain metastases,
neurofibromatosis, gastrointestinal stromal tumors, rheumatoid
arthritis, and multiple sclerosis.
46. A method of for treating a subject suffering from or at risk of
a disease or condition, said method comprising administering to the
subject in need thereof an effective amount of a compound of claim
36, wherein the disease or condition is acute myeloid leukemia.
47. A pharmaceutical composition comprising a compound of claim 1
and another drug, wherein the other drug is selected from: i) an
alkylating agent selected from adozelesin, altretamine, bizelesin,
busulfan, carboplatin, carboquone, carmustine, chlorambucil,
cisplatin, cyclophosphamide, dacarbazine, estramustine,
fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven,
lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan,
semustine, streptozocin, temozolomide, thiotepa, and treosulfan;
ii) an antibiotic selected from bleomycin, dactinomycin,
daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril,
mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and
plicamycin; an antimetabolite, including, but not limited to,
azacitidine, capecitabine, cladribine, clofarabine, cytarabine,
decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur,
gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine,
pemetrexed, raltitrexed, thioguanine, and trimetrexate; iii) an
immunotherapy agent selected from alemtuzumab, bevacizumab,
cetuximab, galiximab, gemtuzamab, panitumumab, pertuzumab,
rituximab, tositumomab, trastuzumab, and 90 Y ibritumomab tiuxetan;
a hormone or hormone antagonist, including, but not limited to
anastrozole, androgens, buserelin, diethylstilbestrol, exemestane,
flutamide, fulvestrant, goserelin, idoxifene, letrozole,
leuprolide, magestrol, raloxifene, tamoxifen, and toremifene; iv) a
taxan selected from DJ-927, docetaxel, TPI 287, paclitaxel and
DHA-paclitaxel; v) a retinoid selected from alitretinoin,
bexarotene, fenretinide, isotretinoin, and tretinoin; vi) an
alkaloid selected from etoposide, homoharringtonine, teniposide,
vinblastine, vincristine, vindesine, and vinorelbine; vii) an
antiangiogenic agent selected from AE-941 (GW786034, Neovastat),
ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide; viii) a
topoisomerase inhibitor selected from amsacrine, edotecarin,
exatecan, irinotecan (also active metabolite SN-38
(7-ethyl-10-hydroxy-camptothecin)), rubitecan, topotecan, and
9-aminocamptothecin; ix) a kinase inhibitor selected from
erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib,
sorafenib, sunitinib malate, AEE-788, AG-013736, AMG 706, AMN 107,
BMS-354825, BMS-599626, UCN-01 (7-hydroxystaurosporine), and
vatalanib; x) a targeted signal transduction inhibitor selected
from bortezomib, geldanamycin, and rapamycin; xi) a biological
response modifier selected from imiquimod, interferon-.alpha., and
interleukin-2; and xii) a chemotherapeutic agent selected from 3-AP
(3-amino-2-carboxyaldehyde thiosemicarbazone), altrasentan,
aminoglutethimide, anagrelide, asparaginase, bryostatin-1,
cilengitide, eleselomol, cribulin mesylate (E7389), ixabepilone,
lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac,
testolactone, tiazofurin, mTOR inhibitors (e.g. temsirolimus,
everolimus, deforolimus), PI3K inhibitors (e.g. BEZ235, GDC-0941,
XL147, XL765), Cdk4 inhibitors (e.g. PD-332991), Akt inhibitors,
Hsp90 inhibitors (e.g. tanespimycin) and farnesyltransferase
inhibitors (e.g. tipifarnib).
48. A method for preparing a compound of Formula I' according to
claim 1, said method composing: contacting a compound of Formula
IV: ##STR01571## with a compound of Formula V: ##STR01572## under
conditions sufficient to form the compound of Formula I, wherein:
P.sup.1 and P.sup.2 are each independently an amino protecting
group; X is H or halogen; Ar is selected from the group consisting
of: ##STR01573## wherein ##STR01574## indicates the point of
attachment of Ar to --CH.sub.2-- of Formula I and wherein
##STR01575## indicates the point of attachment of Ar to --NH-- of
Formula I; R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each
independently selected from the group consisting of --H, lower
alkyl, halogen substituted lower alkyl, alkoxy substituted lower
alkyl, cycloalkylamino, --CN, --O--R.sup.40,
--S(O).sub.2--R.sup.41, --S(O).sub.2--N(H)--R.sup.42,
--N(H)--R.sup.42, --N(R.sup.42).sub.2, and
--N(H)--S(O).sub.2--R.sup.43, provided that at least two of
R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are --H and one of R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 is other than hydrogen, wherein:
R.sup.40 is lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, or cycloalkyl; R.sup.41, R.sup.42 and
R.sup.43 are lower alkyl; R.sup.5 is selected from the group
consisting of --H, --F, --Cl, --Br, lower alkyl, halogen
substituted alkyl, lower alkenyl, lower alkynyl, cycloalkyl,
phenyl, pyrazolyl, --CN, --O--R.sup.10, --C(O)--N(H)--R.sup.11,
--C(O)--O--R.sup.11, --S(O).sub.2--R.sup.12,
--S(O).sub.2--N(H)--R.sup.11, --N(H)--C(O)--R.sup.12, and
--N(H)--S(O).sub.2--R.sup.12, wherein pyrazolyl is optionally
substituted with lower alkyl or heterocycloalkyl; R.sup.6 is
selected from the group consisting of H, halogen, lower alkyl,
halogen substituted alkyl, lower alkenyl, lower alkynyl,
cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.13,
--C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl; R.sup.7 is H halogen or lower alkyl; R.sup.8 is
H, halogen, lower alkyl or lower alkoxy; R.sup.9 is H or halogen;
R.sup.10 and R.sup.13 are independently --H, lower alkyl, lower
alkyl substituted with --O--CH.sub.3, lower alkyl substituted with
di-alkylamine, or lower alkyl substituted with heterocycloalkyl;
R.sup.11 and R.sup.14 are independently hydrogen or lower alkyl;
and R.sup.12 and R.sup.15 are each independently lower alkyl.
49. Use of a compound of claim 34 to selectively modulate the
activity of Fms kinase.
50. Use of a compound of claim 35 to modulate the activity of
Fms/Kit kinases.
51. Use of a compound of claim 36 to modulate the activity of
Fms/Flt kinases.
52. A composition comprising a compound of claim 34 and a
pharmaceutically acceptable excipient or carrier.
53. The compound of claim 22, wherein R.sup.16, R.sup.17, R.sup.18
and R.sup.19 are each independently selected from the group
consisting of --H, --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.20, --S(O).sub.2--R.sup.21,
--S(O).sub.2--N(H)--R.sup.22, --N(H)--R.sup.22, --N(R.sup.22).sub.2
and --N(H)--S(O).sub.2--R.sup.23.
54. The compound of claim 31, wherein R.sup.24, R.sup.25, R.sup.26
and R.sup.27 are each independently selected from the group
consisting of --H, --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, lower alkoxy, methoxy substituted lower alkyl,
cycloalkylamino, --CN, --O--R.sup.20, --S(O).sub.2--R.sup.21,
--S(O).sub.2--N(H)--R.sup.22, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, and --N(H)--S(O).sub.2--R.sup.23.
55. A composition comprising a compound of claim 35 and a
pharmaceutically acceptable excipient or carrier.
56. A composition comprising a compound of claim 36 and a
pharmaceutically acceptable excipient or carrier.
57. The method of claim 40, wherein the disease or condition is
osteoarthritis, rheumatoid arthritis, multiple sclerosis or myeloid
leukemia.
58. A method tier treating a subject suffering from or at risk of a
disease or condition, said method comprising administering to the
subject in need thereof an effective amount of a compound of claim
34, wherein the disease or condition is osteoarthritis, rheumatoid
arthritis, multiple sclerosis or myeloid leukemia.
59. A method for treating a subject suffering from or at risk of a
disease or condition, said method comprising administering to the
subject in need thereof an effective amount of a compound of claim
35, wherein the disease or condition is osteoarthritis, rheumatoid
arthritis, multiple sclerosis or myeloid leukemia.
Description
FIELD OF THE INVENTION
[0001] Disclosed are novel compounds and uses thereof. In certain
embodiments disclosed compounds are Fms kinase inhibitors. In
certain embodiments disclosed compounds are both Fms and Kit kinase
inhibitors. In certain embodiments disclosed compounds are both Fms
and Flt-3 kinase inhibitors.
SUMMARY OF THE INVENTION
[0002] In certain aspects and embodiments disclosed herein,
compounds are provided, as well as various salts thereof,
formulations thereof, conjugates thereof, derivatives thereof,
forms thereof and uses thereof. In some embodiments, compounds are
of Formula I', Formula I, Formula II', Formula II, Formula IIa,
Formula III' or Formula III as described below. In certain
embodiments, the compounds inhibit Fms protein kinase selectively
relative to other protein kinases, including Kit and Flt-3 protein
kinases. In certain embodiments, the compounds inhibit both Fms
protein kinase and Kit protein kinase. In certain embodiments, the
compounds inhibit both Fms protein kinase and Flt-3 protein kinase.
In certain embodiments, the compounds inhibit each of Fms protein
kinase, Kit protein kinase and Flt-3 protein kinase.
[0003] Also contemplated in accordance with the present invention
are methods for the use of the compounds in treating diseases and
conditions associated with regulation of the activity of any of Fms
protein kinase, Kit protein kinase, and Flt-3 protein kinase,
including any mutations of these kinases. Thus, the use of
compounds for therapeutic methods involving modulation of protein
kinases are provided. In certain embodiments, the compounds are
used for therapeutic methods involving modulation of Fms kinase,
Fms and Kit kinases, Fms and Flt-3 kinases, or Fms, Kit and Flt-3
kinases including treatment of a variety of indications, including,
but not limited to, rheumatoid arthritis, osteoarthritis,
osteoporosis, peri-prosthetic osteolysis, systemic sclerosis,
demyelinating disorders, multiple sclerosis, Charcot Marie Tooth
syndrome, amyotrophic lateral sclerosis, Alzheimer's disease,
Parkinson's disease, ulcerative colitis, Crohn's disease, immune
thrombocytopenic purpura, atherosclerosis, systemic lupus
erythematosis, myelopreparation for autologous transplantation,
transplant rejection, glomerulonephritis, interstitial nephritis,
Lupus nephritis, tubular necrosis, diabetic nephropathy, renal
hypertrophy, type I diabetes, acute pain, inflammatory pain,
neuropathic pain, acute myeloid leukemia, melanoma, multiple
myeloma, metastatic breast cancer, prostate cancer, pancreatic
cancer, lung cancer, ovarian cancer, gliomas, glioblastomas,
neurofibromatosis, osteolytic bone metastases, brain metastases,
gastrointestinal stromal tumors, and giant cell tumors.
[0004] In a first aspect, compounds having the structure according
to the following Formula I' are provided:
##STR00001##
or a salt, a prodrug, a tautomer or a stereoisomer thereof,
[0005] wherein:
[0006] Ar is selected from the group consisting of:
##STR00002##
wherein
##STR00003##
indicates the point of attachment of Ar to --CH.sub.2-- of Formula
I' and wherein
##STR00004##
indicates the point of attachment of Ar to --NH-- of Formula I';
[0007] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently
selected from the group consisting of --H, halogen, lower alkyl,
halogen substituted lower alkyl, halogen substituted lower alkoxy,
alkoxy substituted lower alkyl, cycloalkylamino, --CN,
--O--R.sup.40, --S(O).sub.2--R.sup.41,
--S(O).sub.2--N(H)--R.sup.42, --N(H)--R.sup.42,
--N(R.sup.42).sub.2, and --N(H)--S(O).sub.2--R.sup.43, provided
that at least two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are --H
and one of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is other than
hydrogen, wherein: [0008] R.sup.40 is lower alkyl, fluoro
substituted lower alkyl, methoxy substituted lower alkyl, or
cycloalkyl; [0009] R.sup.41, R.sup.42 and R.sup.43 are lower alkyl;
[0010] R.sup.5 is selected from the group consisting of --H, --F,
--Cl, --Br, lower alkyl, halogen substituted alkyl, lower alkenyl,
lower alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.10,
--C(O)--N(H)--R.sup.11, --C(O)--O--R.sup.11,
--S(O).sub.2--R.sup.12, --S(O).sub.2--N(H)--R.sup.11,
--N(H)--C(O)--R.sup.12, and --N(H)--S(O).sub.2--R.sup.12, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl; [0011] R.sup.6 is selected from the group
consisting of H, halogen, lower alkyl, halogen substituted alkyl,
lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN,
--O--R.sup.13, --C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl; [0012] R.sup.7 is H, halogen, or lower alkyl;
[0013] R.sup.8 is H, halogen, or lower alkoxy; [0014] R.sup.9 is H
or halogen; [0015] R.sup.10 and R.sup.13 are independently --H,
lower alkyl, lower alkyl substituted with --O--CH.sub.3, lower
alkyl substituted with di-alklylamine, or lower alkyl substituted
with heterocycloalkyl; [0016] R.sup.11 and R.sup.14 are
independently hydrogen or lower alkyl; and [0017] R.sup.12 and
R.sup.15 are each independently lower alkyl, with the proviso that
the compound is other than those set forth in Table 1.
[0018] In some embodiments, R.sup.1, R.sup.3 and R.sup.4 are each
independently selected from the group consisting of --H, lower
alkoxy, halogen, halogen substituted lower alkyl, alkoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.40,
--S(O).sub.2--R.sup.41, --S(O).sub.2--N(H)--R.sup.42,
--N(H)--R.sup.42, --N(R.sup.42).sub.2, and
--N(H)--S(O).sub.2--R.sup.43, provided that at least two of
R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are --H and R.sup.2 is --F,
--Cl or --Br; or R.sup.1, R.sup.2 and R.sup.3 are --H and R.sup.4
is --CF.sub.3; or R.sup.1 and R.sup.4 are --H, R.sup.2 is
--O--CH.sub.3, and R.sup.3 is --F; or R.sup.2 and R.sup.4 are --H,
R.sup.1 is --O--CH.sub.3, and R.sup.3 is --F; [0019] R.sup.5 is
selected from the group consisting of --H, --F, --Cl, --Br, lower
alkyl, fluoro substituted lower alkyl, lower alkenyl, lower
alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.10,
--C(O)--N(H)--R.sup.11, --C(O)--O--R.sup.11,
--S(O).sub.2--R.sup.12, --S(O).sub.2--N(H)--R.sup.11,
--N(H)--C(O)--R.sup.12, and --N(H)--S(O).sub.2--R.sup.12, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl; [0020] R.sup.6 is selected from the group
consisting of --H, --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl,
pyrazolyl, --CN, --O--R.sup.13, --C(O)--N(H)--R.sup.14,
--C(O)--O--R.sup.14, --S(O).sub.2--R.sup.15,
--S(O).sub.2--N(H)--R.sup.14, --N(H)--C(O)--R.sup.15, and
--N(H)--S(O).sub.2--R.sup.15, wherein pyrazolyl is optionally
substituted with lower alkyl or heterocycloalkyl; [0021] R.sup.7 is
--H, --F, --Cl, or --CH.sub.3; [0022] R.sup.8 is --H, --F,
--CH.sub.3, or --O--CH.sub.3; [0023] R.sup.9 is --H or --Cl; [0024]
R.sup.10 and R.sup.13 are independently --H, lower alkyl, lower
alkyl substituted with --O--CH.sub.3, lower alkyl substituted with
di-alklylamine, or lower alkyl substituted with heterocycloalkyl;
[0025] R.sup.11 and R.sup.14 are independently hydrogen or lower
alkyl; and [0026] R.sup.12 and R.sup.15 are independently lower
alkyl.
[0027] In some embodiments, Ar is
##STR00005##
wherein R.sup.7 is as defined herein.
[0028] In some embodiments, Ar is
##STR00006##
wherein R.sup.8 is as defined herein.
[0029] In some embodiments, Ar is
##STR00007##
[0030] In some embodiments, Ar is
##STR00008##
[0031] In some embodiments,
##STR00009##
wherein R.sup.9 is as defined herein.
[0032] In some embodiments, R.sup.1, R.sup.3 and R.sup.4 are H and
R.sup.2 is halogen. In other embodiments, R.sup.1, R.sup.2 and
R.sup.3 are --H and R.sup.4 is halo substituted lower alkyl. In
other embodiments, R.sup.1 and R.sup.4 are --H and R.sup.2 is lower
alkoxy. In some embodiments, R.sup.3 is halogen. In yet other
embodiments, R.sup.2 and R.sup.4 are --H, R.sup.1 is lower alkoxy
and R.sup.3 is halogen. In certain instances, i) R.sup.1, R.sup.2
and R.sup.3 are --H and R.sup.4 is CF.sub.3; or ii) R.sup.1 and
R.sup.4 are --H and R.sup.2 is --OCH.sub.3; or iii) R.sup.3 is F;
or iv) R.sup.2 and R.sup.4 are --H, R.sup.1 is OCH.sub.3 and
R.sup.3 is F. The variables R.sup.5, R.sup.6 and Ar are as defined
herein.
[0033] In some embodiments of compounds of Formula I', R.sup.5 is
--H, --F, --Cl, --Br, lower alkyl, fluoro substituted lower alkyl,
lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN,
--O--R.sup.10, --C(O)--N(H)--R.sup.11, --C(O)--O--R.sup.11,
--S(O).sub.2--R.sup.12, --S(O).sub.2--N(H)--R.sup.11,
--N(H)--C(O)--R.sup.12, and --N(H)--S(O).sub.2--R.sup.12, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl. In certain instances, R.sup.5 is H. All the other
variables are as defined herein.
[0034] In some embodiments of compounds of Formula I', R.sup.5 is
--H. In some embodiments, R.sup.5 is --H and R.sup.6 is --H, --F,
--Cl, --CH.sub.3, --CF.sub.3, --CN, --O--CH.sub.3,
--S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3, --C(O)--O--CH.sub.3,
--NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or cyclopropyl. All the
other variables are as defined herein.
[0035] In some embodiments of compounds of Formula I', R.sup.6 is
selected from the group consisting of H, halo, lower alkyl, lower
alkoxy, fluoro substituted lower alkyl, lower alkenyl, lower
alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.13,
--C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl. In certain instances, R.sup.6 is halo, lower
alkyl or fluoro substituted lower alkyl. All the other variables
are as defined herein.
[0036] In some embodiments of compounds of Formula I', R.sup.6 is
--H. In some embodiments, R.sup.6 is --H and R.sup.5 is --H, --Cl,
--CN, --C.ident.CH, --O--CH.sub.3, or phenyl. In other embodiments,
R.sup.6 is halo, lower alkyl lower alkoxy, or fluoro substituted
lower alkyl. In yet other embodiments, R.sup.6 is halogen, methyl,
methoxy, trifluoromethyl, or CN. All the other variables are as
defined herein.
[0037] In some embodiments of compounds of Formula I', R.sup.7 is
H, halogen or lower alkyl. In other embodiments, R.sup.7 is H, --F,
--Cl, Br or --CH.sub.3. All the other variables are as defined
herein.
[0038] In some embodiments of compounds of Formula I', R.sup.8 is
H, halogen or lower alkoxy. In other embodiments, R.sup.8 is H,
--F, --Cl, Br or --OCH.sub.3. All the other variables are as
defined herein.
[0039] In some embodiments of compounds of Formula I', R.sup.9 is H
or halogen. In other embodiments, R.sup.9 is --H or --Cl. All the
other variables are as defined herein.
[0040] In some embodiments of compounds of Formula I', R.sup.1,
R.sup.3 and R.sup.4 are --H; R.sup.2 is --F, --Cl or --Br; and
R.sup.5 is --H. In some embodiments, R.sup.1, R.sup.3 and R.sup.4
are --H; R.sup.2 is --F, --Cl or --Br; R.sup.5 is --H; and R.sup.6
is --H, --F, --Cl, --CH.sub.3, --CF.sub.3, --CN, --O--CH.sub.3,
--S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3, --C(O)--O--CH.sub.3,
--NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or cyclopropyl. All the
other variables are as defined herein.
[0041] In some embodiments of compounds of Formula I', R.sup.1,
R.sup.3 and R.sup.4 are --H; R.sup.2 is --F, --Cl or --Br; and
R.sup.6 is --H. In some embodiments, R.sup.1, R.sup.3 and R.sup.4
are --H; R.sup.2 is --F, --Cl or --Br; R.sup.6 is --H; and R.sup.5
is --H, --Cl, --CN, --C.ident.CH, --O--CH.sub.3, or phenyl. All the
other variables are as defined herein.
[0042] In some embodiments of compounds of Formula I', R.sup.1,
R.sup.2 and R.sup.3 are --H; and R.sup.4 is --CF.sub.3; and R.sup.5
is --H. In some embodiments, R.sup.1, R.sup.2 and R.sup.3 are --H;
and R.sup.4 is --CF.sub.3; R.sup.5 is --H; and R.sup.6 is --H, --F,
--Cl, --CH.sub.3, --CF.sub.3, --CN, --O--CH.sub.3,
--S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3, --C(O)--O--CH.sub.3,
--NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or cyclopropyl. All the
other variables are as defined herein.
[0043] In some embodiments of compounds of Formula I', R.sup.1,
R.sup.2 and R.sup.3 are --H; and R.sup.4 is --CF.sub.3; and R.sup.6
is --H. In some embodiments, R.sup.1, R.sup.2 and R.sup.3 are --H;
and R.sup.4 is --CF.sub.3; R.sup.6 is --H; and R.sup.5 is --H,
--Cl, --CN, --C.ident.CH, --O--CH.sub.3, or phenyl. All the other
variables are as defined herein.
[0044] In some embodiments of compounds of Formula I', R.sup.1 and
R.sup.4 are --H; R.sup.2 is --O--CH.sub.3; R.sup.3 is --F; and
R.sup.5 is --H. In some embodiments, R.sup.1 and R.sup.4 are --H;
R.sup.2 is --O--CH.sub.3; R.sup.3 is --F; R.sup.5 is --H; and
R.sup.6 is --H, --F, --Cl, --CH.sub.3, --CF.sub.3, --CN,
--O--CH.sub.3, --S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3,
--C(O)--O--CH.sub.3, --NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or
cyclopropyl. All the other variables are as defined herein.
[0045] In some embodiments of compounds of Formula I', R.sup.1 and
R.sup.4 are --H; R.sup.2 is --O--CH.sub.3; R.sup.3 is --F; and
R.sup.6 is --H. In some embodiments, R.sup.1 and R.sup.4 are --H;
R.sup.2 is --O--CH.sub.3; R.sup.3 is --F; R.sup.6 is --H; and
R.sup.5 is --H, --Cl, --CN, --C.ident.CH, --O--CH.sub.3, or phenyl.
All the other variables are as defined herein.
[0046] In some embodiments of compounds of Formula I', R.sup.2 and
R.sup.4 are --H; R.sup.1 is --O--CH.sub.3; R.sup.3 is --F; and
R.sup.5 is --H. In some embodiments, R.sup.2 and R.sup.4 are --H;
R.sup.1 is --O--CH.sub.3; R.sup.3 is --F; R.sup.5 is --H; and
R.sup.6 is --H, --F, --Cl, --CH.sub.3, --CF.sub.3, --CN,
--O--CH.sub.3, --S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3,
--C(O)--O--CH.sub.3, --NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or
cyclopropyl. All the other variables are as defined herein.
[0047] In some embodiments of compounds of Formula I', R.sup.2 and
R.sup.4 are --H; R.sup.1 is --O--CH.sub.3; R.sup.3 is --F; and
R.sup.6 is --H. In some embodiments, R.sup.2 and R.sup.4 are --H;
R.sup.1 is --O--CH.sub.3; R.sup.3 is --F; R.sup.6 is --H; and
R.sup.5 is --H, --Cl, --CN, --C.ident.CH, --O--CH.sub.3, or phenyl.
All the other variables are as defined herein.
[0048] In another aspect, compounds having the structure according
to the following Formula I are provided:
##STR00010##
or a salt, a prodrug, a tautomer or a stereoisomer thereof,
[0049] wherein:
[0050] Ar is selected from the group consisting of:
##STR00011##
wherein
##STR00012##
indicates the point of attachment of Ar to --CH.sub.2-- of Formula
I and wherein
##STR00013##
indicates the point of attachment of Ar to --NH-- of Formula I;
[0051] R.sup.1, R.sup.3 and R.sup.4 are --H and R.sup.2 is --F,
--Cl or --Br; or R.sup.1, R.sup.2 and R.sup.3 are --H and R.sup.4
is --CF.sub.3; or R.sup.1 and R.sup.4 are --H, R.sup.2 is
--O--CH.sub.3, and R.sup.3 is --F; or R.sup.2 and R.sup.4 are --H,
R.sup.1 is --O--CH.sub.3, and R.sup.3 is --F; [0052] R.sup.5 is
selected from the group consisting of --H, --F, --Cl, --Br, lower
alkyl, fluoro substituted lower alkyl, lower alkenyl, lower
alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.10,
--C(O)--N(H)--R.sup.11, --C(O)--O--R.sup.11,
--S(O).sub.2--R.sup.12, --S(O).sub.2--N(H)--R.sup.11,
--N(H)--C(O)--R.sup.12, and --N(H)--S(O).sub.2--R.sup.12, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl; [0053] R.sup.6 is selected from the group
consisting of --H, --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl,
pyrazolyl, --CN, --O--R.sup.13, --C(O)--N(H)--R.sup.14,
--C(O)--O--R.sup.14, --S(O).sub.2--R.sup.15,
--S(O).sub.2--N(H)--R.sup.14, --N(H)--C(O)--R.sup.15, and
--N(H)--S(O).sub.2--R.sup.15, wherein pyrazolyl is optionally
substituted with lower alkyl or heterocycloalkyl; [0054] R.sup.7 is
--H, --F, --Cl, or --CH.sub.3; [0055] R.sup.8 is --H, --F,
--CH.sub.3, or --O--CH.sub.3; [0056] R.sup.9 is --H or --Cl; [0057]
R.sup.10 and R.sup.13 are independently --H, lower alkyl, lower
alkyl substituted with --O--CH.sub.3, lower alkyl substituted with
di-alklylamine, or lower alkyl substituted with heterocycloalkyl;
[0058] R.sup.11 and R.sup.14 are independently hydrogen or lower
alkyl; and [0059] R.sup.12 and R.sup.15 are independently lower
alkyl.
[0060] In some embodiments of compounds of Formula I, R.sup.5 is
--H. In some embodiments, R.sup.5 is --H and R.sup.6 is --H, --F,
--Cl, --CH.sub.3, --CF.sub.3, --CN, --O--CH.sub.3,
--S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3, --C(O)--O--CH.sub.3,
--NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or cyclopropyl.
[0061] In some embodiments of compounds of Formula I, R.sup.6 is
--H. In some embodiments, R.sup.6 is --H and R.sup.5 is --H, --Cl,
--CN, --C.ident.CH, --O--CH.sub.3, or phenyl.
[0062] In some embodiments of compounds of Formula I, R.sup.1,
R.sup.3 and R.sup.4 are --H; R.sup.2 is --F, --Cl or --Br; and
R.sup.5 is --H. In some embodiments, R.sup.1, R.sup.3 and R.sup.4
are --H; R.sup.2 is --F, --Cl or --Br; R.sup.5 is --H; and R.sup.6
is --H, --F, --Cl, --CH.sub.3, --CF.sub.3, --CN, --O--CH.sub.3,
--S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3, --C(O)--O--CH.sub.3,
--NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or cyclopropyl.
[0063] In some embodiments of compounds of Formula I, R.sup.1,
R.sup.3 and R.sup.4 are --H; R.sup.2 is --F, --Cl or --Br; and
R.sup.6 is --H. In some embodiments, R.sup.1, R.sup.3 and R.sup.4
are --H; R.sup.2 is --F, --Cl or --Br; R.sup.6 is --H; and R.sup.5
is --H, --Cl, --CN, --C.ident.CH, --O--CH.sub.3, or phenyl.
[0064] In some embodiments of compounds of Formula I, R.sup.1,
R.sup.2 and R.sup.3 are --H; and R.sup.4 is --CF.sub.3; and R.sup.5
is --H. In some embodiments, R.sup.1, R.sup.2 and R.sup.3 are --H;
and R.sup.4 is --CF.sub.3; R.sup.5 is --H; and R.sup.6 is --H, --F,
--Cl, --CH.sub.3, --CF.sub.3, --CN, --O--CH.sub.3,
--S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3, --C(O)--O--CH.sub.3,
--NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or cyclopropyl.
[0065] In some embodiments of compounds of Formula I, R.sup.1,
R.sup.2 and R.sup.3 are --H; and R.sup.4 is --CF.sub.3; and R.sup.6
is --H. In some embodiments, R.sup.1, R.sup.2 and R.sup.3 are --H;
and R.sup.4 is --CF.sub.3; R.sup.6 is --H; and R.sup.5 is --H,
--Cl, --CN, --C.ident.CH, --O--CH.sub.3, or phenyl.
[0066] In some embodiments of compounds of Formula I, R.sup.1 and
R.sup.4 are --H; R.sup.2 is --O--CH.sub.3; R.sup.3 is --F; and
R.sup.5 is --H. In some embodiments, R.sup.1 and R.sup.4 are --H;
R.sup.2 is --O--CH.sub.3; R.sup.3 is --F; R.sup.5 is --H; and
R.sup.6 is --H, --F, --Cl, --CH.sub.3, --CF.sub.3, --CN,
--O--CH.sub.3, --S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3,
--C(O)--O--CH.sub.3, --NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or
cyclopropyl.
[0067] In some embodiments of compounds of Formula I, R.sup.1 and
R.sup.4 are --H; R.sup.2 is --O--CH.sub.3; R.sup.3 is --F; and
R.sup.6 is --H. In some embodiments, R.sup.1 and R.sup.4 are --H;
R.sup.2 is --O--CH.sub.3; R.sup.3 is --F; R.sup.6 is --H; and
R.sup.5 is --H, --Cl, --CN, --C.ident.CH, --O--CH.sub.3, or
phenyl.
[0068] In some embodiments of compounds of Formula I, R.sup.2 and
R.sup.4 are --H; R.sup.1 is --O--CH.sub.3; R.sup.3 is --F; and
R.sup.5 is --H. In some embodiments, R.sup.2 and R.sup.4 are --H;
R.sup.1 is --O--CH.sub.3; R.sup.3 is --F; R.sup.5 is --H; and
R.sup.6 is --H, --F, --Cl, --CH.sub.3, --CF.sub.3, --CN,
--O--CH.sub.3, --S(O).sub.2--CH.sub.3, --C(O)--NH--CH.sub.3,
--C(O)--O--CH.sub.3, --NHC(O)CH.sub.3, --NHS(O).sub.2CH.sub.3, or
cyclopropyl.
[0069] In some embodiments of compounds of Formula I, R.sup.2 and
R.sup.4 are --H; R.sup.1 is --O--CH.sub.3; R.sup.3 is --F; and
R.sup.6 is --H. In some embodiments, R.sup.2 and R.sup.4 are --H;
R.sup.1 is --O--CH.sub.3; R.sup.3 is --F; R.sup.6 is --H; and
R.sup.5 is --H, --Cl, --CN, --C.ident.CH, --O--CH.sub.3, or
phenyl.
[0070] In one embodiment of compounds of Formulae I and I', the
compound is selected from the group consisting of: [0071]
[5-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(-
5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1497), [0072]
(6-Chloro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
ridin-2-yl]-amine (P-1498), [0073]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-1499), [0074]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1500), [0075]
[6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-1501), [0076]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1502), [0077]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1403), [0078]
[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-trifluoromethyl-
-pyridin-3-ylmethyl)-amine (P-1504), [0079]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-1505), [0080]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-6-methoxy-pyridin-3-ylmethyl)-amine (P-1506), [0081]
(6-Chloro-pyridin-3-ylmethyl)-[6-chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-1508), [0082]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-1509), [0083]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-1510), [0084]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-1513), [0085]
(6-Chloro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
rimidin-2-yl]-amine (P-1515), [0086]
[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluorometh-
yl-pyridin-3-ylmethyl)-amine (P-1516), [0087]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-1520), [0088]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-
-6-methoxy-pyridin-3-ylmethyl)-amine (P-1521), [0089]
(6-Chloro-pyridin-3-ylmethyl)-[4-chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-thiazol-2-yl]-amine (P-1523), [0090]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-1524), [0091]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-1525), [0092]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1528), [0093]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1529), [0094]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-1531), [0095]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1533), [0096]
(6-Chloro-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1535), [0097]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1536), [0098]
[6-Methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1537), [0099]
[6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1540), [0100]
[6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-chloro-pyridin-3-ylmethyl)-amine (P-1542), [0101]
[6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1543), [0102]
[6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1544), [0103]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1547), [0104]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1548), [0105]
(6-Chloro-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1550), [0106]
[3-Methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1551), [0107]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1555), [0108]
(6-Chloro-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1557), [0109]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1558), [0110]
[3-Methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1559), [0111]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[3-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1563), [0112]
(6-Chloro-pyridin-3-ylmethyl)-[3-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1565), [0113]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[3-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1566), [0114]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1567), [0115]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-1570), [0116]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-thiazol-2-yl]-amine (P-1579), [0117]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-thiazol-2-yl]-amine (P-1581), [0118]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-1582), [0119]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1584), [0120]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1586), [0121]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1587), [0122]
[5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine (P-1588), [0123]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1590), [0124]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-chloro-pyridin-3-ylmethyl)-amine (P-1592), [0125]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1593), [0126]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1594), [0127]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1597), [0128]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1598), [0129]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-1599), [0130]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-1600), [0131]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-1602), [0132]
[5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-tri-
fluoromethyl-pyridin-3-ylmethyl)-amine (P-1603), [0133]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-6-fluoro-pyridin-2-yl]-amine (P-1607), [0134]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1608), [0135]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1611), [0136]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-1612), [0137]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-1613), [0138]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1623), [0139]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1625), [0140]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1626), [0141]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1627), [0142]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-1630), [0143]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-1632), [0144]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-1633), [0145]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-1634), [0146]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1638), [0147]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1640), [0148]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1641), [0149]
(4-Trifluoromethyl-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1642), [0150]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-
-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1646),
[0151]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1648), [0152]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-
-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1649),
[0153]
[6-Fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1650),
[0154]
3-{2-Fluoro-6-[(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1654), [0155]
3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-fluoro-pyridin-3-ylmethyl}-1-
H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1655), [0156]
3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1656), [0157]
3-{2-Fluoro-6-[(4-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-
methyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1657), [0158]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-f-
luoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1661), [0159]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-cyclopropyl-1H-pyrrolo[2,3-b]pyridin--
3-ylmethyl)-pyridin-2-yl]-amine (P-1663), [0160]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-f-
luoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1664), [0161]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-t-
rifluoromethyl-pyridin-3-ylmethyl)-amine (P-1665), [0162]
N-(3-{2-Fluoro-6-[(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin--
3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1670),
[0163]
N-(3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-fluoro-pyridin-3-ylmethyl-
}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1672), [0164]
N-(3-{2-Fluoro-6-[(4-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-
-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1673),
[0165]
N-(3-{2-Fluoro-6-[(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin--
3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1677), [0166]
N-(3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-p-
yridin-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1680), [0167]
N-(3-{2-Fluoro-6-[(4-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-
-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1681), [0168]
[6-Fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl-
)-pyridin-2-yl]-(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine
(P-1685), [0169]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methanesulfonyl-1H-py-
rrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1687),
[0170]
[6-Fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1688),
[0171]
[6-Fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1689),
[0172]
3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester
(P-1693), [0173]
3-{2-Fluoro-6-[(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide
(P-1694), [0174]
3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyri-
din-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid
methylamide (P-1696), [0175]
3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-fluoro-pyridin-3-ylmethyl}-1-
H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide (P-1697),
[0176]
3-{2-Fluoro-6-[(4-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-
methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide
(P-1698), [0177]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-{6-fluoro-5-[5-(1-piperidi-
n-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-yl}-
-amine (P-1703), [0178]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-{6-fluoro-5-[5-(1-piperidin-4-yl--
1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-yl}-amine
(P-1704), [0179]
(6-Chloro-pyridin-3-ylmethyl)-{6-fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-
-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-yl}-amine
(P-1706), [0180]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b-
]pyridin-3-ylmethyl]-pyridin-2-yl}-(4-trifluoromethyl-pyridin-3-ylmethyl)--
amine (P-1707), [0181]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluor-
o-6-methoxy-pyridin-3-ylmethyl)-amine (P-1711), [0182]
(6-Chloro-pyridin-3-ylmethyl)-[5-(4-ethynyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1713), [0183]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluor-
o-2-methoxy-pyridin-3-ylmethyl)-amine (P-1714),
[0184]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(-
4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1715), [0185]
3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo-
[2,3-b]pyridine-4-carbonitrile (P-1720), [0186]
3-{6-[(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-4-carbonitrile (P-1721), [0187]
3-{6-[(4-Trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1-
H-pyrrolo[2,3-b]pyridine-4-carbonitrile (P-1722), [0188]
3-{6-[(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-4-carbonitrile (P-1726), [0189]
(6-Bromo-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylme-
thyl)-pyridin-2-yl]-amine (P-2002), [0190]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2003), [0191]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-fluoro-
-pyridin-3-ylmethyl)-amine (P-2004), [0192]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2040), [0193]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2041), [0194]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2042), [0195]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2048), [0196]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2049), [0197]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2061), [0198]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2062), [0199]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2063), [0200]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-2-methoxy-pyridin-3-ylmethyl)-amine (P-2064), [0201]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2070), [0202]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2073), [0203]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2078), [0204]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2088), [0205]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-2152), [0206]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-thiazol-2-yl]-amine (P-2153), [0207]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-2165), [0208]
[5-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-2170), [0209]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(4-phenyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2171), [0210]
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-fluoro-6-
-methoxy-3-pyridyl)methyl]pyridin-2-amine (P-2203), [0211]
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204), [0212]
6-chloro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine (P-2205), [0213]
6-fluoro-N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-5-[[5-(trifluoromethyl)-
-1H-pyrrolo[2,3-b]pyridin-3-yl]methyl]pyridin-2-amine (P-2206), and
any salt, prodrug, tautomer, or stereoisomer thereof.
[0214] In some embodiments of compounds of Formulae I and I',
R.sup.7 is other than hydrogen. All the other variables are as
defined herein.
[0215] In one group of embodiments of compounds of Formulae I and
I', R.sup.6 and R.sup.7 are not simulataneously H. All the other
variables are as defined herein.
[0216] In another group of embodiments of compounds of Formulae I
and I', when R.sup.7 is halogen, R.sup.6 is other than H, halogen,
heteroaryl, CN or lower alkyl. In certain instances, when R.sup.7
is Cl, R.sup.6 is other than H, Cl, pyrrazolyl, CN or CH.sub.3. All
the other variables are as defined herein.
[0217] In another group of embodiments of compounds of Formulae I
and I', when R.sup.7 is halogen, R.sup.6 is other than halo
substituted lower alkyl. In certain instances, when R.sup.7 is Cl,
R.sup.6 is other than CF.sub.3. All the other variables are as
defined herein.
[0218] In one group of embodiments of compounds of Formulae I and
I', when R.sup.7 is halogen, R.sup.2 is other than halogen
substituted lower alkyl or lower alkoxy. In certain instances, when
R.sup.7 is F, R.sup.2 is other than CF.sub.3 or --OCH.sub.3. All
the other variables are as defined herein.
[0219] In another group of embodiments of compounds of Formulae I
and I', when R.sup.7 is halogen,
[0220] R.sup.6 is other than halogen, lower alkoxy, hydrogen or CN.
In certain instances, when R.sup.7 is --F, R.sup.6 is other than
Cl, OCH.sub.3, hydrogen or CN. In other instances, when R.sup.7 is
--F, R.sup.3 is other than F. All the other variables are as
defined herein.
[0221] In one group of embodiments of compounds of Formulae I and
I', when R.sup.7 is hydrogen, R.sup.6 is other than halogen,
hydrogen, lower alkyl, CN, or lower alkoxy. In certain instances,
when R.sup.7 is hydrogen, R.sup.6 is other than H, Cl, F, CH.sub.3,
CN, --OCH.sub.3. All the other variables are as defined herein.
[0222] In another group of embodiments of compounds of Formulae I
and I', when R.sup.9 is halogen,
[0223] R.sup.6 is other than H or halogen. In certain instances,
when R.sup.9 is Cl, R.sup.6 is other than H or Cl. All the other
variables are as defined herein.
[0224] In another group of embodiments of compounds of Formulae I
and I', when Ar is
##STR00014##
R.sup.6 is other than hydrogen. All the other variables are as
defined herein.
[0225] In another group of embodiments of compounds of Formulae I
and I', when Ar is
##STR00015##
R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are not simultaneously
hydrogen. All the other variables are as defined herein.
[0226] In another group of embodiments of compounds of Formulae I
and I', when Ar is
##STR00016##
R.sup.2 is other than halo substituted lower alkyl, for example, in
one embodiment, R.sup.2 is other than CF.sub.3. All the other
variables are as defined herein.
[0227] The compounds excluded from Formula I' and Formula I are
listed in Table 1 below.
TABLE-US-00001 TABLE 1
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluo-
romethyl-pyridin-3- ylmethyl)-amine (P-0174),
[6-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(-
6-trifluoromethyl-pyridin- 3-ylmethyl)-amine (P-0176),
{6-Chloro-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl]-pyridin-2-yl}-(6- trifluoromethyl-pyridin-3-ylmethyl)-amine
(P-0179),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(-
6-trifluoromethyl-pyridin- 3-ylmethyl)-amine (P-0186),
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl- pyridin-3-ylmethyl)-amine (P-0187),
[6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluo-
romethyl-pyridin-3- ylmethyl)-amine (P-0188),
3-{2-Chloro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylm-
ethyl}-1H-pyrrolo[2,3- b]pyridine-5-carbonitrile (P-0232),
[6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(-
6-trifluoromethyl- pyridin-3-ylmethyl)-amine (P-0233),
[6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(-
6-trifluoromethyl- pyridin-3-ylmethyl)-amine (P-0234),
[6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-
-pyridin-3-ylmethyl)- amine (P-0378),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(-
6-methoxy-pyridin-3- ylmethyl)-amine (P-0379),
(5-Fluoro-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylme-
thyl)-pyridin-2-yl]-amine (P-0414),
3-{2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-
-pyrrolo[2,3-b]pyridine- 5-carbonitrile (P-0415),
3-[6-(4-Chloro-benzylamino)-2-fluoro-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]-
pyridine-5-carbonitrile (P-0432),
Pyridin-3-ylmethyl-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
amine (P-0094),
(2-Methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
ridin-2-yl]-amine (P-0215),
(6-Methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
ridin-2-yl]-amine (P-0219),
(5-Methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
ridin-2-yl]-amine (P-0222),
(5-Fluoro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyr-
idin-2-yl]-amine (P-0230),
3-{6-[(6-Trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-
-pyrrolo[2,3- b]pyridine-5-carbonitrile (P-0273),
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]- amine (P-0282),
3-{6-[(6-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo-
[2,3-b]pyridine-5- carbonitrile (P-0284),
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]- amine (P-0285),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methoxy-
-pyridin-3-ylmethyl)- amine (P-0286),
3-{6-[(2-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo-
[2,3-b]pyridine-5- carbonitrile (P-0287),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro--
pyridin-3-ylmethyl)- amine (P-0324),
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-
-pyridin-3-ylmethyl)- amine (P-0331),
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]- amine (P-0332),
(2-Morpholin-4-yl-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-0347),
(2,6-Dimethoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl-
)-pyridin-2-yl]-amine (P-0370),
(6-Cyclopentyloxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]- amine (P-0374),
[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-[2-(2,2,2-trifluoro-
-ethoxy)-pyridin-3- ylmethyl]-amine (P-0376),
(5-Chloro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyr-
idin-2-yl]-amine (P-0400),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-[6-(2,2,2--
trifluoro-ethoxy)-pyridin- 3-ylmethyl]-amine (P-0409),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluo-
romethyl-pyridin-3- ylmethyl)-amine (P-0181),
[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl--
pyridin-3-ylmethyl)-amine (P-0182),
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-3--
ylmethyl-amine (P-0164),
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-trifluo-
romethyl-pyridin-3- ylmethyl)-amine (P-0173),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin--
3-ylmethyl-amine (P-0422),
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-trifl-
uoromethyl-pyridin-3- ylmethyl)-amine (P-0429),
2,2-Dimethyl-N-(3-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylam-
ino]-methyl}-pyridin- 2-yl)-propionamide (P-0384),
Methyl-(3-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-met-
hyl}-pyridin-2-yl)- amine (P-0385),
Dimethyl-(3-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-m-
ethyl}-pyridin-2-yl)- amine (P-0399),
[4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(-
3-fluoro-pyridin-4- ylmethyl)-amine (P-0200),
[4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-p-
yridin-3-ylmethyl-amine (P-0236),
[4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(-
5-methoxy-pyridin-3- ylmethyl)-amine (P-0241),
[4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(-
6-trifluoromethyl-pyridin- 3-ylmethyl)-amine (P-0242),
[4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(-
2-methoxy-pyridin-3- ylmethyl)-amine (P-0247), and
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-methoxy-
-pyridin-3-ylmethyl)- amine (P-0207).
[0228] In a second aspect, the present invention provides compounds
having Formula II':
##STR00017##
or a salt, a prodrug, a tautomer or a stereoisomer thereof,
[0229] wherein: [0230] R.sup.16, R.sup.17,
[0231] R.sup.18 and R.sup.19 are each independently selected from
the group consisting of H, halogen, lower alkyl, lower alkoxy, halo
substituted lower alkyl, alkoxy substituted lower alkyl,
cycloalkylamino, --CN, --O--R.sup.20, --S(O).sub.2--R.sup.21,
--S(O).sub.2--N(H)--R.sup.22, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, and --N(H)--S(O).sub.2--R.sup.23, provided
that at least two of R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are
--H; [0232] R.sup.20 is lower alkyl, fluoro substituted lower
alkyl, methoxy substituted lower alkyl, or cycloalkyl; R.sup.21 is
lower alkyl; R.sup.22 is lower alkyl; and R.sup.23 is lower
alkyl.
[0233] In some embodiments of compounds of Formula II', R.sup.6 is
selected from the group consisting of halogen, lower alkyl, fluoro
substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl,
phenyl, pyrazolyl, --CN, --O--R.sup.13, --C(O)--N(H)--R.sup.14,
--C(O)--O--R.sup.14, --S(O).sub.2--R.sup.15,
--S(O).sub.2--N(H)--R.sup.14, --N(H)--C(O)--R.sup.15, and
--N(H)--S(O).sub.2--R.sup.15, wherein pyrazolyl is optionally
substituted with lower alkyl or heterocycloalkyl. In certain
instances, R.sup.6 is F, Cl, Br, lower alkyl, fluoro substituted
lower alkyl, lower alkenyl, --CN, --C(O)--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14 or
--N(H)--S(O).sub.2--R.sup.15. In other instances, R.sup.6 is
methyl, ethyl, propyl, butyl, pentyl or hexyl. All other variables
are as defined herein.
[0234] In some embodiments, compounds having the structure
according to the following Formula II are provided:
##STR00018##
or a salt, a prodrug, a tautomer or a stereoisomer thereof,
[0235] wherein: [0236] R.sup.16, R.sup.17, R.sup.18 and R.sup.19
are independently selected from the group consisting of --H, --F,
--Cl, --Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --S(O).sub.2--N(H)--R.sup.22,
--N(H)--R.sup.22, --N(R.sup.22).sub.2, and
--N(H)--S(O).sub.2--R.sup.23, provided that at least two of
R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are --H; [0237] R.sup.20
is lower alkyl, fluoro substituted lower alkyl, methoxy substituted
lower alkyl, or cycloalkyl; [0238] R.sup.21 is lower alkyl; [0239]
R.sup.22 is lower alkyl; and [0240] R.sup.23 is lower alkyl.
[0241] In some embodiments of compounds of Formulae II and II',
R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are each independently
selected from the group consisting of --H, --F, --Cl, --Br, lower
alkyl, fluoro substituted lower alkyl, methoxy substituted lower
alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --S(O).sub.2--N(H)--R.sup.22,
--N(H)--R.sup.22, --N(R.sup.22).sub.2, and
--N(H)--S(O).sub.2--R.sup.23, provided that at least two of
R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are --H. In some
embodiments, R.sup.17 and R.sup.19 are H, halogen or lower alkyl.
All other variables are as defined herein.
[0242] In other embodiments of compounds of Formulae II and II',
R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are each independently
selected from H, halogen, lower alkyl, lower alkoxy, halo
substituted lower alkyl, --OR.sup.20, or alkoxy substituted lower
alkyl, provided that at least two of R.sup.16, R.sup.17, R.sup.18
and R.sup.19 are --H. All other variables are as defined
herein.
[0243] In some embodiments of compounds of Formulae II and II',
R.sup.16, R.sup.17, and R.sup.18 are H and R.sup.19 is --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --N(H)--R.sup.22, --N(R.sup.22).sub.2, or
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.16,
R.sup.17, and R.sup.18 are H and R.sup.19 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.16, R.sup.17, and R.sup.18 are H and R.sup.19 is
fluoro substituted lower alkyl or --O--R.sup.20. In some
embodiments R.sup.16, R.sup.17, and R.sup.18 are H and R.sup.19 is
--CF.sub.3 or --O--CH.sub.3. All other variables are as defined
herein.
[0244] In some embodiments of compounds of Formulae II and II',
R.sup.16, R.sup.17, and R.sup.19 are H and R.sup.18 is --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --N(H)--R.sup.22, --N(R.sup.22).sub.2, or
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.16,
R.sup.17, and R.sup.19 are H and R.sup.18 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)--R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.16, R.sup.17, and R.sup.19 are H and R.sup.18 is
--F, --Cl, or --O--R.sup.20. In some embodiments R.sup.16,
R.sup.17, and R.sup.19 are H and R.sup.18 is --F, --Cl, or
--O--CH.sub.3. All other variables are as defined herein.
[0245] In some embodiments of compounds of Formulae II and II',
R.sup.16, R.sup.18, and R.sup.19 are H and R.sup.17 is --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --N(H)--R.sup.22, --N(R.sup.22).sub.2, or
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.16,
R.sup.18, and R.sup.19 are H and R.sup.17 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)--R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.16, R.sup.18, and R.sup.19 are H and R.sup.17 is
--Cl, fluoro substituted lower alkyl, cycloalkylamino, or
--O--R.sup.20. In some embodiments R.sup.16, R.sup.18, and R.sup.19
are H and R.sup.17 is --Cl, --CF.sub.3, --O--CH.sub.3, or
morpholin-4-yl. All other variables are as defined herein.
[0246] In some embodiments of compounds of Formulae II and II',
R.sup.17, R.sup.18, and R.sup.19 are H and R.sup.16 is --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --N(H)--R.sup.22, --N(R.sup.22).sub.2, or
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.17,
R.sup.18, and R.sup.19 are H and R.sup.16 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)--R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.17, R.sup.18, and R.sup.19 are H and R.sup.16 is
--F, --CF.sub.3, morpholin-4-yl, --O--CH.sub.3,
--O--CH.sub.2CH.sub.3, --O--CH(CH.sub.3).sub.2,
--O--CH.sub.2CF.sub.3, --O-cyclopentyl, --O-cyclohexyl, or
--N(H)--CH.sub.3. In some embodiments R.sup.17, R.sup.18, and
R.sup.19 are H and R.sup.16 is --F, --CF.sub.3, or --O--CH.sub.3.
All other variables are as defined herein.
[0247] In some embodiments of compounds of Formulae II and II',
R.sup.16 and R.sup.17 are H; and R.sup.18 and R.sup.19 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.20, --S(O).sub.2--R.sup.21, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.16 and R.sup.17 are H; and R.sup.18 and R.sup.19
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, or --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.16 and R.sup.17 are
H; and R.sup.18 and R.sup.19 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. All other variables are as
defined herein.
[0248] In some embodiments of compounds of Formulae II and II',
R.sup.16 and R.sup.18 are H; and R.sup.17 and R.sup.19 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.20--S(O).sub.2--R.sup.21--N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.16 and R.sup.18 are H; and R.sup.17 and R.sup.19
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.16 and R.sup.18 are
H; and R.sup.17 and R.sup.19 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.16
and R.sup.18 are H; and R.sup.17 and R.sup.19 are independently
--CF.sub.3 or --O--CH.sub.3. All other variables are as defined
herein.
[0249] In some embodiments of compounds of Formulae II and II',
R.sup.16 and R.sup.19 are H; and R.sup.17 and R.sup.18 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.20, --S(O).sub.2--R.sup.21, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.16 and R.sup.19 are H; and R.sup.17 and R.sup.18
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.16 and R.sup.19 are
H; and R.sup.17 and R.sup.18 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.16
and R.sup.19 are H; and R.sup.17 and R.sup.18 are independently --F
or --O--CH.sub.3. All other variables are as defined herein.
[0250] In some embodiments of compounds of Formulae II and II',
R.sup.17 and R.sup.18 are H; and R.sup.16 and R.sup.19 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.20, --S(O).sub.2--R.sup.21, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.17 and R.sup.18 are H; and R.sup.16 and R.sup.19
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.17 and R.sup.18 are
H; and R.sup.16 and R.sup.19 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. All other variables are as
defined herein.
[0251] In some embodiments of compounds of Formula II, R.sup.17 and
R.sup.19 are H; and R.sup.16 and R.sup.18 are independently --F,
--Cl, --Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --N(H)--R.sup.22, --N(R.sup.22).sub.2, or
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.17 and
R.sup.19 are H; and R.sup.16 and R.sup.18 are independently --F,
--Cl, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)--R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.17 and R.sup.19 are H; and R.sup.16 and R.sup.18
are independently --F, --Cl, CF.sub.3, --O--CH.sub.3, or
--N(CH.sub.3).sub.2. In some embodiments R.sup.17 and R.sup.19 are
H; and R.sup.16 and R.sup.18 are independently --F, --Cl, or
--O--CH.sub.3. All other variables are as defined herein.
[0252] In some embodiments of compounds of Formulae II and II',
R.sup.18 and R.sup.19 are H; and R.sup.16 and R.sup.17 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.20, --S(O).sub.2--R.sup.21, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.18 and R.sup.19 are H; and R.sup.16 and R.sup.17
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.18 and R.sup.19 are
H; and R.sup.16 and R.sup.17 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.18
and R.sup.19 are H; and R.sup.16 and R.sup.17 are independently
--CF.sub.3, --O--CH.sub.3, or --N(CH.sub.3).sub.2. All other
variables are as defined herein.
[0253] In some embodiments, compounds having the structure
according to the following Formula IIa are provided:
##STR00019##
or a salt, a prodrug, a tautomer or a stereoisomer thereof,
[0254] wherein: [0255] R.sup.16, R.sup.17, R.sup.18 and R.sup.19
are independently selected from the group consisting of --H, --F,
--Cl, --Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --S(O).sub.2--N(H)--R.sup.22,
--N(H)--R.sup.22, --N(R.sup.22).sub.2, and
--N(H)--S(O).sub.2--R.sup.23, provided that at least two of
R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are --H; [0256] R.sup.20
is lower alkyl, fluoro substituted lower alkyl, methoxy substituted
lower alkyl, or cycloalkyl; [0257] R.sup.21 is lower alkyl; [0258]
R.sup.22 is lower alkyl; and [0259] R.sup.23 is lower alkyl.
[0260] In some embodiments of compounds of Formula IIa, R.sup.16,
R.sup.17, R.sup.18 and R.sup.19 are each independently from the
group consisting of --H, --F, --Cl, --Br, lower alkyl, fluoro
substituted lower alkyl, methoxy substituted lower alkyl,
cycloalkylamino, --CN, --O--R.sup.20, --S(O).sub.2--R.sup.21,
--S(O).sub.2--N(H)--R.sup.22, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, and --N(H)--S(O).sub.2--R.sup.23, provided
that at least two of R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are
--H. In some embodiments, R.sup.17 and R.sup.19 are H, halogen or
lower alkyl. All other variables are as defined herein.
[0261] In other embodiments of compounds of Formula IIa, R.sup.16,
R.sup.17, R.sup.18 and R.sup.19 are each independently selected
from H, halogen, lower alkyl, lower alkoxy, halo substituted lower
alkyl, --OR.sup.20, or alkoxy substituted lower alkyl, provided
that at least two of R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are
--H. All other variables are as defined herein.
[0262] In some embodiments of compounds of Formula IIa, R.sup.16,
R.sup.17, and R.sup.18 are H and R.sup.19 is --F, --Cl, --Br, lower
alkyl, fluoro substituted lower alkyl, methoxy substituted lower
alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --N(H)--R.sup.22, --N(R.sup.22).sub.2, or
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.16,
R.sup.17, and R.sup.18 are H and R.sup.19 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)--R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.16, R.sup.17, and R.sup.18 are H and R.sup.19 is
fluoro substituted lower alkyl or --O--R.sup.20. In some
embodiments R.sup.16, R.sup.17, and R.sup.18 are H and R.sup.19 is
--CF.sub.3 or --O--CH.sub.3. All other variables are as defined
herein.
[0263] In some embodiments of compounds of Formula IIa, R.sup.16,
R.sup.17, and R.sup.19 are H and R.sup.18 is --F, --Cl, --Br, lower
alkyl, fluoro substituted lower alkyl, methoxy substituted lower
alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --N(H)--R.sup.22, --N(R.sup.22).sub.2, or
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.16,
R.sup.17, and R.sup.19 are H and R.sup.18 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)--R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.16, R.sup.17, and R.sup.19 are H and R.sup.18 is
--F, --Cl, or --O--R.sup.20. In some embodiments R.sup.16,
R.sup.17, and R.sup.19 are H and R.sup.18 is --F, --Cl, or
--O--CH.sub.3. All other variables are as defined herein.
[0264] In some embodiments of compounds of Formula IIa, R.sup.16,
R.sup.18, and R.sup.19 are H and R.sup.17 is --F, --Cl, --Br, lower
alkyl, fluoro substituted lower alkyl, methoxy substituted lower
alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --N(H)--R.sup.22, --N(R.sup.22).sub.2, or
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.16,
R.sup.18, and R.sup.19 are H and R.sup.17 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)--R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.16, R.sup.18, and R.sup.19 are H and R.sup.17 is
--Cl, fluoro substituted lower alkyl, cycloalkylamino, or
--O--R.sup.20. In some embodiments R.sup.16, R.sup.18, and R.sup.19
are H and R.sup.17 is --Cl, --CF.sub.3, --O--CH.sub.3, or
morpholin-4-yl. All other variables are as defined herein.
[0265] In some embodiments of compounds of Formula IIa, R.sup.17,
R.sup.18, and R.sup.19 are H and R.sup.16 is --F, --Cl, --Br, lower
alkyl, fluoro substituted lower alkyl, methoxy substituted lower
alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --N(H)--R.sup.22, --N(R.sup.22).sub.2, or
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.17,
R.sup.18, and R.sup.19 are H and R.sup.16 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)--R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.17, R.sup.18, and R.sup.19 are H and R.sup.16 is
--F, --CF.sub.3, morpholin-4-yl, --O--CH.sub.3,
--O--CH.sub.2CH.sub.3, --O--CH(CH.sub.3).sub.2,
--O--CH.sub.2CF.sub.3, --O-cyclopentyl, --O-cyclohexyl, or
--N(H)--CH.sub.3. In some embodiments R.sup.17, R.sup.18, and
R.sup.19 are H and R.sup.16 is --F, --CF.sub.3, or --O--CH.sub.3.
All other variables are as defined herein.
[0266] In some embodiments of compounds of Formula IIa, R.sup.16
and R.sup.17 are H; and R.sup.18 and R.sup.19 are independently
--F, --Cl, --Br, lower alkyl, fluoro substituted lower alkyl,
methoxy substituted lower alkyl, cycloalkylamino, --CN,
--O--R.sup.20, --S(O).sub.2--R.sup.21,
--N(H)--S(O).sub.2--R.sup.23. In some embodiments R.sup.16 and
R.sup.17 are H; and R.sup.18 and R.sup.19 are independently --F,
--Cl, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.20, --N(H)--R.sup.22, or --N(R.sup.22).sub.2. In some
embodiments R.sup.16 and R.sup.17 are H; and R.sup.18 and R.sup.19
are independently --F, --Cl, CF.sub.3, --O--CH.sub.3, or
--N(CH.sub.3).sub.2. All other variables are as defined herein.
[0267] In some embodiments of compounds of Formula IIa, R.sup.16
and R.sup.18 are H; and R.sup.17 and R.sup.19 are independently
--F, --Cl, --Br, lower alkyl, fluoro substituted lower alkyl,
methoxy substituted lower alkyl, cycloalkylamino, --CN,
--O--R.sup.20, --S(O).sub.2--R.sup.21, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.16 and R.sup.18 are H; and R.sup.17 and R.sup.19
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.16 and R.sup.18 are
H; and R.sup.17 and R.sup.19 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.16
and R.sup.18 are H; and R.sup.17 and R.sup.19 are independently
--CF.sub.3 or --O--CH.sub.3. All other variables are as defined
herein.
[0268] In some embodiments of compounds of Formula IIa, R.sup.16
and R.sup.19 are H; and R.sup.17 and R.sup.18 are independently
--F, --Cl, --Br, lower alkyl, fluoro substituted lower alkyl,
methoxy substituted lower alkyl, cycloalkylamino, --CN,
--O--R.sup.20, --S(O).sub.2--R.sup.21, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.16 and R.sup.19 are H; and R.sup.17 and R.sup.18
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.16 and R.sup.19 are
H; and R.sup.17 and R.sup.18 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.16
and R.sup.19 are H; and R.sup.17 and R.sup.18 are independently --F
or --O--CH.sub.3. All other variables are as defined herein.
[0269] In some embodiments of compounds of Formula IIa, R.sup.17
and R.sup.18 are H; and R.sup.16 and R.sup.19 are independently
--F, --Cl, --Br, lower alkyl, fluoro substituted lower alkyl,
methoxy substituted lower alkyl, cycloalkylamino, --CN,
--O--R.sup.20, --S(O).sub.2--R.sup.21, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.17 and R.sup.18 are H; and R.sup.16 and R.sup.19
are independently --F, --Cl, lower alkyl, fluoro, substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.17 and R.sup.18 are
H; and R.sup.16 and R.sup.19 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. All the other variables are
as defined herein.
[0270] In some embodiments of compounds of Formula IIa, R.sup.17
and R.sup.19 are H; and R.sup.16 and R.sup.18 are independently
--F, --Cl, --Br, lower alkyl, fluoro substituted lower alkyl,
methoxy substituted lower alkyl, cycloalkylamino, --CN,
--O--R.sup.20, --S(O).sub.2--R.sup.21, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.17 and R.sup.19 are H; and R.sup.16 and R.sup.18
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.17 and R.sup.19 are
H; and R.sup.16 and R.sup.18 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.17
and R.sup.19 are H; and R.sup.16 and R.sup.18 are independently
--F, --Cl, or --O--CH.sub.3. All the other variables are as defined
herein.
[0271] In some embodiments of compounds of Formula IIa, R.sup.18
and R.sup.19 are H; and R.sup.16 and R.sup.17 are independently
--F, --Cl, --Br, lower alkyl, fluoro substituted lower alkyl,
methoxy substituted lower alkyl, cycloalkylamino, --CN,
--O--R.sup.20, --S(O).sub.2--R.sup.21, --N(H)--R.sup.22,
--N(R.sup.22).sub.2, or --N(H)--S(O).sub.2--R.sup.23. In some
embodiments R.sup.18 and R.sup.19 are H; and R.sup.16 and R.sup.17
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.20, --N(H)--R.sup.22, or
--N(R.sup.22).sub.2. In some embodiments R.sup.18 and R.sup.19 are
H; and R.sup.16 and R.sup.17 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.18
and R.sup.19 are H; and R.sup.16 and R.sup.17 are independently
--CF.sub.3, --O--CH.sub.3, or --N(CH.sub.3).sub.2. All the other
variables are as defined herein.
[0272] In one embodiment of compounds of Formulae II and II' and
IIa, the compound is selected from the group consisting of: [0273]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-2027), [0274]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-2029), [0275]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2031), [0276]
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2047), [0277]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2048), [0278]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2049), [0279]
(4-Chloro-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyridin-2-yl]-amine (P-2050), [0280]
(2-Chloro-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyridin-2-yl]-amine (P-2051), [0281]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-2052), [0282]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
[(S)-1-(4-fluoro-phenyl)-ethyl]-amine (P-2058), [0283]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2062), [0284]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-4-ylmethyl)-amine (P-2065), [0285]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methyl-pyridin-4-ylmethyl)-amine (P-2067), [0286]
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2071), [0287]
(2,5-Dimethoxy-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyridin-2-yl]-amine (P-2086), [0288]
(3,5-Dimethoxy-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyridin-2-yl]-amine (P-2087), [0289]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2088), [0290]
(3-Bromo-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyridin-2-yl]-amine (P-2089), [0291]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-morpholin-4-yl-pyridin-3-ylmethyl)-amine (P-2090), [0292]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-morpholin-4-yl-pyridin-3-ylmethyl)-amine (P-2091), [0293]
(3-Chloro-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2092), [0294]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-2-ylmethyl)-amine (P-2093), [0295]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(3-fluoro-pyridin-4-ylmethyl)-amine (P-2094), [0296]
(5-{[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2--
ylamino]-methyl}-pyrimidin-2-yl)-methyl-amine (P-2095), [0297]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
[2-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylmethyl]-amine (P-2096),
[0298]
(2,6-Dimethoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b-
]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2097), [0299]
(5-Fluoro-2-methanesulfonyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3--
b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2098), [0300]
(5-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2099), [0301]
(5-Bromo-pyridin-2-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyridin-2-yl]-amine (P-2100), [0302]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(3-methyl-pyridin-4-ylmethyl)-amine (P-2101), [0303]
(3-Chloro-5-fluoro-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-
-3-ylmethyl)-pyridin-2-yl]-amine (P-2102), [0304]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-fluoro-pyridin-3-ylmethyl)-amine (P-2103), [0305]
(3,5-Dimethyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-2104), [0306]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-methoxy-pyridin-3-ylmethyl)-amine (P-2105), [0307]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methyl-pyrimidin-5-ylmethyl)-amine (P-2106), [0308]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methylamino-pyridin-3-ylmethyl)-amine (P-2107), [0309]
(3,5-Bis-trifluoromethyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]p-
yridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2108), [0310]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-methoxy-pyridin-3-ylmethyl)-amine (P-2109), [0311]
(2-Ethoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2110), [0312]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-isopropoxy-pyridin-3-ylmethyl)-amine (P-2111), [0313]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-methyl-pyridin-2-ylmethyl)-amine (P-2112), [0314]
(2-Cyclopentyloxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,-
3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2113), [0315]
(2-Cyclohexyloxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-
-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2114), [0316]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2115), [0317]
(2-Chloro-5-fluoro-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2116), [0318]
4-{[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y-
lamino]-methyl}-pyridine-2-carbonitrile (P-2117), [0319]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-fluoro-pyridin-4-ylmethyl)-amine (P-2118), [0320]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-trifluoromethyl-pyridin-4-ylmethyl)-amine (P-2119), [0321]
(2-Chloro-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2120), [0322]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-morpholin-4-yl-pyridin-4-ylmethyl)-amine (P-2121), [0323]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-pyrrolidin-1-yl-pyridin-4-ylmethyl)-amine (P-2122), [0324]
(5-Chloro-2-fluoro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2123), [0325]
(4-Chloro-2-methane
sulfonyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-yl]-amine (P-2124), [0326]
(2-Dimethylamino-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-
-ylmethyl)-pyridin-2-yl]-amine (P-2125), [0327]
(2-Ethyl-pyrimidin-5-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2126), [0328]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-propyl-pyrimidin-5-ylmethyl)-amine (P-2127), [0329]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-isopropyl-pyrimidin-5-ylmethyl)-amine (P-2128), [0330]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
[2-(2-methoxy-ethyl)-pyrimidin-5-ylmethyl]-amine (P-2129), [0331]
(2-Butyl-pyrimidin-5-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2130), [0332]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-methyl-pyridin-2-ylmethyl)-amine (P-2131), [0333]
(3-Fluoro-5-methyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-
-3-ylmethyl)-pyridin-2-yl]-amine (P-2132), [0334]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(3-methoxy-5-trifluoromethyl-benzyl)-amine (P-2133), [0335]
(3-Fluoro-5-methoxy-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl)-pyridin-2-yl]-amine (P-2134), [0336]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(3,4,5-trimethoxy-benzyl)-amine (P-2150), [0337]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-pyrrolidin-1-yl-pyridin-2-ylmethyl)-amine (P-2151), [0338]
5-Fluoro-3-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
ridin-2-ylamino]-methyl}-1-methyl-1H-pyridin-2-one (P-2156), [0339]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-2165), [0340]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2166),
[0341]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-dimethylamino-6-trifluoromethyl-pyridin-3-ylmethyl)-amine
(P-2167), [0342]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-
-2-yl]-(6-methoxy-4-trifluoromethyl-pyridin-3-ylmethyl)-amine
(P-2186), [0343] Ethanesulfonic
acid(2-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridi-
n-2-ylamino]-methyl}-phenyl)-amide (P-2198), [0344] Ethanesulfonic
acid(4-fluoro-3-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-ylamino]-methyl}-phenyl)-amide (P-2199), [0345]
Ethanesulfonic
acid(3-fluoro-5-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-ylamino]-methyl}-phenyl)-amide (P-2202), [0346]
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-fluoro-6-
-methoxy-3-pyridyl)methyl]pyridin-2-amine (P-2203), [0347]
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204), [0348]
6-chloro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine (P-2205), [0349]
6-fluoro-N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-5-[[5-(trifluoromethyl)-
-1H-pyrrolo[2,3-b]pyridin-3-yl]methyl]pyridin-2-amine (P-2206), and
any salt, prodrug, tautomer, or stereoisomer thereof.
[0350] In a third aspect, the invention provides compounds having
Formula III':
##STR00020##
or a salt, a prodrug, a tautomer or a stereoisomer thereof,
[0351] wherein: [0352] R.sup.24, R.sup.25, R.sup.26 and R.sup.27
are each independently selected from the group consisting of --H,
halogen, lower alkyl, lower alkoxy, halo substituted lower alkyl,
lower alkoxy, alkoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.28, --S(O).sub.2--R.sup.29,
--S(O).sub.2--N(H)--R.sup.30, --N(H)--R.sup.30,
--N(R.sup.30).sub.2, and --N(H)--S(O).sub.2--R.sup.31, provided
that at least two of R.sup.24, R.sup.25, R.sup.26 and R.sup.27 are
--H; R.sup.28 is lower alkyl, fluoro substituted lower alkyl,
methoxy substituted lower alkyl, or cycloalkyl; R.sup.29 is lower
alkyl; R.sup.30 is lower alkyl; and R.sup.31 is lower alkyl.
[0353] In some embodiments of compounds of Formula III', R.sup.6 is
selected from the group consisting of halogen, lower alkyl, lower
alkoxy, fluoro substituted lower alkyl, lower alkenyl, lower
alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.13,
--C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl. In other embodiments of compounds of Formula
III', R.sup.6 is F, Cl, Br, lower alkyl, fluoro substituted lower
alkyl, lower alkenyl, --CN, --C(O)--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14 or
--N(H)--S(O).sub.2--R.sup.15. In some embodiments, R.sup.6 is
methyl, ethyl, propyl, butyl, pentyl or hexyl. All other variables
are as defined herein.
[0354] In some embodiments, compounds having the structure
according to the following Formula III are provided:
##STR00021##
or a salt, a prodrug, a tautomer or a stereoisomer thereof,
[0355] wherein: [0356] R.sup.24, R.sup.25, R.sup.26 and R.sup.27
are independently selected from the group consisting of --H, --F,
--Cl, --Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.28,
--S(O).sub.2--R.sup.29, --S(O).sub.2--N(H)--R.sup.30,
--N(H)--R.sup.30, --N(R.sup.30).sub.2, and
--N(H)--S(O).sub.2--R.sup.31, provided that at least two of
R.sup.24, R.sup.25, R.sup.26 and R.sup.27 are --H; [0357] R.sup.28
is lower alkyl, fluoro substituted lower alkyl, methoxy substituted
lower alkyl, or cycloalkyl; [0358] R.sup.29 is lower alkyl; [0359]
R.sup.30 is lower alkyl; and [0360] R.sup.31 is lower alkyl.
[0361] In some embodiments of compounds of Formulae III and III'
R.sup.24, R.sup.25, R.sup.26 and R.sup.27 are each independently
selected from the group consisting of --H, --F, --Cl, --Br, lower
alkyl, fluoro substituted lower alkyl, lower alkoxy, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.20,
--S(O).sub.2--R.sup.21, --S(O).sub.2--N(H)--R.sup.22,
--N(H)--R.sup.22, --N(R.sup.22).sub.2, and
--N(H)--S(O).sub.2--R.sup.23, provided that at least two of
R.sup.24, R.sup.25, R.sup.26 and R.sup.27 are --H. In some
embodiments, R.sup.24, R.sup.25, R.sup.26 and R.sup.27 are each
independently selected from H, halogen, lower alkyl, lower alkoxy,
halo substituted lower alkyl, --OR.sup.20, or alkoxy substituted
lower alkyl. All other variables are as defined herein.
[0362] In some embodiments of compounds of Formulae III and III',
R.sup.24, R.sup.25, and R.sup.26 are H and R.sup.27 is --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.28,
--S(O).sub.2--R.sup.29, --N(H)--R.sup.30, --N(R.sup.30).sub.2, or
--N(H)--S(O).sub.2--R.sup.31. In some embodiments R.sup.24,
R.sup.25, and R.sup.26 are H and R.sup.27 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.28, --N(H)--R.sup.30, or --N(R.sup.30).sub.2. In some
embodiments R.sup.24, R.sup.25, and R.sup.26 are H and R.sup.27 is
fluoro substituted lower alkyl or --O--R.sup.28. In some
embodiments R.sup.24, R.sup.25, and R.sup.26 are H and R.sup.27 is
--CF.sub.3 or --O--CH.sub.3. All other variables are as defined
herein.
[0363] In some embodiments of compounds of Formulae III and III',
R.sup.24, R.sup.25, and R.sup.27 are H and R.sup.26 is --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.28,
--S(O).sub.2--R.sup.29, --N(H)--R.sup.30, --N(R.sup.30).sub.2, or
--N(H)--S(O).sub.2--R.sup.31. In some embodiments R.sup.24,
R.sup.25, and R.sup.27 are H and R.sup.26 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.28, --N(H)--R.sup.30, or --N(R.sup.30).sub.2. In some
embodiments R.sup.24, R.sup.25, and R.sup.27 are H and R.sup.26 is
--F, --Cl, or --O--R.sup.28. In some embodiments R.sup.24,
R.sup.25, and R.sup.27 are H and R.sup.26 is --F, --Cl, or
--O--CH.sub.3. All other variables are as defined herein.
[0364] In some embodiments of compounds of Formulae III and III',
R.sup.24, R.sup.26, and R.sup.27 are H and R.sup.25 is --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.28,
--S(O).sub.2--R.sup.29, --N(H)--R.sup.30, --N(R.sup.30).sub.2, or
--N(H)--S(O).sub.2--R.sup.31. In some embodiments R.sup.24,
R.sup.26, and R.sup.27 are H and R.sup.25 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.28, --N(H)--R.sup.30, or --N(R.sup.30).sub.2. In some
embodiments R.sup.24, R.sup.26, and R.sup.27 are H and R.sup.25 is
--Cl, fluoro substituted lower alkyl, cycloalkylamino, or
--O--R.sup.28. In some embodiments R.sup.24, R.sup.26, and R.sup.27
are H and R.sup.25 is --Cl, --CF.sub.3, --O--CH.sub.3, or
4-methyl-piperazin-1-yl. All other variables are as defined
herein.
[0365] In some embodiments of compounds of Formulae III and III',
R.sup.25, R.sup.26, and R.sup.27 are H and R.sup.24 is --F, --Cl,
--Br, lower alkyl, fluoro substituted lower alkyl, methoxy
substituted lower alkyl, cycloalkylamino, --CN, --O--R.sup.28,
--S(O).sub.2--R.sup.29, --N(H)--R.sup.30, --N(R.sup.30).sub.2, or
--N(H)--S(O).sub.2--R.sup.31. In some embodiments R.sup.25,
R.sup.26, and R.sup.27 are H and R.sup.24 is --F, --Cl, lower
alkyl, fluoro substituted lower alkyl, cycloalkylamino,
--O--R.sup.28, --N(H)--R.sup.30, or --N(R.sup.30).sub.2. In some
embodiments R.sup.25, R.sup.26, and R.sup.27 are H and R.sup.24 is
--F, --CF.sub.3, morpholin-4-yl, --O--CH.sub.3,
--O--CH.sub.2CH.sub.3, --O--CH(CH.sub.3).sub.2,
--O--CH.sub.2CF.sub.3, --O-cyclopentyl, --O-cyclohexyl, or
--N(H)--CH.sub.3. In some embodiments R.sup.25. R.sup.26, and
R.sup.27 are H and R.sup.24 is --F, --CF.sub.3, --O--CH.sub.3,
--O--CH.sub.2CH.sub.3, or --O-cyclopentyl. All other variables are
as defined herein.
[0366] In some embodiments of compounds of Formulae III and III',
R.sup.24 and R.sup.25 are H; and R.sup.26 and R.sup.27 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.28, --S(O).sub.2--R.sup.29, --N(H)--R.sup.30,
--N(R.sup.30).sub.2, or --N(H)--S(O).sub.2--R.sup.31. In some
embodiments R.sup.24 and R.sup.25 are H; and R.sup.26 and R.sup.27
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.28, --N(H)--R.sup.30, or
--N(R.sup.30).sub.2. In some embodiments R.sup.24 and R.sup.25 are
H; and R.sup.26 and R.sup.27 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. All other variables are as
defined herein.
[0367] In some embodiments of compounds of Formulae III and III',
R.sup.24 and R.sup.26 are H; and R.sup.25 and R.sup.27 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.28, --S(O).sub.2--R.sup.29, --N(H)--R.sup.30,
--N(R.sup.30).sub.2, or --N(H)--S(O).sub.2--R.sup.31. In some
embodiments R.sup.24 and R.sup.26 are H; and R.sup.25 and R.sup.27
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.28, --N(H)--R.sup.30, or
--N(R.sup.30).sub.2. In some embodiments R.sup.24 and R.sup.26 are
H; and R.sup.25 and R.sup.27 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.24
and R.sup.26 are H; and R.sup.25 and R.sup.27 are independently
--CF.sub.3 or --O--CH.sub.3. All other variables are as defined
herein.
[0368] In some embodiments of compounds of Formulae III and III',
R.sup.24 and R.sup.27 are H; and R.sup.25 and R.sup.26 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.28, --S(O).sub.2--R.sup.29, --N(H)--R.sup.30,
--N(R.sup.30).sub.2, or --N(H)--S(O).sub.2--R.sup.31. In some
embodiments R.sup.24 and R.sup.27 are H; and R.sup.25 and R.sup.26
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.28, --N(H)--R.sup.30, or
--N(R.sup.30).sub.2. In some embodiments R.sup.24 and R.sup.27 are
H; and R.sup.25 and R.sup.26 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.24
and R.sup.27 are H; and R.sup.25 and R.sup.26 are independently --F
or --O--CH.sub.3. All other variables are as defined herein.
[0369] In some embodiments of compounds of Formulae III and III',
R.sup.25 and R.sup.26 are H; and R.sup.24 and R.sup.27 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.28, --S(O).sub.2--R.sup.29, --N(H)--R.sup.30,
--N(R.sup.30).sub.2, or --N(H)--S(O).sub.2--R.sup.31. In some
embodiments R.sup.25 and R.sup.26 are H; and R.sup.24 and R.sup.27
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.28, --N(H)--R.sup.30, or
--N(R.sup.30).sub.2. In some embodiments R.sup.25 and R.sup.26 are
H; and R.sup.24 and R.sup.27 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. All other variables are as
defined herein.
[0370] In some embodiments of compounds of Formulae III and III',
R.sup.25 and R.sup.27 are H; and R.sup.24 and R.sup.26 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.28, --S(O).sub.2--R.sup.29, --N(H)--R.sup.30,
--N(R.sup.30).sub.2, or --N(H)--S(O).sub.2--R.sup.31. In some
embodiments R.sup.25 and R.sup.27 are H; and R.sup.24 and R.sup.26
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.28, --N(H)--R.sup.30, or
--N(R.sup.30).sub.2. In some embodiments R.sup.25 and R.sup.27 are
H; and R.sup.24 and R.sup.26 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.25
and R.sup.27 are H; and R.sup.24 and R.sup.26 are independently --F
or --O--CH.sub.3. All other variables are as defined herein.
[0371] In some embodiments of compounds of Formulae III and III',
R.sup.26 and R.sup.27 are H; and R.sup.24 and R.sup.25 are
independently --F, --Cl, --Br, lower alkyl, fluoro substituted
lower alkyl, methoxy substituted lower alkyl, cycloalkylamino,
--CN, --O--R.sup.28, --S(O).sub.2--R.sup.29, --N(H)--R.sup.30,
--N(R.sup.30).sub.2, or --N(H)--S(O).sub.2--R.sup.31. In some
embodiments R.sup.26 and R.sup.27 are H; and R.sup.24 and R.sup.25
are independently --F, --Cl, lower alkyl, fluoro substituted lower
alkyl, cycloalkylamino, --O--R.sup.28, --N(H)--R.sup.30, or
--N(R.sup.30).sub.2. In some embodiments R.sup.26 and R.sup.27 are
H; and R.sup.24 and R.sup.25 are independently --F, --Cl, CF.sub.3,
--O--CH.sub.3, or --N(CH.sub.3).sub.2. In some embodiments R.sup.26
and R.sup.27 are H; and R.sup.24 and R.sup.25 are independently
--CF.sub.3, --O--CH.sub.3, or --N(CH.sub.3).sub.2. All other
variables are as defined herein.
[0372] In one embodiment of compounds of Formulae III and III', the
compound is selected from the group consisting of: [0373]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-1569), [0374]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-1570), [0375]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2057), [0376]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2061), [0377]
(2-Methoxy-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2069), [0378]
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2072), [0379]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2073), [0380]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin-
-2-ylmethyl-amine (P-2076), [0381]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin-
-3-ylmethyl-amine (P-2077), [0382]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2078), [0383]
(6-Methyl-pyridin-2-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2079), [0384]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-2080), [0385]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-morp-
holin-4-yl-pyridin-2-ylmethyl)-amine (P-2081), [0386]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-pyrr-
olidin-1-yl-pyridin-2-ylmethyl)-amine (P-2082), [0387]
(5-Ethyl-pyridin-2-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylme-
thyl)-pyrimidin-2-yl]-amine (P-2083), [0388]
(3-Methyl-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2084), [0389]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-morp-
holin-4-yl-pyridin-4-ylmethyl)-amine (P-2085), [0390]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin-
-4-ylmethyl-amine (P-2138), [0391]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2139), [0392]
[6-(4-Methyl-piperazin-1-yl)-pyridin-3-ylmethyl]-[5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2140), [0393]
(2-Methyl-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2141), [0394]
(2-Ethoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2142), [0395]
(2-Cyclopentyloxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2148), [0396]
(2-Cyclopentyloxy-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2149), and any salt,
prodrug, tautomer, or stereoisomer thereof.
[0397] In a fourth aspect, compounds are provided, wherein the
compound is selected from the group consisting of: [0398]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)pyridin-2-yl]-(2,6-dimet-
hoxy-pyridin-3-ylmethyl)-amine (P-1496), [0399]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-pyridin-3-ylmethyl)-amine (P-1507), [0400]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methox-
y-pyridin-3-ylmethyl)-amine (P-1511), [0401]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-1512), [0402]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
rimidin-2-yl]-amine (P-1514), [0403]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p-
yrimidin-2-yl]-amine (P-1517), [0404]
[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-trifluorometh-
yl-pyridin-3-ylmethyl)-amine (P-1518), [0405]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p-
yrimidin-2-yl]-amine (P-1519), [0406]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-
-pyridin-3-ylmethyl)-amine (P-1522), [0407]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-3-ylmethyl)-amine (P-1526), [0408]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-1527), [0409]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-1530), [0410]
(6-Methoxy-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1532), [0411]
(5-Fluoro-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1534), [0412]
[6-Methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1538), [0413]
(2-Methoxy-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1539), [0414]
[6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-1541), [0415]
[6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-1545), [0416]
[6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-1546), [0417]
(5-Fluoro-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1549), [0418]
[3-Methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-1552), [0419]
[3-Methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(2-methoxy-pyridin-3-ylmethyl)-amine (P-1553), [0420]
(6-Methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1554), [0421]
(5-Fluoro-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1556), [0422]
[3-Methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1560), [0423]
(2-Methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1561), [0424]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-1562), [0425]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-1564), [0426]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-1568), [0427]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-thiazol-2-yl]-amine (P-1580), [0428]
[5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine (P-1583), [0429]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1585), [0430]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyridin-2-yl]-amine (P-1589), [0431]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(5-fluoro-pyridin-3-ylmethyl)-amine (P-1591), [0432]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-1595), [0433]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(2-methoxy-pyridin-3-ylmethyl)-amine (P-1596), [0434]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-1601), [0435]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyrimidin-2-yl]-amine (P-1604), [0436]
[5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-tri-
fluoromethyl-pyridin-3-ylmethyl)-amine (P-1605), [0437]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyrimidin-2-yl]-amine (P-1606), [0438]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-1609), [0439]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-meth-
oxy-pyridin-3-ylmethyl)-amine (P-1614), [0440]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-1622), [0441]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-1624), [0442]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1628), [0443]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-1629), [0444]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-1631), [0445]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-meth-
oxy-pyridin-3-ylmethyl)-amine (P-1635), [0446]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-1636), [0447]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-meth-
oxy-pyridin-3-ylmethyl)-amine (P-1637), [0448]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1639), [0449]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1643), [0450]
(6-Trifluoromethyl-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1644), [0451]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1645), [0452]
(5-Fluoro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1647), [0453]
[6-Fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amine (P-1651), [0454]
[6-Fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1652),
[0455]
[6-Fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(2-methoxy-pyridin-3-ylmethyl)-amine (P-1653), [0456]
3-{2-Fluoro-6-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1658), [0457]
3-{2-Fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-
methyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1659), [0458]
3-{2-Fluoro-6-[(2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1660), [0459]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-f-
luoro-pyridin-3-ylmethyl)-amine (P-1662), [0460]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-m-
ethoxy-pyridin-3-ylmethyl)-amine (P-1666), [0461]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-t-
rifluoromethyl-pyridin-3-ylmethyl)-amine (P-1667), [0462]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-m-
ethoxy-pyridin-3-ylmethyl)-amine (P-1668), [0463]
N-(3-{2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl-
}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1671), [0464]
N-(3-{2-Fluoro-6-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethy-
l}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1674), [0465]
N-(3-{2-Fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-
-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1675),
[0466]
N-(3-{2-Fluoro-6-[(2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethy-
l}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1676), [0467]
N-(3-{2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl-
}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide (P-1678),
[0468]
N-(3-{2-Fluoro-6-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethy-
l}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide (P-1682),
[0469]
N-(3-{2-Fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-
-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1683), [0470]
N-(3-{2-Fluoro-6-[(2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3--
ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1684), [0471] [6-Fluoro-5-(5-methane
sulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-pyr-
idin-3-ylmethyl)-amine (P-1686), [0472] [6-Fluoro-5-(5-methane
sulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-py-
ridin-3-ylmethyl)-amine (P-1690), [0473] [6-Fluoro-5-(5-methane
sulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluorom-
ethyl-pyridin-3-ylmethyl)-amine (P-1691), [0474]
[6-Fluoro-5-(5-methane
sulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methoxy-py-
ridin-3-ylmethyl)-amine (P-1692), [0475]
3-{2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1-
H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide (P-1695),
[0476]
3-{2-Fluoro-6-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide (P-1699),
[0477]
3-{2-Fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-
methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide
(P-1700), [0478]
3-{2-Fluoro-6-[(2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylm-
ethyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide
(P-1701), [0479]
4-[4-(3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino-
]-pyridin-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrazol-1-yl]-piperid-
ine-1-carboxylic acid tert-butyl ester (P-1702), [0480]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl]-pyridin-2-yl}-(5-fluoro-pyridin-3-ylmethyl)-amine
(P-1705), [0481]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b-
]pyridin-3-ylmethyl]-pyridin-2-yl}-(6-methoxy-pyridin-3-ylmethyl)-amine
(P-1708), [0482]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl]-pyridin-2-yl}-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine
(P-1709), [0483]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl]-pyridin-2-yl}-(2-methoxy-pyridin-3-ylmethyl)-amine
(P-1710), [0484]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(-
5-fluoro-pyridin-3-ylmethyl)-amine (P-1712), [0485]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-metho-
xy-pyridin-3-ylmethyl)-amine (P-1716), [0486]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine (P-1717), [0487]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-metho-
xy-pyridin-3-ylmethyl)-amine (P-1718), [0488]
3-{6-[(5-Fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo-
[2,3-b]pyridine-4-carbonitrile (P-1719), [0489]
3-{6-[(6-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrol-
o[2,3-b]pyridine-4-carbonitrile (P-1723), [0490]
3-{6-[(6-Trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1-
H-pyrrolo[2,3-b]pyridine-4-carbonitrile (P-1724), [0491]
3-{6-[(2-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrol-
o[2,3-b]pyridine-4-carbonitrile (P-1725), [0492]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(5-fluoro-pyridin-3-ylmethyl)-amine (P-1727), [0493]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyri-
midin-5-ylmethyl)-pyridin-2-yl]-amine (P-1728), [0494]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(4-methyl-7H-pyrrolo[-
2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl]-amine (P-1729), [0495]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1730), [0496]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(6-methoxy-pyridin-3-ylmethyl)-amine (P-1731), [0497]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1732), [0498]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(4-methyl-7H-pyrrolo[-
2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl]-amine (P-1733), [0499]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(2-methoxy-pyridin-3-ylmethyl)-amine (P-1734), [0500]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-2001), [0501]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[(S)-1--
(4-fluoro-phenyl)-ethyl]-amine (P-2005), [0502]
(3-Chloro-benzyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-met-
hyl-1H-pyrazol-3-yl]-amine (P-2006), [0503]
(3-Chloro-4-methyl-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyrimidin-2-yl]-amine (P-2007), [0504]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3,4-di-
fluoro-benzyl)-amine (P-2008), [0505]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluo-
ro-5-trifluoromethyl-benzyl)-amine (P-2009), [0506]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-trif-
luoromethoxy-benzyl)-amine (P-2010), [0507]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluo-
ro-4-trifluoromethyl-benzyl)-amine (P-2011), [0508]
(4-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrim-
idin-2-yl]-methyl-amine (P-2012), [0509]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-meth-
yl-benzyl)-amine (P-2013), [0510]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluo-
ro-4-methyl-benzyl)-amine (P-2014), [0511]
[2-(3-Chloro-phenyl)-ethyl]-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyrimidin-2-yl]-amine (P-2015), [0512]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1H-pyrazol-3-yl]-(4-flu-
oro-benzyl)-amine (P-2016), [0513]
[5-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-
-pyridin-3-ylmethyl)-amine (P-2017),
[0514]
[5-(4-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(-
6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2018), [0515]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2019), [0516]
[2-(2-Chloro-phenyl)-ethyl]-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyrimidin-2-yl]-amine (P-2020), [0517]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[2-(4-f-
luoro-phenyl)-ethyl]-amine (P-2021), [0518]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[2-(6-m-
ethyl-pyridin-2-yl)-ethyl]-amine (P-2022), [0519]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2023), [0520]
[5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine (P-2024), [0521]
Butyl-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-a-
mine (P-2026), [0522]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(5-fluoro-pyridin-3-ylmethyl)-amine (P-2028), [0523]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-2030), [0524]
(4-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2032), [0525]
(2-Fluoro-benzyl)-[5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyri-
din-2-yl]-amine (P-2033), [0526]
(2-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2034), [0527]
(2-Chloro-benzyl)-[6-fluoro-5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2035), [0528]
(2-Chloro-benzyl)-[5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyri-
din-2-yl]-amine (P-2036), [0529]
(4-Chloro-benzyl)-[6-fluoro-5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2037), [0530]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-meth-
oxy-pyridin-3-ylmethyl)-amine (P-2038), [0531]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(1-thia-
zol-2-yl-ethyl)-amine (P-2039), [0532]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(2-methoxy-pyridin-3-ylmethyl)-amine (P-2043), [0533]
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2044), [0534]
[6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-2045), [0535]
[1-(4-Fluoro-phenyl)-propyl]-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylme-
thyl)-pyrimidin-2-yl]-amine (P-2053), [0536]
[1-(4-Fluoro-phenyl)-cyclopropyl]-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-
-ylmethyl)-pyrimidin-2-yl]-amine (P-2055), [0537]
[(S)-1-(4-Fluoro-phenyl)-ethyl]-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyrimidin-2-yl]-amine (P-2056), [0538]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-meth-
oxy-pyridin-4-ylmethyl)-amine (P-2074), [0539]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(2-methyl-pyridin-4-ylmethyl)-amine (P-2075), [0540]
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2135), [0541]
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2136), [0542]
[3-Methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2143), [0543]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2144), [0544]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2145), [0545]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2146), [0546]
[3-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2147), [0547]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-3-ylmethyl)-amine (P-2154), [0548]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-thiazol-2-yl]-amine (P-2155), [0549]
3-{[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-ylamino]-
-methyl}-5-fluoro-1-methyl-1H-pyridin-2-one (P-2157), [0550]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-2158), [0551]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-thiazol-2-yl]-amine (P-2159), [0552]
(6-Methoxy-pyridin-2-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-thiazol-2-yl]-amine (P-2162), [0553]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-2-ylmethyl)-amine (P-2163), [0554]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2,6-dime-
thoxy-pyridin-3-ylmethyl)-amine (P-2164), [0555]
5-Fluoro-N-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyr-
idin-2-yl]-2-methoxy-nicotinamide (P-2168), [0556]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3-fluoro-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2172), [0557]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-pyridin-3-ylmethyl)-amine (P-2176), [0558]
N-[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl-
]-C-phenyl-methanesulfonamide (P-2181), and any salt, prodrug,
tautomer, or stereoisomer thereof.
[0559] In reference to compounds herein, unless clearly indicated
to the contrary, specification of a compound or group of compounds
includes salts of such compound(s) (including pharmaceutically
acceptable salts), formulations of such compound(s) (including
pharmaceutically acceptable formulations), conjugates thereof,
derivatives thereof, forms thereof, prodrugs thereof, and all
stereoisomers thereof. In reference to compositions, kits, methods
of use, etc. of compounds as described herein (i.e. compounds of
the invention), it is understood (unless indicated otherwise) that
a compound as described herein includes compounds of Formulae I and
I' including all sub-embodiments thereof, compounds of Formulae II,
II' and IIa, including all sub-embodiments thereof, compounds of
Formulae III and III' including all sub-embodiments thereof, and
compounds as listed in the fourth aspect above.
[0560] In a fifth aspect, methods are provided for treating any of
a Fms and/or Kit and/or Flt-3 protein kinase mediated disease or
condition in an animal subject in need thereof, wherein the method
involves administering to the subject an effective amount of any
one or more compound(s) as described herein. In certain
embodiments, the method involves administering to the subject an
effective amount of a compound as described herein in combination
with one or more other therapies for the disease or condition.
[0561] In a sixth aspect, the invention provides methods for
treating a Fms protein kinase mediated disease or condition in an
animal subject in need thereof, wherein the method involves
administering to the subject an effective amount of any one or more
compound(s) as described herein. In one embodiment, the method
involves administering to the subject an effective amount of a
compound as described herein in combination with one or more other
therapies for the disease or condition.
[0562] In a seventh aspect, the invention provides methods for
treating a Kit protein kinase mediated disease or condition in an
animal subject in need thereof, wherein the method involves
administering to the subject an effective amount of any one or more
compound(s) as described herein.
[0563] In one embodiment, the method involves administering to the
subject an effective amount of a compound described herein in
combination with one or more other therapies for the disease or
condition.
[0564] In an eighth aspect, a compound as described herein will
have an IC.sub.50 of less than 500 nm, less than 100 nM, less than
50 nM, less than 20 nM, less than 10 nM, less than 5 nM, or less
than 1 nM as determined in a generally accepted Fms kinase activity
assay. In some embodiments, the compound is selective relative to
other protein kinases, such that the ratio of IC.sub.50 for another
kinase assessed comparably, divided by the IC.sub.50 for Fms kinase
is >20, also >30, also >40, also >50, also >60, also
>70, also >80, also >90, also >100, wherein the other
protein kinase includes, but is not limited to CSK, Insulin
receptor kinase, AMPK, PDGFR or VEGFR.
[0565] In a ninth aspect, a compound as described herein will have
an IC.sub.50 of less than 500 nm, less than 100 nM, less than 50
nM, less than 20 nM, less than 10 nM, less than 5 nM, or less than
1 nM as determined in a generally accepted Kit kinase activity
assay. In some embodiments, the compound is selective relative to
other protein kinases, such that the ratio of IC.sub.50 for another
kinase assessed comparably divided by the IC.sub.50 for Kit kinase
is >20, also >30, also >40, also >50, also >60, also
>70, also >80, also >90, also >100, wherein the other
protein kinase includes, but is not limited to CSK, Insulin
receptor kinase, AMPK, PDGFR or VEGFR.
[0566] In a tenth aspect, a compound as described herein is a dual
Fms/Kit inhibitor, i.e. will be approximately equipotent with
respect to inhibition of Fms kinase and Kit kinase. In some
embodiments the compound will have an IC.sub.50 of less than 500
nm, less than 100 nM, less than 50 nM, less than 20 nM, less than
10 nM, less than 5 nM, or less than 1 nM as determined in a
generally accepted Fms kinase activity assay and will have an
IC.sub.50 of less than 500 nm, less than 100 nM, less than 50 nM,
less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM
as determined in a comparable generally accepted Kit kinase
activity assay, wherein the ratio of IC.sub.50 for Kit kinase
divided by the IC.sub.50 for Fms kinase is in the range of 20 to
0.05, also 10 to 0.1, also 5 to 0.2. In some embodiments, the
compound is selective relative to protein kinases other than Kit,
such that the ratio of IC.sub.50 for another kinase assessed
comparably, divided by the IC.sub.50 for Fms kinase is >20, also
>30, also >40, also >50, also >60, also >70, also
>80, also >90, also >100, wherein the other protein kinase
includes, but is not limited to CSK, Insulin receptor kinase, AMPK,
PDGFR or VEGFR. In one embodiment, the dual Fms/Kit inhibitor is a
compound selected from the group consisting of: [0567]
(6-Methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1554), [0568]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-1562), [0569]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2003), [0570]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-fluoro-
-pyridin-3-ylmethyl)-amine (P-2004), [0571]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3,4-di-
fluoro-benzyl)-amine (P-2008), [0572]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-meth-
yl-benzyl)-amine (P-2013), [0573]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2019), [0574]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2031), [0575]
(4-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2032), [0576]
(4-Chloro-benzyl)-[6-fluoro-5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2037), [0577]
(6-Methyl-pyridin-2-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2079), [0578]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-morp-
holin-4-yl-pyridin-2-ylmethyl)-amine (P-2081), [0579]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-pyrr-
olidin-1-yl-pyridin-2-ylmethyl)-amine (P-2082), [0580]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-methyl-pyridin-2-ylmethyl)-amine (P-2131), [0581]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2146), [0582]
[3-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2147), [0583]
(2-Cyclopentyloxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2148), [0584]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-3-ylmethyl)-amine (P-2154), [0585]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-2-ylmethyl)-amine (P-2163), [0586]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3-fluoro-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2172), [0587]
Ethanesulfonic
acid(2-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridi-
n-2-ylamino]-methyl}-phenyl)-amide (P-2198), [0588] Ethanesulfonic
acid(3-fluoro-5-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-ylamino]-methyl}-phenyl)-amide (P-2202), [0589]
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-fluoro-6-
-methoxy-3-pyridyl)methyl]pyridin-2-amine (P-2203), [0590]
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204), [0591]
6-chloro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine (P-2205), [0592]
6-fluoro-N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-5-[[5-(trifluoromethyl)-
-1H-pyrrolo[2,3-b]pyridin-3-yl]methyl]pyridin-2-amine (P-2206), and
any salt, prodrug, tautomer, or stereoisomer thereof.
[0593] In an eleventh aspect, a compound as described herein is a
Fms selective inhibitor, i.e. will selectively inhibit Fms kinase
relative to Kit kinase. In some embodiments the compound will have
an IC.sub.50 of less than 500 nm, less than 100 nM, less than 50
nM, less than 20 nM, less than 10 nM, less than 5 nM, or less than
1 nM as determined in a generally accepted Fms kinase activity
assay and when determined in a comparable generally accepted Kit
kinase activity assay will have a ratio of IC.sub.50 for Kit kinase
divided by the IC.sub.50 for Fms kinase of >20, also >30,
also >40, also >50, also >60, also >70, also >80,
also >90, also >100. In some embodiments, the compound is
also selective relative to protein kinases other than Kit, such
that the ratio of IC.sub.50 for another kinase assessed comparably,
divided by the IC.sub.50 for Fms kinase is >20, also >30,
also >40, also >50, also >60, also >70, also >80,
also >90, also >100, wherein the other protein kinase
includes, but is not limited to Flt-3, CSK, Insulin receptor
kinase, AMPK, PDGFR or VEGFR. In one embodiment, the Fms selective
inhibitor is a compound selected from the group consisting of:
[0594]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,6-dime-
thoxy-pyridin-3-ylmethyl)-amine (P-1496), [0595]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-1622), [0596]
N-(3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin--
3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1669),
[0597]
N-(3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-fluoro-pyridin-3-ylmethyl-
}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide (P-1679),
[0598]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-2001), [0599]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(5-fluoro-pyridin-3-ylmethyl)-amine (P-2028), [0600]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-2029), [0601]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-2030), [0602]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-meth-
oxy-pyridin-3-ylmethyl)-amine (P-2038), [0603]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(2-methoxy-pyridin-3-ylmethyl)-amine (P-2043), [0604]
[6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-2045), [0605]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2048), [0606]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2049), [0607]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-2052), [0608]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2057), [0609]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2061), [0610]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2062), [0611]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2063), [0612]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-2-methoxy-pyridin-3-ylmethyl)-amine (P-2064), [0613]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methyl-pyridin-4-ylmethyl)-amine (P-2067), [0614]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2070), [0615]
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2071), [0616]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2073), [0617]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(2-methyl-pyridin-4-ylmethyl)-amine (P-2075), [0618]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2078), [0619]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2088), [0620]
(2,6-Dimethoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b-
]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2097), [0621]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-fluoro-pyridin-3-ylmethyl)-amine (P-2103), [0622]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-fluoro-pyridin-4-ylmethyl)-amine (P-2118), [0623]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2139), [0624]
3-{[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-ylamino]-
-methyl}-5-fluoro-1-methyl-1H-pyridin-2-one (P-2157), [0625]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-2165), [0626]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-pyridin-3-ylmethyl)-amine (P-2176), [0627]
3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2193), [0628]
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-fluoro-6-
-methoxy-3-pyridyl)methyl]pyridin-2-amine (P-2203), [0629]
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204), [0630]
6-chloro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine (P-2205), [0631]
6-fluoro-N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-5-[[5-(trifluoromethyl)-
-1H-pyrrolo[2,3-b]pyridin-3-yl]methyl]pyridin-2-amine (P-2206), and
any salt, prodrug, tautomer, or stereoisomer thereof.
[0632] In a twelfth aspect, a compound as described herein is a
dual Fms/Flt-3 inhibitor, i.e. will be approximately equipotent
with respect to inhibition of Fms kinase and Flt-3 kinase. In some
embodiments the compound will have an IC.sub.50 of less than 500
nm, less than 100 nM, less than 50 nM, less than 20 nM, less than
10 nM, less than 5 nM, or less than 1 nM as determined in a
generally accepted Fms kinase activity assay and will have an
IC.sub.50 of less than 500 nm, less than 100 nM, less than 50 nM,
less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM
as determined in a comparable generally accepted Flt-3 kinase
activity assay, wherein the ratio of IC.sub.50 for Flt-3 kinase
divided by the IC.sub.50 for Fms kinase is in the range of 20 to
0.05, also 10 to 0.1, also 5 to 0.2. In some embodiments, the
compound is selective relative to protein kinases other than Flt-3,
such that the ratio of IC.sub.50 for another kinase assessed
comparably, divided by the IC.sub.50 for Fms kinase is >20, also
>30, also >40, also >50, also >60, also >70, also
>80, also >90, also >100, wherein the other protein kinase
includes, but is not limited to CSK, Insulin receptor kinase, AMPK,
PDGFR or VEGFR. In some embodiments, the dual Fms/Flt-3 inhibitor
also inhibits Kit. In one embodiment, the dual Fms/Flt-3 inhibitor
is a compound selected from the group consisting of: [0633]
(6-Trifluoromethyl-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-py-
rrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1644),
[0634]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-
-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1646),
[0635]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-t-
rifluoromethyl-pyridin-3-ylmethyl)-amine (P-1667), [0636]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2003), [0637]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-fluoro-
-pyridin-3-ylmethyl)-amine (P-2004), [0638]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluo-
ro-5-trifluoromethyl-benzyl)-amine (P-2009), [0639]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2019), [0640]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-2029), [0641]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-2030), [0642]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2031), [0643]
(4-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2032), [0644]
(2-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2034), [0645]
(4-Chloro-benzyl)-[6-fluoro-5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2037), [0646]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-meth-
oxy-pyridin-3-ylmethyl)-amine (P-2038), [0647]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2040), [0648]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2041), [0649]
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2044), [0650]
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2047), [0651]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2048), [0652]
(4-Chloro-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyridin-2-yl]-amine (P-2050), [0653]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2057), [0654]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-2165), [0655]
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-fluoro-6-
-methoxy-3-pyridyl)methyl]pyridin-2-amine (P-2203), [0656]
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204), [0657]
6-chloro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine (P-2205), [0658]
6-fluoro-N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-5-[[5-(trifluoromethyl)-
-1H-pyrrolo[2,3-b]pyridin-3-yl]methyl]pyridin-2-amine (P-2206), and
any salt, prodrug, tautomer, or stereoisomer thereof.
[0659] In one embodiment, the dual Fms/Flt-3 inhibitor is a
compound selected from the group consisting of: [0660]
(6-Trifluoromethyl-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1644), [0661]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-
-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1646),
[0662]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-t-
rifluoromethyl-pyridin-3-ylmethyl)-amine (P-1667), [0663]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluo-
ro-5-trifluoromethyl-benzyl)-amine (P-2009), [0664]
(2-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2034), [0665]
(4-Chloro-benzyl)-[6-fluoro-5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2037), [0666]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2040), [0667]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2041), [0668]
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2044), [0669]
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2047), [0670]
(4-Chloro-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyridin-2-yl]-amine (P-2050), [0671]
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-fluoro-6-
-methoxy-3-pyridyl)methyl]pyridin-2-amine (P-2203), [0672]
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204), [0673]
6-chloro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine (P-2205), [0674]
6-fluoro-N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-5-[[5-(trifluoromethyl)-
-1H-pyrrolo[2,3-b]pyridin-3-yl]methyl]pyridin-2-amine (P-2206), and
any salt, prodrug, tautomer, or stereoisomer thereof.
[0675] Further to any of the aspects and embodiments referred to
herein, a compound as described herein also inhibits the effects of
a mutation of the kinase (e.g. Fms mutant, Kit mutant, Flt-3
mutant), including, but not limited to, a mutation that is related
to a disease state, such as a cancer.
[0676] In a thirteenth aspect, compositions are provided that
include a therapeutically effective amount of any one or more
compound(s) as described herein and at least one pharmaceutically
acceptable carrier, excipient, and/or diluent, including
combinations of any two or more compounds as described herein. The
composition can further include a plurality of different
pharmacologically active compounds, which can include a plurality
of compounds as described herein. In certain embodiments, the
composition can include any one or more compound(s) as described
herein along with one or more compounds that are therapeutically
effective for the same disease indication. In one aspect, the
composition includes any one or more compound(s) as described
herein along with one or more compounds that are therapeutically
effective for the same disease indication, wherein the compounds
have a synergistic effect on the disease indication. In one
embodiment, the composition includes any one or more compound(s) as
described herein effective in treating a cancer and one or more
other compounds that are effective in treating the same cancer,
further wherein the compounds are synergistically effective in
treating the cancer.
[0677] In a fourteenth aspect, methods are provided for modulating
the activity of a Fms and/or Kit and/or Flt-3 protein kinase,
including any mutations thereof, by contacting the protein kinase
with an effective amount of any one or more compound(s) as
described herein.
[0678] In a fifteenth aspect, the invention provides methods for
treating a disease or condition mediated by Fms and/or Kit and/or
Flt-3, including any mutations thereof, in a subject in need
thereof by administering to the subject an effective amount of a
composition including any one or more compound(s) as described
herein. In one embodiment, the invention provides methods for
treating a disease or condition mediated by Fms and/or Kit,
including any mutations thereof, in a subject in need thereof by
administering to the subject an effective amount of a composition
including any one or more compound(s) as described herein in
combination with one or more other suitable therapies for treating
the disease.
[0679] In a sixteenth aspect, the invention provides methods for
treating a disease or condition mediated by Fms, including any
mutations thereof, in a subject in need thereof by administering to
the subject an effective amount of a composition including any one
or more compound(s) as described herein. In one embodiment, the
invention provides methods for treating a disease or condition
mediated by Fms, including any mutations thereof, in a subject in
need thereof by administering to the subject an effective amount of
a composition including any one or more compound(s) as described
herein in combination with one or more other suitable therapies for
treating the disease.
[0680] In a seventeenth aspect, the invention provides methods for
treating a disease or condition mediated by Kit, including any
mutations thereof, in a subject in need thereof by administering to
the subject an effective amount of a composition including any one
or more compound(s) as described herein. In one embodiment, the
invention provides methods for treating a disease or condition
mediated by Kit, including any mutations thereof, in a subject in
need thereof by administering to the subject an effective amount of
a composition including any one or more compound(s) as described
herein in combination with one or more other suitable therapies for
treating the disease.
[0681] In an eighteenth aspect, the invention provides methods for
treating a disease or condition mediated by Flt-3, including any
mutations thereof, in a subject in need thereof by administering to
the subject an effective amount of a composition including any one
or more compound(s) as described herein. In one embodiment, the
invention provides methods for treating a disease or condition
mediated by Flt-3, including any mutations thereof, in a subject in
need thereof by administering to the subject an effective amount of
a composition including any one or more compound(s) as described
herein in combination with one or more other suitable therapies for
treating the disease.
[0682] In a nineteenth aspect, the invention provides methods for
treating a disease or condition mediated by Fms and Flt-3,
including any mutations thereof, in a subject in need thereof by
administering to the subject an effective amount of a composition
including any one or more compound(s) as described herein. In one
embodiment, the invention provides methods for treating a disease
or condition mediated by Fms and Flt-3, including any mutations
thereof, in a subject in need thereof by administering to the
subject an effective amount of a composition including any one or
more compound(s) as described herein in combination with one or
more other suitable therapies for treating the disease.
[0683] In a twentieth aspect, the invention provides methods for
treating a disease or condition mediated by Fms and Kit, including
any mutations thereof, in a subject in need thereof by
administering to the subject an effective amount of a composition
including any one or more compound(s) as described herein. In one
embodiment, the invention provides methods for treating a disease
or condition mediated by Fms and Kit, including any mutations
thereof, in a subject in need thereof by administering to the
subject an effective amount of a composition including any one or
more compound(s) as described herein in combination with one or
more other suitable therapies for treating the disease.
[0684] In a twenty-first aspect, the invention provides a method of
treating a cancer in a subject in need thereof by administering to
the subject an effective amount of a composition including any one
or more compound(s) as described herein, in combination with one or
more other therapies or medical procedures effective in treating
the cancer. Other therapies or medical procedures include suitable
anticancer therapy (e.g. drug therapy, vaccine therapy, gene
therapy, photodynamic therapy) or medical procedure (e.g. surgery,
radiation treatment, hyperthermia heating, bone marrow or stem cell
transplant). In one embodiment, the one or more suitable anticancer
therapies or medical procedures is selected from treatment with a
chemotherapeutic agent (e.g. chemotherapeutic drug), radiation
treatment (e.g. x-ray, .gamma.-ray, or electron, proton, neutron,
or a particle beam), hyperthermia heating (e.g. microwave,
ultrasound, radiofrequency ablation), Vaccine therapy (e.g. AFP
gene hepatocellular carcinoma vaccine, AFP adenoviral vector
vaccine, AG-858, allogeneic GM-CSF-secretion breast cancer vaccine,
dendritic cell peptide vaccines), gene therapy (e.g. Ad5CMV-p53
vector, adenovector encoding MDA7, adenovirus 5-tumor necrosis
factor alpha), photodynamic therapy (e.g. aminolevulinic acid,
motexafin lutetium), surgery, or bone marrow and stem cell
transplantation.
[0685] In a twenty-second aspect, the invention provides a method
of treating a cancer in a subject in need thereof by administering
to the subject an effective amount of a composition including any
one or more compound(s) as described herein, in combination with
one or more suitable chemotherapeutic agents. In one embodiment,
the one or more suitable chemotherapeutic agents is selected from
an alkylating agent, including, but not limited to, adozelesin,
altretamine, bendamustine, bizelesin, busulfan, carboplatin,
carboquone, carmofur, carmustine, chlorambucil, cisplatin,
cyclophosphamide, dacarbazine, estramustine, etoglucid,
fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven,
lomustine, mannosulfan, mechlorethamine, melphalan, mitobronitol,
nedaplatin, nimustine, oxaliplatin, piposulfan, prednimustine,
procarbazine, ranimustine, satraplatin, semustine, streptozocin,
temozolomide, thiotepa, treosulfan, triaziquone,
triethylenemelamine, triplatin tetranitrate, trofosphamide, and
uramustine; an antibiotic, including, but not limited to,
aclarubicin, amrubicin, bleomycin, dactinomycin, daunorubicin,
doxorubicin, elsamitrucin, epirubicin, idarubicin, menogaril,
mitomycin, neocarzinostatin, pentostatin, pirarubicin, plicamycin,
valrubicin, and zorubicin; an antimetabolite, including, but not
limited to, aminopterin, azacitidine, azathioprine, capecitabine,
cladribine, clofarabine, cytarabine, decitabine, floxuridine,
fludarabine, 5-fluorouracil, gemcitabine, hydroxyurea,
mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed,
tegafur-uracil, thioguanine, trimethoprim, trimetrexate, and
vidarabine; an immunotherapy, including, but not limited to,
alemtuzumab, bevacizumab, cetuximab, galiximab, gemtuzumab,
panitumumab, pertuzumab, rituximab, tositumomab, trastuzumab, 90 Y
ibritumomab tiuxetan, ipilimumab, and tremelimumab; a hormone or
hormone antagonist, including, but not limited to, anastrozole,
androgens, buserelin, diethylstilbestrol, exemestane, flutamide,
fulvestrant, goserelin, idoxifene, letrozole, leuprolide,
magestrol, raloxifene, tamoxifen, and toremifene; a taxane,
including, but not limited to, DJ-927, docetaxel, TPI 287,
larotaxel, ortataxel, paclitaxel, DHA-paclitaxel, and tesetaxel; a
retinoid, including, but not limited to, alitretinoin, bexarotene,
fenretinide, isotretinoin, and tretinoin; an alkaloid, including,
but not limited to, demecolcine, homoharringtonine, vinblastine,
vincristine, vindesine, vinflunine, and vinorelbine; an
antiangiogenic agent, including, but not limited to, AE-941
(GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide,
and thalidomide; a topoisomerase inhibitor, including, but not
limited to, amsacrine, belotecan, edotecarin, etoposide, etoposide
phosphate, exatecan, irinotecan (also active metabolite SN-38
(7-ethyl-10-hydroxy-camptothecin)), lucanthone, mitoxantrone,
pixantrone, rubitecan, teniposide, topotecan, and
9-aminocamptothecin; a kinase inhibitor, including, but not limited
to, axitinib (AG 013736), dasatinib (BMS 354825), erlotinib,
gefitinib, flavopiridol, imatinib mesylate, lapatinib, motesanib
diphosphate (AMG 706), nilotinib (AMN107), seliciclib, sorafenib,
sunitinib malate, AEE-788, BMS-599626, UCN-01
(7-hydroxystaurosporine), and vatalanib; a targeted signal
transduction inhibitor including, but not limited to bortezomib,
geldanamycin, and rapamycin; a biological response modifier,
including, but not limited to, imiquimod, interferon-.alpha., and
interleukin-2; and other chemotherapeutics, including, but not
limited to 3-AP (3-amino-2-carboxyaldehyde thiosemicarbazone),
altrasentan, aminoglutethimide, anagrelide, asparaginase,
bryostatin-1, cilengitide, elesclomol, eribulin mesylate (E7389),
ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen,
sulindac, testolactone, tiazofurin, mTOR inhibitors (e.g.
temsirolimus, everolimus, deforolimus), PI3K inhibitors (e.g.
BEZ235, GDC-0941, XL147, XL765), Cdk4 inhibitors (e.g. PD-332991),
Akt inhibitors, Hsp90 inhibitors (e.g. tanespimycin) and
farnesyltransferase inhibitors (e.g. tipifarnib). Preferably, the
method of treating a cancer involves administering to the subject
an effective amount of a composition including any one or more
compound(s) of Formulae I or I' in combination with a
chemotherapeutic agent selected from capecitabine, 5-fluorouracil,
carboplatin, dacarbazine, gefitinib, oxaliplatin, paclitaxel,
SN-38, temozolomide, vinblastine, bevacizumab, cetuximab,
interferon-.alpha., interleukin-2, or erlotinib.
[0686] In a twenty-third aspect, the invention provides a method of
treating a disease or condition in a subject in need thereof, by
administering to the subject a therapeutically effective amount of
any one or more compound(s) as described herein, a prodrug of such
compound, a pharmaceutically acceptable salt of such compound or
prodrug, or a pharmaceutically acceptable formulation of such
compound or prodrug. The compound can be alone or can be part of a
composition. In one embodiment, the invention provides a method of
treating a disease or condition in a subject in need thereof, by
administering to the subject a therapeutically effective amount of
any one or more compound(s) as described herein, a prodrug of such
compound, a pharmaceutically acceptable salt of such compound or
prodrug, or a pharmaceutically acceptable formulation of such
compound or prodrug in combination with one or more other suitable
therapies for the disease or condition.
[0687] In a twenty-fourth aspect, the invention provides kits that
include a compound or composition thereof as described herein. In
some embodiments, the compound or composition is packaged, e.g., in
a vial, bottle, flask, which may be further packaged, e.g., within
a box, envelope, or bag; the compound or composition is approved by
the U.S. Food and Drug Administration or similar regulatory agency
for administration to a mammal, e.g., a human; the compound or
composition is approved for administration to a mammal, e.g., a
human, for a Fms and/or Kit protein kinase mediated disease or
condition; the invention kit includes written instructions for use
and/or other indication that the compound or composition is
suitable or approved for administration to a mammal, e.g., a human,
for a Fms and/or Kit protein kinase-mediated disease or condition;
and the compound or composition is packaged in unit dose or single
dose form, e.g., single dose pills, capsules, or the like.
[0688] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
the invention provides methods for treating a Kit-mediated disease
or condition in a subject in need thereof (e.g. a mammal such as a
human, other primates, sports animals, animals of commercial
interest such as cattle, farm animals such as horses, or pets such
as dogs and cats), e.g., a disease or condition characterized by
abnormal Kit activity (e.g. kinase activity). In some embodiments
invention methods may involve administering to the subject
suffering from or at risk of a c-kit-mediated disease or condition
an effective amount of one or more compound(s) as described herein.
In one embodiment, the Kit mediated disease is selected from the
group consisting of malignancies, including, but not limited to,
mast cell tumors, small cell lung cancer, non-small cell lung
cancer (NSCLC), testicular cancer, pancreatic cancer, breast
cancer, merkel cell carcinoma, carcinomas of the female genital
tract, sarcomas of neuroectodermal origin, colorectal carcinoma,
carcinoma in situ, gastrointestinal stromal tumors (GISTs), tumor
angiogenesis, glioblastoma, astrocytoma, neuroblastoma,
neurofibromatosis (including Schwann cell neoplasia associated with
neurofibromatosis), acute myeloid leukemia, acute lymphocytic
leukemia, chronic myeloid leukemia, mastocytosis, melanoma, and
canine mast cell tumors; cardiovascular disease, including but not
limited to atherosclerosis, cardiomyopathy, heart failure,
pulmonary arterial hypertension and pulmonary fibrosis;
inflammatory and autoimmune indications, including, but not limited
to, allergy, anaphylaxis, asthma, rheumatoid arthritis, allergic
rhinitis, multiple sclerosis, inflammatory bowel disease,
transplant rejection, hypereosinophilia, urticaria and dermatitis;
gastrointestinal indications, including but not limited to
gastroesophageal reflux disease (GERD), esophagitis, and
gastrointestinal tract ulcers; ophthalmic indications, including
but not limited to uveitis and retinitis; and neurologic
indications, including but not limited to migraine.
[0689] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
the invention provides methods for treating a Fms-mediated disease
or condition in a subject in need thereof (e.g. a mammal such as a
human, other primates, sports animals, animals of commercial
interest such as cattle, farm animals such as horses, or pets such
as dogs and cats), e.g., a disease or condition characterized by
abnormal Fms activity (e.g. kinase activity). In some embodiments,
invention methods may involve administering to the subject
suffering from or at risk of a Fms-mediated disease or condition an
effective amount of one or more compound(s) as described herein. In
one embodiment, the Fms mediated disease is selected from the group
consisting of inflammatory and autoimmune indications, including,
but not limited to, rheumatoid arthritis, osteoarthritis, psoriatic
arthritis, psoriasis, dermatitis, ankylosing spondylitis,
polymyositis, dermatomyositis, systemic sclerosis, juvenile
idiopathic arthritis, polymyalgia rheumatica, Sjogren's disease,
Langerhan's cell histiocytosis (LCH), Still's disease, inflammatory
bowel disease, ulcerative colitis, Crohn's disease, systemic lupus
erythematosis (SLE), immune thrombocytopenic purpura (ITP),
myelopreparation for autologous transplantation, transplant
rejection, chronic obstructive pulmonary disease (COPD), emphysema,
Kawasaki's Disease, hemophagocytic syndrome (macrophage activation
syndrome), multicentric reticulohistiocytosis, and atherosclerosis;
metabolic disorders, including, but not limited to, Type I
diabetes, Type II diabetes, insulin resistance, hyperglycemia,
obesity, and lipolysis; disorders of bone structure, mineralization
and bone formation and resorption, including, but not limited to,
osteoporosis, osteodystrophy, increased risk of fracture, Paget's
disease, hypercalcemia, infection-mediated osteolysis (e.g.
osteomyelitis), and peri-prosthetic or wear-debris-mediated
osteolysis; kidney and genitourinary diseases, including, but not
limited to, endometriosis, nephritis (e.g. glomerulonephritis,
interstitial nephritis, Lupus nephritis), tubular necrosis,
diabetes-associated renal complications (e.g. diabetic
nephropathy), and renal hypertrophy; disorders of the nervous
system, including, but not limited to, demyelinating disorders
(e.g. multiple sclerosis, Charcot Marie Tooth syndrome),
amyotrophic lateral sclerosis (ALS), myasthenia gravis, chronic
demyelinating polyneuropathy, other demyelinating disorders,
stroke, Alzheimer's disease and Parkinson's disease; pain,
including, but not limited to, chronic pain, acute pain,
inflammatory pain, neuropathic pain, bone pain; malignancies,
including, but not limited to, multiple myeloma, acute myeloid
leukemia (AML), chronic myeloid leukemia (CML), lung cancer,
pancreatic cancer, prostate cancer, breast cancer, ovarian cancer,
neuroblastoma, sarcoma, osteosarcoma, giant cell tumors, (e.g.
giant cell tumor of bone, giant cell tumor of tendon sheath
(TGCT)), pigmented villonodular synovitis (PVNS), tumor
angiogenesis, melanoma, glioblastoma multiforme, glioma, other
tumors of the central nervous system, metastasis of tumors to other
tissues, osteolytic bone metastases, and other chronic
myeloproliferative diseases such as myelofibrosis; vasculitis,
including but not limited to collagen vascular disease,
polyarteritis nodosa, Behcet's disease, sarcoidosis, familiar
Mediterranean fever, Churg-Strauss vasculitis, temporal arteritis,
giant cell arteritis, Takayasu's arteritis; ophthalmic indications,
including but not limited to uveitis, scleritis, retinitis, age
related macular degeneration, choroidal neovascularization,
diabetic retinopathy; inherited disorders, including but not
limited to cherubism, neurofibromatosis; infectious disease
indications, including but not limited to infections associated
with human immunodeficiency virus, hepatitis B virus, hepatitis C
virus, human granulocytic anaplasmosis; lysosomal storage
disorders, including but not limited to Gaucher's disease, Fabry's
disease, Niemann-Pick disease; gastrointestinal indications,
including but not limited to liver cirrhosis; pulmonary
indications, including but not limited to pulmonary fibrosis, acute
lung injury (e.g. ventilator-induced, smoke- or toxin-induced); and
surgical indications, including but not limited to
(cardiopulmonary) bypass surgery, vascular surgery, and vascular
grafts.
[0690] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
the invention provides methods for treating a disease or condition
mediated by Fms and Kit in a subject in need thereof (e.g. a mammal
such as a human, other primates, sports animals, animals of
commercial interest such as cattle, farm animals such as horses, or
pets such as dogs and cats), e.g., a disease or condition
characterized by abnormal Fms activity and Kit activity (e.g.
kinase activity). In some embodiments, invention methods may
involve administering to the subject suffering from or at risk of a
disease or condition mediated by Fms and Kit an effective amount of
one or more compound(s) as described herein. In one embodiment, the
condition mediated by Fms and Kit is selected from the group
consisting of rheumatoid arthritis, osteoarthritis, psoriatic
arthritis, psoriasis, dermatitis, allergy, anaphylaxis, asthma,
allergic rhinitis, ankylosing spondylitis, polymyositis,
dermatomyositis, systemic sclerosis, juvenile idiopathic arthritis,
polymyalgia rheumatica, Sjogren's disease, Langerhan's cell
histiocytosis, Still's disease, inflammatory bowel disease,
ulcerative colitis, Crohn's disease, systemic lupus erythematosis,
immune thrombocytopenic purpura, myelopreparation for autologous
transplantation, transplant rejection, chronic obstructive
pulmonary disease, emphysema, Kawasaki's Disease, hemophagocytic
syndrome, multicentric reticulohistiocytosis, hypereosinophilia,
and urticaria type I diabetes, type II diabetes, insulin
resistance, hyperglycemia, obesity, and lipolysis, osteoporosis,
osteodystrophy, increased risk of fracture, Paget's disease,
hypercalcemia, infection-mediated osteolysis, and peri-prosthetic
or wear-debris-mediated osteolysis, endometriosis, nephritis,
tubular necrosis, diabetes-associated renal complications, and
renal hypertrophy, multiple sclerosis, Charcot Marie Tooth
syndrome, amyotrophic lateral sclerosis, myasthenia gravis, chronic
demyelinating polyneuropathy, other demyelinating disorders,
stroke, Alzheimer's disease and Parkinson's disease, acute pain,
neuropathic pain, inflammatory pain, chronic pain, migraine,
multiple myeloma, acute lymphocytic leukemia, acute myeloid
leukemia, chronic myeloid leukemia, mast cell tumors, canine mast
cell tumors, lung cancer, testicular cancer, pancreatic cancer,
prostate cancer, breast cancer, ovarian cancer, merkel cell
carcinoma, carcinomas of the female genital tract, colorectal
carcinoma, carcinoma in situ, gastrointestinal stromal tumors,
tumor angiogenesis, astrocytoma, neuroblastoma, sarcoma,
osteosarcoma, sarcomas of neuroectodermal origin, giant cell tumor
of bone, giant cell tumor of tendon sheath, pigmented villonodular
synovitis, melanoma, glioblastoma, glioblastoma multiforme, glioma,
other tumors of the central nervous system, neurofibromatosis
(including Schwann cell neoplasia associated with
neurofibromatosis), mastocytosis, metastasis of tumors to other
tissues, osteolytic bone metastases, and other chronic
myeloproliferative diseases such as myelofibrosis, collagen
vascular disease, polyarteritis nodosa, Behcet's disease,
sarcoidosis, familiar Mediterranean fever, Churg-Strauss
vasculitis, temporal arteritis, giant cell arteritis, Takayasu's
arteritis, uveitis, scleritis, retinitis, age related macular
degeneration, choroidal neovascularization, diabetic retinopathy,
cherubism, neurofibromatosis, infections associated with human
immunodeficiency virus, hepatitis B virus, hepatitis C virus, human
granulocytic anaplasmosis, Gaucher's disease, Fabry's disease,
Niemann-Pick disease, liver cirrhosis, gastroesophageal reflux
disease, esophagitis, and gastrointestinal tract ulcers, pulmonary
fibrosis, acute lung injury, bypass surgery, vascular surgery, and
vascular grafts, atherosclerosis, cardiomyopathy, heart failure,
and pulmonary arterial hypertension.
[0691] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
the invention provides methods for treating a disease or condition
mediated by Fms and Flt-3 in a subject in need thereof (e.g. a
mammal such as a human, other primates, sports animals, animals of
commercial interest such as cattle, farm animals such as horses, or
pets such as dogs and cats), e.g., a disease or condition
characterized by abnormal Fms activity and flt-3 activity (e.g.
kinase activity). In some embodiments, invention methods may
involve administering to the subject suffering from or at risk of a
disease or condition mediated by Fms and Flt-3 an effective amount
of one or more compound(s) as described herein. In one embodiment,
the condition mediated by Fms and Flt-3 is acute myeloid
leukemia.
[0692] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
invention methods may involve administering an effective amount of
one or more compound(s) as described herein to a subject in need
thereof suffering from or at risk of a disease or condition
selected from the group consisting of rheumatoid arthritis,
osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic
sclerosis, demyelinating disorders, multiple sclerosis, Charcot
Marie Tooth syndrome, amyotrophic lateral sclerosis, Alzheimer's
disease, Parkinson's disease, ulcerative colitis, Crohn's disease,
immune thrombocytopenic purpura, atherosclerosis, systemic lupus
erythematosis, myelopreparation for autologous transplantation,
transplant rejection, glomerulonephritis, interstitial nephritis,
Lupus nephritis, tubular necrosis, diabetic nephropathy, renal
hypertrophy, type I diabetes, acute pain, inflammatory pain,
neuropathic pain, acute myeloid leukemia, melanoma, multiple
myeloma, metastatic breast cancer, prostate cancer, pancreatic
cancer, lung cancer, ovarian cancer, gliomas, glioblastomas,
neurofibromatosis, osteolytic bone metastases, brain metastases,
gastrointestinal stromal tumors, and giant cell tumors.
[0693] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
invention methods may involve administering an effective amount of
one or more compound(s) as described herein to a subject in need
thereof suffering from or at risk of a disease or condition
selected from the group consisting of rheumatoid arthritis,
gastrointestinal stromal tumors, melanoma, and neurofibromatosis,
wherein the compound is an inhibitor of Kit, i.e. has an IC.sub.50
of less than 500 nm, less than 100 nM, less than 50 nM, less than
20 nM, less than 10 nM, less than 5 nM, or less than 1 nM as
determined in a generally accepted Kit kinase activity assay.
[0694] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
invention methods may involve administering an effective amount of
one or more compound(s) as described herein to a subject in need
thereof suffering from or at risk of a disease or condition
selected from the group consisting of multiple sclerosis,
glioblastoma, Alzheimer's disease, Parkinson's disease, rheumatoid
arthritis, osteoarthritis, atherosclerosis, systemic lupus
erythematosus, glomerulonephritis, interstitial nephritis, Lupus
nephritis, tubular necrosis, diabetic nephropathy, and renal
hypertrophy, wherein the compound is a Fms selective inhibitor,
i.e. has an IC.sub.50 of less than 500 nm, less than 100 nM, less
than 50 nM, less than 20 nM, less than 10 nM, less than 5 nM, or
less than 1 nM as determined in a generally accepted Fms kinase
activity assay and when determined in a comparable generally
accepted Kit kinase activity assay will have a ratio of IC.sub.50
for Kit kinase divided by the IC.sub.50 for Fms kinase of >20,
also >30, also >40, also >50, also >60, also >70,
also >80, also >90, also >100; in some embodiments, the
compound is also selective relative to protein kinases other than
Kit, such that the ratio of IC.sub.50 for another kinase assessed
comparably, divided by the IC.sub.50 for Fms kinase is >20, also
>30, also >40, also >50, also >60, also >70, also
>80, also >90, also >100, wherein the other protein kinase
includes, but is not limited to Flt-3, CSK, Insulin receptor
kinase, AMPK, PDGFR or VEGFR.
[0695] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
invention methods may involve administering an effective amount of
one or more compound(s) as described herein to a subject in need
thereof suffering from or at risk of a disease or condition
selected from the group consisting of multiple sclerosis,
glioblastoma, Alzheimer's disease, and Parkinson's disease, wherein
the compound is a Fms selective inhibitor, i.e. has an IC.sub.50 of
less than 500 nm, less than 100 nM, less than 50 nM, less than 20
nM, less than 10 nM, less than 5 nM, or less than 1 nM as
determined in a generally accepted Fms kinase activity assay and
when determined in a comparable generally accepted Kit kinase
activity assay will have a ratio of IC.sub.50 for Kit kinase
divided by the IC.sub.50 for Fms kinase of >20, also >30,
also >40, also >50, also >60, also >70, also >80,
also >90, also >100, and wherein the compound effectively
crosses the blood brain barrier; in some embodiments, the compound
is also selective relative to protein kinase other than Kit, such
that the ratio of IC.sub.50 for another kinase assessed comparably
divided by the IC.sub.50 for Fms kinase is >20, also >30,
also >40, also >50, also >60, also >70, also >80,
also >90, also >100, wherein the other protein kinase
includes, but is not limited to Flt-3, CSK, Insulin receptor
kinase, AMPK, PDGFR or VEGFR.
[0696] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
invention methods may involve administering an effective amount of
one or more compound(s) as described herein to a subject in need
thereof suffering from or at risk of a disease or condition
selected from the group consisting of rheumatoid arthritis,
osteoarthritis, atherosclerosis, systemic lupus erythematosus,
glomerulonephritis, interstitial nephritis, Lupus nephritis,
tubular necrosis, diabetic nephropathy, and renal hypertrophy,
wherein the compound is a Fms selective inhibitor, i.e. has an
IC.sub.50 of less than 500 nm, less than 100 nM, less than 50 nM,
less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM
as determined in a generally accepted Fms kinase activity assay and
when determined in a comparable generally accepted Kit kinase
activity assay will have a ratio of IC.sub.50 for Kit kinase
divided by the IC.sub.50 for Fms kinase of >20, also >30,
also >40, also >50, also >60, also >70, also >80,
also >90, also >100, and wherein the compound does not
effectively cross the blood brain barrier; in some embodiments, the
compound is also selective relative to protein kinase other than
Kit, such that the ratio of IC.sub.50 for another kinase assessed
comparably divided by the IC.sub.50 for Fms kinase is >20, also
>30, also >40, also >50, also >60, also >70, also
>80, also >90, also >100, wherein the other protein kinase
includes, but is not limited to Flt-3, CSK, Insulin receptor
kinase, AMPK, PDGFR or VEGFR.
[0697] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
invention methods may involve administering an effective amount of
one or more compound(s) as described herein to a subject in need
thereof suffering from or at risk of a disease or condition
selected from the group consisting of metastatic breast cancer,
prostate cancer, multiple myeloma, melanoma, brain metastases,
neurofibromatosis, gastrointestinal stromal tumors, rheumatoid
arthritis, and multiple sclerosis, wherein the compound is a dual
Fms/Kit inhibitor, i.e. has an IC.sub.50 of less than 500 nm, less
than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM,
less than 5 nM, or less than 1 nM as determined in a generally
accepted Fms kinase activity assay and will have an IC.sub.50 of
less than 500 nm, less than 100 nM, less than 50 nM, less than 20
nM, less than 10 nM, less than 5 nM, or less than 1 nM as
determined in a comparable generally accepted Kit kinase activity
assay, wherein the ratio of IC.sub.50 for Kit kinase divided by the
IC.sub.50 for Fms kinase is in the range of 20 to 0.05, also 10 to
0.1, also 5 to 0.2; in some embodiments, the compound is also
selective relative to protein kinase other than Kit, such that the
ratio of IC.sub.50 for another kinase assessed comparably divided
by the IC.sub.50 for Fms kinase is >20, also >30, also
>40, also >50, also >60, also >70, also >80, also
>90, also >100, wherein the other protein kinase includes,
but is not limited to CSK, Insulin receptor kinase, AMPK, PDGFR or
VEGFR.
[0698] In aspects and embodiments involving treatment of a disease
or condition with one or more of the compounds described herein,
invention methods may involve administering an effective amount of
one or more compound(s) as described herein to a subject in need
thereof suffering from or at risk of acute myeloid leukemia,
wherein the compound is a dual Fms/Flt-3 inhibitor, i.e. has an
IC.sub.50 of less than 500 nm, less than 100 nM, less than 50 nM,
less than 20 nM, less than 10 nM, less than 5 nM, or less than 1 nM
as determined in a generally accepted Fms kinase activity assay and
will have an IC.sub.50 of less than 500 nm, less than 100 nM, less
than 50 nM, less than 20 nM, less than 10 nM, less than 5 nM, or
less than 1 nM as determined in a comparable generally accepted
Flt-3 kinase activity assay, wherein the ratio of IC.sub.50 for
Flt-3 kinase divided by the IC.sub.50 for Fms kinase is in the
range of 20 to 0.05, also 10 to 0.1, also 5 to 0.2; in some
embodiments, the compound is also selective relative to protein
kinase other than Flt-3, such that the ratio of IC.sub.50 for
another kinase assessed comparably divided by the IC.sub.50 for Fms
kinase is >20, also >30, also >40, also >50, also
>60, also >70, also >80, also >90, also >100,
wherein the other protein kinase includes, but is not limited to
CSK, Insulin receptor kinase, AMPK, PDGFR or VEGFR.
[0699] In a twenty-fifth aspect, one or more compounds or
compositions as described herein can be used in the preparation of
a medicament for the treatment of a Kit-mediated disease or
condition selected from the group consisting of malignancies,
including, but not limited to, mast cell tumors, small cell lung
cancer, non-small cell lung cancer, testicular cancer, pancreatic
cancer, breast cancer, merkel cell carcinoma, carcinomas of the
female genital tract, sarcomas of neuroectodermal origin,
colorectal carcinoma, carcinoma in situ, gastrointestinal stromal
tumors, tumor angiogenesis, glioblastoma, astrocytoma,
neuroblastoma, neurofibromatosis (including Schwann cell neoplasia
associated with neurofibromatosis), acute myeloid leukemia, acute
lymphocytic leukemia, chronic myeloid leukemia, mastocytosis,
melanoma, and canine mast cell tumors; cardiovascular disease,
including but not limited to atherosclerosis, cardiomyopathy, heart
failure, pulmonary arterial hypertension, and pulmonary fibrosis;
inflammatory and autoimmune indications, including, but not limited
to, allergy, anaphylaxis, asthma, rheumatoid arthritis, allergic
rhinitis, multiple sclerosis, inflammatory bowel disease,
transplant rejection, hypereosinophilia, urticaria and dermatitis;
gastrointestinal indications, including but not limited to
gastroesophageal reflux disease, esophagitis, and gastrointestinal
tract ulcers; ophthalmic indications, including but not limited to
uveitis and retinitis; and neurologic indications, including but
not limited to migraine. The invention further provides one or more
compounds or compositions as described herein for use in treating a
Kit-mediated disease or condition as described herein.
[0700] In a twenty-sixth aspect, one or more compounds as described
herein can be used in the preparation of a medicament for the
treatment of a Fms-mediated disease or condition selected from the
group consisting of inflammatory and autoimmune indications,
including, but not limited to, rheumatoid arthritis,
osteoarthritis, psoriatic arthritis, psoriasis, dermatitis,
ankylosing spondylitis, polymyositis, dermatomyositis, systemic
sclerosis, juvenile idiopathic arthritis, polymyalgia rheumatica,
Sjogren's disease, Langerhan's cell histiocytosis (LCH), Still's
disease, inflammatory bowel disease, ulcerative colitis, Crohn's
disease, systemic lupus erythematosis (SLE), immune
thrombocytopenic purpura (ITP), myelopreparation for autologous
transplantation, transplant rejection, chronic obstructive
pulmonary disease (COPD), emphysema, Kawasaki's Disease,
hemophagocytic syndrome (macrophage activation syndrome),
multicentric reticulohistiocytosis, and atherosclerosis; metabolic
disorders, including, but not limited to, Type I diabetes, Type II
diabetes, insulin resistance, hyperglycemia, obesity, and
lipolysis; disorders of bone structure, mineralization and bone
formation and resorption, including, but not limited to,
osteoporosis, osteodystrophy, increased risk of fracture, Paget's
disease, hypercalcemia, infection-mediated osteolysis (e.g.
osteomyelitis), and peri-prosthetic or wear-debris-mediated
osteolysis; kidney and genitourinary diseases, including, but not
limited to, endometriosis, nephritis (e.g. glomerulonephritis,
interstitial nephritis, Lupus nephritis), tubular necrosis,
diabetes-associated renal complications (e.g. diabetic
nephropathy), and renal hypertrophy; disorders of the nervous
system, including, but not limited to, demyelinating disorders
(e.g. multiple sclerosis, Charcot Marie Tooth syndrome),
amyotrophic lateral sclerosis (ALS), myasthenia gravis, chronic
demyelinating polyneuropathy, other demyelinating disorders,
stroke, Alzheimer's disease and Parkinson's disease; pain,
including, but not limited to, chronic pain, acute pain,
inflammatory pain, neuropathic pain, bone pain; malignancies,
including, but not limited to, multiple myeloma, acute myeloid
leukemia (AML), chronic myeloid leukemia (CML), lung cancer,
pancreatic cancer, prostate cancer, breast cancer, ovarian cancer,
neuroblastoma, sarcoma, osteosarcoma, giant cell tumors, (e.g.
giant cell tumor of bone, giant cell tumor of tendon sheath
(TGCT)), pigmented villonodular synovitis (PVNS), tumor
angiogenesis, melanoma, glioblastoma multiforme, glioma, other
tumors of the central nervous system, metastasis of tumors to other
tissues, osteolytic bone metastases, and other chronic
myeloproliferative diseases such as myelofibrosis; vasculitis,
including but not limited to collagen vascular disease,
polyarteritis nodosa, Behcet's disease, sarcoidosis, familiar
Mediterranean fever, Churg-Strauss vasculitis, temporal arteritis,
giant cell arteritis, Takayasu's arteritis; ophthalmic indications,
including but not limited to uveitis, scleritis, retinitis, age
related macular degeneration, choroidal neovascularization,
diabetic retinopathy; inherited disorders, including but not
limited to cherubism, neurofibromatosis; infectious disease
indications, including but not limited to infections associated
with human immunodeficiency virus, hepatitis B virus, hepatitis C
virus, human granulocytic anaplasmosis; lysosomal storage
disorders, including but not limited to Gaucher's disease, Fabry's
disease, Niemann-Pick disease; gastrointestinal indications,
including but not limited to liver cirrhosis; pulmonary
indications, including but not limited to pulmonary fibrosis, acute
lung injury (e.g. ventilator-induced, smoke- or toxin-induced); and
surgical indications, including but not limited to
(cardiopulmonary) bypass surgery, vascular surgery, and vascular
grafts. The invention further provides one or more compounds or
compositions as described herein for use in treating a Fms-mediated
disease or condition as described herein.
[0701] In a twenty-seventh aspect, one or more compounds as
described herein can be used in the preparation of a medicament for
the treatment of a Fms-mediated and Kit-mediated disease or
condition selected from the group consisting of rheumatoid
arthritis, osteoarthritis, psoriatic arthritis, psoriasis,
dermatitis, allergy, anaphylaxis, asthma, allergic rhinitis,
ankylosing spondylitis, polymyositis, dermatomyositis, systemic
sclerosis, juvenile idiopathic arthritis, polymyalgia rheumatica,
Sjogren's disease, Langerhan's cell histiocytosis, Still's disease,
inflammatory bowel disease, ulcerative colitis, Crohn's disease,
systemic lupus erythematosis, immune thrombocytopenic purpura,
myelopreparation for autologous transplantation, transplant
rejection, chronic obstructive pulmonary disease, emphysema,
Kawasaki's Disease, hemophagocytic syndrome, multicentric
reticulohistiocytosis, hypereosinophilia, and urticaria type I
diabetes, type II diabetes, insulin resistance, hyperglycemia,
obesity, and lipolysis, osteoporosis, osteodystrophy, increased
risk of fracture, Paget's disease, hypercalcemia,
infection-mediated osteolysis, and peri-prosthetic or
wear-debris-mediated osteolysis, endometriosis, nephritis, tubular
necrosis, diabetes-associated renal complications, and renal
hypertrophy, multiple sclerosis, Charcot Marie Tooth syndrome,
amyotrophic lateral sclerosis, myasthenia gravis, chronic
demyelinating polyneuropathy, other demyelinating disorders,
stroke, Alzheimer's disease and Parkinson's disease, acute pain,
neuropathic pain, inflammatory pain, chronic pain, migraine,
multiple myeloma, acute lymphocytic leukemia, acute myeloid
leukemia, chronic myeloid leukemia, mast cell tumors, canine mast
cell tumors, lung cancer, testicular cancer, pancreatic cancer,
prostate cancer, breast cancer, ovarian cancer, merkel cell
carcinoma, carcinomas of the female genital tract, colorectal
carcinoma, carcinoma in situ, gastrointestinal stromal tumors,
tumor angiogenesis, astrocytoma, neuroblastoma, sarcoma,
osteosarcoma, sarcomas of neuroectodermal origin, giant cell tumor
of bone, giant cell tumor of tendon sheath, pigmented villonodular
synovitis, melanoma, glioblastoma, glioblastoma multiforme, glioma,
other tumors of the central nervous system, neurofibromatosis
(including Schwann cell neoplasia associated with
neurofibromatosis), mastocytosis, metastasis of tumors to other
tissues, osteolytic bone metastases, and other chronic
myeloproliferative diseases such as myelofibrosis, collagen
vascular disease, polyarteritis nodosa, Behcet's disease,
sarcoidosis, familiar Mediterranean fever, Churg-Strauss
vasculitis, temporal arteritis, giant cell arteritis, Takayasu's
arteritis, uveitis, scleritis, retinitis, age related macular
degeneration, choroidal neovascularization, diabetic retinopathy,
cherubism, neurofibromatosis, infections associated with human
immunodeficiency virus, hepatitis B virus, hepatitis C virus, human
granulocytic anaplasmosis, Gaucher's disease, Fabry's disease,
Niemann-Pick disease, liver cirrhosis, gastroesophageal reflux
disease, esophagitis, and gastrointestinal tract ulcers, pulmonary
fibrosis, acute lung injury, bypass surgery, vascular surgery, and
vascular grafts, atherosclerosis, cardiomyopathy, heart failure,
and pulmonary arterial hypertension. The invention further provides
one or more compounds or compositions as described herein for use
in treating a Fms-mediated and Kit-mediated disease or condition as
described herein.
[0702] In a twenty-eighth aspect, one or more compounds as
described herein can be used in the preparation of a medicament for
the treatment of a disease or condition selected from the group
consisting of rheumatoid arthritis, osteoarthritis, osteoporosis,
peri-prosthetic osteolysis, systemic sclerosis, demyelinating
disorders, multiple sclerosis, Charcot Marie Tooth syndrome,
amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's
disease, ulcerative colitis, Crohn's disease, immune
thrombocytopenic purpura, myelopreparation for autologous
transplantation, transplant rejection, glomerulonephritis,
interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic
nephropathy, renal hypertrophy, type I diabetes, acute pain,
inflammatory pain, neuropathic pain, acute myeloid leukemia,
melanoma, multiple myeloma, metastatic breast cancer, prostate
cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas,
glioblastomas, neurofibromatosis, osteolytic bone metastases, brain
metastases, gastrointestinal stromal tumors, and giant cell
tumors.
[0703] In a twenty-ninth aspect, one or more compounds as described
herein that are Kit inhibitors can be used in the preparation of a
medicament for the treatment of rheumatoid arthritis,
gastrointestinal stromal tumors, melanoma or neurofibromatosis.
[0704] In a thirtieth aspect, one or more compounds as described
herein that are Fms selective inhibitors can be used in the
preparation of a medicament for the treatment of multiple
sclerosis, glioblastoma, Alzheimer's disease, Parkinson's disease,
rheumatoid arthritis, osteoarthritis, atherosclerosis, systemic
lupus erythematosus, glomerulonephritis, interstitial nephritis,
Lupus nephritis, tubular necrosis, diabetic nephropathy, or renal
hypertrophy.
[0705] In a thirty-first aspect, one or more compounds as described
herein that are Fms selective inhibitors that effectively cross the
blood brain barrier can be used in the preparation of a medicament
for the treatment of multiple sclerosis, glioblastoma, Alzheimer's
disease, or Parkinson's disease.
[0706] In a thirty-second aspect, one or more compounds as
described herein that are Fms selective inhibitors that do not
effectively cross the blood brain barrier can be used in the
preparation of a medicament for the treatment of rheumatoid
arthritis, osteoarthritis, atherosclerosis, systemic lupus
erythematosus, glomerulonephritis, interstitial nephritis, Lupus
nephritis, tubular necrosis, diabetic nephropathy, or renal
hypertrophy.
[0707] In a thirty-third aspect, one or more compounds as described
herein that are dual Fms/Kit inhibitors can be used in the
preparation of a medicament for the treatment of metastatic breast
cancer, prostate cancer, multiple myeloma, melanoma, acute myeloid
leukemia, brain metastases, neurofibromatosis, gastrointestinal
stromal tumors, rheumatoid arthritis, or multiple sclerosis.
[0708] In a thirty-fourth aspect, one or more compounds as
described herein that are dual Fms/Flt-3 inhibitors can be used in
the preparation of a medicament for the treatment of acute myeloid
leukemia.
[0709] In a thirty-fifth aspect, the invention provides an
intermediate compound of Formula V:
##STR00022##
or a stereoisomer thereof,
[0710] wherein:
[0711] P.sup.2 is an amino protecting group;
[0712] Ar is selected from the group consisting of:
##STR00023##
wherein
##STR00024##
indicates the point of attachment of Ar to --CH.sub.2-- of Formula
I and wherein
##STR00025##
indicates the point of attachment of Ar to --NH-- of Formula I;
[0713] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently
selected from the group consisting of --H, halogen, lower alkyl,
halogen substituted lower alkyl, alkoxy substituted lower alkyl,
cycloalkylamino, --CN, --O--R.sup.40, --S(O).sub.2--R.sup.4I,
--S(O).sub.2--N(H)--R.sup.42, --N(H)--R.sup.42,
--N(R.sup.42).sub.2, and --N(H)--S(O).sub.2--R.sup.43, provided
that at least two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are --H
and one of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is other than
hydrogen, wherein: [0714] R.sup.40 is lower alkyl, fluoro
substituted lower alkyl, methoxy substituted lower alkyl, or
cycloalkyl; [0715] R.sup.41, R.sup.42 and R.sup.43 are lower alkyl.
In some embodiments, the variables Ar, R.sup.7, R.sup.8, R.sup.9,
R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein.
[0716] In a thirty-sixth aspect, the invention provides a method
for preparing a compound of Formula I':
##STR00026##
The method includes contacting a compound of Formula IV:
##STR00027##
[0717] with a compound of Formula V:
##STR00028##
[0718] under conditions sufficient to form the compound of Formula
I, wherein:
[0719] P.sup.1 and P.sup.2 are each independently an amino
protecting group;
[0720] X is H or a halogen;
[0721] Ar is selected from the group consisting of:
##STR00029##
wherein
##STR00030##
indicates the point of attachment of Ar to --CH.sub.2-- of Formula
I and wherein
##STR00031##
indicates the point of attachment of Ar to --NH-- of Formula I;
[0722] R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently
selected from the group consisting of --H, lower alkyl, halogen
substituted lower alkyl, alkoxy substituted lower alkyl,
cycloalkylamino, --CN, --O--R.sup.40, --S(O).sub.2--R.sup.41,
--S(O).sub.2--N(H)--R.sup.42, --N(H)--R.sup.42,
--N(R.sup.42).sub.2, and --N(H)--S(O).sub.2--R.sup.43, provided
that at least two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are --H
and one of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is other than
hydrogen, wherein: [0723] R.sup.40 is lower alkyl, fluoro
substituted lower alkyl, methoxy substituted lower alkyl, or
cycloalkyl; [0724] R.sup.41, R.sup.42 and R.sup.43 are lower alkyl;
[0725] R.sup.5 is selected from the group consisting of --H, --F,
--Cl, --Br, lower alkyl, halogen substituted alkyl, lower alkenyl,
lower alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN, --O--R.sup.10,
--C(O)--N(H)--R.sup.11, --C(O)--O--R.sup.11,
--S(O).sub.2--R.sup.12, --S(O).sub.2--N(H)--R.sup.11,
--N(H)--C(O)--R.sup.12, and --N(H)--S(O).sub.2--R.sup.12, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl; [0726] R.sup.6 is selected from the group
consisting of H, halogen, lower alkyl, halogen substituted alkyl,
lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, --CN,
--O--R.sup.13, --C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl; [0727] R.sup.7 is H, halogen or lower alkyl;
[0728] R.sup.8 is H, halogen, lower alkyl or lower alkoxy; [0729]
R.sup.9 is H or halogen; [0730] R.sup.10 and R.sup.13 are
independently --H, lower alkyl, lower alkyl substituted with
--O--CH.sub.3, lower alkyl substituted with di-alklylamine, or
lower alkyl substituted with heterocycloalkyl; [0731] R.sup.11 and
R.sup.14 are independently hydrogen or lower alkyl; and R.sup.12
and R.sup.15 are each independently lower alkyl, with the proviso
that the compound is other than those set forth in Table 1. P.sup.1
and P.sup.2 are amino protecting groups as described herein. In one
embodiment, P.sup.2 is t-butoxycarbonyl. In another embodiment,
P.sup.1 is phenylsulfonyl. In one embodiment, the contacting is
performed by reacting the compounds of Formula IV with the
compounds of Formula V in the presence of a strong base, such as
alkali metal hydroxide. Exemplary alkali metal hydroxides include
NaOH, KOH and LiOH. In another embodiment, the contacting includes
forming a Grignard reagent of compounds of Formula IV and further
reacting the Grignard reagent of compounds of Formula IV with the
compounds of Formula V. In yet another embodiment, the contacting
includes reacting the compounds of Formula IV with the compounds of
Formula V in the presence of a palladium complex. In some
embodiments, the variables R.sup.5 and R.sup.6 are as defined in
any of the embodiments above for compounds of Formula I. In some
embodiments, the variables R.sup.1, R.sup.2, R.sup.3 and R.sup.4
are as defined in any of the embodiments above for compounds of
Formula I.
[0732] In some embodiments, the invention provides a method of
preparing a compound of Formula II':
##STR00032##
The method includes contacting a compound of Formula VI:
##STR00033##
[0733] with a compound of Formula VII:
##STR00034##
under conditions sufficient to form the compound of Formula II',
wherein P.sup.1 and P.sup.2 are each independently an amino
protecting group; X is H or a halogen; R.sup.6 is selected from the
group consisting of H, halogen, lower alkyl, halogen substituted
alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl,
--CN, --O--R.sup.13, --C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl. R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are
each independently selected from H, halogen, lower alkyl, lower
alkoxy, halo substituted lower alkyl, --OR.sup.20, or alkoxy
substituted lower alkyl. In one embodiment, R.sup.6 is lower alkyl.
In another embodiment, R.sup.6 is CH.sub.3 or CN. In another
embodiment, R.sup.6 is methyl, ethyl or propyl. P.sup.1 and P.sup.2
are amino protecting groups as described herein. In one embodiment,
P.sup.2 is t-butoxycarbonyl. In another embodiment, P.sup.1 is
phenylsulfonyl. In one embodiment, the contacting is performed by
reacting the compounds of Formula VI with the compounds of Formula
VII in the presence of a strong base, such as alkali metal
hydroxide. Exemplary alkali metal hydroxide include NaOH, KOH and
LiOH. In another embodiment, the contacting includes forming a
Grignard reagent of compounds of Formula VI and further reacting
the Grignard reagent of compounds of Formula VI with the compounds
of Formula VII.
[0734] In some embodiments, the invention provides a method of
preparing a compound of Formula III':
##STR00035##
The method includes contacting a compound of Formula VI:
##STR00036##
[0735] with a compound of Formula VII:
##STR00037##
under conditions sufficient to form the compound of Formula II',
wherein P.sup.1 and P.sup.2 are each independently an amino
protecting group; X is H or a halogen; R.sup.6 is selected from the
group consisting of H, halogen, lower alkyl, halogen substituted
alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl,
--CN, --O--R.sup.13, --C(O)--N(H)--R.sup.14, --C(O)--O--R.sup.14,
--S(O).sub.2--R.sup.15, --S(O).sub.2--N(H)--R.sup.14,
--N(H)--C(O)--R.sup.15, and --N(H)--S(O).sub.2--R.sup.15, wherein
pyrazolyl is optionally substituted with lower alkyl or
heterocycloalkyl. R.sup.16, R.sup.17, R.sup.18 and R.sup.19 are
each independently selected from H, halogen, lower alkyl, lower
alkoxy, halo substituted lower alkyl, --OR.sup.20, or alkoxy
substituted lower alkyl. In one embodiment, R.sup.6 is lower alkyl.
In another embodiment, R.sup.6 is CH.sub.3 or CN. In another
embodiment, R.sup.6 is methyl, ethyl or propyl. P.sup.1 and P.sup.2
are amino protecting groups as described herein. In one embodiment,
P.sup.2 is t-butoxycarbonyl. In another embodiment, P.sup.1 is
phenylsulfonyl. In one embodiment, the contacting is performed by
reacting the compounds of Formula VI with the compounds of Formula
VIII in the presence of a strong base, such as alkali metal
hydroxide. Exemplary alkali metal hydroxide include NaOH, KOH and
LiOH. In another embodiment, the contacting includes forming a
Grignard reagent of compounds of Formula VI and further reacting
the Grignard reagent of compounds of Formula VI with the compounds
of Formula VII.
[0736] Additional aspects and embodiments will be apparent from the
following Detailed Description of the Invention and from the
claims.
DETAILED DESCRIPTION OF THE INVENTION
[0737] As used herein the following definitions apply unless
clearly indicated otherwise:
[0738] All atoms designated within a Formula described herein,
either within a structure provided, or within the definitions of
variables related to the structure, is intended to include any
isotope thereof, unless clearly indicated to the contrary. It is
understood that for any given atom, the isotopes may be present
essentially in ratios according to their natural occurrence, or one
or more particular atoms may be enhanced with respect to one or
more isotopes using synthetic methods known to one skilled in the
art. Thus, hydrogen includes for example .sup.1H, .sup.2H, .sup.3H;
carbon includes for example .sup.11C, .sup.12C, .sup.13C, .sup.14C;
oxygen includes for example .sup.16O, .sup.17O, .sup.18O; nitrogen
includes for example .sup.13N, .sup.14N, .sup.15N; sulfur includes
for example .sup.32S, .sup.33S, .sup.34S, .sup.35S, .sup.36S,
.sup.37S, .sup.38S; fluoro includes for example .sup.17F, .sup.18F,
.sup.19F; chloro includes for example .sup.35Cl, .sup.36Cl,
.sup.37Cl, .sup.38Cl, .sup.39Cl; and the like.
[0739] "Halogen" or "Halo" refers to all halogens, that is, chloro
(Cl), fluoro (F), bromo (Br), or iodo (I).
[0740] "Lower alkyl" alone or in combination means an
alkane-derived radical containing from 1 to 6 carbon atoms (unless
specifically defined) that includes a straight chain alkyl or
branched alkyl. In many embodiments, a lower alkyl is a straight or
branched alkyl group containing from 1-6, 1-4, or 1-2, carbon
atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl,
and the like. A lower alkyl may be independently substituted as
described herein, unless indicated otherwise, with one or more,
preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, wherein
the substituents are as indicated. Furthermore, possible
substitutions are attached at any available atom to produce a
stable compound. For example "halo substituted lower alkyl" denotes
a lower alkyl group substituted with one or more halogen atoms,
where preferably the lower alkyl is substituted with 1, 2, 3, 4 or
5 halogen atoms, also 1, 2, or 3 halogen atoms. Furthermore,
possible substitutions are attached at any available atom to
produce a stable compound. For example "fluoro substituted lower
alkyl" denotes a lower alkyl group substituted with one or more
fluoro atoms, such as perfluoroalkyl, where preferably the lower
alkyl is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2,
or 3 fluoro atoms. Exemplary fluoro substituted lower alkyl
includes, but is not limited to, CF.sub.3, CF.sub.2CF.sub.3,
CH.sub.2CF.sub.3, and the like. It is understood that substitutions
are chemically feasible and attached at any available atom to
provide a stable compound.
[0741] "Lower alkoxy" refers to those lower alkyl groups as defined
herein attached to the remainder of the molecule via an oxygen
atom. Representative alkoxy groups include methoxy, ethoxy,
n-propoxy, i-propoxy, n-butoxy, n-pentoxy, n-heptoxy, and the like,
as well as isomers thereof.
[0742] "Lower alkenyl" alone or in combination means a straight or
branched hydrocarbon containing 2-6 carbon atoms (unless
specifically defined) and at least one, preferably 1-3, more
preferably 1-2, most preferably one, carbon to carbon double bond.
Carbon to carbon double bonds may be either contained within a
straight chain or branched portion. The straight chain or branched
lower alkenyl group is chemically feasible and attached at any
available point to provide a stable compound. Examples of lower
alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, and
the like.
[0743] "Lower alkynyl" alone or in combination means a straight or
branched hydrocarbon containing 2-6 carbon atoms (unless
specifically defined) containing at least one, preferably one,
carbon to carbon triple bond. The straight chain or branched lower
alkynyl group is chemically feasible and attached at any available
point to provide a stable compound. Examples of alkynyl groups
include ethynyl, propynyl, butynyl, and the like.
[0744] "Cycloalkyl" refers to saturated or unsaturated,
non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems
of 3-10, also 3-8, more preferably 3-6, ring members per ring, such
as cyclopropyl, cyclopentyl, cyclohexyl, adamantyl, and the
like.
[0745] "Heterocycloalkyl" refers to a saturated or unsaturated
non-aromatic cycloalkyl group having from 5 to 10 atoms in which
from 1 to 3 carbon atoms in the ring are replaced by heteroatoms of
O, S or N, and are optionally fused with benzo or heteroaryl of 5-6
ring members. Heterocycloalkyl is also intended to include oxidized
S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring
nitrogen. Heterocycloalkyl is also intended to include compounds in
which a ring carbon may be oxo substituted, i.e. the ring carbon is
a carbonyl group, such as lactones and lactams. The point of
attachment of the heterocycloalkyl ring is at a carbon or nitrogen
atom such that a stable ring is retained. Examples of
heterocycloalkyl groups include, but are not limited to,
morpholino, tetrahydrofuranyl, dihydropyridinyl, piperidinyl,
pyrrolidinyl, pyrrolidonyl, piperazinyl, dihydrobenzofuryl, and
dihydroindolyl.
[0746] "Cycloalkylamino" denotes the group --NR.sup.aR.sup.b, where
R.sup.a and R.sup.b combine with the nitrogen to form a 5-7
membered heterocycloalkyl, where the heterocycloalkyl may contain
an additional heteroatom within the ring, such as O, N, or S, and
may also be further substituted with lower alkyl. Examples of 5-7
membered heterocycloalkyl include, but are not limited to,
piperidine, piperazine, 4-methylpiperazine, morpholine, and
thiomorpholine. It is understood that when cycloalkylamino is a
substituent on other moieties, these are chemically feasible and
attached at any available atom to provide a stable compound.
[0747] As used herein "Protecting group" refers to a grouping of
atoms that when attached to a reactive group in a molecule masks,
reduces or prevents that reactivity. Examples of protecting groups
can be found in T. W. Greene and P. G. Wuts, PROTECTIVE GROUPS IN
ORGANIC CHEMISTRY, (Wiley, 4th ed. 2006), Beaucage and Iyer,
Tetrahedron 48:2223-2311 (1992), and Harrison and Harrison et al.,
COMPENDIUM OF SYNTHETIC ORGANIC METHODS, Vols. 1-8 (John Wiley and
Sons. 1971-1996). Representative amino protecting groups include
formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ),
tert-butoxycarbonyl (Boc), trimethyl silyl (TMS),
2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted
trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl
(FMOC), nitro-veratryloxycarbonyl (NVOC), tri-isopropylsilyl
(TIPS), phenylsulphonyl and the like (see also, Boyle, A. L.
(Editor), CURRENT PROTOCOLS IN NUCLEIC ACID CHEMISTRY, John Wiley
and Sons, New York, Volume 1, 2000).
[0748] As used herein, "Leaving group" has the meaning
conventionally associated with it in synthetic organic chemistry,
i.e., an atom or a group capable of being displaced by a
nucleophile and includes halo (such as chloro, bromo, and iodo),
alkanesulfonyloxy, arenesulfonyloxy, alkylcarbonyloxy (e.g.,
acetoxy), arylcarbonyloxy, mesyloxy, tosyloxy,
trifluoromethanesulfonyloxy, aryloxy (e.g., 2,4-dinitrophenoxy),
methoxy, N,O-dimethylhydroxylamino, and the like.
[0749] As used herein, the terms "treat", "treating", "therapy",
"therapies", and like terms refer to the administration of
material, e.g., any one or more compound(s) as described herein in
an amount effective to prevent, alleviate, or ameliorate one or
more symptoms of a disease or condition, i.e., indication, and/or
to prolong the survival of the subject being treated.
[0750] As used herein, the term "Fms and/or Kit protein kinase
mediated disease or condition" refers to a disease or condition in
which the biological function of a Fms protein kinase, including
any mutation thereof, a Kit protein kinase, including any mutation
thereof, or both a Fms and Kit protein kinase, including any
mutations thereof, affects the development, course, and/or symptoms
of the disease or condition, and/or in which modulation of the Fms
and/or Kit protein kinase alters the development, course, and/or
symptoms of the disease or condition. A Fms and/or Kit protein
kinase mediated disease or condition includes a disease or
condition for which modulation provides a therapeutic benefit, e.g.
wherein treatment with Fms and/or Kit protein kinase inhibitor(s),
including one or more compound(s) described herein, provides a
therapeutic benefit to the subject suffering from or at risk of the
disease or condition.
[0751] As used herein, the terms "Fms protein kinase mediated
disease or condition," "c-fms mediated disease or condition," and
the like refer to a disease or condition in which the biological
function of a Fms protein kinase, including any mutations thereof,
affects the development, course, and/or symptoms of the disease or
condition, and/or in which modulation of the Fms protein kinase
alters the development, course, and/or symptoms of the disease or
condition. The Fms protein kinase mediated disease or condition
includes a disease or condition for which Fms inhibition provides a
therapeutic benefit, e.g. wherein treatment with Fms inhibitor(s),
including one or more compound(s) described herein, provides a
therapeutic benefit to the subject suffering from or at risk of the
disease or condition.
[0752] As used herein, the terms "Kit protein kinase mediated
disease or condition," "c-kit mediated disease or condition," and
the like refer to a disease or condition in which the biological
function of a Kit protein kinase, including any mutations thereof,
affects the development, course, and/or symptoms of the disease or
condition, and/or in which modulation of the Kit protein kinase
alters the development, course, and/or symptoms of the disease or
condition. The Kit protein kinase mediated disease or condition
includes a disease or condition for which Kit inhibition provides a
therapeutic benefit, e.g. wherein treatment with Kit inhibitor(s),
including one or more compound(s) described herein, provides a
therapeutic benefit to the subject suffering from or at risk of the
disease or condition.
[0753] As used herein, the term "dual Fms/Kit inhibitor" refers to
a compound that inhibits both Fms and Kit protein kinases, i.e. a
compound having an IC.sub.50 of less than 500 nm, less than 100 nM,
less than 50 nM, less than 20 nM, less than 10 nM, less than 5 nM,
or less than 1 nM as determined in a generally accepted Fms kinase
activity assay and having an IC.sub.50 of less than 500 nm, less
than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM,
less than 5 nM, or less than 1 nM as determined in a comparable
generally accepted Kit kinase activity assay, wherein the activity
is approximately equipotent on each. Compounds are considered
approximately equipotent if the ratio of IC.sub.50 for Kit kinase
activity divided by the IC.sub.50 for Fms kinase activity is in the
range of 20 to 0.05, also 10 to 0.1, also 5 to 0.2. Such compounds
are effective in treating a disease or condition that is either or
both of a Fms protein kinase mediated and Kit protein kinase
mediated disease or condition. Such compounds are preferably, but
not necessarily, selective with respect to other protein kinases,
i.e. when compared to another protein kinase, the IC.sub.50 for the
other kinase divided by the IC.sub.50 for Fms kinase is >20,
also >30, also >40, also >50, also >60, also >70,
also >80, also >90, also >100. Preferably, the compounds
are selective relative to other protein kinases including, but not
limited to, CSK, Insulin receptor kinase, AMPK, PDGFR or VEGFR.
While it is understood that a dual Fms/Kit inhibitor may be used to
treat any Fms protein kinase mediated disease or condition, the
dual inhibition of Fms and Kit provides beneficial effects in
treating certain diseases or conditions, including, but not limited
to, metastatic breast cancer, prostate cancer, multiple myeloma,
melanoma, acute myeloid leukemia, brain metastases,
neurofibromatosis, gastrointestinal stromal tumors, rheumatoid
arthritis, or multiple sclerosis.
[0754] As used herein, the term "dual Fms/Flt-3 inhibitor" refers
to a compound that inhibits both Fms and Flt-3 protein kinases,
i.e. a compound having an IC.sub.50 of less than 500 nm, less than
100 nM, less than 50 nM, less than 20 nM, less than 10 nM, less
than 5 nM, or less than 1 nM as determined in a generally accepted
Fms kinase activity assay and having an IC.sub.50 of less than 500
nm, less than 100 nM, less than 50 nM, less than 20 nM, less than
10 nM, less than 5 nM, or less than 1 nM as determined in a
comparable generally accepted Flt-3 kinase activity assay, wherein
the activity is approximately equipotent on each. Compounds are
considered approximately equipotent if the ratio of IC.sub.50 for
Flt-3 kinase activity divided by the IC.sub.50 for Fms kinase
activity is in the range of 20 to 0.05, also 10 to 0.1, also 5 to
0.2. Such compounds are effective in treating a disease or
condition that is either or both of a Fms protein kinase mediated
and Flt-3 protein kinase mediated disease or condition. Such
compounds are preferably, but not necessarily, selective with
respect to other protein kinases, i.e. when compared to another
protein kinase, the IC.sub.50 for the other kinase divided by the
IC.sub.50 for Fms kinase is >20, also >30, also >40, also
>50, also >60, also >70, also >80, also >90, also
>100. Preferably, the compounds are selective relative to other
protein kinases including, but not limited to, CSK, Insulin
receptor kinase, AMPK, PDGFR or VEGFR. While it is understood that
a dual Fms/Flt-3 inhibitor may be used to treat any Fms protein
kinase mediated disease or condition, the dual inhibition of Fms
and Flt-3 provides beneficial effects in treating certain diseases
or conditions, including, but not limited to, acute myeloid
leukemia.
[0755] As used herein, the term "Fms selective inhibitor" refers to
a compound that selectively inhibits Fms kinase relative to Kit
kinase, i.e. a compound having an IC.sub.50 of less than 500 nm,
less than 100 nM, less than 50 nM, less than 20 nM, less than 10
nM, less than 5 nM, or less than 1 nM as determined in a generally
accepted Fms kinase activity assay and when determined in a
comparable generally accepted Kit kinase activity assay will have a
ratio of IC.sub.50 for Kit kinase divided by the IC.sub.50 for Fms
kinase of >20, also >30, also >40, also >50, also
>60, also >70, also >80, also >90, also >100. Such
compounds are effective in treating a disease or condition that is
Fms protein kinase mediated, without effecting Kit protein kinase.
Such compounds are preferably, but not necessarily, selective with
respect to other protein kinases, i.e. when compared to another
protein kinase, the IC.sub.50 for the other kinase divided by the
IC.sub.50 for Fms kinase is >20, also >30, also >40, also
>50, also >60, also >70, also >80, also >90, also
>100. Preferably, the compounds are selective relative to other
protein kinases including, but not limited to, CSK, Insulin
receptor kinase, AMPK, PDGFR or VEGFR. While it is understood that
a Fms selective inhibitor may be used to treat any Fms protein
kinase mediated disease or condition, the Fms selectivity provides
beneficial effects in treating certain diseases or conditions,
including, but not limited to, rheumatoid arthritis, Alzheimer's
disease, Parkinson's disease, osteoarthritis, nephritis, diabetic
nephropathy, or renal hypertrophy.
[0756] As used herein, the term "blood brain barrier" refers to the
physical barrier in the circulation system that prevents many
substances, including certain small molecule drugs, from entering
into the central nervous system (CNS). Drugs which are intended to
interact with molecular targets in the CNS must cross the blood
brain barrier to reach their intended targets. Conversely,
peripherally acting agents should not cross the blood brain barrier
so as to avoid any CNS related side effects. The ability of a
compound to penetrate the blood brain barrier is expressed as the
blood brain barrier permeability or the ratio of the steady-state
concentrations of the compound in the brain and in the blood. The
experimental blood brain barrier permeability can be measured by in
vivo methods. Various methods can be employed for measuring the
fraction of compound transported from the blood to brain tissue,
including brain blood partitioning, brain perfusion, brain uptake
index, and intracerebral microdialysis. However, these in vivo
methods are laborious and low-throughput in nature. In practice, in
silico computational methods are often used to predict the blood
brain barrier permeability prior to in vivo confirmation. Most of
the blood brain barrier models that have been built so far are
based on the assumption that the majority of the compounds are
transported across the blood brain barrier by passive diffusion. Of
all the physicochemical properties, polar surface area (PSA) shows
the best correlation with the blood brain barrier permeability for
passively diffused compounds. Empirical evidence suggests that
compounds having a polar surface area of 100 or greater typically
have a low probability of crossing the blood brain barrier. Polar
surface area is readily calculated from the compound structure
using a published algorithm (Ertl et al., J. Med. Chem. 2000,
43:3714-3717). While it is understood that a Fms selective
inhibitor may be used to treat any Fms protein kinase mediated
disease or condition, compounds that effectively cross the blood
brain barrier provide beneficial effects in treating certain
diseases or conditions, including, but not limited to, multiple
sclerosis, glioblastoma, Alzheimer's disease, and Parkinson's
disease, while compounds that do not effectively cross the blood
brain barrier provide beneficial effects in treating certain
diseases or conditions, including, but not limited to, rheumatoid
arthritis, osteoarthritis, atherosclerosis, systemic lupus
erythematosus, glomerulonephritis, interstitial nephritis, Lupus
nephritis, tubular necrosis, diabetic nephropathy, or renal
hypertrophy.
[0757] As used herein, the term "solid form" refers to a solid
preparation (i.e. a preparation that is neither gas nor liquid) of
a pharmaceutically active compound that is suitable for
administration to an intended animal subject for therapeutic
purposes. The solid form includes any complex, such as a salt,
co-crystal or an amorphous complex, as well as any polymorph of the
compound. The solid form may be substantially crystalline,
semi-crystalline or substantially amorphous. The solid form may be
administered directly or used in the preparation of a suitable
composition having improved pharmaceutical properties. For example,
the solid form may be used in a formulation comprising at least one
pharmaceutically acceptable carrier or excipient.
[0758] As used herein, the term "substantially crystalline"
material embraces material which has greater than about 90%
crystallinity; and "crystalline" material embraces material which
has greater than about 98% crystallinity.
[0759] As used herein, the term "substantially amorphous" material
embraces material which has no more than about 10% crystallinity;
and "amorphous" material embraces material which has no more than
about 2% crystallinity.
[0760] As used herein, the term "semi-crystalline" material
embraces material which is greater than 10% crystallinity, but no
greater than 90% crystallinity; preferably "semi-crystalline"
material embraces material which is greater than 20% crystallinity,
but no greater than 80% crystallinity. In one aspect of the present
invention, a mixture of solid forms of a compound may be prepared,
for example, a mixture of amorphous and crystalline solid forms,
e.g. to provide a "semi-crystalline" solid form. Such a
"semi-crystalline" solid form may be prepared by methods known in
the art, for example by mixing an amorphous solid form with a
crystalline solid form in the desired ratio. In some instances, a
compound mixed with acid or base forms an amorphous complex; a
semi-crystalline solid can be prepared employing an amount of
compound component in excess of the stoichiometry of the compound
and acid or base in the amorphous complex, thereby resulting in an
amount of the amorphous complex that is based on the stoichiometry
thereof, with excess compound in a crystalline form. The amount of
excess compound used in the preparation of the complex can be
adjusted to provide the desired ratio of amorphous complex to
crystalline compound in the resulting mixture of solid forms. For
example, where the amorphous complex of acid or base and compound
has a 1:1 stoichiometry, preparing said complex with a 2:1 mole
ratio of compound to acid or base will result in a solid form of
50% amorphous complex and 50% crystalline compound. Such a mixture
of solid forms may be beneficial as a drug product, for example, by
providing an amorphous component having improved biopharmaceutical
properties along with the crystalline component. The amorphous
component would be more readily bioavailable while the crystalline
component would have a delayed bioavailability. Such a mixture may
provide both rapid and extended exposure to the active
compound.
[0761] As used herein, the term "complex" refers to a combination
of a pharmaceutically active compound and an additional molecular
species that forms or produces a new chemical species in a solid
form. In some instances, the complex may be a salt, i.e. where the
additional molecular species provides an acid/base counter ion to
an acid/base group of the compound resulting in an acid:base
interaction that forms a typical salt. While such salt forms are
typically substantially crystalline, they can also be partially
crystalline, substantially amorphous, or amorphous forms. In some
instances, the additional molecular species, in combination with
the pharmaceutically active compound, forms a non-salt co-crystal,
i.e. the compound and molecular species do not interact by way of a
typical acid:base interaction, but still form a substantially
crystalline structure. Co-crystals may also be formed from a salt
of the compound and an additional molecular species. In some
instances, the complex is a substantially amorphous complex, which
may contain salt-like acid:base interactions that do not form
typical salt crystals, but instead form a substantially amorphous
solid, i.e. a solid whose X-ray powder diffraction pattern exhibits
no sharp peaks (e.g. exhibits an amorphous halo).
[0762] As used herein, the term "stoichiometry" refers to the molar
ratio of two or more reactants that combine to form a complex, for
example, the molar ratio of acid or base to compound that form an
amorphous complex. For example, a 1:1 mixture of acid or base with
compound (i.e. 1 mole acid or base per mole of compound) resulting
in an amorphous solid form has a 1:1 stoichiometry.
[0763] As used herein, the term "composition" refers to a
pharmaceutical preparation suitable for administration to an
intended subject for therapeutic purposes that contains at least
one pharmaceutically active compound, including any solid form
thereof. The composition may include at least one pharmaceutically
acceptable component to provide an improved formulation of the
compound, such as a suitable carrier or excipient.
[0764] As used herein, the term "subject" refers to a living
organism that is treated with compounds as described herein,
including, but not limited to, any mammal, such as a human, other
primates, sports animals, animals of commercial interest such as
cattle, farm animals such as horses, or pets such as dogs and
cats.
[0765] As used herein, the term "biopharmaceutical properties"
refers to the pharmacokinetic action of a compound or complex of
the present invention, including the dissolution, absorption and
distribution of the compound on administration to a subject. As
such, certain solid forms of compounds of the invention, such as
amorphous complexes of compounds of the invention, are intended to
provide improved dissolution and absorption of the active compound,
which is typically reflected in improved C.sub.max (i.e. the
maximum achieved concentration in the plasma after administration
of the drug) and improved AUC (i.e. area under the curve of drug
plasma concentration vs. time after administration of the
drug).
[0766] The term "pharmaceutically acceptable" indicates that the
indicated material does not have properties that would cause a
reasonably prudent medical practitioner to avoid administration of
the material to a patient, taking into consideration the disease or
conditions to be treated and the respective route of
administration. For example, it is commonly required that such a
material be essentially sterile, e.g., for injectables.
[0767] Certain compounds of the present invention can exist in
unsolvated forms as well as solvated forms, including hydrated
forms. "Hydrate" refers to a complex formed by combination of water
molecules with molecules or ions of the solute. "Solvate" refers to
a complex formed by combination of solvent molecules with molecules
or ions of the solute. The solvent can be an organic compound, an
inorganic compound, or a mixture of both. Solvate is meant to
include hydrate. Some examples of solvents include, but are not
limited to, methanol, N,N-dimethylformamide, tetrahydrofuran,
dimethylsulfoxide, and water. In general, the solvated forms are
equivalent to unsolvated forms and are encompassed within the scope
of the present invention. Certain compounds of the present
invention may exist in multiple crystalline or amorphous forms. In
general, all physical forms are equivalent for the uses
contemplated by the present invention and are intended to be within
the scope of the present invention.
[0768] In the present context, the term "therapeutically effective"
or "effective amount" indicates that the materials or amount of
material is effective to prevent, alleviate, or ameliorate one or
more symptoms of a disease or medical condition, and/or to prolong
the survival of the subject being treated.
[0769] In the present context, the terms "synergistically
effective" or "synergistic effect" indicate that two or more
compounds that are therapeutically effective, when used in
combination, provide improved therapeutic effects greater than the
additive effect that would be expected based on the effect of each
compound used by itself.
[0770] By "assaying" is meant the creation of experimental
conditions and the gathering of data regarding a particular result
of the experimental conditions. For example, enzymes can be assayed
based on their ability to act upon a detectable substrate. A
compound can be assayed based on its ability to bind to a
particular target molecule or molecules.
[0771] As used herein, the term "modulating" or "modulate" refers
to an effect of altering a biological activity, especially a
biological activity associated with a particular biomolecule such
as a protein kinase. For example, an inhibitor of a particular
biomolecule modulates the activity of that biomolecule, e.g., an
enzyme, by decreasing the activity of the biomolecule, such as an
enzyme. Such activity is typically indicated in terms of an
inhibitory concentration (IC.sub.50) of the compound for an
inhibitor with respect to, for example, an enzyme.
[0772] In the context of the use, testing, or screening of
compounds that are or may be modulators, the term "contacting"
means that the compound(s) are caused to be in sufficient proximity
to a particular molecule, complex, cell, tissue, organism, or other
specified material that potential binding interactions and/or
chemical reaction between the compound and other specified material
can occur.
[0773] "Pain" or a "pain condition" can be acute and/or chronic
pain, including, without limitation, arachnoiditis; arthritis (e.g.
osteoarthritis, rheumatoid arthritis, ankylosing spondylitis,
gout); back pain (e.g. sciatica, ruptured disc, spondylolisthesis,
radiculopathy); burn pain; cancer pain; dysmenorrhea; headaches
(e.g. migraine, cluster headaches, tension headaches); head and
facial pain (e.g. cranial neuralgia, trigeminal neuralgia);
hyperalgesia; hyperpathia; inflammatory pain (e.g. pain associated
with irritable bowel syndrome, inflammatory bowel disease,
ulcerative colitis, Crohn's disease, cystitis, pain from bacterial,
fungal or viral infection); keloid or scar tissue formation; labor
or delivery pain; muscle pain (e.g. as a result of polymyositis,
dermatomyositis, inclusion body myositis, repetitive stress injury
(e.g. writer's cramp, carpal tunnel syndrome, tendonitis,
tenosynovitis)); myofascial pain syndromes (e.g. fibromyalgia);
neuropathic pain (e.g. diabetic neuropathy, causalgia, entrapment
neuropathy, brachial plexus avulsion, occipital neuralgia, gout,
reflex sympathetic dystrophy syndrome, phantom limb or
post-amputation pain, postherpetic neuralgia, central pain
syndrome, or nerve pain resulting from trauma (e.g. nerve injury),
disease (e.g. diabetes, multiple sclerosis, Guillan-Barre Syndrome,
myasthenia gravis, neurodegenerative diseases such as Parkinson's
disease, Alzheimer's disease, amyotrophic lateral sclerosis, or
cancer treatment); pain associated with skin disorders (e.g.
shingles, herpes simplex, skin tumors, cysts, neurofibromatosis);
sports injuries (e.g. cuts, sprains, strains, bruises,
dislocations, fractures, spinal chord, head); spinal stenosis;
surgical pain; tactile allodynia; temporomandibular disorders;
vascular disease or injury (e.g. vasculitis, coronary artery
disease, reperfusion injury (e.g. following ischemia, stroke, or
myocardial infarcts)); other specific organ or tissue pain (e.g.
ocular pain, corneal pain, bone pain, heart pain, visceral pain
(e.g. kidney, gall bladder, gastrointestinal), joint pain, dental
pain, pelvic hypersensitivity, pelvic pain, renal colic, urinary
incontinence); other disease associated pain (e.g. sickle cell
anemia, AIDS, herpes zoster, psoriasis, endometriosis, asthma,
chronic obstructive pulmonary disease (COPD), silicosis, pulmonary
sarcoidosis, esophagitis, heart burn, gastroesophageal reflux
disorder, stomach and duodenal ulcers, functional dyspepsia, bone
resorption disease, osteoporosis, cerebral malaria, bacterial
meningitis); or pain due to graft v. host rejection or allograft
rejections.
Kinase Targets and Indications
[0774] Protein kinases play key roles in propagating biochemical
signals in diverse biological pathways. More than 500 kinases have
been described, and specific kinases have been implicated in a wide
range of diseases or conditions (i.e., indications), including for
example without limitation, cancer, cardiovascular disease,
inflammatory disease, neurological disease, and other diseases. As
such, kinases represent important control points for small molecule
therapeutic intervention. Specific target protein kinases, i.e. Fms
kinase and Kit kinase, contemplated by the present invention are
described in the art, including, without limitation, as described
in U.S. patent application Ser. No. 11/473,347 (see also, PCT
publication WO2007002433), the disclosure of which is hereby
incorporated by reference with respect to such kinase targets, as
well as the following:
[0775] Fms: Target kinase Fms (i.e., feline McDonough sarcoma) is a
member of the family of genes originally isolated from the Susan
McDonough strain of feline sarcoma viruses. Fms is a transmembrane
tyrosine kinase of 108.0 kDa coded by chromosome 5q33.2-q33.3
(symbol: CSF1R). The structure of the transmembrane receptor Fms
comprises two Ig-like domains, a IgC2-like domain, two additional
Ig-like domains, a TM domain, and the TK domain.
[0776] Fms is the receptor for the macrophage colony-stimulating
factor (M-CSF), and is crucial for the growth and differentiation
of the monocyte-macrophage lineage. Upon binding of M-CSF to the
extracellular domain of Fms, the receptor dimerizes and
trans-autophosphorylates cytoplasmic tyrosine residues.
[0777] M-CSF, first described by Robinson and co-workers (Blood.
1969, 33:396-9), is a cytokine that controls the production,
differentiation, and function of macrophages. M-CSF stimulates
differentiation of progenitor cells to mature monocytes, and
prolongs the survival of monocytes. Furthermore, M-CSF enhances
cytotoxicity, superoxide production, phagocytosis, chemotaxis, and
secondary cytokine production of additional factors in monocytes
and macrophages. Examples of such additional factors include
granulocyte colony stimulating factor (G-CSF), interleukin-6
(IL-6), and interleukin-8 (IL-8). M-CSF stimulates hematopoiesis,
promotes differentiation and proliferation of osteoclast progenitor
cells, and has profound effects on lipid metabolism. Furthermore,
M-CSF is important in pregnancy. Physiologically, large amounts of
M-CSF are produced in the placenta, and M-CSF is believed to play
an essential role in trophoblast differentiation (Motoyoshi, Int J
Hematol. 1998, 67:109-22). The elevated serum M-CSF levels of early
pregnancy may participate in the immunologic mechanisms responsible
for the maintenance of the pregnancy (Flanagan & Lader, Curr
Opin Hematol. 1998, 5:181-5).
[0778] Aberrant expression and/or activation of Fms has been
implicated in acute myeloid leukemia, AML (Ridge et al, Proc. Nat.
Acad. Sci., 1990, 87:1377-1380). Mutations at codon 301 are
believed to lead to neoplastic transformation by ligand
independence and constitutive tyrosine kinase activity of the
receptor. The tyrosine residue at codon 969 has been shown to be
involved in a negative regulatory activity, which is disrupted by
amino acid substitutions. Accordingly, Fms mutations are most
prevalent (20%) in chronic myelomonocytic leukemia and AML type M4
(23%), both of which are characterized by monocytic
differentiation.
[0779] A condition related to AML is chronic myeloid leukemia
(CML). During the myeloid blast crisis (BC) of CML, non-random
additional chromosome abnormalities occur in over 80% of patients.
However, these cytogenetic changes have been reported to precede
the clinical signs of CML-BC by several months to years suggesting
that other biological events may participate in the multistep
process of acute transformation of CML. The autocrine production of
growth factors has been shown to occur in several hematological
malignancies and particularly in AML. Specchia et al [Br J
Haematol. 1992 March; 80(3):310-6] have demonstrated that IL-1 beta
gene is expressed in almost all cases of CML in myeloid blast
crisis, and that a high proportion of cases showed constitutive
expression of the M-CSF gene. Many of the same patients in the
Specchia et al study demonstrated simultaneous co-expression of
Fms. After exposure of leukemic cells to phorbol myristate acetate
(PMA), release of M-CSF protein was documented in three of five
patients studied; however, no significant interleukin-3 (IL-3),
granulocyte-macrophage colony-stimulating factor (GM-CSF) or
granulocyte colony-stimulating factor (G-CSF), was detected in
these patients. This demonstrates that different patterns of growth
factors secretion exist in AML and CML, and that distinct molecular
events are likely involved in the control of leukemic
proliferation.
[0780] The observation that production of M-CSF, the major
macrophage growth factor, is increased in tissues during
inflammation (Le Meur et al, J. Leukocyte Biology. 2002;
72:530-537) provides a role for Fms in certain diseases. For
example, COPD is characterized by airflow limitation that is not
fully reversible. The airflow limitation is usually progressive and
associated with an abnormal inflammatory response of the lungs to
noxious particles or gases. The chronic inflammation of COPD is
observed through the airways, parenchyma, and pulmonary
vasculature. The inflammatory cell population consists of
neutrophils, macrophages, and T lymphocytes, along with eosinophils
in some patients. Macrophages are postulated to play an
orchestrating role in COPD inflammation by releasing mediators such
as TNF-a, IL-8 and LTB4, which are capable of damaging lung
structures and/or sustaining neutrophilic inflammation.
[0781] Further, M-CSF/fms signaling is critical to osteoclast
formation and survival of osteoclast precursors. For example,
estrogen loss in menopause results in increased M-CSF and thus
increased osteoclast number and bone resorption which leads to
increased risk of fracture and osteoporosis. Accordingly, blockage
of this signal is a target for the inhibition of bone resorption
(Teitelbaum, Science. 2000; 289:1504; Rohan, Science. 2000;
289:1508).
[0782] Atherosclerosis, an inflammatory disease of the vessel
walls, is associated with significant morbidity and mortality. A
effect for Fms inhibition in the treatment and prevention of
atherosclerosis depends on several observations (Libby, Nature.
2002; 420:868-874). First, monocytes resident in the arterial
intima increase expression of scavenger receptors and internalize
modified lipoproteins. The resulting lipid-laden macrophages
develop into foam cells characteristic of the atherosclerotic
lesion. Macrophages in atheroma secrete cytokines and growth
factors involved in lesion progression. Additionally, macrophages
replicate within the intima. Through Fms, M-CSF activates the
transition from monocyte to lipid-laden macrophage and augments
expression of scavenger receptor A. Indeed, atherosclerotic plaques
over-express M-CSF which is critical for atherosclerotic
progression. Mice deficient in M-CSF have been found to experience
less severe atherosclerosis than mice with normal M-CSF
(Rajavashisth, et. al., J. Clin. Invest. 1998; 101:2702-2710; Qiao,
et. al., Am. J. Path. 1997; 150:1687-1699). Accordingly, inhibitors
of Fms disrupt M-CSF signaling, compromising monocyte to macrophage
foam cell progression, macrophage survival and replication, and
cytokine signaling that participates in lesion progression.
[0783] The role of M-CSF and Fms in emphysema appears to involve
the regulation of elastin metabolism through control of matrix
metalloproteins. M-CSF has a role in the modulation of the
accumulation and function of alveolar macrophages (AMs) in vivo
(Shibata et al, Blood 2001, 98: pp. 2845-2852). Osteopetrotic
(Op/Op) mice have no detectable M-CSF and show variable
tissue-specific reductions in macrophage numbers. Accordingly, it
was hypothesized that AMs would be decreased in number and have
altered function in Op/Op mice because of the absence of M-CSF.
Shibata et al found that lung macrophages identified in lung
sections were decreased in number in 20-day-old Op/Op mice but not
Op/Op mice older than 4 months compared with findings in
age-matched littermate controls. The numbers of AMs recovered by
bronchoalveolar lavage (BAL) were also reduced in young but not
adult Op/Op mice compared with controls. Importantly, AMs of Op/Op
mice spontaneously release higher levels of matrix
metalloproteinases (MMPs) than AMs of controls. Consistent with an
increased release of MMP, Op/Op mice have abnormal elastin
deposition and spontaneously develop emphysema in the absence of
molecular or cellular evidence of lung inflammation. Accordingly,
the modulation of metalloelastase activity in macrophages by M-CSF
may control the degradation of elastin fibers in lungs or blood
vessels.
[0784] Metastatic cancer cells cause bone destruction, with
associated fracture, pain, deformation, and hypercalcaemia, due to
production of osteoclasticogenic factors including M-CSF by tumor
cells (Clohisy et al, Clin. Orthop. 2000, 373: 104-14). Binding of
M-CSF to the Fms product stimulates formation of osteoclasts and
osteolytic activity (Kodama et al, J. Exp. Med. 1991, 173: 269-72;
Feng et al, Endocrinology 2002, 143: 4868-74). Accordingly,
inhibition of osteoclast activity at the level of Fms offers a
compelling target for amelioration of bone metastasis. Fms is also
a target for amelioration of metastatic breast cancer (Lawicki et
al., Clin Chim Acta. 2006, September, 371(1-2):112-6; Wyckoff et
al., Cancer Res. 2007, Mar. 15, 67(6):2649-56).
[0785] Nephritis is inflammation of the kidneys. It may be caused
for example by a bacterial infection of the kidneys or exposure to
a toxin. However, nephritis more commonly develops from an abnormal
immune reaction, which can occur, for example, when an antibody
attacks either the kidney itself or an antigen attached to kidney
cells, or when an antigen-antibody complex formed elsewhere in the
body attaches to cells in the kidney. Some types of nephritis
involve infiltration of kidney tissues by white blood cells and
deposits of antibodies. In other types of nephritis, inflammation
may consist of tissue swelling or scarring without white blood
cells or antibodies. Furthermore, nephritis can occur anywhere in
the kidneys. With respect to the glomeruli, progressive damage to
glomeruli causes urine production to fall and metabolic waste
products to build up in the blood. When damage to glomeruli is
severe, inflammatory cells and injured glomerular cells accumulate,
compressing the capillaries within the glomerulus and interfering
with filtration. Scarring may develop, impairing kidney function
and reducing urine production. In some cases, microthrombi may form
in the small blood vessels, further decreasing kidney function.
Less commonly, nephritis involves the tubulointerstitial tissues;
such inflammation is called tubulointerstitial nephritis. When
inflammation damages the tubules and the tubulointerstitial
tissues, the kidneys may become unable to concentrate urine,
eliminate (excrete) metabolic waste products from the body, or
balance the excretion of sodium and other electrolytes, such as
potassium. When the tubules and tubulointerstitial tissues are
damaged, kidney failure often develops. Accordingly, inhibition of
Fms offers a target for therapeutic intervention in nephritis due
to the modulation of the inflammatory response comprising the
etiology of the disease.
[0786] Lupus nephritis, i.e., renal involvement in systemic lupus
erythematosus (SLE), is a common disease manifestation with a poor
prognosis. At least three potentially overlapping,
immuno-pathogenic mechanisms for lupus nephritis are supported by
experimental data. First, circulating immune complexes consisting
chiefly of DNA and anti-DNA are deposited in the kidney. Resulting
complement activation and chemotaxis of neutrophils leads to a
local inflammatory process. Second, in situ formation of antigen
and antibody complexes may similarly lead to complement activation
and leucocyte mediated injury. Third, antibodies against specific
cellular targets may produce renal injury. An additional mechanism
is observed in SLE patients with the antiphospholipid antibody
syndrome. Glomerular thrombosis can result from the
hypercoagulability that accompanies antibodies directed against
negatively charged phospholipid-protein complexes (e.g. biologic
false positive VDRL, anticardiolipin antibodies, and lupus
anticoagulant). Mesangial lupus nephritis is accompanied by normal
diagnostic findings or with a mild degree of proteinuria but
typically absence of hypertension or abnormal urinary sediment.
Focal and diffuse proliferative lupus glomerulonephritis are often
associated with the worst prognosis for renal survival and can be
accompanied by nephrotic syndrome, significant hypertension and
abnormal urine sediment. Membranous lupus nephritis often presents
with proteinuria, moderate to high grade, but usually normal
urinary sediment in the absence of hypertension. Mesangial lupus
nephropathy is generally associated with an excellent prognosis,
whereas proliferative lupus nephropathy, especially diffuse
variant, is often characterized by hypertension, red cell casts and
significant deterioration of renal function. Nephrotic syndrome in
the absence of hypertension, active urinary sediment or significant
hypocomplementemia suggest the membranous variant of lupus
nephropathy. Membranous nephropathy generally is associated with a
good prognosis and relative preservation of renal function.
However, in the presence of persistent nephrotic range proteinuria,
membranous lupus nephropathy can, in fact, lead to loss of renal
function and end stage renal disease (ESRD). Accordingly,
inhibition of Fms offers a target for therapeutic intervention in
lupus due to the modulation of the inflammatory response comprising
the etiology of the disease.
[0787] Macrophage accumulation is a prominent feature in many forms
of glomerulonephritis. Local proliferation of macrophages within
the kidney has been described in human and experimental
glomerulonephritis and may have an important role in augmenting the
inflammatory response. Isbel et al (Nephrol Dial Transplant 2001,
16: 1638-1647) examined the relationship between local macrophage
proliferation and renal expression of M-CSF. Glomerular and
tubulointerstitial M-CSF expression was found to be up-regulated in
human glomerulonephritis, being most prominent in proliferative
forms of disease. Because this correlates with local macrophage
proliferation, it suggests that increased renal M-CSF production
plays an important role in regulating local macrophage
proliferation in human glomerulonephritis. In a model of renal
inflammation (UUO--unilateral ureteric obstruction) anti-Fms
antibody treatment reduced macrophage accumulation (Le Meur et.
al., J Leukocyte Biology, 2002, 72: 530-537). Accordingly,
inhibition of Fms offers a target for therapeutic intervention in
glomerulonephritis.
[0788] Insulin resistance and obesity are hallmark of type II
diabetes and there is a strong correlation between insulin
resistance and abdominal visceral fact accumulation (Bjorntrop,
Diabetes Metab. Res. Rev., 1999, 15: 427-441). Current evidence
indicates that macrophages accumulating in adipose tissue release
TNF-a and other factors that cause adipocyte changes (hypertrophy,
lipolysis, reduced insulin sensitivity) and also promote insulin
resistance in surrounding tissues. Therefore, macrophage
accumulation in type 2 diabetes is important for disease
progression. Accordingly, inhibition of Fms has potential in
preventing the development of insulin resistance and
hyperglycemia.
[0789] Similarly, the observation that production of M-CSF, the
major macrophage growth factor, is increased in tissues during
inflammation points out a role for Fms in diseases, such as for
example inflammatory diseases. More particularly, because elevated
levels of M-CSF are found in the disease state, modulation of the
activity of Fms can ameliorate disease associated with increased
levels of M-C SF.
[0790] A Fms inhibitor may be useful in treating inflammatory and
autoimmune indications, including, but not limited to, rheumatoid
arthritis, osteoarthritis, psoriatic arthritis, psoriasis,
dermatitis, ankylosing spondylitis, polymyositis, dermatomyositis,
systemic sclerosis, juvenile idiopathic arthritis, polymyalgia
rheumatica, Sjogren's disease, Langerhan's cell histiocytosis
(LCH), Still's disease, inflammatory bowel syndrome, ulcerative
colitis, Crohn's disease, systemic lupus erythematosis (SLE),
transplant rejection, chronic obstructive pulmonary disease (COPD),
emphysema, Kawasaki's Disease, hemophagocytic syndrome (macrophage
activation syndrome), multicentric reticulohistiocytosis, and
atherosclerosis; metabolic disorders, including, but not limited
to, Type I diabetes, Type II diabetes, insulin resistance,
hyperglycemia, obesity, and lipolysis; disorders of bone structure,
mineralization and bone formation and resorption, including, but
not limited to, osteoporosis, osteodystrophy, increased risk of
fracture, Paget's disease, hypercalcemia, infection-mediated
osteolysis (e.g. osteomyelitis), and peri-prosthetic or
wear-debris-mediated osteolysis; kidney and genitourinary diseases,
including, but not limited to, endometriosis, nephritis (e.g.
glomerulonephritis, interstitial nephritis, Lupus nephritis),
tubular necrosis, diabetes-associated renal complications (e.g.
diabetic nephropathy), and renal hypertrophy; disorders of the
central nervous system, including, but not limited to, multiple
sclerosis, amyotrophic lateral sclerosis (ALS), myasthenia gravis,
chronic demyelinating polyneuropathy, other demyelinating
disorders, stroke, Alzheimer's disease and Parkinson's disease;
inflammatory and chronic pain, including, but not limited to, bone
pain; malignancies, including, but not limited to, multiple
myeloma, acute myeloid leukemia (AML), chronic myeloid leukemia
(CML), lung cancer, pancreatic cancer, prostate cancer, breast
cancer, ovarian cancer, neuroblastoma, sarcoma, osteosarcoma, giant
cell tumor of bone, giant cell tumor of tendon sheath (TGCT),
pigmented villonodular synovitis (PVNS), tumor angiogenesis,
melanoma, glioblastoma multiforme, glioma, other tumors of the
central nervous system, metastasis of tumors to other tissues, and
other chronic myeloproliferative diseases such as myelofibrosis;
vasculitis, including but not limited to collagen vascular disease,
polyarteritis nodosa, Behcet's disease, sarcoidosis, familiar
Mediterranean fever, Churg-Strauss vasculitis, temporal arteritis,
giant cell arteritis, Takayasu's arteritis; ophthalmic indications,
including but not limited to uveitis, scleritis, retinitis, age
related macular degeneration, choroidal neovascularization,
diabetic retinopathy; inherited disorders, including but not
limited to cherubism, neurofibromatosis; infectious disease
indications, including but not limited to infections associated
with human immunodeficiency virus, hepatitis B virus, hepatitis C
virus, human granulocytic anaplasmosis; lysosomal storage
disorders, including but not limited to Gaucher's disease, Fabry's
disease, Niemann-Pick disease; gastrointestinal indications,
including but not limited to liver cirrhosis; pulmonary
indications, including but not limited to pulmonary fibrosis, acute
lung injury (e.g. ventilator-induced, smoke- or toxin-induced); and
surgical indications, including but not limited to
(cardiopulmonary) bypass surgery, vascular surgery, and vascular
grafts.
[0791] Kit: Target kinase Kit (i.e., feline Hardy-Zuckerman 4
sarcoma viral oncogene) is a 109.9 kDa transmembrane tyrosine
kinase encoded by chromosome 4q12 (symbol: KIT). Receptor protein
tyrosine kinases (RPTKs) regulate key signal transduction cascades
that control cellular growth and proliferation. The Stem Cell
Factor (SCF) receptor Kit is a type III transmembrane RPTK that
includes five extracellular immunoglobulin (IG) domains, a single
transmembrane domain, and a split cytoplasmic kinase domain
separated by a kinase insert segment. Kit plays an important role
in the development of melanocytes, mast, germ, and hematopoietic
cells.
[0792] Stem Cell Factor (SCF) is a protein encoded by the S1 locus,
and has also been called kit ligand (KL) and mast cell growth
factor (MGF), based on the biological properties used to identify
it (reviewed in Tsujimura, Pathol Int 1996, 46:933-938; Loveland,
et al., J. Endocrinol 1997, 153:337-344; Vliagoftis, et al., Clin
Immunol 1997, 100:435-440; Broudy, Blood 1997, 90:1345-1364;
Pignon, Hermatol Cell Ther 1997, 39:114-116; and Lyman, et al.,
Blood 1998, 91:1101-1134). Herein the abbreviation SCF refers to
the ligand for Kit.
[0793] SCF is synthesized as a transmembrane protein with a
molecular weight of 220 or 248 Dalton, depending on alternative
splicing of the mRNA to encode exon 6. The larger protein can be
proteolytically cleaved to form a soluble, glycosylated protein
which noncovalently dimerizes. Both the soluble and membrane-bound
forms of SCF can bind to and activate Kit. For example, in the
skin, SCF is predominantly expressed by fibroblasts, keratinocytes,
and endothelial cells, which modulate the activity of melanocytes
and mast cells expressing Kit. In bone, marrow stromal cells
express SCF and regulate hematopoiesis of Kit expressing stem
cells. In the gastrointestinal tract, intestinal epithelial cells
express SCF and affect the interstitial cells of Cajal and
intraepithelial lymphocytes. In the testis, sertoli cells and
granulosa cells express SCF which regulates spermatogenesis by
interaction with Kit on germ cells.
[0794] According to OMIM, signaling from Kit is essential for
primordial germ cell growth both in vivo and in vitro. Many
downstream effectors of the KIT signaling pathway have been
identified in other cell types, but how these molecules control
primordial germ cell survival and proliferation are unknown.
Determination of the KIT effectors acting in primordial germ cells
has been hampered by the lack of effective methods to manipulate
easily gene expression in these cells. De Miguel et al. (2002)
overcame this problem by testing the efficacy of
retroviral-mediated gene transfer for manipulating gene expression
in mammalian germ cells. They found that primordial germ cells can
successfully be infected with a variety of types of retroviruses.
They used this method to demonstrate an important role of the AKT1
in regulating primordial germ cell growth (OMIM MIM Number: 164920:
Apr. 17, 2006).
[0795] Aberrant expression and/or activation of Kit has been
implicated in a variety of pathologic states. For example, evidence
for a contribution of Kit to neoplastic pathology includes its
association with leukemias and mast cell tumors, small cell lung
cancer, testicular cancer, and some cancers of the gastrointestinal
tract and central nervous system. In addition, Kit has been
implicated in playing a role in carcinogenesis of the female
genital tract sarcomas of neuroectodermal origin, and Schwann cell
neoplasia associated with neurofibromatosis. It was found that mast
cells are involved in modifying the tumor microenvironment and
enhancing tumor growth (Yang et al., J Clin Invest. 2003,
112:1851-1861; Viskochil, J Clin Invest. 2003, 112:1791-1793). Kit
inihibitors can also be used to target melanoma (Smalley et al.,
Histol Histopathol. 2009, May, 24(5):643-50), gastrointestinal
stromal tumors (Demetri, G D, Semin Oncol. 2001, October, 28(5
Suppl 17):19-26), neurofibromatosis (Yang et al., Cell, 2008, Oct.
31, 135(3):437-48), and multiple sclerosis (Secor et al., J Exp
Med. 2000, Mar. 6, 191(5):813-22).
[0796] A Kit inhibitor may be useful in treating malignancies,
including, but not limited to, mast cell tumors, small cell lung
cancer, non-small cell lung cancer (NSCLC), testicular cancer,
pancreatic cancer, breast cancer, merkel cell carcinoma, carcinomas
of the female genital tract, sarcomas of neuroectodermal origin,
colorectal carcinoma, carcinoma in situ, gastrointestinal stromal
tumors (GISTs), tumor angiogenesis, glioblastoma, astrocytoma,
neuroblastoma, neurofibromatosis (including Schwann cell neoplasia
associated with neurofibromatosis), acute myelocytic leukemia,
acute lymphocytic leukemia, chronic myelogenous leukemia,
mastocytosis, melanoma, and canine mast cell tumors; cardiovascular
disease, including but not limited to atherosclerosis,
cardiomyopathy, heart failure, pulmonary arterial hypertension, and
pulmonary fibrosis; inflammatory and autoimmune indications,
including, but not limited to, allergy, anaphylaxis, asthma,
rheumatoid arthritis, allergic rhinitis, multiple sclerosis,
inflammatory bowel syndrome, transplant rejection,
hypereosinophilia, urticaria and dermatitis; gastrointestinal
indications, including but not limited to gastroesophageal reflux
disease (GERD), esophagitis, and gastrointestinal tract ulcers;
ophthalmic indications, including but not limited to uveitis and
retinitis; and neurologic indications, including but not limited to
migraine.
[0797] Flt3: Target kinase Flt3 (i.e., Fms-like tyrosine kinase 3)
is a transmembrane tyrosine kinase of 112.8 kDa encoded by
chromosome 13q12 (symbol: FLT3). According to OMIM, Rosnet et al.
(Genomics 1991, 9: 380-385) isolated a novel member of the class 3
receptors discussed above. They demonstrated that this gene of the
tyrosine kinase family, called FLT3, has strong sequence
similarities with other members of the group. Lymphohematopoietic
stem cells serve as a reservoir for virtually all blood cells but
make up only approximately 0.01% of human or murine marrow cells.
The ability to isolate and expand this population has clinical
applications in bone marrow transplantations for cancer and genetic
diseases. Small et al. (Proc. Nat. Acad. Sci. 1994, 91: 459-463)
cloned the cDNA for stem cell tyrosine kinase 1, the human homolog
of murine Flk2/Flt3, from a CD34+ hematopoietic stem cell-enriched
library. The cDNA encded a protein of 993 amino acids with 85%
identity and 92% similarity to the murine homolog. STK1, which is
identical to FLT3, is a member of the type III receptor tyrosine
kinase family that includes KIT, FMS, and platelet-derived growth
factor receptor. STK1 expression in human blood and marrow is
restricted to CD34+ cells, a population greatly enriched by
stem/progenitor cells. Antisense oligonucleotides directed against
STK1 sequences inhibited hematopoietic colony formation, most
strongly in long-term bone marrow cultures. The data suggested that
STK1 may function as a growth factor receptor on hematopoietic stem
and/or progenitor cells (OMIM MIM Number: 136351: May 3, 2005).
[0798] Levis et al., state that Internal tandem duplication (ITD)
mutations of the receptor tyrosine kinase FLT3 have been found in
20% to 30% of patients with acute myeloid leukemia (AML). These
mutations constitutively activate the receptor and appear to be
associated with a poor prognosis. In their study, dose-response
cytotoxic assays were performed with AG1295, a tyrosine kinase
inhibitor active against FLT3, on primary blasts from patients with
AML, and they found that AG1295 was specifically cytotoxic to AML
blasts harboring FLT3/ITD mutations. They suggest that these
mutations contribute to the leukemic process and that the FLT3
receptor represents a therapeutic target in AML (Levis et al.,
Blood 2001, 98:885-887). An Flt3 inhibitor may be useful in
treating acute myeloid leukemia, myelodysplastic syndrome, acute
lymphoblastic leukemia.
Kinase Activity Assays
[0799] A number of different assays for kinase activity can be
utilized for assaying for active modulators and/or determining
specificity of a modulator for a particular kinase or group of
kinases. In addition to the assays mentioned in the Examples below,
one of ordinary skill in the art can readily identify other assays
that can be utilized and can modify an assay for a particular
application. For example, numerous papers concerning kinases
describe assays that can be used.
[0800] Additional alternative assays can employ binding
determinations. For example, this sort of assay can be formatted
either in a fluorescence resonance energy transfer (FRET) format,
or using an AlphaScreen (amplified luminescent proximity
homogeneous assay) format by varying the donor and acceptor
reagents that are attached to streptavidin or the phosphor-specific
antibody.
Organic Synthetic Techniques
[0801] A wide array of organic synthetic techniques exist in the
art to facilitate the construction of potential modulators. Many of
these organic synthetic methods are described in detail in standard
reference sources utilized by those skilled in the art. One example
of such a reference is March, 1994, Advanced Organic Chemistry;
Reactions, Mechanisms and Structure, New York, McGraw Hill. Thus,
the techniques useful to synthesize a potential modulator of kinase
function are readily available to those skilled in the art of
organic chemical synthesis.
Alternative Compound Forms or Derivatives
[0802] Compounds contemplated herein are described with reference
to both generic formulae and specific compounds. In addition,
invention compounds may exist in a number of different forms or
derivatives, all within the scope of the present invention.
Alternative forms or derivatives, include, for example, (a)
prodrugs, and active metabolites (b) tautomers, isomers (including
stereoisomers and regioisomers), and racemic mixtures (c)
pharmaceutically acceptable salts and (d) solid forms, including
different crystal forms, polymorphic or amorphous solids, including
hydrates and solvates thereof, and other forms.
[0803] (a) Prodrugs and Metabolites
[0804] In addition to the present formulae and compounds described
herein, the invention also includes prodrugs (generally
pharmaceutically acceptable prodrugs), active metabolic derivatives
(active metabolites), and their pharmaceutically acceptable
salts.
[0805] Prodrugs are compounds or pharmaceutically acceptable salts
thereof which, when metabolized under physiological conditions or
when converted by solvolysis, yield the desired active compound.
Prodrugs include, without limitation, esters, amides, carbamates,
carbonates, ureides, solvates, or hydrates of the active compound.
Typically, the prodrug is inactive, or less active than the active
compound, but may provide one or more advantageous handling,
administration, and/or metabolic properties. For example, some
prodrugs are esters of the active compound; during metabolysis, the
ester group is cleaved to yield the active drug. Esters include,
for example, esters of a carboxylic acid group, or S-acyl or O-acyl
derivatives of thiol, alcohol, or phenol groups. In this context, a
common example is an alkyl ester of a carboxylic acid. Prodrugs may
also include variants wherein an --NH group of the compound has
undergone acylation, such as the 7-position of the
pyrrolo[2,3-d]pyrimidine ring or the 1-position of the
1H-pyrrolo[2,3-b]pyridine ring of compounds as described herein,
where cleavage of the acyl group provides the free --NH group of
the active drug. Some prodrugs are activated enzymatically to yield
the active compound, or a compound may undergo further chemical
reaction to yield the active compound. Prodrugs may proceed from
prodrug form to active form in a single step or may have one or
more intermediate forms which may themselves have activity or may
be inactive.
[0806] As described in The Practice of Medicinal Chemistry, Ch.
31-32 (Ed. Wermuth, Academic Press, San Diego, Calif., 2001),
prodrugs can be conceptually divided into two non-exclusive
categories, bioprecursor prodrugs and carrier prodrugs. Generally,
bioprecursor prodrugs are compounds that are inactive or have low
activity compared to the corresponding active drug compound, that
contain one or more protective groups and are converted to an
active form by metabolism or solvolysis. Both the active drug form
and any released metabolic products should have acceptably low
toxicity. Typically, the formation of active drug compound involves
a metabolic process or reaction that is one of the following
types:
[0807] Oxidative reactions: Oxidative reactions are exemplified
without limitation by reactions such as oxidation of alcohol,
carbonyl, and acid functionalities, hydroxylation of aliphatic
carbons, hydroxylation of alicyclic carbon atoms, oxidation of
aromatic carbon atoms, oxidation of carbon-carbon double bonds,
oxidation of nitrogen-containing functional groups, oxidation of
silicon, phosphorus, arsenic, and sulfur, oxidative N-dealkylation,
oxidative O- and S-dealkylation, oxidative deamination, as well as
other oxidative reactions.
[0808] Reductive reactions: Reductive reactions are exemplified
without limitation by reactions such as reduction of carbonyl
functionalitites, reduction of alcohol functionalities and
carbon-carbon double bonds, reduction of nitrogen-containing
functional groups, and other reduction reactions.
[0809] Reactions without change in the oxidation state: Reactions
without change in the state of oxidation are exemplified without
limitation to reactions such as hydrolysis of esters and ethers,
hydrolytic cleavage of carbon-nitrogen single bonds, hydrolytic
cleavage of non-aromatic heterocycles, hydration and dehydration at
multiple bonds, new atomic linkages resulting from dehydration
reactions, hydrolytic dehalogenation, removal of hydrogen halide
molecule, and other such reactions.
[0810] Carrier prodrugs are drug compounds that contain a transport
moiety, e.g., that improves uptake and/or localized delivery to a
site(s) of action. Desirably for such a carrier prodrug, the
linkage between the drug moiety and the transport moiety is a
covalent bond, the prodrug is inactive or less active than the drug
compound, the prodrug and any release transport moiety are
acceptably non-toxic. For prodrugs where the transport moiety is
intended to enhance uptake, typically the release of the transport
moiety should be rapid. In other cases, it is desirable to utilize
a moiety that provides slow release, e.g., certain polymers or
other moieties, such as cyclodextrins. (See, e.g., Cheng et al.,
U.S. Patent Publ. No. 20040077595, application Ser. No. 10/656,838,
incorporated herein by reference.) Such carrier prodrugs are often
advantageous for orally administered drugs. In some instances, the
transport moiety provides targeted delivery of the drug, for
example the drug may be conjugated to an antibody or antibody
fragment. Carrier prodrugs can, for example, be used to improve one
or more of the following properties: increased lipophilicity,
increased duration of pharmacological effects, increased
site-specificity, decreased toxicity and adverse reactions, and/or
improvement in drug formulation (e.g., stability, water solubility,
suppression of an undesirable organoleptic or physiochemical
property). For example, lipophilicity can be increased by
esterification of hydroxyl groups with lipophilic carboxylic acids,
or of carboxylic acid groups with alcohols, e.g., aliphatic
alcohols. Wermuth, supra.
[0811] Metabolites, e.g., active metabolites, overlap with prodrugs
as described above, e.g., bioprecursor prodrugs. Thus, such
metabolites are pharmacologically active compounds or compounds
that further metabolize to pharmacologically active compounds that
are derivatives resulting from metabolic processes in the body of a
subject. Of these, active metabolites are such pharmacologically
active derivative compounds. For prodrugs, the prodrug compound is
generally inactive or of lower activity than the metabolic product.
For active metabolites, the parent compound may be either an active
compound or may be an inactive prodrug. For example, in some
compounds, one or more alkoxy groups can be metabolized to hydroxyl
groups while retaining pharmacologic activity and/or carboxyl
groups can be esterified, e.g., glucuronidation. In some cases,
there can be more than one metabolite, where an intermediate
metabolite(s) is further metabolized to provide an active
metabolite. For example, in some cases a derivative compound
resulting from metabolic glucuronidation may be inactive or of low
activity, and can be further metabolized to provide an active
metabolite.
[0812] Metabolites of a compound may be identified using routine
techniques known in the art, and their activities determined using
tests such as those described herein. See, e.g., Bertolini et al.,
1997, J. Med. Chem., 40:2011-2016; Shan et al., 1997, J Pharm Sci
86(7):756-757; Bagshawe, 1995, Drug Dev. Res., 34:220-230; Wermuth,
supra.
[0813] (b) Tautomers, Stereoisomers, and Regioisomers
[0814] It is understood that some compounds may exhibit
tautomerism. In such cases, the formulae provided herein expressly
depict only one of the possible tautomeric forms. It is therefore
to be understood that the formulae provided herein are intended to
represent any tautomeric form of the depicted compounds and are not
to be limited merely to the specific tautomeric form depicted by
the drawings of the formulae.
[0815] Likewise, some of the compounds according to the present
invention may exist as stereoisomers, i.e. having the same atomic
connectivity of covalently bonded atoms yet differing in the
spatial orientation of the atoms. For example, compounds may be
optical stereoisomers, which contain one or more chiral centers,
and therefore, may exist in two or more stereoisomeric forms (e.g.
enantiomers or diastereomers). Thus, such compounds may be present
as single stereoisomers (i.e., essentially free of other
stereoisomers), racemates, and/or mixtures of enantiomers and/or
diastereomers. As another example, stereoisomers include geometric
isomers, such as cis- or trans-orientation of substituents on
adjacent carbons of a double bond. All such single stereoisomers,
racemates and mixtures thereof are intended to be within the scope
of the present invention. Unless specified to the contrary, all
such steroisomeric forms are included within the formulae provided
herein.
[0816] In some embodiments, a chiral compound of the present
invention is in a form that contains at least 80% of a single
isomer (60% enantiomeric excess ("e.e.") or diastereomeric excess
("d.e.")), or at least 85% (70% e.e. or d.e.), 90% (80% e.e. or
d.e.), 95% (90% e.e. or d.e.), 97.5% (95% e.e. or d.e.), or 99%
(98% e.e. or d.e.). As generally understood by those skilled in the
art, an optically pure compound having one chiral center is one
that consists essentially of one of the two possible enantiomers
(i.e., is enantiomerically pure), and an optically pure compound
having more than one chiral center is one that is both
diastereomerically pure and enantiomerically pure. In some
embodiments, the compound is present in optically pure form, such
optically pure form being prepared and/or isolated by methods known
in the art (e.g. by recrystallization techniques, chiral synthetic
techniques (including synthesis from optically pure starting
materials), and chromatographic separation using a chiral
column.
[0817] (c) Pharmaceutically Acceptable Salts
[0818] Unless specified to the contrary, specification of a
compound herein includes pharmaceutically acceptable salts of such
compound. Thus, compounds described herein can be in the form of
pharmaceutically acceptable salts, or can be formulated as
pharmaceutically acceptable salts. Contemplated pharmaceutically
acceptable salt forms include, without limitation, mono, bis, tris,
tetrakis, and so on. Pharmaceutically acceptable salts are
non-toxic in the amounts and concentrations at which they are
administered. The preparation of such salts can facilitate the
pharmacological use by altering the physical characteristics of a
compound without preventing it from exerting its physiological
effect. Useful alterations in physical properties include lowering
the melting point to facilitate transmucosal administration and
increasing the solubility to facilitate administering higher
concentrations of the drug. A compound of the invention may possess
a sufficiently acidic, a sufficiently basic, or both functional
groups, and accordingly can react with any of a number of inorganic
or organic bases, and inorganic and organic acids, to form a
pharmaceutically acceptable salt.
[0819] Pharmaceutically acceptable salts include acid addition
salts such as those containing chloride, bromide, iodide,
hydrochloride, acetate, phenylacetate, acrylate, ascorbate,
aspartate, benzoate, 2-phenoxybenzoate, 2-acetoxybenzoate,
dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate,
bicarbonate, butyne-1,4 dioate, hexyne-1,6-dioate, caproate,
caprylate, chlorobenzoate, cinnamate, citrate, decanoate, formate,
fumarate, glycolate, gluconate, glucarate, glucuronate,
glucose-6-phosphate, glutamate, heptanoate, hexanoate, isethionate,
isobutyrate, gamma-hydroxybutyrate, phenylbutyrate, lactate,
malate, maleate, hydroxymaleate, methylmaleate, malonate,
mandelate, nicotinate, nitrate, isonicotinate, octanoate, oleate,
oxalate, pamoate, phosphate, monohydrogenphosphate,
dihydrogenphosphate, orthophosphate, metaphosphate, pyrophosphate,
2-phosphoglycerate, 3-phosphoglycerate, phthalate, propionate,
phenylpropionate, propiolate, pyruvate, quinate, salicylate,
4-aminosalicylate, sebacate, stearate, suberate, succinate,
sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, sulfamate,
sulfonate, benzenesulfonate (i.e. besylate), ethanesulfonate (i.e.
esylate), ethane-1,2-disulfonate, 2-hydroxyethanesulfonate (i.e.
isethionate), methanesulfonate (i.e. mesylate),
naphthalene-1-sulfonate, naphthalene-2-sulfonate (i.e. napsylate),
propanesulfonate, p-toluenesulfonate (i.e. tosylate),
xylenesulfonates, cyclohexylsulfamate, tartrate, and
trifluoroacetate. These pharmaceutically acceptable acid addition
salts can be prepared using the appropriate corresponding acid.
[0820] When acidic functional groups, such as carboxylic acid or
phenol are present, pharmaceutically acceptable salts also include
basic addition salts such as those containing benzathine,
chloroprocaine, choline, ethanolamine, diethanolamine,
triethanolamine, t-butylamine, dicyclohexylamine, ethylenediamine,
N,N'-dibenzylethylenediamine, meglumine, hydroxyethylpyrrolidine,
piperidine, morpholine, piperazine, procaine, aluminum, calcium,
copper, iron, lithium, magnesium, manganese, potassium, sodium,
zinc, ammonium, and mono-, di-, or tri-alkylamines (e.g.
diethylamine), or salts derived from amino acids such as
L-histidine, L-glycine, L-lysine, and L-arginine. For example, see
Remington's Pharmaceutical Sciences, 19.sup.th ed., Mack Publishing
Co., Easton, Pa., Vol. 2, p. 1457, 1995. These pharmaceutically
acceptable base addition salts can be prepared using the
appropriate corresponding base.
[0821] Pharmaceutically acceptable salts can be prepared by
standard techniques. For example, the free-base form of a compound
can be dissolved in a suitable solvent, such as an aqueous or
aqueous-alcohol solution containing the appropriate acid and then
isolated by evaporating the solution. In another example, a salt
can be prepared by reacting the free base and acid in an organic
solvent. If the particular compound is an acid, the desired
pharmaceutically acceptable salt may be prepared by any suitable
method, for example, treatment of the free acid with an appropriate
inorganic or organic base.
[0822] (d) Other Compound Forms
[0823] In the case of agents that are solids, it is understood by
those skilled in the art that the compounds and salts may exist in
different crystal or polymorphic forms, or may be formulated as
co-crystals, or may be in an amorphous form, or may be any
combination thereof (e.g. partially crystalline, partially
amorphous, or mixtures of polymorphs) all of which are intended to
be within the scope of the present invention and specified
formulae. Whereas salts are formed by acid/base addition, i.e. a
free base or free acid of the compound of interest forms an
acid/base reaction with a corresponding addition base or addition
acid, respectively, resulting in an ionic charge interaction,
co-crystals are a new chemical species that is formed between
neutral compounds, resulting in the compound and an additional
molecular species in the same crystal structure.
[0824] In some instances, compounds of the invention are complexed
with an acid or a base, including base addition salts such as
ammonium, diethylamine, ethanolamine, ethylenediamine,
diethanolamine, t-butylamine, piperazine, meglumine; acid addition
salts, such as acetate, acetylsalicylate, besylate, camsylate,
citrate, formate, fumarate, glutarate, hydrochlorate, maleate,
mesylate, nitrate, oxalate, phosphate, succinate, sulfate,
tartrate, thiocyanate and tosylate; and amino acids such as
alanine, arginine, asparagine, aspartic acid, cysteine, glutamine,
glutamic acid, glycine, histidine, isoleucine, leucine, lysine,
methionine, phenylalanine, proline, serine, threonine, tryptophan,
tyrosine or valine. In combining the compound of the invention with
the acid or base, an amorphous complex is preferably formed rather
than a crystalline material such as a typical salt or co-crystal.
In some instances, the amorphous form of the complex is facilitated
by additional processing, such as by spray-drying, mechanochemical
methods such as roller compaction, or microwave irradiation of the
parent compound mixed with the acid or base. Such methods may also
include addition of ionic and/or non-ionic polymer systems,
including, but not limited to, hydroxypropyl methyl cellulose
acetate succinate (HPMCAS) and methacrylic acid copolymer (e.g.
Eudragit.RTM. L100-55), that further stabilize the amorphous nature
of the complex. Such amorphous complexes provide several
advantages. For example, lowering of the melting temperature
relative to the free base facilitiates additional processing, such
as hot melt extrusion, to further improve the biopharmaceutical
properties of the compound. Also, the amorphous complex is readily
friable, which provides improved compression for loading of the
solid into capsule or tablet form.
[0825] Additionally, the formulae are intended to cover hydrated or
solvated as well as unhydrated or unsolvated forms of the
identified structures. For example, the indicated compounds include
both hydrated and non-hydrated forms. Other examples of solvates
include the structures in combination with a suitable solvent, such
as isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic
acid, or ethanolamine
Formulations and Administration
[0826] The methods and compounds will typically be used in therapy
for human subjects. However, they may also be used to treat similar
or identical indications in other animal subjects. Compounds
described herein can be administered by different routes, including
injection (i.e. parenteral, including intravenous, intraperitoneal,
subcutaneous, and intramuscular), oral, transdermal, transmucosal,
rectal, or inhalant. Such dosage forms should allow the compound to
reach target cells. Other factors are well known in the art, and
include considerations such as toxicity and dosage forms that
retard the compound or composition from exerting its effects.
Techniques and formulations generally may be found in Remington:
The Science and Practice of Pharmacy, 21.sup.st edition,
Lippincott, Williams and Wilkins, Philadelphia, Pa., 2005 (hereby
incorporated by reference herein).
[0827] In some embodiments, compositions will comprise
pharmaceutically acceptable carriers or excipients, such as
fillers, binders, disintegrants, glidants, lubricants, complexing
agents, solubilizers, and surfactants, which may be chosen to
facilitate administration of the compound by a particular route.
Examples of carriers include calcium carbonate, calcium phosphate,
various sugars such as lactose, glucose, or sucrose, types of
starch, cellulose derivatives, gelatin, lipids, liposomes,
nanoparticles, and the like. Carriers also include physiologically
compatible liquids as solvents or for suspensions, including, for
example, sterile solutions of water for injection (WFI), saline
solution, dextrose solution, Hank's solution, Ringer's solution,
vegetable oils, mineral oils, animal oils, polyethylene glycols,
liquid paraffin, and the like. Excipients may also include, for
example, colloidal silicon dioxide, silica gel, talc, magnesium
silicate, calcium silicate, sodium aluminosilicate, magnesium
trisilicate, powdered cellulose, macrocrystalline cellulose,
carboxymethyl cellulose, cross-linked sodium
carboxymethylcellulose, sodium benzoate, calcium carbonate,
magnesium carbonate, stearic acid, aluminum stearate, calcium
stearate, magnesium stearate, zinc stearate, sodium stearyl
fumarate, syloid, stearowet C, magnesium oxide, starch, sodium
starch glycolate, glyceryl monostearate, glyceryl dibehenate,
glyceryl palmitostearate, hydrogenated vegetable oil, hydrogenated
cotton seed oil, castor seed oil mineral oil, polyethylene glycol
(e.g. PEG 4000-8000), polyoxyethylene glycol, poloxamers, povidone,
crospovidone, croscarmellose sodium, alginic acid, casein,
methacrylic acid divinylbenzene copolymer, sodium docusate,
cyclodextrins (e.g. 2-hydroxypropyl-.delta.-cyclodextrin),
polysorbates (e.g. polysorbate 80), cetrimide, TPGS
(d-alpha-tocopheryl polyethylene glycol 1000 succinate), magnesium
lauryl sulfate, sodium lauryl sulfate, polyethylene glycol ethers,
di-fatty acid ester of polyethylene glycols, or a polyoxyalkylene
sorbitan fatty acid ester (e.g., polyoxyethylene sorbitan ester
Tween.RTM.), polyoxyethylene sorbitan fatty acid esters, sorbitan
fatty acid ester, e.g. a sorbitan fatty acid ester from a fatty
acid such as oleic, stearic or palmitic acid, mannitol, xylitol,
sorbitol, maltose, lactose, lactose monohydrate or lactose spray
dried, sucrose, fructose, calcium phosphate, dibasic calcium
phosphate, tribasic calcium phosphate, calcium sulfate, dextrates,
dextran, dextrin, dextrose, cellulose acetate, maltodextrin,
simethicone, polydextrosem, chitosan, gelatin, HPMC (hydroxypropyl
methyl celluloses), HPC (hydroxypropyl cellulose), hydroxyethyl
cellulose, and the like.
[0828] In some embodiments, oral administration may be used.
Pharmaceutical preparations for oral use can be formulated into
conventional oral dosage forms such as capsules, tablets, and
liquid preparations such as syrups, elixirs, and concentrated
drops. Compounds described herein may be combined with solid
excipients, optionally grinding a resulting mixture, and processing
the mixture of granules, after adding suitable auxiliaries, if
desired, to obtain, for example, tablets, coated tablets, hard
capsules, soft capsules, solutions (e.g. aqueous, alcoholic, or
oily solutions) and the like. Suitable excipients are, in
particular, fillers such as sugars, including lactose, glucose,
sucrose, mannitol, or sorbitol; cellulose preparations, for
example, corn starch, wheat starch, rice starch, potato starch,
gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose (CMC),
and/or polyvinylpyrrolidone (PVP: povidone); oily excipients,
including vegetable and animal oils, such as sunflower oil, olive
oil, or codliver oil. The oral dosage formulations may also contain
disintegrating agents, such as the cross-linked
polyvinylpyrrolidone, agar, or alginic acid, or a salt thereof such
as sodium alginate; a lubricant, such as talc or magnesium
stearate; a plasticizer, such as glycerol or sorbitol; a sweetening
such as sucrose, fructose, lactose, or aspartame; a natural or
artificial flavoring agent, such as peppermint, oil of wintergreen,
or cherry flavoring; or dye-stuffs or pigments, which may be used
for identification or characterization of different doses or
combinations. Also provided are dragee cores with suitable
coatings. For this purpose, concentrated sugar solutions may be
used, which may optionally contain, for example, gum arabic, talc,
poly-vinylpyrrolidone, carbopol gel, polyethylene glycol, and/or
titanium dioxide, lacquer solutions, and suitable organic solvents
or solvent mixtures.
[0829] Pharmaceutical preparations that can be used orally include
push-fit capsules made of gelatin ("gelcaps"), as well as soft,
sealed capsules made of gelatin, and a plasticizer, such as
glycerol or sorbitol. The push-fit capsules can contain the active
ingredients in admixture with filler such as lactose, binders such
as starches, and/or lubricants such as talc or magnesium stearate
and, optionally, stabilizers. In soft capsules, the active
compounds may be dissolved or suspended in suitable liquids, such
as fatty oils, liquid paraffin, or liquid polyethylene glycols.
[0830] In some embodiments, injection (parenteral administration)
may be used, e.g., intramuscular, intravenous, intraperitoneal,
and/or subcutaneous. Compounds described herein for injection may
be formulated in sterile liquid solutions, preferably in
physiologically compatible buffers or solutions, such as saline
solution, Hank's solution, or Ringer's solution. Dispersions may
also be prepared in non-aqueous solutions, such as glycerol,
propylene glycol, ethanol, liquid polyethylene glycols, triacetin,
and vegetable oils. Solutions may also contain a preservative, such
as methylparaben, propylparaben, chlorobutanol, phenol, sorbic
acid, thimerosal, and the like. In addition, the compounds may be
formulated in solid form, including, for example, lyophilized
forms, and redissolved or suspended prior to use.
[0831] In some embodiments, transmucosal, topical or transdermal
administration may be used. In such formulations of compounds
described herein, penetrants appropriate to the barrier to be
permeated are used. Such penetrants are generally known in the art,
and include, for example, for transmucosal administration, bile
salts and fusidic acid derivatives. In addition, detergents may be
used to facilitate permeation. Transmucosal administration, for
example, may be through nasal sprays or suppositories (rectal or
vaginal). Compositions of compounds described herein for topical
administration may be formulated as oils, creams, lotions,
ointments, and the like by choice of appropriate carriers known in
the art. Suitable carriers include vegetable or mineral oils, white
petrolatum (white soft paraffin), branched chain fats or oils,
animal fats and high molecular weight alcohol (greater than
C.sub.12). In some embodiments, carriers are selected such that the
active ingredient is soluble. Emulsifiers, stabilizers, humectants
and antioxidants may also be included as well as agents imparting
color or fragrance, if desired. Creams for topical application are
preferably formulated from a mixture of mineral oil,
self-emulsifying beeswax and water in which mixture the active
ingredient, dissolved in a small amount of solvent (e.g., an oil),
is admixed. Additionally, administration by transdermal means may
comprise a transdermal patch or dressing such as a bandage
impregnated with an active ingredient and optionally one or more
carriers or diluents known in the art. To be administered in the
form of a transdermal delivery system, the dosage administration
will be continuous rather than intermittent throughout the dosage
regimen.
[0832] In some embodiments, compounds are administered as
inhalants. Compounds described herein may be formulated as dry
powder or a suitable solution, suspension, or aerosol. Powders and
solutions may be formulated with suitable additives known in the
art. For example, powders may include a suitable powder base such
as lactose or starch, and solutions may comprise propylene glycol,
sterile water, ethanol, sodium chloride and other additives, such
as acid, alkali and buffer salts. Such solutions or suspensions may
be administered by inhaling via spray, pump, atomizer, or
nebulizer, and the like. The compounds described herein may also be
used in combination with other inhaled therapies, for example
corticosteroids such as fluticasone proprionate, beclomethasone
dipropionate, triamcinolone acetonide, budesonide, and mometasone
furoate; beta agonists such as albuterol, salmeterol, and
formoterol; anticholinergic agents such as ipratroprium bromide or
tiotropium; vasodilators such as treprostinal and iloprost; enzymes
such as DNAase; therapeutic proteins; immunoglobulin antibodies; an
oligonucleotide, such as single or double stranded DNA or RNA,
siRNA; antibiotics such as tobramycin; muscarinic receptor
antagonists; leukotriene antagonists; cytokine antagonists;
protease inhibitors; cromolyn sodium; nedocril sodium; and sodium
cromoglycate.
[0833] The amounts of various compounds to be administered can be
determined by standard procedures taking into account factors such
as the compound activity (in vitro, e.g. the compound IC.sub.50 vs.
target, or in vivo activity in animal efficacy models),
pharmacokinetic results in animal models (e.g. biological half-life
or bioavailability), the age, size, and weight of the subject, and
the disorder associated with the subject. The importance of these
and other factors are well known to those of ordinary skill in the
art. Generally, a dose will be in the range of about 0.01 to 50
mg/kg, also about 0.1 to 20 mg/kg of the subject being treated.
Multiple doses may be used.
[0834] The compounds described herein may also be used in
combination with other therapies for treating the same disease.
Such combination use includes administration of the compounds and
one or more other therapeutics at different times, or
co-administration of the compound and one or more other therapies.
In some embodiments, dosage may be modified for one or more of the
compounds of the invention or other therapeutics used in
combination, e.g., reduction in the amount dosed relative to a
compound or therapy used alone, by methods well known to those of
ordinary skill in the art.
[0835] It is understood that use in combination includes use with
other therapies, drugs, medical procedures etc., where the other
therapy or procedure may be administered at different times (e.g.
within a short time, such as within hours (e.g. 1, 2, 3, 4-24
hours), or within a longer time (e.g. 1-2 days, 2-4 days, 4-7 days,
1-4 weeks)) than a compound described herein, or at the same time
as a compound described herein. Use in combination also includes
use with a therapy or medical procedure that is administered once
or infrequently, such as surgery, along with a compound described
herein administered within a short time or longer time before or
after the other therapy or procedure. In some embodiments, the
present invention provides for delivery of a compound described
herein and one or more other drug therapeutics delivered by a
different route of administration or by the same route of
administration. The use in combination for any route of
administration includes delivery of a compound described herein and
one or more other drug therapeutics delivered by the same route of
administration together in any formulation, including formulations
where the two compounds are chemically linked in such a way that
they maintain their therapeutic activity when administered. In one
aspect, the other drug therapy may be co-administered with a
compound described herein. Use in combination by co-administration
includes administration of co-formulations or formulations of
chemically joined compounds, or administration of two or more
compounds in separate formulations within a short time of each
other (e.g. within an hour, 2 hours, 3 hours, up to 24 hours),
administered by the same or different routes. Co-administration of
separate formulations includes co-administration by delivery via
one device, for example the same inhalant device, the same syringe,
etc., or administration from separate devices within a short time
of each other. Co-formulations of a compound described herein and
one or more additional drug therapies delivered by the same route
includes preparation of the materials together such that they can
be administered by one device, including the separate compounds
combined in one formulation, or compounds that are modified such
that they are chemically joined, yet still maintain their
biological activity. Such chemically joined compounds may have a
linkage that is substantially maintained in vivo, or the linkage
may break down in vivo, separating the two active components.
EXAMPLES
[0836] Examples related to the present invention are described
below. In most cases, alternative techniques can be used. The
examples are intended to be illustrative and are not limiting or
restrictive to the scope of the invention. In some examples, the
mass spectrometry result indicated for a compound may have more
than one value due to the isotope distribution of an atom in the
molecule, such as a compound having a bromo or chloro substituent.
Compounds in the following examples are characterized by .sup.1H
and .sup.13C NMR spectroscopy as well as mass spectrometry.
[0837] Unless specifically indicated otherwise, the Formula
enumeration and R group enumeration used in the following examples
is not related to such enumeration in other sections of this
application. The reagents and solvents used in these examples can
be readily substituted with appropriate alternatives as are known
in the art and isolation of products is readily achieved by methods
known in the art, including, but not limited to, extraction,
crystallization, and chromatographic methods.
[0838] Ring numbering for the 1H-pyrrolo[2,3-b]pyridine in the
following Examples is as follows:
##STR00038##
[0839] Ring numbering for the 7H-pyrrolo[2,3-d]pyrimidine in the
following Examples is as follows:
##STR00039##
Example 1
Synthesis of 5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 2
[0840] 5-Chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 2 was prepared in
one step from 5-chloro-1H-pyrrolo[2,3-b]pyridine 1 as shown in
Scheme 1.
##STR00040##
Step 1--Preparation of 5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine
(2)
[0841] To a solution of 5-chloro-1H-pyrrolo[2,3-b]pyridine (1,
15.00 g, 98.31 mmol) in 300 mL of dichloromethane under nitrogen,
pyridine (7.951 mL, 98.31 mmol) and iodine monochloride (110 mL,
1.0 M in dichloromethane, 110 mmol) were added slowly over 20
minutes. The reaction was stirred at room temperature for 2 hours,
then quenched with 100 mL of 1 M aqueous sodium thiosulfate
pentahydrate. The layers were separated, solids collected from the
aqueous layer by filtration and combined with the organic layer.
The aqueous layer was extracted with ethyl acetate, organic layers
were combined and washed with brine, then concentrated under
vacuum. The resulting solid was washed with 20% ethyl acetate in
hexane to provide the desired compound.
5-fluoro-3-iodo-1H-pyrrolo[2,3-b]pyridine is prepared similarly
from 5-fluoro-1H-pyrrolo[2,3-b]pyridine.
Example 2
Synthesis of
5-chloro-3-iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine
4
[0842]
5-Chloro-3-iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 4
was prepared in one step from
5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 2 as shown in Scheme
2.
##STR00041##
Step 1--Preparation of
5-chloro-3-iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine
(4)
[0843] To 5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine (2, 16.50 g,
59.25 mmol) in 250.0 mL of N,N-dimethylformamide, sodium hydride
(3.10 g, 60% in mineral oil, 77.5 mmol) was added. The reaction was
stirred at room temperature for 90 minutes, then triisopropysilyl
chloride (3, 13.00 mL, 61.36 mmol) was added slowly. The reaction
was stirred at room temperature overnight, then poured into water
and extracted with ethyl acetate. The organic layer was dried over
sodium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material was purified by silica gel column
chromatography, eluting with 20-100% ethyl acetate in hexane.
Appropriate fractions were combined and concentrated under vacuum
to provide the desired compound (4, 10.0 g).
5-fluoro-3-iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine is
prepared similarly from
5-fluoro-3-iodo-1H-pyrrolo[2,3-b]pyridine.
[0844]
3-Iodo-5-methoxy-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine
5,3-iodo-5-trifluoromethyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-
e 6, and
3-iodo-4-methoxy-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine
7
##STR00042##
are prepared similarly to the protocol of Scheme 2, replacing
5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 2 with
3-iodo-5-methoxy-1H-pyrrolo[2,3-b]pyridine,
3-iodo-5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridine, and
3-iodo-4-methoxy-1H-pyrrolo[2,3-b]pyridine, respectively. MS (ESI)
[M+H.sup.+].sup.+=431.2 (compound 5) and 469.4 (compound 6).
Example 3
Synthesis of
3-iodo-5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine
9
[0845]
3-Iodo-5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 9
was prepared in one step from
5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 8 as shown
in Scheme 3.
##STR00043##
Step 1--Preparation of
3-iodo-5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine
(9)
[0846] 5-Methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine (8,
1.1 g, 3.8 mmol) and 10 mL of dichloromethane were combined in a
round bottom flask and stirred for 10 minutes. A slurry of
N-iodosuccinimide (1.0 g, 4.6 mmol) in 5 mL of dichloromethane was
added and stirred at room temperature overnight. The reaction was
quenched with sodium thiosulfate (20 mL, 1M in water) and the
aqueous layer was extracted with ethyl acetate. The combined
organic layer was washed with water and brine, dried with sodium
sulfate, filtered and the filtrate concentrated under vacuum. The
resulting material was purified by silica gel column
chromatography, eluting with ethyl acetate and hexanes. Appropriate
fractions were combined and concentrated under vacuum to provide
the desired compound as a light yellow oil (9, 1.2 g, 75%). MS
(ESI) [M+H.sup.+].sup.+=415.08.
Example 4
Synthesis of 3-iodo-5-methyl-1H-pyrrolo[2,3-b]pyridine 10
[0847] 3-Iodo-5-methyl-1H-pyrrolo[2,3-b]pyridine 10 was prepared in
one step from
5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 8 as shown
in Scheme 4.
##STR00044##
Step 1--Preparation of 3-iodo-5-methyl-1H-pyrrolo[2,3-b]pyridine
(10)
[0848] To a solution of
5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine (8, 1 g,
2.0 mmol) in 10 mL of tetrahydrofuran, iodine (0.43 g, 1.7 mmol) in
5 mL of tetrahydrofuran was added. The reaction was stirred at room
temperature overnight, then quenched with 20 mL of 1M aqueous
sodium thiosulfate and extracted with ethyl acetate. The organic
layers were combined and washed with water, brine, dried over
sodium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material was purified by silica gel column
chromatography, eluting with ethyl acetate and hexanes. Appropriate
fractions were combined and concentrated under vacuum to provide
the desired compound as a white solid (10, 20 mg). MS (ESI)
[M+H.sup.+].sup.+=258.70.
Example 5
Synthesis of
1-benzenesulfonyl-5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 12
[0849] 1-Benzenesulfonyl-5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine
12 was prepared in 1 step from
5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 2 and benzenesulfonyl
chloride 11 as shown in Scheme 5.
##STR00045##
Step 1--Preparation of
1-benzenesulfonyl-5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine
(12)
[0850] To a solution of 5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine
(2, 5.00 g, 18.0 mmol) in 80.0 mL of N,N-dimethylformamide, sodium
hydride (1.1 g, 60% in mineral oil, 27.0 mmol) was added slowly. A
solution of benzenesulfonyl chloride (11, 2.40 mL, 18.8 mmol) in
10.0 mL of N,N-dimethylformamide was added dropwise at 0.degree. C.
The reaction mixture was stirred at room temperature for 15 hours,
then poured into ice water and extracted with ethyl acetate. The
organic layer was washed with brine, dried over magnesium sulfate,
filtered and the filtrate concentrated under vacuum. The resulting
solid was washed with 5% ethyl acetate in hexane, isolated by
filtration, and dried to provide the desired compound (12, 5.9 g).
.sup.1H NMR was consistent with the compound structure.
1-Benzenesulfonyl-3-iodo-5-methyl-1H-pyrrolo[2,3-b]pyridine 13
##STR00046##
was prepared similarly to this protocol, replacing
5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 2 with
3-iodo-5-methyl-1H-pyrrolo[2,3-b]pyridine 10.
1-Benzenesulfonyl-5-fluoro-3-iodo-1H-pyrrolo[2,3-b]pyridine is
prepared similarly from
5-fluoro-3-iodo-1H-pyrrolo[2,3-b]pyridine.
Example 6
Synthesis of
1-benzenesulfonyl-3-iodo-5-methoxy-1H-pyrrolo[2,3-b]pyridine 16
[0851] 1-Benzenesulfonyl-3-iodo-5-methoxy-1H-pyrrolo[2,3-b]pyridine
16 was prepared in two steps from
5-methoxy-1H-pyrrolo[2,3-b]pyridine 14 as shown in Scheme 6.
##STR00047##
Step 1--Preparation of 3-iodo-5-methoxy-1H-pyrrolo[2,3-b]pyridine
(15)
[0852] To a solution of 5-methoxy-1H-pyrrolo[2,3-b]pyridine (14,
300 mg, 2.0 mmol) in 30 mL of dichloromethane under nitrogen,
iodine monochloride (3 mL, 1.0 M in dichloromethane, 3.0 mmol) was
added at -40.degree. C. The reaction was stirred to room
temperature, then quenched with 10 mL of 1 M aqueous sodium
thiosulfate pentahydrate. The layers were separated and the aqueous
layer was extracted with ethyl acetate. The organic layers were
combined and washed with water, brine, then dried over sodium
sulfate, decolored with activated carbon, filtered and the filtrate
concentrated under vacuum. The resulting solid was washed with 20%
ethyl acetate in hexane to provide the desired compound (15, 371
mg). MS (ESI) [M+H.sup.+].sup.+=275.03.
Step 2--Preparation of
1-benzenesulfonyl-3-iodo-5-methoxy-1H-pyrrolo[2,3-b]pyridine
(16)
[0853] To a solution of 3-iodo-5-methoxy-1H-pyrrolo[2,3-b]pyridine
(15, 4.30 g, 15.7 mmol) in 53.6 mL of N,N-dimethylformamide under
nitrogen, sodium hydride (0.690 g, 60% in mineral oil, 17.2 mmol)
was added. After 10 minutes, benzenesulfonyl chloride (11, 2.20 mL,
17.2 mmol) was added and the reaction was cooled in a water bath.
The reaction was poured into water and extracted with ethyl
acetate. The organic layer was dried over sodium sulfate, filtered
and the filtrate purified by silica gel column chromatography,
eluting with 30-100% ethyl acetate in hexane. Appropriate fractions
were combined and concentrated under vacuum to provide the desired
compound (16, 4.60 g).
Example 7
Synthesis of
5-iodo-4-methyl-7-triisopropylsilanyl-7H-pyrrolo[2,3-d]pyrimidine
20
[0854]
5-Iodo-4-methyl-7-triisopropylsilanyl-7H-pyrrolo[2,3-d]pyrimidine
20 was prepared in two steps from
4-chloro-7H-pyrrolo[2,3-d]pyrimidine 17 as shown in Scheme 7.
##STR00048##
Step 1--Preparation of 4-methyl-7H-pyrrolo[2,3-d]pyrimidine
(18)
[0855] To 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (17, 5.03 g, 32.8
mmol) in 100 mL of toluene,
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 1:1
complex with dichloromethane (0.627 g, 0.328 mmol) was added under
nitrogen. After stirring for 10 minutes, methylmagnesium bromide
(62.9 mL, 3.00 M in ether, 189 mmol) was added slowly. The reaction
was heated at 55.degree. C. overnight, then cooled to -70 to
-80.degree. C. and quenched by adding ammonium chloride dropwise.
Then 1N hydrochloric acid was added and the pH was adjusted to 7-8
with addition of saturated sodium bicarbonate. This was extracted
3.times. with ethyl acetate. The combined organic layer was washed
with saturated ammonium chloride and brine, then dried with
magnesium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material was purified by silica gel column
chromatography, eluting with ethyl acetate and dichloromethane,
then methanol and dichloromethane. Appropriate fractions were
combined and concentrated under vacuum to provide the desired
compound as a tan solid (18). MS (ESI) [M+H.sup.+].sup.+=134.
Step 2--Preparation of 5-iodo-4-methyl-7H-pyrrolo[2,3-d]pyrimidine
(19)
[0856] To 4-methyl-7H-pyrrolo[2,3-d]pyrimidine (18, 0.634 g, 4.76
mmol) in 50 mL of dichloromethane, N-iodosuccinimide (1.3 g, 5.7
mmol) was added and the reaction stirred at room temperature for 45
minutes. The reaction was concentrated under vacuum, then ethyl
acetate was added and washed with 1 N aqueous sodium thiosulfate.
The organic layer was dried over sodium sulfate, filtered and the
filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography, eluting with 20-100%
ethyl acetate in hexane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound (19, 0.94
g). MS (ESI) [M+H.sup.+].sup.+=260.26.
Step 3--Preparation of
5-iodo-4-methyl-7-triisopropylsilanyl-7H-pyrrolo[2,3-d]pyrimidine
(20)
[0857] To 5-iodo-4-methyl-7H-pyrrolo[2,3-d]pyrimidine (19, 323.6
mg, 1.25 mmol) in 8 mL of tetrahydrofuran under nitrogen, sodium
hydride (57.41 mg, 60% in mineral oil, 1.44 mmol) was added. The
reaction was stirred at room temperature for 10 minutes, then
triisopropysilyl chloride (3, 0.304 mL, 1.44 mmol) was added. The
reaction was stirred at room temperature for 2 hours, then poured
into water and extracted with ethyl acetate. The organic layer was
dried over sodium sulfate, filtered and the filtrate concentrated
under vacuum to provide the desired compound.
Example 8
Synthesis of 5-cyclopropyl-1H-pyrrolo[2,3-b]pyridine 23
[0858] 5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridine 23 was prepared in
one step from 5-iodo-1H-pyrrolo[2,3-b]pyridine 21 as shown in
Scheme 8.
##STR00049##
Step 1--Preparation of 5-cyclopropyl-1H-pyrrolo[2,3-b]pyridine
(23)
[0859] 5-Iodo-1H-pyrrolo[2,3-b]pyridine (21, 0.343 g, 1.40 mmol),
cyclopropylzinc bromide (22, 12.6 mL, 0.500 M in tetrahydrofuran,
6.32 mmol) and [1,3-bis(diphenylphosphino)propane]-nickel(II)
chloride (76.2 mg, 0.14 mmol) and 5.37 mL of 1,4-dioxane were
combined in a reaction vessel. The reaction was heated at
100.degree. C. overnight, then methanol was added and the reaction
was concentrated under vacuum. Ethyl acetate and water were added
to the residue, then filtered through a bed of celite and the
celite bed washed with ethyl acetate. The filtrate was separated
and the aqueous layer extracted with ethyl acetate. The organic
layers were combined and washed with brine, dried over sodium
sulfate, filtered and the filtrate concentrated under vacuum. The
resulting material was purified by silica gel column
chromatography, eluting with ethyl acetate and hexane. Appropriate
fraction were combined and concentrated under vacuum to provide the
desired compound. MS (ESI) [M+H.sup.+].sup.+=159.0.
Example 9
Synthesis of intermediate
5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chlo-
ro-thiazol-2-ylamine 29
[0860]
5-(1-Benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)--
4-chloro-thiazol-2-ylamine 29 was synthesized in 4 steps from
2-amino-4-chloro-thiazole-5-carbaldehyde 24 as shown in Scheme
9.
##STR00050##
Step 1--Synthesis of (4-chloro-5-formyl-thiazol-2-yl)-carbamic acid
tert-butyl ester (26)
[0861] To 2-amino-4-chloro-thiazole-5-carbaldehyde (24, 5.00 g,
0.0308 mol) in 122 mL of tetrahydrofuran, di-tert-butyldicarbonate
(25, 7.38 g, 0.0338 mol) and 4-dimethylaminopyridine (0.35 g,
0.0029 mol) were added. The reaction was stirred at 58.degree. C.
for 2 hours, then concentrated under vacuum and purified with
silica gel column chromatography eluting with 20-80% ethyl acetate
in hexane. Appropriate fractions were combined and concentrated
under vacuum to provide the desired compound as a yellow solid (26,
7.0 g, 87%).
Step 2--Synthesis of
5-[(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-met-
hyl]-4-chloro-thiazol-2-yl-carbamic acid tert-butyl ester (27)
[0862] To a solution of
1-benzenesulfonyl-5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine (12,
4.40 g, 10.5 mmol) in 30.0 mL of tetrahydrofuran at -45.degree. C.
under nitrogen, a solution of isopropylmagnesium chloride (5.4 mL,
2.0 M in tetrahydrofuran) was added slowly over 10 minutes. The
reaction was allowed to warm to -25.degree. C. over 30 minutes,
then cooled to -65.degree. C., followed by adding the cold
deprotonated (4-chloro-5-formyl-thiazol-2-yl)-carbamic acid
tert-butyl ester, which was prepared in situ by adding
isopropylmagnesium chloride (5.0 mL, 2.0 M in tetrahydrofuran) to
(4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester
(26, 2.51 g, 9.55 mmol) in 23.0 mL of tetrahydrofuran at
-78.degree. C. under nitrogen. The reaction was allowed to warm to
room temperature over 2 hours, then poured into aqueous ammonium
chloride, and extracted with ethyl acetate. The organic layer was
dried over anhydrous sodium sulfate, filtered, and the filtrate
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography eluting with 25-100% ethyl acetate
in hexane. Appropriate fractions were combined and concentrated
under vacuum to provide the desired compound (27, 3.70 g, 60.3%).
MS (ESI) [M+H.sup.+].sup.+=554.2.
Step 3--Synthesis of
[5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chl-
oro-thiazol-2-yl]-carbamic acid tert-butyl ester (28)
[0863] To
5-[(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-hy-
droxy-methyl]-4-chloro-thiazol-2-yl-carbamic acid tert-butyl ester
(27, 0.200 g, 0.32 mmol) in 15.0 mL of dichloromethane,
triethylsilane (0.600 mL, 376 mmol) and trifluoroacetic acid (0.300
mL, 3.89 mmol) were added. The reaction was stirred at room
temperature for 3 hours, then concentrated, poured into aqueous
potassium carbonate, and extracted with ethyl acetate. The organic
layer was dried over anhydrous sodium sulfate, filtered, and the
filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography eluting with 25-100%
ethyl acetate in hexane to give the desired compound (28, 0.155 g,
88.7%). MS (ESI) [M+H.sup.+].sup.+=538.9.
Step 4--Synthesis of
5-(1-Benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chlo-
ro-thiazol-2-ylamine (29)
[0864] To
[5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-4-chloro-thiazol-2-yl]-carbamic acid tert-butyl ester (28, 4.30
g, 7.97 mmol) in 70.0 mL of dichloromethane, a solution of hydrogen
chloride (42.0 mL, 4.00 M in 1,4-dioxane) was added. The reaction
was stirred at room temperature for 2 days, then concentrated, and
triturated with ethyl ether and ethyl acetate to provide the
desired compound (29, 2.60 g, 74.2%). MS (ESI)
[M+H.sup.+].sup.+=439.0.
[0865]
5-(1-Benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro--
thiazol-2-ylamine 30
##STR00051##
was prepared following the protocol of Scheme 9, substituting
1-benzenesulfonyl-5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 12 with
1-benzenesulfonyl-3-iodo-1H-pyrrolo[2,3-b]pyridine in Step 2. MS
(ESI) [M+H.sup.+].sup.+=404.4.
Example 10
Synthesis of Aldehyde Reagents
[0866] Aldehyde reagents that are used in making compounds are
prepared according to the following protocols.
[0867] 5-Fluoro-1-methyl-2-oxo-1,2-dihydro-pyridine-3-carbaldehyde
33 was prepared in two steps from 5-fluoro-3-iodo-pyridin-2-ol 31
as shown in Scheme 10a.
##STR00052##
Step 1--Preparation of 5-fluoro-3-iodo-1-methyl-1H-pyridin-2-one
(32)
[0868] To 5-fluoro-3-iodo-pyridin-2-ol (31, 200 g, 838 mmol) in
3000 mL of acetone was cooled in an ice water bath. Cesium
carbonate (354 g, 1088 mmol) was added, then iodomethane (58.1 mL,
929 mmol) was added dropwise over 30 minutes. The reaction was
stirred overnight at room temperature. The reaction was
concentrated under vacuum and the resulting material partitioned
between ethyl acetate and water. The aqueous layer was isolated and
adjusted to pH 3-4 with 3 N hydrochloric acid, then extracted with
ethyl acetate. The combined organic layers were concentrated under
vacuum to provide the desired compound as an off white solid. (32,
150 g, 593 mmol, 70.8%).
Step 2--Preparation of
5-fluoro-1-methyl-2-oxo-1,2-dihydro-pyridine-3-carbaldehyde
(33)
[0869] 5-Fluoro-3-iodo-1-methyl-1H-pyridin-2-one (32, 120.5 g, 476
mmol) was dissolved in 2381 mL of tetrahydrofuran and cooled to
-40.degree. C. in a dry ice acetone bath. Isopropylmagnesium
chloride (310 mL, 619 mmol) was added dropwise and the mixture was
stirred for 30 minutes. Then 92 mL of N,N-dimethylformamide was
added and the mixture was allowed to warm to room temperature and
stirred overnight. The reaction was quenched by adding 200 mL of
10% aqueous hydrochloric acid, then concentrated under vacuum. The
resulting material was purified by silica gel column
chromatography, eluting with 100% ethyl acetate. Appropriate
fractions were combined and concentrated under vacuum to provide
the desired compound as a yellow solid (33, 35 g, 226 mmol,
47.4%).
[0870] 5-Fluoro-2-methoxy-pyridine-3-carbaldehyde 37 was prepared
in three steps from 3-bromo-5-fluoro-2-methoxy-pyridine 34 as shown
in Scheme 10b.
##STR00053##
Step 1--Preparation of 5-fluoro-2-methoxy-nicotinic acid methyl
ester (35)
[0871] In a 2 L Parr bomb, 3-bromo-5-fluoro-2-methoxy-pyridine (34,
14 g, 68.0 mmol), triethylamine (19.10 mL, 136 mmol) and
[1,1'-bis(diphenylposphino)ferrocene]-dichloropalladium(II) (1.443
g, 1.767 mmol) were combined with 300 mL of methanol and heated at
100.degree. C. under 100 psi of carbon monoxide overnight. The
reaction was concentrated under vacuum, the residue dissolved in
dichloromethane, and passed through a plug of silica, eluting with
ethyl acetate to provide the desired compound as a white solid (35,
10 g, 54.0 mmol, 79%).
Step 2--Preparation of (5-fluoro-2-methoxy-pyridin-3-yl)-methanol
(36)
[0872] To 5-fluoro-2-methoxy-nicotinic acid methyl ester (35, 10 g,
54.0 mmol) in 200 mL of tetrahydrofuran, lithium aluminum hydride
(81 mL, 1 M in tetrahydrofuran, 81 mmol) was added dropwise at
-78.degree. C. and stirred for several hours. The reaction was
quenched with dropwise addition of 3 mL water, 3 mL of 15% aqueous
sodium hydroxide, and 10 mL of water sequentially, then 200 mL of
methyl t-butyl ether was added. Solids were filtered out and the
filtrate concentrated under vacuum to provide the desired compound
as a white solid (36, 8 g, 50.9 mmol, 94%).
Step 3--Preparation of 5-fluoro-2-methoxy-pyridine-3-carbaldehyde
(37)
[0873] To (5-fluoro-2-methoxy-pyridin-3-yl)-methanol (36, 8 g, 50.9
mmol) in 300 mL of ethyl acetate, manganese(IV) oxide (39.8 g, 458
mmol) was added and the mixture stirred at room temperature
overnight. The reaction mixture was filtered through celite, and
the celite bed rinsed with ethyl acetate. The filtrate was
concentrated under vacuum, then passed through a plug of silica,
eluting with 50% ethyl acetate in heptane to provide the desired
compound as a light yellow solid (37, 4.5 g, 29.0 mmol, 57.0%
yield).
[0874] (2-Fluoro-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid
tert-butyl ester 42 was prepared in three steps from
5-bromo-pyridin-2-ylamine 38 and 2-fluoro-benzaldehyde 39 as shown
in Scheme 10c.
##STR00054##
Step 1--Preparation of
(5-bromo-pyridin-2-yl)-(2-fluoro-benzyl)-amine (40)
[0875] In a round bottom flask, 5-bromo-pyridin-2-ylamine (38, 4.05
g g, 23.4 mmol) was combined with 70.0 mL of acetonitrile,
2-fluoro-benzaldehyde (39, 2.45 mL, 23.4 mmol), triethylsilane
(20.0 mL, 125 mmol) and trifluoroacetic acid (10.0 mL, 130 mmol).
The reaction was stirred at 80.degree. C. for 3 hours. The reaction
was poured into aqueous potassium carbonate and extracted with
ethyl acetate. The organic layer was dried over sodium sulfate,
filtered and the filtrate concentrated under vacuum. The resulting
material was purified by silica gel column chromatography eluting
with 20-60% ethyl acetate in hexane. Appropriate fractions were
combined and the solvents removed under vacuum to provide the
desired compound (40, 5.0 g).
Step 2--Preparation of
6-(2-fluoro-benzylamino)-pyridine-3-carbaldehyde (41)
[0876] In a round bottom flask,
(5-bromo-pyridin-2-yl)-(2-fluoro-benzyl)-amine (40, 3.90 g, 13.9
mmol) was combined with 60.0 mL of tetrahydrofuran at -78.degree.
C. under nitrogen and tert-butyllithium (5.57 mL, 2.50 M in hexane)
was added over 5 minutes. After 30 minutes additional
tert-butyllithium (17.1 mL, 1.7 M in hexane) was added over 5
minutes. After 25 minutes, N,N-dimethylformamide (2.6 mL, 34 mmol)
was added and the mixture was stirred for 70 minutes at -78.degree.
C., then allowed to warm up to room temperature for 1 hour. The
reaction was poured into aqueous ammonium chloride and extracted
with ethyl acetate. The organic portion was dried with sodium
sulfate, filtered and filtrate concentrated under vacuum to provide
the desired compound (41, 3.0 g), which was used in the next step
without further purification.
Step 3--Preparation of
(2-fluoro-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl
ester (42)
[0877] To 6-(2-fluoro-benzylamino)-pyridine-3-carbaldehyde (41,
3.00 g, 13.0 mmol) in 57.2 mL of tetrahydrofuran,
di-tert-butyldicarbonate (25, 4.26 g, 19.5 mmol) and
4-dimethylaminopyridine (0.16 g, 1.3 mmol) and triethylamine (3.6
mL, 26 mmol) were added. The reaction was stirred at room
temperature overnight, then poured into water and extracted with
ethyl acetate. The organic portion was dried with sodium sulfate,
filtered and filtrate concentrated under vacuum. The resulting
material was purified by silica gel column chromatography eluting
with 20-100% ethyl acetate in hexane. Appropriate fractions were
combined and the solvents removed under vacuum to give the desired
compound (41, 3.50 g).
[0878] Additional aldehydes are prepared similarly to the protocol
of Scheme 10c, as shown in the following table, where Step 1, Step
2 and Step 3 reactants are provided in columns 1, 2, and 3,
respectively, with the resulting Boc protected aldehyde provided in
column 4 Reaction conditions are similar to those described for
Scheme 10c, and may vary slightly for each step, for example, any
of the solvents, reagents, reaction times, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. For example, without limitation, for step 2, the first
addition of t-butyllitium is replaced with n-butyllithium in
pentane or by isopropylmagnesium chloride in tetrahydrofuran; for
step 3, triethylamine is replaced with N,N-diisopropylethylamine,
or dichloromethane is used as solvent. Compounds in the following
table were characterized by .sup.1H and .sup.13C NMR spectroscopy
as well as mass spectrometry.
TABLE-US-00002 Step 1 Step 2 ##STR00055## ##STR00056## ##STR00057##
##STR00058## ##STR00059## ##STR00060## ##STR00061## ##STR00062##
##STR00063## ##STR00064## ##STR00065## ##STR00066## ##STR00067##
##STR00068## ##STR00069## ##STR00070## ##STR00071## ##STR00072##
##STR00073## ##STR00074## ##STR00075## ##STR00076## ##STR00077##
##STR00078## ##STR00079## ##STR00080## ##STR00081## ##STR00082##
Step 3 Final aldehyde ##STR00083## ##STR00084## ##STR00085##
##STR00086## ##STR00087## ##STR00088## ##STR00089## ##STR00090##
##STR00091## ##STR00092## ##STR00093## ##STR00094## ##STR00095##
##STR00096## ##STR00097## ##STR00098## ##STR00099## ##STR00100##
##STR00101## ##STR00102## ##STR00103## ##STR00104## ##STR00105##
##STR00106## ##STR00107## ##STR00108## ##STR00109##
##STR00110##
[0879] (2-Chloro-benzyl)-(6-fluoro-5-formyl-pyridin-2-yl)-carbamic
acid tert-butyl ester 48 was prepared in four steps from
6-fluoro-pyridin-2-ylamine 43 and 2-chloro-benzaldehyde 44 as shown
in Scheme 10d.
##STR00111##
Step 1--Preparation of
(2-chloro-benzyl)-(6-fluoro-pyridin-2-yl)-amine (45)
[0880] To 6-fluoro-pyridin-2-ylamine (43, 2.47 g, 22.0 mmol) in
60.0 mL of acetonitrile, 2-chloro-benzaldehyde (44, 3.09 g, 22.0
mmol), triethylsilane (14.0 mL, 87.6 mmol) and trifluoroacetic acid
(7.00 mL, 90.9 mmol) were added. The reaction was stirred at
80.degree. C. for 4 hours, then solvents removed under vacuum, and
the residue was combined with aqueous potassium carbonate and
extracted with ethyl acetate. The organic layer was washed with
brine, dried over sodium sulfate, filtered and the filtrate
concentrated under vacuum to provide the desired compound, which
was used in the next step without further purification. MS (ESI)
[M+H.sup.+].sup.+=272.1.
Step 2--Preparation of
(5-bromo-6-fluoro-pyridin-2-yl)-(2-chloro-benzyl)-amine (46)
[0881] To (2-chloro-benzyl)-(6-fluoro-pyridin-2-yl)-amine (45, 4.70
g, 19.8 mmol) in 100.0 mL of acetonitrile, N-bromosuccinimide (3.53
g, 19.8 mmol) in 20.0 mL of acetonitrile was added slowly at room
temperature. The reaction was stirred at room temperature for 4
hours, then poured into aqueous potassium carbonate and extracted
with ethyl acetate. The organic layer was dried over sodium
sulfate, filtered and the filtrate concentrated under vacuum. The
resulting material was washed with ethyl acetate in hexane to
provide the desired compound (46, 5.0 g).
Step 3--Preparation of
6-(2-chloro-benzylamino)-2-fluoro-pyridine-3-carbaldehyde (47)
[0882] To (5-bromo-6-fluoro-pyridin-2-yl)-(2-chloro-benzyl)-amine
(46, 1.85 g, 5.86 mmol) in 25.0 mL of tetrahydrofuran under
nitrogen at -78.degree. C., isopropylmagnesium chloride (3.00 mL,
2.00 M in tetrahydrofuran, 6.00 mmol) was added over 10 minutes.
After 50 minutes, tert-butyllithium (7.80 mL, 1.70 M in hexane,
13.3 mmol) was added over 5 minutes. After 20 minutes,
N,N-dimethylformamide (1.09 mL, 14.0 mmol) was added and the
reaction mixture stirred at -78.degree. C. for 20 minutes, then
brought to room temperature over 30 minutes. The reaction mixture
was poured into water and extracted with ethyl acetate. The organic
layer was washed with brine, dried over sodium sulfate, filtered
and the filtrate concentrated under vacuum. The resulting material
was purified by silica gel column chromatography, eluting with 35%
ethyl acetate in hexane. The appropriate fractions were combined
and the solvents removed under vacuum to provide the desired
compound (47, 1.45 g). MS (ESI) [M+H.sup.+].sup.+=265.4.
Step 4--Preparation of
(2-chloro-benzyl)-(6-fluoro-5-formyl-pyridin-2-yl)-carbamic acid
tert-butyl ester (48)
[0883] To 6-(2-chloro-benzylamino)-2-fluoro-pyridine-3-carbaldehyde
(47, 1.45 g, 5.48 mmol) in 31.4 mL of tetrahydrofuran,
di-tert-butyldicarbonate (25, 1.79 g, 8.22 mmol) and
4-dimethylaminopyridine (78.6 mg, 0.643 mmol) were added. The
reaction was stirred at room temperature for 3 hours, then
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography, eluting with 15-35% ethyl acetate
in hexane. Appropriate fractions were combined and the solvents
removed under vacuum to provide the desired compound as a colorless
oil (48, 1.60 g).
[0884] (4-Chloro-benzyl)-(6-fluoro-5-formyl-pyridin-2-yl)-carbamic
acid tert-butyl ester 52
##STR00112##
was prepared similarly to the protocol of Scheme 10d, with the
first step modified by reacting 2,6-difluoro-pyridine 49 and
4-chloro-benzylamine 50 according the following step 1a.
##STR00113##
Step 1--Preparation of
(4-chloro-benzyl)-(6-fluoro-pyridin-2-yl)-amine (51)
[0885] To 2,6-difluoro-pyridine (49, 3.80 g, 33.0 mmol) in 20.0 mL
of N-methylpyrrolidone, 4-chloro-benzylamine (50, 5.6 mL, 46.0
mmol) and N,N-diisopropylethylamine (10.0 mL, 57.4 mmol) were
added. The reaction was stirred at 90.degree. C. overnight, then
poured into water and extracted with ethyl acetate. The organic
layer was dried over sodium sulfate, filtered and the filtrate
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography, eluting with 25% ethyl acetate in
hexane. Appropriate fractions were combined and the solvents
removed under vacuum, and the resulting material was washed with
ethyl acetate/hexane to provide the desired compound as a white
solid (51, 5.30 g).
[0886] 3-methoxy-pyridin-2-ylamine 54, for use in step 1 of Scheme
10d in the preparation of
(5-formyl-3-methoxy-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester 55
##STR00114##
was prepared in one step from 3-methoxy-2-nitro-pyridine 53 by the
following step 1b.
##STR00115##
Step 1--Preparation of 3-methoxy-pyridin-2-ylamine (54)
[0887] 3-Methoxy-2-nitro-pyridine (53, 7.00 g, 45.4 mmol) in 100 mL
of methanol, was degassed and palladium (0.7 g, 20%) was added. The
reaction was stirred at room temperature for one day under a
hydrogen balloon. The reaction was filtered through celite and the
filtrate concentrated under vacuum to provide the desired compound
(54, 5.555 g). MS (ESI) [M+H.sup.+].sup.+=125.3.
[0888] Additional aldehydes are prepared similarly to the protocol
of Scheme 10d, as shown in the following table, where Step 1 (or
1a), Step 2, Step 3 and Step 4 reactants are provided in columns 1,
2, 3, and 4, respectively, with the resulting Boc protected
aldehyde provided in column 5 Step 1a use is indicated in column 1
Reaction conditions are similar to those described for Scheme 10d,
and may vary slightly for each step, for example, any of the
solvents, reagents, reaction times, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. For example, without limitation, for step 1a, no
N,N-diisopropylethylamine is used; for step 3, the addition of
isopropylmagnesium chloride is replaced with n-butyllithium in
hexane; for step 4, triethylamine is included in the reaction and
dichloromethane is used as solvent. Compounds in the following
table were characterized by .sup.1H and .sup.13C NMR spectroscopy
as well as mass spectrometry.
TABLE-US-00003 Step 1 Step 2 Step 3 ##STR00116## ##STR00117##
##STR00118## ##STR00119## ##STR00120## ##STR00121## ##STR00122##
##STR00123## ##STR00124## ##STR00125## ##STR00126## ##STR00127##
##STR00128## ##STR00129## ##STR00130## ##STR00131## ##STR00132##
##STR00133## ##STR00134## ##STR00135## ##STR00136## ##STR00137##
##STR00138## ##STR00139## ##STR00140## ##STR00141## ##STR00142##
##STR00143## ##STR00144## ##STR00145## ##STR00146## ##STR00147##
##STR00148## ##STR00149## ##STR00150## ##STR00151## ##STR00152##
##STR00153## ##STR00154## ##STR00155## ##STR00156## ##STR00157##
##STR00158## ##STR00159## ##STR00160## ##STR00161## ##STR00162##
##STR00163## ##STR00164## ##STR00165## ##STR00166## ##STR00167##
##STR00168## ##STR00169## ##STR00170## ##STR00171## ##STR00172##
Step 4 Final aldehyde ##STR00173## ##STR00174## ##STR00175##
##STR00176## ##STR00177## ##STR00178## ##STR00179## ##STR00180##
##STR00181## ##STR00182## ##STR00183## ##STR00184## ##STR00185##
##STR00186## ##STR00187## ##STR00188## ##STR00189## ##STR00190##
##STR00191## ##STR00192## ##STR00193## ##STR00194## ##STR00195##
##STR00196## ##STR00197## ##STR00198## ##STR00199## ##STR00200##
##STR00201## ##STR00202## ##STR00203## ##STR00204## ##STR00205##
##STR00206## ##STR00207## ##STR00208## ##STR00209##
##STR00210##
[0889]
(5-Bromo-6-fluoro-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carb-
amic acid tert-butyl ester 56
##STR00211##
was prepared from the product of step 2 for the first entry of the
table, which was then Boc protected similarly to the protocol of
Scheme 10d step 4.
[0890]
(6-Fluoro-5-formyl-pyridin-2-yl)-(5-fluoro-6-methoxy-pyridin-3-ylme-
thyl)-carbamic acid tert-butyl ester 61 was prepared in four steps
from 6-fluoro-pyridin-2-ylamine 43 and
5-fluoro-6-methoxy-pyridine-3-carbaldehyde 57 as shown in Scheme
10e.
##STR00212##
Step 1--Preparation of
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-(6-fluoro-pyridin-2-yl)-amine
(58)
[0891] To 6-fluoro-pyridin-2-ylamine (43, 1.50 g, 13.4 mmol) in
52.9 mL of acetonitrile, 5-fluoro-6-methoxy-pyridine-3-carbaldehyde
(57, 2.00 g, 12.9 mmol), triethylsilane (10.6 mL, 66.3 mmol), and
trifluoroacetic acid (5.3 mL, 69.0 mmol) were added. The reaction
was stirred at 80.degree. C. overnight, then concentrated under
vacuum, combined with water and extracted with ethyl acetate. The
organic layer was dried over sodium sulfate, filtered and the
filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography, eluting with 15-100%
ethyl acetate in hexane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound as white
solid (58, 3.21 g).
Step 2--Preparation of
(5-bromo-6-fluoro-pyridin-2-yl)-(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-a-
mine (59)
[0892] To
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-(6-fluoro-pyridin-2-yl)--
amine (58, 3.21 g, 12.8 mmol) in 100 mL of acetonitrile,
N-bromosuccinimide (2.30 g, 12.9 mmol) in 30 mL of acetonitrile was
added slowly at room temperature. The reaction was stirred at room
temperature for 4 hours, then poured into aqueous potassium
carbonate and extracted with ethyl acetate. The organic layer was
dried over sodium sulfate, filtered and the filtrate concentrated
under vacuum. The resulting material was purified by silica gel
column chromatography, eluting with 20% ethyl acetate in hexane.
Appropriate fractions were combined and concentrated under vacuum
to provide the desired compound (59, 3.60 g).
Step 3--Preparation of
(5-bromo-6-fluoro-pyridin-2-yl)-(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-c-
arbamic acid tert-butyl ester (60)
[0893] To
(5-bromo-6-fluoro-pyridin-2-yl)-(5-fluoro-6-methoxy-pyridin-3-yl-
methyl)-amine (59, 2.70 g, 8.18 mmol) in 58.7 mL of
tetrahydrofuran, di-tert-butyldicarbonate (25, 2.2 g, 9.9 mmol) and
4-dimethylaminopyridine (0.29 g, 2.4 mmol) were added. The reaction
was stirred at room temperature for 90 minutes, then concentrated
under vacuum. The resulting material was purified by silica gel
column chromatography, eluting with 20-100% ethyl acetate in
hexane. Appropriate fractions were combined and concentrated under
vacuum to provide the desired compound as a colorless oil (60, 3.0
g).
Step 4--Preparation of
(6-fluoro-5-formyl-pyridin-2-yl)-(5-fluoro-6-methoxy-pyridin-3-ylmethyl)--
carbamic acid tert-butyl ester (61)
[0894] To
(5-bromo-6-fluoro-pyridin-2-yl)-(5-fluoro-6-methoxy-pyridin-3-yl-
methyl)-carbamic acid tert-butyl ester (60, 2.90 g, 6.74 mmol) in
25.0 mL of tetrahydrofuran at -35.degree. C. under nitrogen,
isopropylmagnesium chloride (3.54 mL, 2.00 M in tetrahydrofuran,
7.08 mmol) was added and the reaction was allowed to come to
0.degree. C. over an hour. The reaction was cooled to -45.degree.
C. and N,N-dimethylformamide (1.0 mL, 13.0 mmol) was added. The
reaction was allowed to warm to room temperature over 2 hours, then
poured into aqueous ammonium chloride and extracted with ethyl
acetate. The organic layer was dried over sodium sulfate, filtered
and the filtrate concentrated under vacuum. The resulting material
was purified by silica gel column chromatography, eluting with 20%
ethyl acetate in hexane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound (61, 1.80
g).
[0895] Additional aldehydes are prepared similarly to the protocol
of Scheme 10e, as shown in the following table, where Step 1, Step
2, Step 3 and Step 4 reactants are provided in columns 1, 2, 3, and
4, respectively, with the resulting Boc protected aldehyde provided
in column 5 In some instances, the desired compound is the Boc
protected bromo compound isolated after step 3 for use in
subsequent reactions. Reaction conditions are similar to those
described for Scheme 10e, and may vary slightly for each step, for
example, any of the solvents, reagents, reaction times,
temperatures, work up conditions, or other reaction parameters may
be varied employing alternate solvents, reagents, reaction times,
temperatures, work up conditions, and the like, as are readily
available to one skilled in the art. For example, without
limitation, step 2 is performed under nitrogen; step 3 includes
N,N-diisopropylethylamine. Compounds in the following table were
characterized by .sup.1H and .sup.13C NMR spectroscopy as well as
mass spectrometry.
TABLE-US-00004 Step 1 Step 2 Step 3 ##STR00213## ##STR00214##
##STR00215## ##STR00216## ##STR00217## ##STR00218## ##STR00219##
##STR00220## ##STR00221## ##STR00222## ##STR00223## ##STR00224##
##STR00225## ##STR00226## ##STR00227## ##STR00228## ##STR00229##
##STR00230## ##STR00231## ##STR00232## ##STR00233## ##STR00234##
##STR00235## ##STR00236## ##STR00237## ##STR00238## ##STR00239##
##STR00240## ##STR00241## ##STR00242## ##STR00243## ##STR00244##
##STR00245## ##STR00246## ##STR00247## ##STR00248## Step 4 Final
aldehyde ##STR00249## ##STR00250## ##STR00251## ##STR00252##
##STR00253## ##STR00254## ##STR00255## ##STR00256## ##STR00257##
##STR00258## ##STR00259## ##STR00260## ##STR00261## ##STR00262##
##STR00263## ##STR00264## ##STR00265## ##STR00266## ##STR00267##
##STR00268## ##STR00269## ##STR00270## ##STR00271##
##STR00272##
[0896]
(6-Fluoro-5-formyl-pyridin-2-yl)-[(S)-1-(4-fluoro-phenyl)-ethyl]-ca-
rbamic acid tert-butyl ester 62
##STR00273##
was prepared from 2,6-difluoro-pyridine 49 and
(S)-1-(4-fluoro-phenyl)-ethylamine similarly to the protocol of
step 1a of Scheme 10d, then steps 2-4 of Scheme 10e. Step 3 also
included N,N-diisopropylethylamine, as well as a subsequent
addition of di-tert-butyldicarbonate and
N,N-diisopropylethylamine.
[0897]
(5-Formyl-6-methyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-car-
bamic acid tert-butyl ester 66
##STR00274##
was prepared by reacting
(5-iodo-6-methyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-amine
65 similarly to the protocol of Scheme 10e, steps 3 and 4, where
step 3 included N,N-diisopropylethylamine.
(5-Iodo-6-methyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-amine
65 was prepared in one step from 5-iodo-6-methyl-pyridin-2-ylamine
63 and 6-methoxy-pyridine-3-carbaldehyde 64 as shown in Scheme
10E
##STR00275##
Step 1--Preparation of
(5-iodo-6-methyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-amine
(65)
[0898] 5-Iodo-6-methyl-pyridin-2-ylamine (63, 1.7 g, 7.3 mmol) and
6-methoxy-pyridine-3-carbaldehyde (64, 1.1 g, 8.0 mmol) were
combined in a round bottom flask with trifluoroacetic acid (2.80
mL, 36.3 mmol), triethylsilane (5.80 mL, 36.3 mmol) and 50 mL of
acetonitrile. The reaction was stirred at room temperature
overnight, then heated to reflux for 6 hours. The reaction was
concentrated under vacuum, combined with aqueous potassium
carbonate and extracted with ethyl acetate. The organic layer was
dried over sodium sulfate, filtered and the filtrate concentrated
under vacuum. The resulting material was purified by silica gel
flash column chromatography, eluting with 10-100% ethyl acetate in
hexane. Appropriate fractions were combined and concentrated under
vacuum to provide the desired compound (65, 1.80 g). MS
(ESI)[M+H.sup.+].sup.+=356.80.
[0899] Additional aldehydes are prepared similarly to the protocol
of Scheme 10f followed by Scheme 10e steps 2 and 3, as shown in the
following table, where Step 1 (Scheme 100, Step 3 and Step 4
reactants are provided in columns 1, 2, and 3, respectively, with
the resulting Boc protected aldehyde provided in column 5 Reaction
conditions are similar to those described for Schemes 10e and 10f,
and may vary slightly for each step, for example, any of the
solvents, reagents, reaction times, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art.
TABLE-US-00005 Step 1 Step 3 Step 4 ##STR00276## ##STR00277##
##STR00278## ##STR00279## ##STR00280## ##STR00281## ##STR00282##
##STR00283## ##STR00284## ##STR00285## ##STR00286## ##STR00287##
##STR00288## ##STR00289## ##STR00290## ##STR00291## ##STR00292##
##STR00293## ##STR00294## ##STR00295## ##STR00296## ##STR00297##
##STR00298## ##STR00299## Final aldehyde ##STR00300## ##STR00301##
##STR00302## ##STR00303## ##STR00304## ##STR00305## ##STR00306##
##STR00307##
[0900]
(5-fluoro-pyridin-3-ylmethyl)-(5-iodo-pyrimidin-2-yl)-carbamic acid
tert-butyl ester 67
##STR00308##
was prepared similarly to Scheme 10f, replacing
5-iodo-6-methyl-pyridin-2-ylamine 63 with
5-iodo-pyrimidin-2-ylamine and 6-methoxy-pyridine-3-carbaldehyde 64
with 5-fluoro-pyridine-3-carbaldehyde and Boc-protecting the
nitrogen, for example following similar protocol to Scheme 10e,
step 3.
[0901]
(5-Formyl-pyrimidin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carbamic
acid tert-butyl ester 72 was prepared in three steps from
vinamidinium salt 68 and guanidine hydrochloride 69 as shown in
Scheme 10g.
##STR00309##
Step 2--Preparation of 2-amino-pyrimidine-5-carbaldehyde (70)
[0902] Vinamidinium salt (68, 158 g, 413 mmol) and guanidine
hydrochloride (69, 63.3 g, 455 mmol) were dissolved in 527 mL of
acetonitrile and cooled on an ice/water bath. Sodium hydroxide
(66.1 mL, 50% w/w, 827 mmol) was added dropwise, keeping the
temperature below 25.degree. C. The reaction was allowed to warm to
25.degree. C. and stirred for 4 hours, then diluted with water and
filtered, stripped from ethanol/heptane, then triturated with
heptane. The resulting solid was dried under vacuum to provide the
desired compound (70, 37 g, 301 mmol, 72.7% yield).
Step 2--Preparation of
2-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyrimidine-5-carbaldehyde
(71)
[0903] In a round bottom flask, 2-amino-pyrimidine-5-carbaldehyde
(70, 0.750 g, 6.09 mmol), 6-methoxy-pyridine-3-carbaldehyde (64,
1.67 g, 12.2 mmol), trifluoroacetic acid (2.5 mL, 32.0 mmol), and
triethylsilane (5.00 mL, 31.3 mmol) were combined with 10 mL of
acetonitrile. The reaction was stirred at room temperature
overnight, then concentrated under vacuum and combined with aqueous
potassium carbonate and extracted with ethyl acetate. The organic
layer was dried over sodium sulfate, filtered and the filtrate
concentrated under vacuum. The resulting material was purified by
silica gel flash column chromatography, eluting with 15-100% ethyl
acetate in hexane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound.
Step 3--Preparation of
(5-formyl-pyrimidin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carbamic
acid tert-butyl ester (72)
[0904] To
2-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyrimidine-5-carbaldehy-
de (71, 0.462 g, 1.89 mmol) in 15 mL of tetrahydrofuran,
N,N-diisopropylethylamine (0.72 mL, 4.2 mmol),
4-dimethylaminopyridine (0.02 g, 0.2 mmol) and
di-tert-butyldicarbonate (25, 0.45 g, 2.1 mmol) were added. The
reaction was stirred at room temperature overnight, then poured
into water and extracted with ethyl acetate. The organic layer was
concentrated under vacuum and the resulting material was purified
by silica gel column chromatography, eluting with 20-100% ethyl
acetate in hexane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound. .sup.1H
NMR was consistent with the compound structure.
[0905] Additional aldehydes are prepared similarly to the protocol
of Scheme 10g, as shown in the following table, where Step 1 and
Step 2 reactants are provided in columns 1 and 2, respectively,
with the resulting Boc protected aldehyde provided in column 3
Reaction conditions are similar to those described for Scheme 10g,
and may vary slightly for each step, for example, any of the
solvents, reagents, reaction times, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. For example, without limitation, for step 2,
N,N-diisopropylethylamine is not included in the reaction.
Compounds in the following table were characterized by .sup.1H and
.sup.13C NMR spectroscopy as well as mass spectrometry.
TABLE-US-00006 Step 1 Step 2 Final aldehyde ##STR00310##
##STR00311## ##STR00312## ##STR00313## ##STR00314## ##STR00315##
##STR00316## ##STR00317## ##STR00318## ##STR00319## ##STR00320##
##STR00321## ##STR00322## ##STR00323## ##STR00324## ##STR00325##
##STR00326## ##STR00327## ##STR00328## ##STR00329## ##STR00330##
##STR00331## ##STR00332## ##STR00333## ##STR00334## ##STR00335##
##STR00336## ##STR00337## ##STR00338## ##STR00339## ##STR00340##
##STR00341## ##STR00342## ##STR00343## ##STR00344## ##STR00345##
##STR00346## ##STR00347## ##STR00348## ##STR00349## ##STR00350##
##STR00351## ##STR00352## ##STR00353## ##STR00354## ##STR00355##
##STR00356## ##STR00357## ##STR00358## ##STR00359## ##STR00360##
##STR00361## ##STR00362## ##STR00363## ##STR00364## ##STR00365##
##STR00366## ##STR00367## ##STR00368## ##STR00369## ##STR00370##
##STR00371## ##STR00372##
[0906]
(4-Chloro-5-formyl-thiazol-2-yl)-(6-trifluoromethyl-pyridin-3-ylmet-
hyl)-carbamic acid tert-butyl ester 76 was prepared in two steps
from 2,4-dichloro-thiazole-5-carbaldehyde 73 and
C-(6-trifluoromethyl-pyridin-3-yl)-methylamine 74 as shown in
Scheme 10h.
##STR00373##
Step 1--Preparation of
4-chloro-2-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-thiazole-5-carb-
aldehyde (75)
[0907] To a solution of
C-(6-trifluoromethyl-pyridin-3-yl)-methylamine (74, 1.0 g, 5.7
mmol) and N,N-diisopropylethylamine (2.0 mL, 11 mmol) in 100 mL of
tetrahydrofuran, 2,4-dichloro-thiazole-5-carbaldehyde (73, 1.1 g,
6.2 mmol) in 10 mL of tetrahydrofuran was added dropwise at room
temperature. The reaction mixture was stirred at room temperature
overnight. The reaction mixture was poured into ice water,
extracted with ethyl acetate, washed with brine, dried over sodium
sulfate, filtered and the filtrate concentrated under vacuum. The
resulting material was purified by silica gel column
chromatography, eluting with ethyl acetate in hexane. Appropriate
fractions were combined and concentrated under vacuum to provide
the desired compound (75, 1.2 g, 66%). MS
(ESI)=[M+H.sup.+].sup.+=322.11
Step 2--Preparation of
(4-chloro-5-formyl-thiazol-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-c-
arbamic acid tert-butyl ester (76)
[0908]
4-Chloro-2-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-thiazole--
5-carbaldehyde (75, 1.2 g, 3.7 mmol), di-tert-butyldicarbonate (25,
0.98 g, 4.5 mol), 4-dimethylaminopyridine (0.09 g, 0.7 mmol) and
N,N-diisopropylethylamine (0.96 g, 7.5 mmol) were combined in 170
mL of dichloromethane and stirred at room temperature overnight.
The reaction mixture was poured into ice water, extracted with
dichloromethane, washed with brine, dried over sodium sulfate,
filtered and the filtrate concentrated under vacuum. The resulting
material was purified by silica gel column chromatography, eluting
with ethyl acetate in hexane. Appropriate fractions were combined
and concentrated under vacuum to provide the desired compound as a
yellow solid (76, 1.5 g, 95%).
[0909] Additional aldehydes are prepared similarly to the protocol
of Scheme 10h, as shown in the following table, where Step 1 and
Step 2 reactants are provided in columns 1 and 2, respectively,
with the resulting Boc protected aldehyde provided in column 3
Reaction conditions are similar to those described for Scheme 10h,
and may vary slightly for each step, for example, any of the
solvents, reagents, reaction times, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. Compounds in the following table were characterized by
.sup.1H and .sup.13C NMR spectroscopy as well as mass
spectrometry.
TABLE-US-00007 Step 1 Step 2 Final aldehyde ##STR00374##
##STR00375## ##STR00376## ##STR00377## ##STR00378## ##STR00379##
##STR00380## ##STR00381## ##STR00382## ##STR00383## ##STR00384##
##STR00385## ##STR00386## ##STR00387## ##STR00388## ##STR00389##
##STR00390## ##STR00391## ##STR00392## ##STR00393##
##STR00394##
[0910] (6-fluoro-5-formyl-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic
acid tert-butyl ester 83 was prepared in six steps from
2,6-difluoro-pyridine 49 as shown in Scheme 10i.
##STR00395## ##STR00396##
Step 1--Preparation of
(6-fluoro-pyridin-2-yl)-(4-methoxy-benzyl)-amine (78)
[0911] To 2,6-difluoro-pyridine (49, 100 g, 869 mmol) in 500 mL of
N-methylpyrrolidinone, 4-methoxy-benzylamine (77, 136 mL, 1.043
mol) and N,N-diisopropylethylamine (304 mL, 1.738 mol) were added.
The reaction was stirred at 90.degree. C. overnight, then poured
into 8 L of water. The precipitate collected by filtration and
washed with water, then taken up in ethyl acetate and washed with
water. The organic layer was dried over sodium sulfate, filtered
and the filtrate concentrated under vacuum. The resulting material
was triturated with heptane and collected by filtration to provide
the desired compound (78, 151 g, 650 mmol, 74.8% yield).
Step 2--Preparation of
(5-bromo-6-fluoro-pyridin-2-yl)-(4-methoxy-benzyl)-amine (79)
[0912] To (6-fluoro-pyridin-2-yl)-(4-methoxy-benzyl)-amine (78, 151
g, 650 mmol) in 4 L of acetonitrile under nitrogen,
N-bromosuccinimide (116 g, 650 mmol) was added in portions. After
reacting for 2 hours, the solvent was removed under vacuum and the
residue taken up in ethyl acetate, then poured into aqueous sodium
thiosulfate. The organic layer was washed with warm water, dried
over sodium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material was crystallized from heptane to
provide the desired compound (79, 172 g, 553 mmol, 85% yield).
Step 3--Preparation of 2-fluoro-6-(4-methoxy-benzylamino)-nicotinic
acid methyl ester (80)
[0913] To (5-bromo-6-fluoro-pyridin-2-yl)-(4-methoxy-benzyl)-amine
(79, 85 g, 273 mmol) in 1.5 L methanol in a 2 L Parr flask,
triethylamine (77 mL, 546 mmol) and
[1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (5.80
g, 7.10 mmol) were added. The reaction was heated at 100.degree. C.
under 100 psi of carbon monoxide overnight. The reaction was cooled
and filtered through celite and the filtrate was concentrated under
vacuum. The resulting material was dissolved in dichloromethane and
passed through a plug of silica gel, eluting with ethyl acetate.
The solvent was removed under vacuum to provide the desired
compound as a peach colored solid (80, 70 g, 241 mmol, 88%
yield).
[0914] Step 4--Preparation of
[2-fluoro-6-(4-methoxy-benzylamino)-pyridin-3-yl]-methanol
(81):
[0915] To 2-fluoro-6-(4-methoxy-benzylamino)-nicotinic acid methyl
ester (80, 70 g, 241 mmol) in 350 mL of tetrahydrofuran, lithium
aluminum hydride (362 mL, 1 M in tetrahydrofuran, 362 mmol) was
added dropwise while cooling. The reaction was stirred at room
temperature for 2 hours, then quenched with dropwise addition of 14
mL of water, 14 mL of 15% aqueous sodium hydroxide, and 42 mL of
water, sequentially. Methyl tert-butyl ether (500 mL) was added and
the solids removed by filtration. The filtrate was concentrated
under vacuum and the resulting solid was dissolved in
dichloromethane, passed through a plug of silica gel and eluted
with 50-100% ethyl acetate in heptane. The solvent was removed
under vacuum to provide the desired compound as an off-white solid
(81, 63 g, 240 mmol, 100% yield).
Step 5--Preparation of
2-fluoro-6-(4-methoxy-benzylamino)-pyridine-3-carbaldehyde (82)
[0916] To
[2-fluoro-6-(4-methoxy-benzylamino)-pyridin-3-yl]-methanol (81, 63
g, 240 mmol) in 1.25 L of ethyl acetate, manganese(IV) oxide (210
g, 2.416 mol) was added. The reaction was stirred overnight at room
temperature, then filtered through celite and the celite rinsed
with ethyl acetate. The combined filtrates were concentrated under
vacuum and the resulting solid was triturated with heptane and
collected by filtration to provide the desired compound as a white
solid (82, 62 g, 238 mmol, 99% yield).
Step 6--Preparation of
(6-fluoro-5-formyl-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester (83)
[0917] 2-Fluoro-6-(4-methoxy-benzylamino)-pyridine-3-carbaldehyde
(82, 62 g, 238 mmol), 600 mL of tert-butyl alcohol,
di-tert-butyldicarbonate (25, 83 mL, 357 mmol) and
dimethylaminopyridine (2.91 g, 23.82 mmol) were combined in a round
bottom flask. The reaction was stirred at 30.degree. C. overnight
and then concentrated under vacuum. The resulting material was
purified by silica gel column chromatography, eluting with 0-20%
ethyl acetate in hexane. Appropriate fractions were combined and
the solvents removed under vacuum to provide the desired compound
(83, 54 g, 150 mmol, 62.9% yield).
[0918]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-(5-formyl-pyridin-2-yl)-car-
bamic acid tert-butyl ester 94 was prepared in four steps from
6-amino-nicotinic acid methyl ester 90 and
5-fluoro-2-methoxy-pyridine-3-carbaldehyde 37 as shown in Scheme
10k.
##STR00397##
Step 1--Preparation of
6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-nicotinic acid
methyl ester (91)
[0919] In a round bottom flask, 6-amino-nicotinic acid methyl ester
(90, 0.678 g, 4.46 mmol) was combined with
5-fluoro-2-methoxy-pyridine-3-carbaldehyde (37, 0.532 g, 3.43
mmol), 10.6 mL of acetonitrile, trifluoroacetic acid (1.32 mL, 17.1
mmol) and triethylsilane (3.29 mL, 20.6 mol). The reaction was
heated to reflux for 3 hours, then poured into water and extracted
with ethyl acetate. The organic layer was washed with brine, dried
over sodium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material was purified by silica gel column
chromatography eluting with ethyl acetate and hexane. Appropriate
fractions were combined and concentrated under vacuum to provide
the desired compound (91, 832 mg). MS (ESI)
[M+H.sup.+].sup.+=292.4.
Step 2--Preparation of
{6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]pyridin-3-yl}-methanol
(92)
[0920] To
6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-nicotinic acid
methyl ester (91, 0.825 g, 2.83 mmol) in 11 mL of tetrahydrofuran,
lithium tetrahydroaluminate (5.66 mL, 1.0 M in tetrahydrofuran,
5.66 mmol) was added at -40.degree. C. under nitrogen. The reaction
was allowed to warm to room temperature and stirred overnight. The
reaction was poured into aqueous 1M sodium hydroxide, then
neutralized with aqueous 1M hydrochloric acid. The solids were
filtered out through celite, the celite washed with ethyl acetate
and tetrahydrofuran. The isolated aqueous layer was extracted with
ethyl acetate and all organic layers were combined, washed with
brine, then dried over sodium sulfate, filtered and the filtrate
was concentrated under vacuum. The resulting material was purified
by silica gel column chromatography eluting with ethyl acetate and
hexane. Appropriate fractions were combined and concentrated under
vacuum to provide the desired compound (92, 357 mg). MS (ESI)
[M+H.sup.+].sup.+=264.4.
Step 3--Preparation of
6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridine-3-carbaldehyde
(93)
[0921] To
{6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-yl}-
-methanol (92, 0.353 g, 1.34 mmol) dissolved in 8 mL of
tetrahydrofuran, Dess-Maritn periodinane (0.626 g, 1.47 mmol) was
added and the reaction stirred at room temperature for 1 hour. The
reaction was poured into aqueous saturated sodium thiosulfite and
the aqueous layer was extracted with ethyl acetate. The combined
organic layer was washed with brine, dried over sodium sulfate,
filtered and the filtrate concentrated under vacuum. The resulting
material was purified by silica gel column chromatography eluting
with ethyl acetate and hexane. Appropriate fractions were combined
and concentrated under vacuum to provide the desired compound. MS
(ESI) [M+H.sup.+].sup.+=262.3.
Step 4--Preparation of
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-(5-formyl-pyridin-2-yl)-carbamic
acid tert-butyl ester (94)
[0922] To
6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridine-3-car-
baldehyde (93, 0.310 g, 1.19 mmol) dissolved in 4.72 mL of
tetrahydrofuran, 4-dimethylaminopyridine (14.5 mg, 0.119 mmol) was
added, followed by di-tert-butyldicarbonate (25, 0.285 g, 1.30
mmol). The reaction was stirred at room temperature overnight, then
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography eluting with ethyl acetate and
hexane. Appropriate fractions were combined and concentrated under
vacuum to provide the desired compound (94, 301 mg).
[0923]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-(5-formyl-pyridin-2-yl)-car-
bamic acid tert-butyl ester 95
##STR00398##
was prepared similarly to the protocol of Scheme 10k, replacing
5-fluoro-2-methoxy-pyridine-3-carbaldehyde 37 with
5-fluoro-6-methoxy-pyridine-3-carbaldehyde in step 1.
[0924] 5-(3-Chloro-benzylamino)-2-methyl-2H-pyrazole-3-carbaldehyde
96
##STR00399##
was prepared similarly to the protocol of Scheme 10k, steps 1-2 and
Scheme 10i, step 3, where 6-amino-nicotinic acid methyl ester 90
was replaced with 5-amino-2-methyl-2H-pyrazole-3-carboxylic acid
methyl ester and 5-fluoro-2-methoxy-pyridine-3-carbaldehyde 37 was
replaced with 3-chloro-benzaldehyde in step 1.
[0925]
5-(4-Fluoro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazole-3-carbald-
ehyde 113 was prepared in nine steps from
1H-pyrazole-3,5-dicarboxylic acid 101 as shown in Scheme 10n.
##STR00400## ##STR00401## ##STR00402##
Step 1--Preparation of 1H-pyrazole-3,5-dicarboxylic acid dimethyl
ester (102)
[0926] In a round bottom flask, 1H-pyrazole-3,5-dicarboxylic acid,
hydrate (101, 21.1 g, 121 mmol) was combined with 350 mL of
methanol and 10 mL of hydrochloric acid was added. The reaction was
stirred at reflux overnight and the following day at room
temperature. The reaction was concentrated under vacuum and the
solid washed with ethyl acetate and hexanes to provide the desired
compound. MS (ESI) [M+H.sup.+].sup.+=185.
Step 2--Preparation of
1-(4-methoxy-benzyl)-1H-pyrazole-3,5-dicarboxylic acid dimethyl
ester (104)
[0927] In a round bottom flask, 1H-pyrazole-3,5-dicarboxylic acid
dimethyl ester (102, 15.0 g, 81.4 mmol) was combined with 1500 mL
of acetone and potassium carbonate (15 g, 110 mmol).
1-Chloromethyl-4-methoxy-benzene (103, 10.0 mL, 73.8 mmol) was
added and the reaction was stirred at 60.degree. C. overnight. The
mixture was separated into two flasks and continued stirring for 5
hours. The reactions were concentrated under vacuum and the solids
washed with cold water and dried under vacuum to provide the
desired compound (104, 20.48 g). .sup.1H NMR was consistent with
the compound structure.
Step 3--Preparation of
1-(4-methoxy-benzyl)-1H-pyrazole-3,5-dicarboxylic acid 5-methyl
ester (105)
[0928] In a round bottom flask,
1-(4-methoxy-benzyl)-1H-pyrazole-3,5-dicarboxylic acid dimethyl
ester (104, 28.5 g, 93.6 mmol) was combined with 100 mL of water
and 20 mL of 1,4-dioxane. Sulfuric acid (5.5 mL, 100 mmol) and 2.0
mL of water were added and the reaction was stirred for 2 days at
60-70.degree. C. The reaction was concentrated under vacuum until a
precipitate formed. The solid was collected by filtration and
washed with cold water several times to provide the desired
compound. .sup.1H NMR was consistent with the compound
structure.
Step 4--Preparation of
5-azidocarbonyl-2-(4-methoxy-benzyl)-2H-pyrazole-3-carboxylic acid
methyl ester (106)
[0929] In a round bottom flask,
1-(4-methoxy-benzyl)-1H-pyrazole-3,5-dicarboxylic acid 5-methyl
ester (105, 5.48 g, 18.9 mmol) was combined with 20 mL of toluene
and thionyl chloride (6 mL, 80 mmol). The reaction was heated at
reflux for 40 minutes, then concentrated 2.times. from toluene and
the resulting solid dried under vacuum. This was dissolved in 30.0
mL of acetone and sodium azide (3.8 g, 58 mmol) in 10.0 mL of water
was added and stirred for 1 minute. The reaction was poured into
250 mL of ice water and stirred slowly. The resulting precipitate
was collected by filtration and dried under vacuum to provide the
desired compound.
Step 5--Preparation of
5-benzyloxycarbonylamino-2-(4-methoxy-benzyl)-2H-pyrazole-3-carboxylic
acid methyl ester (108)
[0930] In a round bottom flask,
5-azidocarbonyl-2-(4-methoxy-benzyl)-2H-pyrazole-3-carboxylic acid
methyl ester (106, 5.6 g, 18.0 mmol) was combined with 30 mL of
toluene and benzyl alcohol (107, 1.91 mL, 18.5 mmol) was added and
the reaction heated at reflux for 1 hour. The reaction was
concentrated under vacuum and the resulting material washed with
2.times. methanol to provide the desired compound as a white solid.
.sup.1H NMR was consistent with the compound structure.
Step 6--Preparation of
5-amino-2-(4-methoxy-benzyl)-2H-pyrazole-3-carboxylic acid methyl
ester (109)
[0931] In a round bottom flask,
5-benzyloxycarbonylamino-2-(4-methoxy-benzyl)-2H-pyrazole-3-carboxylic
acid methyl ester (108, 2.3 g, 5.8 mmol) was combined with 30 mL of
methanol and 10 mL of tetrahydrofuran under nitrogen and 10%
palladium on carbon (0.23 g, 13.0 mmol) was added. The reaction was
stirred under hydrogen at 1 atmosphere for 2 hours. The reaction
was filtered and the filtrate concentrated under vacuum to provide
the desired compound (109, 1.4 g).
Step 7--Preparation of
5-(4-fluoro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazole-3-carboxylic
acid methyl ester (111)
[0932] In a round bottom flask,
5-amino-2-(4-methoxy-benzyl)-2H-pyrazole-3-carboxylic acid methyl
ester (109, 1.4 g, 5.4 mmol) was combined with
4-fluoro-benzaldehyde (110, 0.565 mL, 5.36 mmol), trifluoroacetic
acid (2.06 mL, 26.8 mmol), triethylsilane (4.28 mL, 26.8 mmol) and
50 mL of acetonitrile. The reaction was stirred at room temperature
for 15 minutes, then concentrated under vacuum, combined with
aqueous potassium carbonate and extracted with ethyl acetate. The
organic layer was dried over sodium sulfate, filtered and the
filtrate concentrated under vacuum. The residue was recrystallized
from a mixture of ethyl acetate and hexane to provide the desired
compound (111, 1.6 g). .sup.1H NMR was consistent with the compound
structure.
Step 8--Preparation of
[5-(4-fluoro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazol-3-yl]-methanol
(112)
[0933] In a round bottom flask,
5-(4-fluoro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazole-3-carboxylic
acid methyl ester (111, 1.6 g, 4.3 mmol) was combined with 100 mL
of tetrahydrofuran and cooled to -40.degree. C. Lithium
tetrahydroaluminate (4.8 mL, 1.0 M in tetrahydrofuran, 4.8 mmol)
was added and the reaction allowed to warm to 10.degree. C. The
reaction was quenched with sodium sulfate decahydrate, then stirred
for 2 hours, filtered through celite and the filtrate concentrated
under vacuum. The resulting material was washed with ethyl acetate
and hexanes and the solid dried to provide the desired compound. MS
(ESI) [M+H.sup.+].sup.+=342.30
Step 9--Preparation of
5-(4-fluoro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazole-3-carbaldehyde
(113)
[0934] In a round bottom flask,
[5-(4-fluoro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazol-3-yl]-methanol
(112, 1.6 g, 4.2 mmol) was combined with 300 mL of dichloromethane
and manganese(IV) oxide (0.61 g, 7.0 mmol) and stirred overnight
under nitrogen. The reaction was filtered through celite and the
filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography, eluting with 10-100%
ethyl acetate in hexane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound (113, 1.4
g). .sup.1H NMR was consistent with the compound structure.
Example 11
Synthesis of
(6-bromo-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylme-
thyl)-pyridin-2-yl]-amine P-2002
[0935]
(6-Bromo-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin--
3-ylmethyl)-pyridin-2-yl]-amine P-2002 was prepared in five steps
from 5-chloro-1H-pyrrolo[2,3-b]pyridine 1 as shown in Scheme
11.
##STR00403## ##STR00404##
Step 1--Preparation of
5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (114)
[0936] In a round bottom flask, 5-chloro-1H-pyrrolo[2,3-b]pyridine
(1, 10.0 g, 65.5 mmol) was combined with hexamethylenetetramine
(11.9 g, 85.2 mmol), acetic acid (28.3 mL, 0.498 mol) and 56.7 mL
of water. The reaction was heated at reflux overnight, then 200 mL
of water was added. After 30 minutes, solid material was collected
by filtration and dried to give the desired compound (114, 7.0
g).
Step 2--Preparation of
1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde
(115)
[0937] To 5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (114,
3.60 g, 19.9 mmol) in 100 mL of dichloromethane, potassium
hydroxide (50 mL, 9M aqueous, 0.45 mol), tetrabutylammonium
hydrogen sulfate (400 mg, 1.0 mmol) and benzenesulfonyl chloride
(11, 2.9 mL, 23.0 mmol) were added. The reaction was stirred at
room temperature for 3 hours, then poured into water and extracted
with ethyl acetate. The organic layer was dried over sodium
sulfate, filtered and the filtrate concentrated under vacuum. The
resulting material was washed with ethyl acetate to provide the
desired compound as a white solid (115, 2.3 g).
Step 3--Preparation of
(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-[6-(2,2,5,5-te-
tramethyl-[1,2,5]azadisilolidin-1-yl)-pyridin-3-yl]-methanol (118)
and
(6-amino-pyridin-3-yl)-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyrid-
in-3-yl)-methanol (119)
[0938] In a round bottom flask, 2-amino-5-bromopyridine (116, 3.10
g, 17.9 mmol) was combined with 80.0 mL of tetrahydrofuran under
nitrogen at -78.degree. C. and n-butyllithium (7.10 mL, 2.50 M in
hexane, 17.8 mmol) was slowly added. After 30 minutes,
1,2-bis-(chloro-dimethyl-silanyl)-ethane (117, 3.90 g, 18.1 mmol)
in 20 mL of tetrahydrofuran was added slowly, and the reaction was
allowed to come to room temperature over an hour. The reaction was
cooled to -78.degree. C. and additional n-butyllithium (7.10 mL,
2.50 M in hexane, 17.8 mmol) was added. The reaction was stirred
for 30 minutes at -78.degree. C. and allowed to warm to room
temperature over an hour. The reaction was cooled to -78.degree. C.
and additional n-butyllithium (7.50 mL, 2.50 M in hexane, 18.8
mmol) was added slowly. After 1 hour,
1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde
(115, 1.90 g, 5.92 mmol) in 30 mL of tetrahydrofuran was added and
the reaction stirred at -78.degree. C. for 2 hours, then allowed to
warm to room temperature over 1 hour. The reaction was poured into
water, extracted with ethyl acetate and the organic layer was dried
over sodium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material was purified by silica gel column
chromatography eluting with 2-20% methanol in dichloromethane to
provide a mixture of compounds (118, 1.7 g) and (119, 1.25 g). MS
(ESI) [M+H.sup.+].sup.+=554.4 for 118 and [M-H.sup.+].sup.-=415.2
for 119.
Step 4--Preparation of
5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridi-
n-2-ylamine (120)
[0939] To
(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-[6-(2-
,2,5,5-tetramethyl-[1,2,5]azadisilolidin-1-yl)-pyridin-3-yl]-methanol
and
(6-amino-pyridin-3-yl)-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyrid-
in-3-yl)-methanol (118, 119, 1.70/1.25 g mix, 2.41 mmol) in 25.0 mL
of dichloromethane, triethylsilane (3.00 mL, 18.8 mmol) and
trifluoroacetic acid (1.50 mL, 19.5 mmol) were added and the
reaction stirred at room temperature overnight. The reaction was
concentrated under vacuum, combined with aqueous potassium
carbonate and extracted with ethyl acetate. The organic layer was
dried over sodium sulfate, filtered and the filtrate concentrated
under vacuum. The resulting material was purified by silica gel
column chromatography eluting with 20-100% ethyl acetate in hexane
to provide the desired compound (120, 0.70 g).
Step 5--Preparation of
(6-bromo-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylme-
thyl)-pyridin-2-yl]-amine (P-2002)
[0940] To
5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-ylamine (120, 80.0 mg, 0.200 mmol) in 2.00 mL of
ethanol and 0.10 mL of acetic acid, 6-bromo-pyridine-3-carbaldehyde
(121, 100.0 mg, 0.538 mmol) and silica supported cyanoborohydride
(0.50 g, 1.21 mmol/g) were added. The reaction was heated at
110.degree. C. for 25 minutes in microwave. Sodium hydroxide (2.0
mL, 6.0 M aqueous) was added and the reaction heated at 100.degree.
C. for 10 minutes in microwave, then poured into aqueous ammonium
chloride and extracted with ethyl acetate. The organic layer was
separated, dried over sodium sulfate, filtered and the filtrate
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography eluting with 20% ethyl acetate in
hexane. Appropriate fractions were combined and the solvent removed
under vacuum to provide the desired compound (P-2002, 26.6 mg). MS
(ESI) [M+H.sup.+].sup.+=427.7, 429.7.
[0941]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-
-3-ylmethyl)-pyridin-2-yl]-amine P-2003, and
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-fluoro-
-pyridin-3-ylmethyl)-amine P-2004,
##STR00405##
were prepared similarly to the protocol of Scheme 11, replacing
6-bromo-pyridine-3-carbaldehyde 121 with
6-chloro-pyridine-3-carbaldehyde and
6-fluoro-pyridine-3-carbaldehyde, respectively. MS (ESI)
[M+H.sup.+].sup.+=383.9, 385.9 (P-2003) and 367.9, 368.9
(P-2004).
Example 12
Synthesis of
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,6-dime-
thoxy-pyridin-3-ylmethyl)-amineP-1496
[0942]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,-
6-dimethoxy-pyridin-3-ylmethyl)-amine P-1496 was prepared in two
steps from
5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p-
yridin-2-ylamine 120 and 2,6-dimethoxy-pyridine-3-carbaldehyde 121
as shown in Scheme 12.
##STR00406##
Step 1--Preparation of
[5-(1-Benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(2,6-dimethoxy-pyridin-3-ylmethyl)-amine (122)
[0943] To
5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-ylamine (120, 60.0 mg, 0.150 mmol) in 2.0 mL of
ethanol and 0.1 mL of acetic acid,
2,6-dimethoxy-pyridine-3-carbaldehyde (121, 120 mg, 0.75 mmol) and
silica supported cyanoborohydride (0.40 g, 0.484 mmol) were added.
The reaction was heated to 100.degree. C. for 18 minutes at 300
Watts in microwave, then poured into aqueous potassium carbonate
and extracted with ethyl acetate. The organic layer was dried over
sodium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material was purified by silica gel column
chromatography, eluting with 20% ethyl acetate in hexane.
Appropriate fractions were combined and concentrated under vacuum
to provide the desired compound (122, 60 mg).
Step 2--Preparation of
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,6-dime-
thoxy-pyridin-3-ylmethyl)-amine (P-1496)
[0944] To
[5-(1-Benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyridin-2-yl]-(2,6-dimethoxy-pyridin-3-ylmethyl)-amine (122, 60
mg, 0.11 mmol) in 10.0 mL of methanol, potassium hydroxide (0.20 g,
3.6 mmol) was added. The reaction was stirred at 60.degree. C. for
4 hours, then poured into water and extracted with ethyl acetate.
The organic layer was dried over sodium sulfate, filtered and the
filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography, eluting with 20-100%
ethyl acetate in hexane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound (P-1496,
26.1 mg). MS (ESI) [M+H.sup.+].sup.+=410.0.
[0945] Additional compounds are prepared following the protocol of
Scheme 12, where conditions may vary, for example, any of the
solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. For example, without limitation, tetrabutylammonium
fluoride trihydrate is used in place of potassium hydroxide in step
2. Compounds are prepared optionally substituting
2,6-dimethoxy-pyridine-3-carbaldehyde 121 with a suitable aldehyde
and optionally substituting
5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridi-
n-2-ylamine 120 with a suitable 1-benzenesulfonyl protected
1H-pyrrolo[2,3-b]pyridine. The following compounds are made using
this procedure. Compounds in the following table were characterized
by .sup.1H and .sup.13C NMR spectroscopy as well as mass
spectrometry. [0946]
(6-Chloro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
ridin-2-yl]-amine (P-1498), [0947]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1502), [0948]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1503), [0949]
[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-trifluoromethyl-
-pyridin-3-ylmethyl)-amine (P-1504), and [0950]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-1505). The following table
indicates the 1-benzenesulfonyl protected 1H-pyrrolo[2,3-b]pyridine
(column 2) and aldehyde compound (column 3) used in step 1 to
afford the desired compound (column 4). The compound number is
provided in column 1, and the observed mass is in column 5
TABLE-US-00008 [0950] MS Comp. (ESI) num- 1H-pyrrolo[2,3- Aldehyde
[M + ber b]pyridine structure Compound structure H.sup.+].sup.+ P-
1498 ##STR00407## ##STR00408## ##STR00409## P- 1502 ##STR00410##
##STR00411## ##STR00412## P- 1503 ##STR00413## ##STR00414##
##STR00415## P- 1504 ##STR00416## ##STR00417## ##STR00418## P- 1505
##STR00419## ##STR00420## ##STR00421##
Example 13
Synthesis of
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyrimidin-2-yl]-amine P-1599
[0951]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,-
3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine P-1599 is prepared in
three steps from
1-benzenesulfonyl-3-iodo-5-methoxy-1H-pyrrolo[2,3-b]pyridine 16 and
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-(5-formyl-pyrimidin-2-yl)--
carbamic acid tert-butyl ester 123 as shown in Scheme 13.
##STR00422##
Step 1--Preparation of
{5-[(1-benzenesulfonyl-5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-m-
ethyl]-pyrimidin-2-yl}-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-carbamic
acid tert-butyl ester (124)
[0952] To a solution of
1-benzenesulfonyl-3-iodo-5-methoxy-1H-pyrrolo[2,3-b]pyridine (16, 1
equivalent) in 4.0 mL of tetrahydrofuran, isopropylmagnesium
chloride (2.0 M in tetrahydrofuran, 1 equivalent) is added slowly
at -50.degree. C. The reaction is allowed to warm to 5.degree. C.
over 70 minutes, then cooled to -45.degree. C. and
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-(5-formyl-pyrimidin-2-yl)-carbami-
c acid tert-butyl ester (123, 0.78 equivalent) in 2.0 mL of
tetrahydrofuran is added. The reaction is allowed to warm to room
temperature over 1 hour, then poured into aqueous ammonium chloride
and extracted with ethyl ether. The organic layer is dried over
sodium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material is purified by silica gel column
chromatography eluting with 20-100% ethyl acetate in hexane.
Appropriate fractions are combined and concentrated under vacuum to
provide the desired compound.
Step 2--Preparation of
[5-(1-benzenesulfonyl-5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyri-
midin-2-yl]-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (125)
[0953] To
{5-[(1-benzenesulfonyl-5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)--
hydroxy-methyl]-pyrimidin-2-yl}-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-ca-
rbamic acid tert-butyl ester (124, 1 equivalent) in 10.0 mL of
acetonitrile, triethylsilane (15.6 equivalents) and trifluoroacetic
acid (16.9 equivalents) are added. The reaction is heated at
80.degree. C. for 2 hours, then poured into aqueous potassium
carbonate and extracted with ethyl acetate. The organic layer is
dried over sodium sulfate, filtered and the filtrate concentrated
under vacuum to provide the desired compound, which is used in the
next step without further purification.
Step 3--Preparation of
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-1599)
[0954] To
[5-(1-benzenesulfonyl-5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyrimidin-2-yl]-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine
(125, 1 equivalent) in 15.0 mL of tetrahydrofuran,
tetrabutylammonium fluoride trihydrate (2 equivalent) is added. The
reaction is stirred at room temperature overnight, then poured into
water and extracted with ethyl acetate. The organic layer is dried
over sodium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material is purified by silica gel column
chromatography eluting with 20-100% ethyl acetate in hexane.
Appropriate fractions are combined and concentrated under vacuum to
provide the desired compound as a yellow solid.
[0955] Additional compounds are prepared following the protocol of
Scheme 13, where conditions may vary, for example, any of the
solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. Compounds are prepared using a suitable Boc protected
aldehyde in place of
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-(5-formyl-pyrimidin-2-yl)-carbami-
c acid tert-butyl ester 123 in step 1.
[0956] The following compounds are made using this procedure.
Compounds in the following table were characterized by .sup.1H and
.sup.13C NMR spectroscopy as well as mass spectrometry. [0957]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-1600), [0958]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-1601), [0959]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-1602), [0960]
[5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-tri-
fluoromethyl-pyridin-3-ylmethyl)-amine (P-1603), [0961]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyrimidin-2-yl]-amine (P-1604), [0962]
[5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-tri-
fluoromethyl-pyridin-3-ylmethyl)-amine (P-1605), [0963]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyrimidin-2-yl]-amine (P-1606), [0964]
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-fluoro-6-
-methoxy-3-pyridyl)methyl]pyridin-2-amine (P-2203), and [0965]
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204).
[0966] The following table indicates the aldehyde compound (column
2) used in step 1 to afford the desired compound (column 3). The
compound number is provided in column 1, and the observed mass is
in column 4
TABLE-US-00009 Compound MS (ESI) number Aldehyde Compound structure
[M + H.sup.+].sup.+ P-1600 ##STR00423## ##STR00424## P-1601
##STR00425## ##STR00426## P-1602 ##STR00427## ##STR00428## P-1603
##STR00429## ##STR00430## P-1604 ##STR00431## ##STR00432## P-1605
##STR00433## ##STR00434## P-1606 ##STR00435## ##STR00436##
Example 14
Synthesis of
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine P-1547
[0967]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-p-
yrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine P-1547 is
prepared in three steps from
(5-formyl-3-methoxy-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester 55 and 5-methyl-1H-[2,3-b]pyridine 126 as shown in
Scheme 14.
##STR00437##
Step 1--Preparation of
{5-[hydroxy-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-methyl]-3-methoxy-py-
ridin-2-yl}-(4-methoxy-benzyl)-carbamic acid tert-butyl ester
(127)
[0968] In a vial, 5-methyl-1H-[2,3-b]pyridine (126, 1 equivalent)
is combined with
(5-formyl-3-methoxy-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester (55, 1.1 equivalents), 5 mL of methanol, and
potassium hydroxide (3 equivalents). The reaction is stirred at
room temperature overnight, then aqueous 1N hydrochloric acid is
added and the mixture is extracted with ethyl acetate. The organic
layer is washed with water, brine, then dried over magnesium
sulfate, filtered and the filtrate concentrated under vacuum. The
resulting material is purified by silica gel column chromatography
eluting with methanol and dichloromethane. Appropriate fractions
are combined and concentrated under vacuum to provide the desired
compound.
Step 2--Preparation of
3-methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylam-
ine (128)
[0969] In a round bottom flask,
{5-[hydroxy-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-methyl]-3-methoxy-py-
ridin-2-yl}-(4-methoxy-benzyl)-carbamic acid tert-butyl ester (127,
1 equivalent) is combined with 100 mL of acetonitrile,
triethylsilane (18 equivalents), and trifluoroacetic acid (18
equivalents). The reaction is heated at reflux for 24 hours, then
concentrated under vacuum. The resulting material is dissolved in
40 mL of trifluoroacetic acid and stirred at room temperature for
18 hours. This is concentrated under vacuum and combined with water
and sodium bicarbonate, then extracted with ethyl acetate. The
organic layer is washed with sodium bicarbonate, water, brine, then
dried with magnesium sulfate, filtered and the filtrate is
concentrated under vacuum. The resulting material is purified by
silica gel column chromatography eluting with ethyl acetate and
hexane. Appropriate fractions are combined and concentrated under
vacuum to provide the desired compound.
Step 3--Preparation of
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1547)
[0970] To
3-methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-ylamine (128, 1 equivalent) in 2 mL of acetonitrile,
5-fluoro-2-methoxy-pyridine-3-carbaldehyde (37, 1 equivalent),
triethylsilane (5 equivalents) and trifluoroacetic acid (6.9
equivalents) are added. The reaction is heated at 80.degree. C. for
18 hours, then concentrated under vacuum and mixed with aqueous
potassium carbonate and extracted with ethyl acetate. The organic
layer is washed with water, brine, then dried over magnesium
sulfate, filtered and the filtrate concentrated under vacuum. The
resulting material is purified by silica gel column chromatography
eluting with ethyl acetate and hexane. Appropriate fractions are
combined and concentrated under vacuum to provide the desired
compound.
[0971] Additional compounds are prepared following the protocol of
Scheme 14, where conditions may vary, for example, any of the
solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. Compounds are prepared using a suitable aldehyde in
place 5-fluoro-2-methoxy-pyridine-3-carbaldehyde 37 in step 3. The
following compounds are made using this procedure. Compounds in the
following table were characterized by .sup.1H and .sup.13C NMR
spectroscopy as well as mass spectrometry. [0972]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1548), [0973]
(5-Fluoro-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1549), [0974]
(6-Chloro-pyridin-3-ylmethyl)-[3-methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1550), [0975]
[3-Methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1551), [0976]
[3-Methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-1552), and [0977]
[3-Methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(2-methoxy-pyridin-3-ylmethyl)-amine (P-1553). The following table
indicates the aldehyde compound (column 2) used in step 3 to afford
the desired compound (column 3). The compound number is provided in
column 1, and the observed mass is in column 4
TABLE-US-00010 [0977] Compound MS (ESI) number Aldehyde Compound [M
+ H.sup.+].sup.+ P-1548 ##STR00438## ##STR00439## P-1549
##STR00440## ##STR00441## P-1550 ##STR00442## ##STR00443## P-1551
##STR00444## ##STR00445## P-1552 ##STR00446## ##STR00447## P-1553
##STR00448## ##STR00449##
Example 15
Synthesis of
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[(S)-1--
(4-fluoro-phenyl)-ethyl]-amine P-2005
[0978]
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[-
(S)-1-(4-fluoro-phenyl)-ethyl]-amine P-2005 was prepared in 4 steps
from 1-benzenesulfonyl-5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 12
and 2-methylsulfanyl-pyrimidine-5-carbaldehyde 129 as shown in
Scheme 15.
##STR00450##
Step 1--Preparation of
(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-(2-methylsulfa-
nyl-pyrimidin-5-yl)-methanol (130)
[0979] To a solution of
1-benzenesulfonyl-5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine (12,
8.40 g, 20.1 mmol) in 96.3 mL of tetrahydrofuran at -40.degree. C.
under nitrogen, isopropylmagnesium chloride (10.1 mL, 2.0 M in
tetrahydrofuran, 20.3 mmol) was added slowly. The reaction was
allowed to warm to 5.degree. C. over 60 minutes, then cooled to
-40.degree. C., followed by addition of
2-methylsulfanyl-pyrimidine-5-carbaldehyde (129, 2.50 g, 16.2 mmol)
in 15.0 mL of tetrahydrofuran. The reaction was allowed to warm to
10.degree. C. over 2 hours, then poured into aqueous ammonium
chloride and extracted with ethyl acetate. The organic layer was
dried over sodium sulfate, filtered and the filtrate was
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography eluting with 40-100% ethyl acetate
in hexane. Appropriate fractions were combined and the solvents
removed under vacuum to provide the desired compound as an
off-white solid (130, 4.0 g). MS (ESI) [M+H.sup.+].sup.+=447.2.
Step 2--Preparation of
1-benzenesulfonyl-5-chloro-3-(2-methylsulfanyl-pyrimidin-5-ylmethyl)-1H-p-
yrrolo[2,3-b]pyridine (131)
[0980] To
(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-(2-me-
thylsulfanyl-pyrimidin-5-yl)-methanol (130, 4.70 g, 10.5 mmol) in
120.0 mL of acetonitrile, triethylsilane (22.0 mL, 138 mmol) and
trifluoroacetic acid (11.0 mL, 143 mmol) were added. The reaction
was stirred at 80.degree. C. for 3 hours, then concentrated under
vacuum and mixed with aqueous potassium carbonate and extracted
with ethyl acetate. The organic layer was dried over sodium
sulfate, filtered and the filtrate concentrated under vacuum. The
resulting material was purified by silica gel column chromatography
eluting with 20-100% ethyl acetate in hexane. Appropriate fractions
were combined and solvents removed under vacuum to provide the
desired compound (131, 2.90 g).
Step 3--Preparation of
1-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-1H--
pyrrolo[2,3-b]pyridine (132)
[0981] To
1-benzenesulfonyl-5-chloro-3-(2-methylsulfanyl-pyrimidin-5-ylmet-
hyl)-1H-pyrrolo[2,3-b]pyridine (131, 4.40 g, 10.2 mmol) in 100.0 mL
of dichloromethane, meta-chloroperoxybenzoic acid (max. 77%, 4.90
g, 21.9 mmol) was added at 0.degree. C. The reaction was stirred at
0.degree. C. for 40 minutes, then poured into water and extracted
with ethyl acetate. The organic layer was dried over sodium
sulfate, filtered, and the filtrate was concentrated under vacuum.
The resulting material was purified by silica gel column
chromatography eluting with 20% ethyl acetate in hexane.
Appropriate fractions were combined and solvents removed under
vacuum to provide the desired compound (132, 3.76 g). MS (ESI)
[M+H.sup.+].sup.+=463.0.
Step 4--Preparation of
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[(S)-1--
(4-fluorophenyl)-ethyl]-amine (P-2005)
[0982] In a microwave vial,
1-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-1H--
pyrrolo[2,3-b]pyridine (132, 12 mg, 0.026 mmol) was mixed with 600
.mu.L of N-methylpyrrolidinone and
(S)-1-(4-fluoro-phenyl)-ethylamine (133, 25.2 mg, 0.18 mmol). The
reaction was irradiated at 200.degree. C. for 40 minutes in
microwave, then potassium hydroxide (500 .mu.L, 4.00 M in water)
was added and the reaction irradiated at 90.degree. C. for 10
minutes in microwave. The reaction was neutralized with the
addition of 120 .mu.L of acetic acid, solvents were removed under
vacuum, and the resulting material was dissolved in 400 .mu.L of
dimethyl sulfoxide for purification by HPLC. The desired compound
was purified on Phenomenex C18 column (50 mm.times.10 mm ID) with
mobile phase A of 0.1% trifluoroacetic acid in water, mobile phase
B of 0.1% trifluoroacetic acid in acetonitrile, 20-100% B over 16
minutes at a flow rate of 6 mL/min. Appropriate fractions were
collected and solvents removed under vacuum to provide the desired
compound. MS (ESI) [M+H.sup.+].sup.+=381.9.
[0983] 1-Benzenesulfonyl-5-fluoro-3-(2-methane
sulfonyl-pyrimidin-5-ylmethyl)-1H-pyrrolo[2,3-b]pyridine 134 and
1-benzenesulfonyl-3-(2-methane
sulfonyl-pyrimidin-5-ylmethyl)-5-methyl-1H-pyrrolo[2,3-b]pyridine
135
##STR00451##
are similarly prepared following the protocol of Scheme 15, steps
1-3, replacing
1-benzenesulfonyl-5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine 12 with
1-benzenesulfonyl-5-fluoro-3-iodo-1H-pyrrolo[2,3-b]pyridine or
1-benzenesulfonyl-3-iodo-5-methyl-1H-pyrrolo[2,3-b]pyridine
respectively in step 1. These are used following the protocol of
Scheme 15 step 4 to make additional compounds. In some instances
for the 5-fluoro substituted compounds, removal of the
benzenesulfonyl protecting group is done in an additional step by
reacting with tetrabutylammonium fluoride trihydrate in
tetrahydrofuran.
[0984] Additional compounds are prepared following the protocol of
Scheme 15, step 4, where conditions may vary, for example, any of
the solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. Compounds are prepared substituting
(S)-1-(4-fluoro-phenyl)-ethylamine 133 with a suitable amine and
optionally substituting
1-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-1H--
pyrrolo[2,3-b]pyridine 132 with
1-benzenesulfonyl-5-fluoro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-1H--
pyrrolo[2,3-b]pyridine 134 or
1-benzenesulfonyl-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-5-methyl-1H--
pyrrolo[2,3-b]pyridine 135. The following compounds are made using
this procedure. Compounds in the following table were characterized
by .sup.1H and .sup.13C NMR spectroscopy as well as mass
spectrometry. [0985]
(3-Chloro-4-methyl-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyrimidin-2-yl]-amine (P-2007), [0986]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3,4-di-
fluoro-benzyl)-amine (P-2008), [0987]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluo-
ro-5-trifluoromethyl-benzyl)-amine (P-2009), [0988]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-trif-
luoromethoxy-benzyl)-amine (P-2010), [0989]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluo-
ro-4-trifluoromethyl-benzyl)-amine (P-2011),
[0990]
(4-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-
-pyrimidin-2-yl]-methyl-amine (P-2012), [0991]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-meth-
yl-benzyl)-amine (P-2013), [0992]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluo-
ro-4-methyl-benzyl)-amine (P-2014), [0993]
[2-(3-Chloro-phenyl)-ethyl]-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyrimidin-2-yl]-amine (P-2015), [0994]
[2-(2-Chloro-phenyl)-ethyl]-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyrimidin-2-yl]-amine (P-2020), [0995]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[2-(4-f-
luoro-phenyl)-ethyl]-amine (P-2021), [0996]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[2-(6-m-
ethyl-pyridin-2-yl)-ethyl]-amine (P-2022), [0997]
Butyl-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-a-
mine (P-2026), [0998]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(1-thia-
zol-2-yl-ethyl)-amine (P-2039), [0999]
[1-(4-Fluoro-phenyl)-propyl]-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylme-
thyl)-pyrimidin-2-yl]-amine (P-2053), [1000]
[1-(4-Fluoro-phenyl)-cyclopropyl]-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-
-ylmethyl)-pyrimidin-2-yl]-amine (P-2055), [1001]
[(S)-1-(4-Fluoro-phenyl)-ethyl]-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyrimidin-2-yl]-amine (P-2056), [1002]
(2-Methoxy-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2069), [1003]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-meth-
oxy-pyridin-4-ylmethyl)-amine (P-2074), [1004]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin-
-2-ylmethyl-amine (P-2076), [1005]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin-
-3-ylmethyl-amine (P-2077), [1006]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2078), [1007]
(6-Methyl-pyridin-2-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2079), [1008]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-2080), [1009]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-morp-
holin-4-yl-pyridin-2-ylmethyl)-amine (P-2081), [1010]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-pyrr-
olidin-1-yl-pyridin-2-ylmethyl)-amine (P-2082), [1011]
(5-Ethyl-pyridin-2-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylme-
thyl)-pyrimidin-2-yl]-amine (P-2083), [1012]
(3-Methyl-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2084), [1013]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-morp-
holin-4-yl-pyridin-4-ylmethyl)-amine (P-2085), [1014]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin-
-4-ylmethyl-amine (P-2138), [1015]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2139), [1016]
[6-(4-Methyl-piperazin-1-yl)-pyridin-3-ylmethyl]-[5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2140), [1017]
(2-Methyl-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2141), [1018]
(2-Ethoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-2142), [1019]
(2-Cyclopentyloxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2148), and [1020]
(2-Cyclopentyloxy-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2149). The following table
indicates the 1H-pyrrolo[2,3-b]pyridine (column 2) and the amine
compound (column 3) used in step 4 to afford the desired compound
(column 4). The compound number is provided in column 1, and the
observed mass is in column 5
TABLE-US-00011 [1020] 1H-pyrrolo[2,3- Amine MS Comp. number
b]pyridine structure Compound structure (ESI) [M + H.sup.+].sup.+
P-2007 ##STR00452## ##STR00453## ##STR00454## 397.9 P-2008
##STR00455## ##STR00456## ##STR00457## 386.3 P-2009 ##STR00458##
##STR00459## ##STR00460## 436.3 P-2010 ##STR00461## ##STR00462##
##STR00463## 434.3 P-2011 ##STR00464## ##STR00465## ##STR00466##
435.9 P-2012 ##STR00467## ##STR00468## ##STR00469## P-2013
##STR00470## ##STR00471## ##STR00472## 364.3 P-2014 ##STR00473##
##STR00474## ##STR00475## 381.9 P-2015 ##STR00476## ##STR00477##
##STR00478## 397.9 P-2020 ##STR00479## ##STR00480## ##STR00481##
397.9 399.95 P-2021 ##STR00482## ##STR00483## ##STR00484## 384.0
P-2022 ##STR00485## ##STR00486## ##STR00487## 379.4 P-2026
##STR00488## ##STR00489## ##STR00490## P-2039 ##STR00491##
##STR00492## ##STR00493## P-2053 ##STR00494## ##STR00495##
##STR00496## P-2055 ##STR00497## ##STR00498## ##STR00499## 377.9
P-2056 ##STR00500## ##STR00501## ##STR00502## 366.0 P-2069
##STR00503## ##STR00504## ##STR00505## 366.0 P-2074 ##STR00506##
##STR00507## ##STR00508## 380.9 P-2076 ##STR00509## ##STR00510##
##STR00511## P-2077 ##STR00512## ##STR00513## ##STR00514## P-2078
##STR00515## ##STR00516## ##STR00517## 365.1 P-2079 ##STR00518##
##STR00519## ##STR00520## 345.1 P-2080 ##STR00521## ##STR00522##
##STR00523## P-2081 ##STR00524## ##STR00525## ##STR00526## 416.3
P-2082 ##STR00527## ##STR00528## ##STR00529## 400.3 P-2083
##STR00530## ##STR00531## ##STR00532## P-2084 ##STR00533##
##STR00534## ##STR00535## P-2085 ##STR00536## ##STR00537##
##STR00538## P-2138 ##STR00539## ##STR00540## ##STR00541## P-2139
##STR00542## ##STR00543## ##STR00544## 361.5 P-2140 ##STR00545##
##STR00546## ##STR00547## P-2141 ##STR00548## ##STR00549##
##STR00550## P-2142 ##STR00551## ##STR00552## ##STR00553## P-2148
##STR00554## ##STR00555## ##STR00556## 415.5 P-2149 ##STR00557##
##STR00558## ##STR00559##
Example 16
Synthesis of
(5-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2--
ylamino]-methyl}-pyrimidin-2-yl)-methyl-amine P-2095
[1021]
(5-{[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyri-
din-2-ylamino]-methyl}-pyrimidin-2-yl)-methyl-amine P-2095 was
prepared in three steps from
3-iodo-5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 9
and (6-fluoro-5-formyl-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic
acid tert-butyl ester 83 as shown in Scheme 16.
##STR00560##
Step 1--Preparation of
{6-fluoro-5-[hydroxy-(5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyr-
idin-3-yl)-methyl]-pyridin-2-yl}-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester (136)
[1022] To
3-iodo-5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine (9,
40 g, 97.0 mmol) in 400 mL of tetrahydrofuran under nitrogen at
-20.degree. C., isopropylmagnesium chloride (54.8 mL, 2 M in
tetrahydrofuran, 110 mmol) was added and the reaction allowed to
warm to 0.degree. C. over 30 minutes. The reaction was cooled to
-40.degree. C. and
(6-fluoro-5-formyl-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester (83, 15.81 g, 43.9 mmol) in tetrahydrofuran was
added. The reaction was allowed to warm to 0.degree. C. over an
hour, then quenched with brine and extracted with ethyl acetate.
The organic layer was dried over sodium sulfate, filtered and the
filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography, eluting with 0-40%
ethyl acetate in hexane. Appropriate fractions were combined and
the solvents removed under vacuum to provide the desired compound
(136, 21 g, 32.4 mmol, 73.8% yield).
Step 2--Preparation of
6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylami-
ne (137)
[1023] To
{6-fluoro-5-[hydroxy-(5-methyl-1-triisopropylsilanyl-1H-pyrrolo[-
2,3-b]pyridin-3-yl)-methyl]-pyridin-2-yl}-(4-methoxy-benzyl)-carbamic
acid tert-butyl ester (136, 21 g, 32.4 mmol) in 500 mL of
acetonitrile, triethylsilane (51.7 mL, 324 mmol) and
trifluoroacetic acid (24.93 mL, 324 mmol) were added. The reaction
was stirred at 50.degree. C. for several hours, solvents removed
under vacuum, and the residue taken up in 250 mL of dichloromethane
and 250 mL of trifluoroacetic acid was added. The mixture was
stirred at reflux for several hours, then concentrated under
vacuum. The residue was taken up in ethyl acetate and poured into
aqueous potassium carbonate. The organic layer was separated,
concentrated under vacuum and purified by silica gel column
chromatography, eluting with 0-5% methanol in dichloromethane.
Appropriate fractions were combined and the solvents removed under
vacuum to provide the desired compound (137, 5.2 g, 20.29 mmol,
62.7% yield).
Step 3--Preparation of
(5-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2--
ylamino]methyl}-pyrimidin-2-yl)-methyl-amine (P-2095)
[1024] In a 2 mL microwave vial,
6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylami-
ne (137, 9.72 mg, 0.04 mmol) and
2-methylamino-pyrimidine-5-carbaldehyde (138, 11.0 mg, 0.08 mmol)
were dissolved in 600 .mu.L of 95:5 ethanol:acetic acid, and silica
supported cyanoborohydride (50 mg, 1 mmol/g, 0.05 mmol) was added.
The reaction was irradiated for 10 minutes at 160.degree. C. in a
microwave. The vial was centrifuged to condense the silica and the
supernatant was removed by pipette into another vial. The residual
silica was rinsed with 500 .mu.L of ethanol, centrifuged and the
supernatant added to the first supernatant. The solvents were
removed under vacuum and the resulting material dissolved in 400
.mu.L of dimethyl sulfoxide for purification by HPLC. Samples were
purified on Phenomenex C18 column (50 mm.times.10 mm ID) with
mobile phase A of 0.1% trifluoroacetic acid in water, mobile phase
B of 0.1% trifluoroacetic acid in acetonitrile, 20-100% B over 16
minutes at a flow rate of 6 mL/min. Appropriate fractions were
collected and solvents removed under vacuum to provide the desired
compound. MS (ESI) [M+H.sup.+].sup.+=378.3.
[1025]
5-Fluoro-3-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyridin-2-ylamino]-methyl}-1-methyl-1H-pyridin-2-one P-2156
##STR00561##
was prepared similarly to the protocol of Scheme 16, where step 3
was replaced by the following step 3a:
##STR00562##
Step 3a--Preparation of
5-fluoro-3-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
ridin-2-ylamino]methyl}-1-methyl-1H-pyridin-2-one (P-2156)
[1026] To
6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridi-
n-2-ylamine (137, 3.99 g, 15.59 mmol) and
5-fluoro-1-methyl-2-oxo-1,2-dihydro-pyridine-3-carbaldehyde (33,
2.66 g, 17.15 mmol) in 50 mL of acetonitrile, triethylsilane (9.96
mL, 62.4 mmol) and trifluoroacetic acid (4.80 mL, 62.4 mmol) were
added. The reaction was stirred at 80.degree. C. for several hours,
then concentrated under vacuum and the residue was taken up in
ethyl acetate and poured into aqueous potassium carbonate. The
organic layer was separated, concentrated under vacuum, and the
residue purified by silica gel column chromatography, eluting with
0-5% methanol in dichloromethane. Appropriate fractions were
combined and concentrated under vacuum, and the residue triturated
with methanol to provide the desired compound (P-2156, 3.1 g, 7.84
mmol, 50.3% yield).
[1027]
N-[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridi-
n-2-yl]-C-phenyl-methanesulfonamide P-2181
##STR00563##
similarly to the protocol of Scheme 16, where step 3 was replaced
by the following step 3b:
##STR00564##
Step 3b--Preparation of
N-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl-
]-C-phenyl-methanesulfonamide (P-2181)
[1028] In a vial,
6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylami-
ne (137, 157 mg, 0.614 mmol) was mixed with 4 mL of dichloromethane
and pyridine (149 .mu.L, 1.84 mmol) and cooled to 0.degree. C. in
an ice water bath. Phenyl-methanesulfonyl chloride (139, 0.234 g,
1.23 mmol) was added and the reaction stirred at 0.degree. C. for 1
hour, then warmed to room temperature and stirred overnight.
Aqueous saturated sodium bicarbonate was added and extracted with
ethyl acetate. The organic layer was washed with water and brine,
then dried over magnesium sulfate, filtered and the filtrate
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography, eluting with 0-10% methanol in
dichloromethane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound as a
yellow solid (P-2181, 39 mg). MS (ESI) [M+H.sup.+].sup.+=411.1.
[1029] Additional compounds are prepared following the protocol of
Scheme 16 (step 3a may be substituted for step 3) where conditions
may vary, for example, any of the solvents, reaction times,
reagents, temperatures, work up conditions, or other reaction
parameters may be varied employing alternate solvents, reagents,
reaction times, temperatures, work up conditions, and the like, as
are readily available to one skilled in the art. Compounds are
prepared optionally substituting
3-iodo-5-methyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 9
with a suitable 1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine in
step 1; optionally replacing
(6-fluoro-5-formyl-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester 83 with
(5-formyl-pyrimidin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester in step 1; and optionally replacing
2-methylamino-pyrimidine-5-carbaldehyde 138 with a suitable
aldehyde in step 3. The following compounds are made using this
procedure. Compounds in the following table were characterized by
.sup.1H and .sup.13C NMR spectroscopy as well as mass spectrometry.
[1030]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-1569), [1031]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-1570), [1032]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1611), [1033]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-1612), [1034]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-1613), [1035]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-meth-
oxy-pyridin-3-ylmethyl)-amine (P-1614), [1036]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-
-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1646),
[1037]
(5-Fluoro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1647), [1038]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1648), [1039]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-trifluoromethyl-1H-
-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1649),
[1040]
[6-Fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1650),
[1041]
[6-Fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amine (P-1651), [1042]
[6-Fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1652),
[1043]
[6-Fluoro-5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(2-methoxy-pyridin-3-ylmethyl)-amine (P-1653), [1044]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2049), [1045]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2061), [1046]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-2-methoxy-pyridin-3-ylmethyl)-amine (P-2064), [1047]
(2,5-Dimethoxy-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyridin-2-yl]-amine (P-2086), [1048]
(3,5-Dimethoxy-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyridin-2-yl]-amine (P-2087), [1049]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2088), [1050]
(3-Bromo-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyridin-2-yl]-amine (P-2089), [1051]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-morpholin-4-yl-pyridin-3-ylmethyl)-amine (P-2090), [1052]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-morpholin-4-yl-pyridin-3-ylmethyl)-amine (P-2091), [1053]
(3-Chloro-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2092), [1054]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-2-ylmethyl)-amine (P-2093), [1055]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(3-fluoro-pyridin-4-ylmethyl)-amine (P-2094), [1056]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
[2-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylmethyl]-amine (P-2096),
[1057]
(2,6-Dimethoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b-
]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2097), [1058]
(5-Fluoro-2-methane
sulfonyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-yl]-amine (P-2098), [1059]
(5-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2099), [1060]
(5-Bromo-pyridin-2-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyrid-
in-3-ylmethyl)-pyridin-2-yl]-amine (P-2100), [1061]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(3-methyl-pyridin-4-ylmethyl)-amine (P-2101), [1062]
(3-Chloro-5-fluoro-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-
-3-ylmethyl)-pyridin-2-yl]-amine (P-2102), [1063]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-fluoro-pyridin-3-ylmethyl)-amine (P-2103), [1064]
(3,5-Dimethyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-2104), [1065]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-methoxy-pyridin-3-ylmethyl)-amine (P-2105), [1066]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methyl-pyrimidin-5-ylmethyl)-amine (P-2106), [1067]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methylamino-pyridin-3-ylmethyl)-amine (P-2107), [1068]
(3,5-Bis-trifluoromethyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]p-
yridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2108), [1069]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-methoxy-pyridin-3-ylmethyl)-amine (P-2109), [1070]
(2-Ethoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2110), [1071]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-isopropoxy-pyridin-3-ylmethyl)-amine (P-2111), [1072]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-methyl-pyridin-2-ylmethyl)-amine (P-2112), [1073]
(2-Cyclopentyloxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,-
3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2113), [1074]
(2-Cyclohexyloxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-
-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2114), [1075]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2115), [1076]
(2-Chloro-5-fluoro-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2116), [1077]
4-{[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y-
lamino]-methyl}-pyridine-2-carbonitrile (P-2117), [1078]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-fluoro-pyridin-4-ylmethyl)-amine (P-2118), [1079]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-trifluoromethyl-pyridin-4-ylmethyl)-amine (P-2119), [1080]
(2-Chloro-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2120), [1081]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-morpholin-4-yl-pyridin-4-ylmethyl)-amine (P-2121), [1082]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-pyrrolidin-1-yl-pyridin-4-ylmethyl)-amine (P-2122), [1083]
(5-Chloro-2-fluoro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2123), [1084]
(4-Chloro-2-methanesulfonyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3--
b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2124), [1085]
(2-Dimethylamino-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-
-ylmethyl)-pyridin-2-yl]-amine (P-2125), [1086]
(2-Ethyl-pyrimidin-5-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2126), [1087]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-propyl-pyrimidin-5-ylmethyl)-amine (P-2127), [1088]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-isopropyl-pyrimidin-5-ylmethyl)-amine (P-2128), [1089]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
[2-(2-methoxy-ethyl)-pyrimidin-5-ylmethyl]-amine (P-2129), [1090]
(2-Butyl-pyrimidin-5-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2130), [1091]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-methyl-pyridin-2-ylmethyl)-amine (P-2131), [1092]
(3-Fluoro-5-methyl-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-
-3-ylmethyl)-pyridin-2-yl]-amine (P-2132), [1093]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(3-methoxy-5-trifluoromethyl-benzyl)-amine (P-2133), [1094]
(3-Fluoro-5-methoxy-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl)-pyridin-2-yl]-amine (P-2134), [1095]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(3,4,5-trimethoxy-benzyl)-amine (P-2150), [1096]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-pyrrolidin-1-yl-pyridin-2-ylmethyl)-amine (P-2151), [1097]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2166),
[1098]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-dimethylamino-6-trifluoromethyl-pyridin-3-ylmethyl)-amine
(P-2167), [1099]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-
-2-yl]-(6-methoxy-4-trifluoromethyl-pyridin-3-ylmethyl)-amine
(P-2186), [1100] Ethanesulfonic
acid(2-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridi-
n-2-ylamino]-methyl}-phenyl)-amide (P-2198), [1101] Ethanesulfonic
acid(4-fluoro-3-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-ylamino]-methyl}-phenyl)-amide (P-2199), and [1102]
Ethanesulfonic
acid(3-fluoro-5-{[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-ylamino]-methyl}-phenyl)-amide (P-2202). The following
table indicates the 1H-pyrrolo[2,3-b]pyridine (column 2) and
Boc-protected aldehyde (column 3) used in step 1, and the aldehyde
compound (column 4) used in step 3 (or 3a if indicated in column 1)
to afford the desired compound (column 5). The compound number is
provided in column 1, and the observed mass is in column 6
TABLE-US-00012 [1102] MS pyrrolo[2,3- Boc Step 3 (ESI) Comp. number
b]pyridine Aldehyde aldehyde Compound [M + H.sup.+].sup.+ P-1569
##STR00565## ##STR00566## ##STR00567## ##STR00568## P-1570
##STR00569## ##STR00570## ##STR00571## ##STR00572## P-1611
##STR00573## ##STR00574## ##STR00575## ##STR00576## P-1612
##STR00577## ##STR00578## ##STR00579## ##STR00580## P-1613
##STR00581## ##STR00582## ##STR00583## ##STR00584## P-1614
##STR00585## ##STR00586## ##STR00587## ##STR00588## P-1646 (3a)
##STR00589## ##STR00590## ##STR00591## ##STR00592## 450.0 P-1647
(3a) ##STR00593## ##STR00594## ##STR00595## ##STR00596## P-1648
(3a) ##STR00597## ##STR00598## ##STR00599## ##STR00600## P-1649
(3a) ##STR00601## ##STR00602## ##STR00603## ##STR00604## 450.1
P-1650 (3a) ##STR00605## ##STR00606## ##STR00607## ##STR00608##
P-1651 (3a) ##STR00609## ##STR00610## ##STR00611## ##STR00612##
P-1652 (3a) ##STR00613## ##STR00614## ##STR00615## ##STR00616##
P-1653 (3a) ##STR00617## ##STR00618## ##STR00619## ##STR00620##
P-2049 (3a) ##STR00621## ##STR00622## ##STR00623## ##STR00624##
396.0 P-2061 ##STR00625## ##STR00626## ##STR00627## ##STR00628##
379.0 P-2064 ##STR00629## ##STR00630## ##STR00631## ##STR00632##
398.9 P-2086 ##STR00633## ##STR00634## ##STR00635## ##STR00636##
P-2087 ##STR00637## ##STR00638## ##STR00639## ##STR00640## P-2088
##STR00641## ##STR00642## ##STR00643## ##STR00644## 382.3 P-2089
##STR00645## ##STR00646## ##STR00647## ##STR00648## P-2090
##STR00649## ##STR00650## ##STR00651## ##STR00652## 433.1 P-2092
##STR00653## ##STR00654## ##STR00655## ##STR00656## 382.3 P-2093
##STR00657## ##STR00658## ##STR00659## ##STR00660## P-2094
##STR00661## ##STR00662## ##STR00663## ##STR00664## 366.3 P-2096
##STR00665## ##STR00666## ##STR00667## ##STR00668## P-2097
##STR00669## ##STR00670## ##STR00671## ##STR00672## 408.3 P-2098
##STR00673## ##STR00674## ##STR00675## ##STR00676## 443.1 P-2099
##STR00677## ##STR00678## ##STR00679## ##STR00680## 382.3 P-2100
##STR00681## ##STR00682## ##STR00683## ##STR00684## P-2101
##STR00685## ##STR00686## ##STR00687## ##STR00688## P-2102
##STR00689## ##STR00690## ##STR00691## ##STR00692## P-2103
##STR00693## ##STR00694## ##STR00695## ##STR00696## 366.3 P-2104
##STR00697## ##STR00698## ##STR00699## ##STR00700## P-2105
##STR00701## ##STR00702## ##STR00703## ##STR00704## 378.3 P-2106
##STR00705## ##STR00706## ##STR00707## ##STR00708## P-2107
##STR00709## ##STR00710## ##STR00711## ##STR00712## P-2108
##STR00713## ##STR00714## ##STR00715## ##STR00716## P-2109
##STR00717## ##STR00718## ##STR00719## ##STR00720## 378.3 P-2110
##STR00721## ##STR00722## ##STR00723## ##STR00724## P-2111
##STR00725## ##STR00726## ##STR00727## ##STR00728## P-2112
##STR00729## ##STR00730## ##STR00731## ##STR00732## P-2113
##STR00733## ##STR00734## ##STR00735## ##STR00736## P-2114
##STR00737## ##STR00738## ##STR00739## ##STR00740## P-2115
##STR00741## ##STR00742## ##STR00743## ##STR00744## 416.3 P-2116
##STR00745## ##STR00746## ##STR00747## ##STR00748## P-2117
##STR00749## ##STR00750## ##STR00751## ##STR00752## P-2118
##STR00753## ##STR00754## ##STR00755## ##STR00756## 366.3 P-2119
##STR00757## ##STR00758## ##STR00759## ##STR00760## 416.3 P-2120
##STR00761## ##STR00762## ##STR00763## ##STR00764## 382.3 P-2121
##STR00765## ##STR00766## ##STR00767## ##STR00768## P-2122
##STR00769## ##STR00770## ##STR00771## ##STR00772## P-2123
##STR00773## ##STR00774## ##STR00775## ##STR00776## P-2124
##STR00777## ##STR00778## ##STR00779## ##STR00780## P-2125
##STR00781## ##STR00782## ##STR00783## ##STR00784## P-2126
##STR00785## ##STR00786## ##STR00787## ##STR00788## P-2127
##STR00789## ##STR00790## ##STR00791## ##STR00792## P-2128
##STR00793## ##STR00794## ##STR00795## ##STR00796## P-2129
##STR00797## ##STR00798## ##STR00799## ##STR00800## P-2130
##STR00801## ##STR00802## ##STR00803## ##STR00804## P-2131
##STR00805## ##STR00806## ##STR00807## ##STR00808## 362.3 P-2132
##STR00809## ##STR00810## ##STR00811## ##STR00812## P-2133
##STR00813## ##STR00814## ##STR00815## ##STR00816## P-2134
##STR00817## ##STR00818## ##STR00819## ##STR00820## 395.1 P-2150
##STR00821## ##STR00822## ##STR00823## ##STR00824## P-2151
##STR00825## ##STR00826## ##STR00827## ##STR00828## P-2166 (step
3a) ##STR00829## ##STR00830## ##STR00831## ##STR00832## 446.2
P-2167 (step 3a) ##STR00833## ##STR00834## ##STR00835##
##STR00836## 459.1 P-2186 (step 3a) ##STR00837## ##STR00838##
##STR00839## ##STR00840## 446.4 P-2198 (step 3a) ##STR00841##
##STR00842## ##STR00843## ##STR00844## 454.0 P-2199 (step 3a)
##STR00845## ##STR00846## ##STR00847## ##STR00848## 472.0 P-2202
(step 3a) ##STR00849## ##STR00850## ##STR00851## ##STR00852##
472.1
Example 17
Synthesis of
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine P-2001
[1103]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin--
2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine P-2001 was prepared in
five steps from 5-chloro-1H-pyrrolo[2,3-b]pyridine 1 as shown in
Scheme 17.
##STR00853##
Step 1--Preparation of
(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-dimethyl-amine
(140)
[1104] To 5-chloro-1H-pyrrolo[2,3-b]pyridine (1, 8.00 g, 0.0524
mol) in 250 mL of isopropyl alcohol, dimethylamine hydrochloride
(4.79 g, 0.0587 mol) and formaldehyde (1.77 g, 0.0589 mol) were
added. The reaction was stirred at room temperature overnight,
followed by refluxing for 4 hours. The reaction was concentrated,
poured into water, and extracted with ethyl acetate. The organic
layer was dried over anhydrous sodium sulfate and filtered. The
filtrate was concentrated to give crude compound (140, 10.0 g,
91%), that was used directly in the next step.
Step 2: Preparation of
5-chloro-3-dimethylaminomethyl-pyrrolo[2,3-b]pyridine-1-carboxylic
acid tert-butyl ester (141)
[1105] To
(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-dimethyl-amine (140,
5.00 g, 23.8 mmol) in 60.0 mL of N,N-dimethylformamide, sodium
hydride (1.05 g, 60% in mineral oil, 26.2 mmol) was added. After 10
minutes, di-tert-butyldicarbonate (25, 6.24 g, 28.6 mmol) was added
and the reaction was stirred at room temperature overnight, then
poured into water and extracted with ethyl acetate. The organic
layer was dried over sodium sulfate, filtered and the filtrate was
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography eluting with 5% methanol in
dichloromethane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound as a
white solid (141, 5.20 g).
Step 3: Preparation of
5-chloro-3-chloromethyl-pyrrolo[2,3-b]pyridine-1-carboxylic acid
tert-butyl ester (142)
[1106] To
5-chloro-3-dimethylaminomethyl-pyrrolo[2,3-b]pyridine-1-carboxyl-
ic acid tert-butyl ester (141, 4.20 g, 13.6 mmol) in 100 mL of
toluene, ethyl chloroformate (1.48 mL, 15.5 mmol) was added under
nitrogen. The reaction was stirred at room temperature for 2 hours,
then concentrated under vacuum and combined with water and
extracted with ethyl acetate. The organic layer was dried over
sodium sulfate, filtered and the filtrate was concentrated under
vacuum. The resulting material was purified by silica gel column
chromatography eluting with 25% ethyl acetate in hexane to provide
the desired compound (142, 1.60 g).
[1107] Step 4--Preparation of
3-{6-[tert-butoxycarbonyl-(5-fluoro-pyridin-3-ylmethyl)-amino]-2-fluoro-p-
yridin-3-ylmethyl}-5-chloro-pyrrolo[2,3-b]pyridine-1-carboxylic
acid tert-butyl ester (144):
[1108] To
(5-bromo-6-fluoro-pyridin-2-yl)-(5-fluoro-pyridin-3-ylmethyl)-ca-
rbamic acid tert-butyl ester (143, 0.600 g, 1.50 mmol) in 10.0 mL
of tetrahydrofuran at -25.degree. C. under nitrogen,
isopropylmagnesium chloride (0.730 mL, 2.0 M in tetrahydrofuran,
1.46 mmol) was added and the reaction allowed to come to 5.degree.
C. over 1 hour. The reaction was then cooled to -35.degree. C., and
CuCN.2LiCl (2.0 mL, 0.75 M in tetrahydrofuran, 1.5 mmol) was added.
After 5 minutes,
5-chloro-3-chloromethyl-pyrrolo[2,3-b]pyridine-1-carboxylic acid
tert-butyl ester (142, 0.300 g, 0.996 mmol) in 4.0 mL of
tetrahydrofuran was added and the reaction allowed to come to room
temperature over 1 hour. The reaction was poured into dilute
ammonia solution and extracted with ethyl acetate. The organic
layer was separated, dried over sodium sulfate, filtered and the
filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography eluting with 20-100%
ethyl acetate in hexane. Appropriate fractions were combined and
the solvent removed under vacuum to provide the desired compound
(144, 130 mg). MS (ESI) [M+H.sup.+].sup.+=586.2.
Step 5--Preparation of
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-2001)
[1109] To
3-{6-[tert-butoxycarbonyl-(5-fluoro-pyridin-3-ylmethyl)-amino]-2-
-fluoro-pyridin-3-ylmethyl}-5-chloro-pyrrolo[2,3-b]pyridine-1-carboxylic
acid tert-butyl ester (144, 0.280 g, 0.478 mmol) in 10.0 mL of
dichloromethane, trifluoroacetic acid (1.00 mL, 13.0 mmol) was
added and the reaction stirred at room temperature overnight. This
was pooled with a separate reaction run similarly and concentrated
under vacuum. The resulting material was combined with aqueous
potassium carbonate and ethyl acetate and mixed. The aqueous layer
was separated and the organic layer was dried over sodium sulfate,
filtered and the filtrate concentrated under vacuum. The resulting
material was purified by silica gel column chromatography eluting
with 20% ethyl acetate in hexane. Appropriate fractions were
combined and the solvent removed under vacuum to provide the
desired compound (P-2001, 99 mg). MS (ESI)
[M+H.sup.+].sup.+=386.0.
Preparation of
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204)
[1110] To
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-
-fluoro-6-methoxy-3-pyridyl)methyl]pyridin-2-amine (125 mg, 0.27
mmol) was added 2 mL of N,N-dimethylacetamide. The mixture
suspension was degassed by bubbling with argon. To this suspension
was added Zinc (5 mg, 0.08 mmol),
11,1'-Bis(diphenylphosphino)ferrocene (6 mg, 0.01 mmol), Zinc
Cyanide (0.01 ml, 0.19 mmol), and
Tris(dibenzylideneacetone)dipalladium (0) (7 mg, 0.01 mmol) at room
temperature under argon. The mixture was heated to 120.degree. C.
for 2 hrs and cooled to room temperature. The reaction mixture was
extracted with ethyl acetate and water (+saturated sodium
chloride). The organic layer was washed with water and brine, dried
by MgSO.sub.4. The volatiles were removed under vacuum. The residue
was suspended in acetonitrile and sonicated for 45 mins. The
precipitate was collected by filtration and washed with
acetonitrile. A tan solid was obtained (98 mg, 88.8% yield). LC-MS
showed one major peak with 98.6% purity. The structure of the
product is confirmed by H.sup.1--NMR (DMSO-d6). MS (ESI)
[M+H].sup.+=406.9.
[1111] Additional compounds are prepared following the protocol of
Scheme 17, where conditions may vary, for example, any of the
solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. Compounds are prepared optionally replacing
5-chloro-1H-pyrrolo[2,3-b]pyridine 1 with a suitable
5-substituted-1H-pyrrolo[2,3-b]pyridine in step 1 and optionally
replacing
(5-bromo-6-fluoro-pyridin-2-yl)-(5-fluoro-pyridin-3-ylmethyl)-c-
arbamic acid tert-butyl ester 143 with a suitable N-protected bromo
(or other suitable halo) compound in step 4. The following
compounds are made using this procedure. Compounds in the following
table were characterized by .sup.1H and .sup.13C NMR spectroscopy
as well as mass spectrometry. [1112]
3-{2-Fluoro-6-[(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyri-
din-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1654),
[1113]
3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-fluoro-pyridin-3-ylmethyl}-1-
H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1655), [1114]
3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1656), [1115]
3-{2-Fluoro-6-[(4-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-
methyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1657), [1116]
3-{2-Fluoro-6-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1658), [1117]
3-{2-Fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-
methyl}-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1659), [1118]
3-{2-Fluoro-6-[(2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-1660), [1119]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-2027), [1120]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(5-fluoro-pyridin-3-ylmethyl)-amine (P-2028), [1121]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-2029), [1122]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-2030), [1123]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2031), [1124]
(4-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2032), [1125]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-2041), [1126]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-pyridin-3-ylmethyl)-amine (P-2176), [1127]
5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-6-fluoro-N-[(5-fluoro-6-
-methoxy-3-pyridyl)methyl]pyridin-2-amine (P-2203), [1128]
3-[[2-fluoro-6-[(5-fluoro-6-methoxy-3-pyridyl)methylamino]-3-pyridyl]meth-
yl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-2204), [1129]
6-chloro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine (P-2205), and [1130]
6-fluoro-N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-5-[[5-(trifluoromethyl)-
-1H-pyrrolo[2,3-b]pyridin-3-yl]methyl]pyridin-2-amine (P-2206). The
following table indicates the 1H-pyrrolo[2,3-b]pyridine compound
(column 2) used in step 1 and halogen substituted compound (column
3) used in step 4 to afford the desired compound (column 4). The
compound number is provided in column 1, and the observed mass is
in column 5
TABLE-US-00013 [1130] 1H- Comp. pyrrolo[2,3- number b]pyridine
Halogen compound P-1654 ##STR00854## ##STR00855## P-1655
##STR00856## ##STR00857## P-1656 ##STR00858## ##STR00859## P-1657
##STR00860## ##STR00861## P-1658 ##STR00862## ##STR00863## P-1659
##STR00864## ##STR00865## P-1660 ##STR00866## ##STR00867## P-2027
##STR00868## ##STR00869## P-2028 ##STR00870## ##STR00871## P-2029
##STR00872## ##STR00873## P-2030 ##STR00874## ##STR00875## P-2031
##STR00876## ##STR00877## P-2032 ##STR00878## ##STR00879## P-2041
##STR00880## ##STR00881## P-2176 ##STR00882## ##STR00883## Comp. MS
(ESI) number Compound structure [M + H.sup.+].sup.+ P-1654
##STR00884## P-1655 ##STR00885## P-1656 ##STR00886## 407.2 P-1657
##STR00887## P-1658 ##STR00888## P-1659 ##STR00889## P-1660
##STR00890## P-2027 ##STR00891## 366.0 P-2028 ##STR00892## 381.9
P-2029 ##STR00893## 378.0 P-2030 ##STR00894## 394.2 P-2031
##STR00895## 381.9 P-2032 ##STR00896## 396.9 P-2041 ##STR00897##
P-2176 ##STR00898## 369.1
Example 18
Synthesis of
(3-chloro-benzyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-met-
hyl-1H-pyrazol-3-yl]-amine P-2006
[1131]
(3-Chloro-benzyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-
-1-methyl-1H-pyrazol-3-yl]-amine P-2006 was prepared in two steps
from 5-(3-chloro-benzylamino)-2-methyl-2H-pyrazole-3-carb aldehyde
145 and
5-fluoro-3-iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 146
as shown in Scheme 18.
##STR00899##
Step 1--Preparation of
[5-(3-chloro-benzylamino)-2-methyl-2H-pyrazol-3-yl]-(5-fluoro-1-triisopro-
pylsilanyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-methanol (147)
[1132]
5-Fluoro-3-iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine
(146, 0.33 g, 0.79 mmol) and 1.5 mL of tetrahydrofuran were
combined in a round bottom flask and cooled to -20.degree. C.
Isopropylmagnesium chloride (400 .mu.L, 2.0 M in tetrahydrofuran,
0.8 mmol) was added dropwise and the reaction stirred and brought
to -5.degree. C. The reaction was cooled to -20.degree. C. and
5-(3-chloro-benzylamino)-2-methyl-2H-pyrazole-3-carbaldehyde (145,
0.090 g, 0.36 mmol) in tetrahydrofuran was added and the reaction
stirred and brought to 0.degree. C. The reaction was concentrated
under vacuum, diluted with ethyl acetate and washed with saturated
aqueous sodium bicarbonate, then brine. The organic layer was
separated and dried over sodium sulfate, filtered and the filtrate
purified by silica gel flash column chromatography eluting with a
gradient of 5-80% ethyl acetate in hexane. Appropriate fractions
were combined and concentrated under vacuum to provide the desired
compound. MS (ESI) [M+H.sup.+].sup.+=542.7, 543.95.
Step 2--Preparation of
(3-chloro-benzyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-met-
hyl-1H-pyrazol-3-yl]-amine (P-2006)
[1133] To
[5-(3-chloro-benzylamino)-2-methyl-2H-pyrazol-3-yl]-(5-fluoro-1--
triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-methanol (147,
0.070 g, 0.13 mmol) in 4 mL of dichloromethane, triethylsilane
(0.210 mL, 1.31 mmol) and trifluoroacetic acid (0.100 mL, 1.30
mmol) were added and the reaction stirred overnight at room
temperature. The reaction was concentrated under vacuum, then ethyl
acetate was added, then washed with 1M aqueous potassium carbonate,
then brine. The organic layer was dried over sodium sulfate,
filtered and the filtrate purified by silica gel flash column
chromatography eluting with a gradient of 2-20% methanol in
dichloromethane. Appropriate fractions were combined and
concentrated under vacuum and the resulting solid washed with ethyl
acetate in hexane to provide the desired compound.
[1134] The following compounds are prepared following the protocol
of Scheme 18, where conditions may vary, for example, any of the
solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. The following compounds were characterized by .sup.1H
and .sup.13C NMR spectroscopy as well as mass spectrometry. [1135]
6-chloro-N-[(5-fluoro-2-methoxy-3-pyridyl)methyl]-5-[(5-methyl-1H-pyrrolo-
[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine (P-2205), and [1136]
6-fluoro-N-[(5-fluoro-6-methoxy-3-pyridyl)methyl]-5-[[5-(trifluoromethyl)-
-1H-pyrrolo[2,3-b]pyridin-3-yl]methyl]pyridin-2-amine (P-2206).
Example 19
Synthesis of
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1H-pyrazol-3-yl]-(4-flu-
oro-benzyl)-amine P-2016
[1137]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1H-pyrazol-3-yl]--
(4-fluoro-benzyl)-amine P-2016 was prepared in three steps from
5-(4-fluoro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazole-3-carbaldehyde
113 and
5-chloro-3-iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 4
as shown in Scheme 19.
##STR00900##
Step 1--Preparation of
(5-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-[5-(4-fluo-
ro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazol-3-yl]-methanol
(148)
[1138] In a round bottom flask,
5-chloro-3-iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine (4,
1.7 g, 3.9 mmol) was combined with 1.3 mL of tetrahydrofuran and
cooled to -20.degree. C. Isopropylmagnesium chloride (2.0 mL, 2 M
in tetrahydrofuran, 4.0 mmol) was added dropwise and the reaction
stirred at -5.degree. C. The reaction was cooled to -20.degree. C.
and
5-(4-fluoro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazole-3-carbaldehyde
(113, 0.622 g, 1.83 mmol) in 2 mL of tetrahydrofuran was added and
the reaction stirred at 0.degree. C. The reaction was concentrated
under vacuum, diluted with ethyl acetate and washed with sodium
bicarbonate and brine. The organic layer was dried with sodium
sulfate and purified by silica gel column chromatography, eluting
with 5-80% ethyl acetate in hexanes. Appropriate fractions were
combined and concentrated under vacuum to provide the desired
compound. MS (ESI) [M+H.sup.+].sup.+=648.38 and 649.74.
Step 2--Preparation of
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-(4-methoxy-benzyl)-1H-
-pyrazol-3-yl]-(4-fluoro-benzyl)-amine (149)
[1139] In a quartz vial,
(5-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-[5-(4-fluo-
ro-benzylamino)-2-(4-methoxy-benzyl)-2H-pyrazol-3-yl]-methanol
(148, 0.328 g, 0.506 mmol) was combined with 20 mL of
dichloromethane, triethylsilane (0.4 mL, 2.0 mmol) was added,
followed by trifluoroacetic acid (0.2 mL, 2.0 mmol). The reaction
was stirred overnight at room temperature, then concentrated under
vacuum and ethyl acetate was added. This was washed with 1 M
aqueous potassium carbonate and brine, dried with sodium sulfate,
and purified by silica gel column chromatography, eluting with
2-20% methanol in dichloromethane. Appropriate fractions were
combined and concentrated under vacuum, and the solid further
washed with ethyl acetate and hexane to provide the desired
compound. .sup.1H NMR was consistent with compound structure.
Step 3--Preparation of
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1H-pyrazol-3-yl]-(4-flu-
oro-benzyl)-amine (P-2016)
[1140] Into a round bottom flask,
[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-(4-methoxy-benzyl)-1H-
-pyrazol-3-yl]-(4-fluoro-benzyl)-amine (149, 0.060 g, 0.13 mmol)
was dissolved in 5 mL of trifluoroacetic acid (60 mmol) and the
reaction was heated at 70.degree. C. overnight. The reaction was
cooled to room temperature, then concentrated under vacuum and
ethyl acetate was added. This was washed with 1 M aqueous potassium
carbonate and brine, dried with sodium sulfate and purified by
silica gel column chromatography, eluting with 2-20% methanol in
dichloromethane. Appropriate fractions were combined and
concentrated under vacuum, and the solid further washed with ethyl
acetate and hexane to provide the desired compound. .sup.1H NMR was
consistent with compound structure. MS (ESI)
[M+H.sup.+].sup.+=356.85.
Example 20
Synthesis of
5-fluoro-N-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyr-
idin-2-yl]-2-methoxy-nicotinamide P-2168
[1141]
5-Fluoro-N-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethy-
l)-pyridin-2-yl]-2-methoxy-nicotinamide P-2168 was prepared in
three steps from 5-fluoro-2-methoxy-pyridine-3-carbaldehyde 37 as
shown in Scheme 20.
##STR00901##
Step 2--Preparation of 5-fluoro-2-methoxy-nicotinic acid (150)
[1142] In a round bottom flask,
5-fluoro-2-methoxy-pyridine-3-carbaldehyde (37, 0.500 g, 3.22 mmol)
was combined with sodium chlorite (0.6734 g, 5.957 mmol), 30 mL of
1,4-dioxane, 10 mL of water, and sulfamic acid (2.39 g, 24.6 mmol).
The reaction mixture was stirred at room temperature for 5 minutes,
then poured into 100 mL of water and extracted with 100 mL of ethyl
acetate. The organic layer was washed with water, brine, then dried
over magnesium sulfate, filtered and the filtrate concentrated
under vacuum to provide the desired compound (150, 512 mg), used in
the next step without further purification.
Step 2--Preparation of 5-fluoro-2-methoxy-nicotinoyl chloride
(151)
[1143] In a round bottom flask, 5-fluoro-2-methoxy-nicotinic acid
(150, 250 mg, 1.46 mmol) was combined with thionyl chloride (3.00
mL, 41.1 mmol) and the suspension was stirred at room temperature
for 3 hours. The reaction was concentrated to dryness under vacuum
to provide the desired compound, used in the next step without
further purification.
Step 3--Preparation of
5-fluoro-N-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyr-
idin-2-yl]-2-methoxy-nicotinamide (P-2168)
[1144] In a reaction flask,
6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylami-
ne (137, 100 mg, 0.3902 mmol) was combined with
5-fluoro-2-methoxy-nicotinoyl chloride (151, 81.37 mg, 0.4292
mmol), 3.00 mL of tetrahydrofuran, and pyridine (0.06312 mL, 0.7804
mmol). The reaction was stirred at room temperature overnight, then
poured into aqueous 1N hydrochloric acid and extracted with ethyl
acetate. The organic layer was dried over sodium sulfate, filtered
and the filtrate concentrated under vacuum. The resulting material
was purified by silica gel column chromatography, eluting with 1-5%
methanol in dichloromethane. Appropriate fractions were combined
and concentrated under vacuum to provide the desired compound
(P-2168, 100 mg). MS (ESI) [M+H.sup.+].sup.+=409.9.
Example 21
Synthesis of
[5-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-
-pyridin-3-ylmethyl)-amine P-2017
[1145]
[5-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-m-
ethoxy-pyridin-3-ylmethyl)-amine P-2017 was prepared in two steps
from 5-bromo-1H-pyrrolo[2,3-b]pyridine 152 and
(5-formyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carbamic
acid tert-butyl ester 153 as shown in Scheme 21.
##STR00902##
Step 1--Preparation
{5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-methoxy-methyl]-pyridin-2-yl}-
-(6-methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester
(154)
[1146] To 5-bromo-1H-pyrrolo[2,3-b]pyridine (152, 0.622 g, 3.16
mmol) in 50.0 mL of methanol under nitrogen,
(5-formyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carbamic
acid tert-butyl ester (153, 1.05 g, 3.06 mmol) and potassium
hydroxide (1.50 g, 26.7 mmol) were added and the reaction stirred
at room temperature overnight. The reaction was poured into water,
extracted with ethyl acetate, the organic layer dried over sodium
sulfate, filtered and the filtrate concentrated under vacuum. The
resulting material was purified by silica gel column chromatography
eluting with a gradient of 20-100% ethyl acetate in hexane.
Appropriate fractions were combined and concentrated under vacuum
to provide the desired compound (154, 0.35 g).
{5-[(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-pyridin-2-yl}-
-(6-methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester was
also formed in this procedure and could be isolated and reacted
similarly to the following step to form the desired product.
Step 2--Preparation of
[5-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-
-pyridin-3-ylmethyl)-amine (P-2017)
[1147] To
{5-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-methoxy-methyl]-pyri-
din-2-yl}-(6-methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl
ester (154, 0.35 g, 0.63 mmol) in 20.0 mL of acetonitrile,
triethylsilane (1.0 mL, 6.3 mmol) and trifluoroacetic acid (0.50
mL, 6.5 mmol) were added and the reaction stirred at 80.degree. C.
for 4 hours. The reaction was concentrated under vacuum and
combined with aqueous potassium carbonate and extracted with ethyl
acetate. The organic layer was filtered and the filtrate
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography eluting with 20-100% ethyl acetate
in hexane. Appropriate fractions were combined and concentrated
under vacuum to provide the desired compound (P-2017, 165.1 mg). MS
(ESI) [M+H.sup.+].sup.+=423.8, 425.8.
[1148]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin--
2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amine P-1622 is prepared
similarly to Scheme 21, reacting in a single step 1a as
follows.
##STR00903##
Step 1a--Preparation of
[6-fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-1622)
[1149] In a round bottom flask, 5-fluoro-1H-pyrrolo[2,3-b]pyridine
(155, 0.115 g, 0.845 mmol) was combined with
(6-fluoro-5-formyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carbamic
acid tert-butyl ester (156, 0.397 g, 1.10 mmol), 2.60 mL of
acetonitrile, trifluoroacetic acid (0.325 mL, 4.22 mmol) and
triethylsilane (0.810 mL, 5.07 mmol) and the reaction was heated to
reflux for 3 hours. The reaction was poured into water and
extracted with ethyl acetate. The organic layer was washed with
brine, dried over sodium sulfate, filtered and the filtrate
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography eluting with ethyl acetate in
hexane. Appropriate fractions were combined and concentrated under
vacuum to provide the desired compound (P-1622, 28 mg). MS (ESI)
[M+H.sup.+].sup.+=382.1.
[1150] Additional compounds are prepared following the protocol of
Scheme 21 (or single step 1a), where conditions may vary, for
example, any of the solvents, reaction times, reagents,
temperatures, work up conditions, or other reaction parameters may
be varied employing alternate solvents, reagents, reaction times,
temperatures, work up conditions, and the like, as are readily
available to one skilled in the art. Compounds are prepared
optionally using a suitable 1H-pyrrolo[2,3-b]pyridine in place of
5-bromo-1H-pyrrolo[2,3-b]pyridine 152 and optionally using a
suitable aldehyde in place of
(5-formyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carbamic
acid tert-butyl ester 153 in step 1. Further, either or both of the
methoxy or hydroxy intermediate formed in step 1 are reacted in the
second step. The following compounds are made using this procedure.
Compounds in the following table were characterized by .sup.1H and
.sup.13C NMR spectroscopy as well as mass spectrometry. [1151]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-6-methoxy-pyridin-3-ylmethyl)-amine (P-1506), [1152]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-pyridin-3-ylmethyl)-amine (P-1507), [1153]
(6-Chloro-pyridin-3-ylmethyl)-[6-chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-1508), [1154]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-1509), [1155]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-1510), [1156]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methox-
y-pyridin-3-ylmethyl)-amine (P-1511), [1157]
[6-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-1512), [1158]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1528), [1159]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1529), [1160]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-1530), [1161]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-1531), [1162]
[5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine (P-1583), [1163]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1584), [1164]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1585), [1165]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1586), [1166]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1587), [1167]
[5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine (P-1588), [1168]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-y-
lmethyl)-pyridin-2-yl]-amine (P-1589), [1169]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1590),
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-1591),
[1169] [1170]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-chloro-pyridin-3-ylmethyl)-amine (P-1592), [1171]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1593), [1172]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1594), [1173]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-methoxy-pyridin-3-ylmethyl)-amine (P-1595), [1174]
[6-Chloro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(2-methoxy-pyridin-3-ylmethyl)-amine (P-1596), [1175]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1623), [1176]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-1624), [1177]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1625), [1178]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1626), [1179]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1627), [1180]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1628), [1181]
[6-Fluoro-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-1629), [1182]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1638), [1183]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1639), [1184]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1640), [1185]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1641), [1186]
(4-Trifluoromethyl-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1642), [1187]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1643), [1188]
(6-Trifluoromethyl-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1644), [1189]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1645), [1190]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-f-
luoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1661), [1191]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-f-
luoro-pyridin-3-ylmethyl)-amine (P-1662), [1192]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-cyclopropyl-1H-pyrrolo[2,3-b]pyridin--
3-ylmethyl)-pyridin-2-yl]-amine (P-1663), [1193]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-f-
luoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1664), [1194]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-t-
rifluoromethyl-pyridin-3-ylmethyl)-amine (P-1665), [1195]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-m-
ethoxy-pyridin-3-ylmethyl)-amine (P-1666), [1196]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-t-
rifluoromethyl-pyridin-3-ylmethyl)-amine (P-1667), [1197]
[5-(5-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-m-
ethoxy-pyridin-3-ylmethyl)-amine (P-1668), [1198]
3-{6-[(5-Fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo-
[2,3-b]pyridine-4-carbonitrile (P-1719), [1199]
3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo-
[2,3-b]pyridine-4-carbonitrile (P-1720), [1200]
3-{6-[(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-4-carbonitrile (P-1721), [1201]
3-{6-[(4-Trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1-
H-pyrrolo[2,3-b]pyridine-4-carbonitrile (P-1722), [1202]
3-{6-[(6-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrol-
o[2,3-b]pyridine-4-carbonitrile (P-1723), [1203]
3-{6-[(6-Trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1-
H-pyrrolo[2,3-b]pyridine-4-carbonitrile (P-1724), [1204]
3-{6-[(2-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrol-
o[2,3-b]pyridine-4-carbonitrile (P-1725), [1205]
3-{6-[(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-4-carbonitrile (P-1726), [1206]
[5-(4-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine (P-2018), [1207]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2019), [1208]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2023), [1209]
(2-Fluoro-benzyl)-[5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyri-
din-2-yl]-amine (P-2033), and [1210]
[5-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-2170). The following table
indicates the 1H-pyrrolo[2,3-b]pyridine compound (column 2) and
aldehyde compound (column 3) used in step 1 to afford the desired
compound (column 4). The compound number is provided in column 1,
and the observed mass is in column 5
TABLE-US-00014 [1210] Comp. number 1H-pyrrolo[2,3-b]pyridine
Aldehyde Compound structure MS (ESI) [M + H.sup.+].sup.+ P-1506
##STR00904## ##STR00905## ##STR00906## P-1507 ##STR00907##
##STR00908## ##STR00909## P-1508 ##STR00910## ##STR00911##
##STR00912## P-1509 ##STR00913## ##STR00914## ##STR00915## P-1510
##STR00916## ##STR00917## ##STR00918## P-1511 ##STR00919##
##STR00920## ##STR00921## P-1512 ##STR00922## ##STR00923##
##STR00924## P-1528 ##STR00925## ##STR00926## ##STR00927## P-1529
##STR00928## ##STR00929## ##STR00930## P-1530 ##STR00931##
##STR00932## ##STR00933## P-1531 ##STR00934## ##STR00935##
##STR00936## P-1540 ##STR00937## ##STR00938## ##STR00939## P-1541
##STR00940## ##STR00941## ##STR00942## P-1542 ##STR00943##
##STR00944## ##STR00945## P-1543 ##STR00946## ##STR00947##
##STR00948## P-1544 ##STR00949## ##STR00950## ##STR00951## P-1545
##STR00952## ##STR00953## ##STR00954## P-1546 ##STR00955##
##STR00956## ##STR00957## P-1583 ##STR00958## ##STR00959##
##STR00960## P-1584 ##STR00961## ##STR00962## ##STR00963## P-1585
##STR00964## ##STR00965## ##STR00966## P-1586 ##STR00967##
##STR00968## ##STR00969## P-1587 ##STR00970## ##STR00971##
##STR00972## P-1588 ##STR00973## ##STR00974## ##STR00975## P-1589
##STR00976## ##STR00977## ##STR00978## P-1590 ##STR00979##
##STR00980## ##STR00981## P-1591 ##STR00982## ##STR00983##
##STR00984## P-1592 ##STR00985## ##STR00986## ##STR00987## P-1593
##STR00988## ##STR00989## ##STR00990## P-1594 ##STR00991##
##STR00992## ##STR00993## P-1595 ##STR00994## ##STR00995##
##STR00996## P-1596 ##STR00997## ##STR00998## ##STR00999## P-1623
##STR01000## ##STR01001## ##STR01002## P-1624 ##STR01003##
##STR01004## ##STR01005## P-1625 ##STR01006## ##STR01007##
##STR01008## P-1626 ##STR01009## ##STR01010## ##STR01011## P-1627
##STR01012## ##STR01013## ##STR01014## P-1628 ##STR01015##
##STR01016## ##STR01017## P-1629 ##STR01018## ##STR01019##
##STR01020## P-1638 ##STR01021## ##STR01022## ##STR01023## P-1639
##STR01024## ##STR01025## ##STR01026## P-1640 ##STR01027##
##STR01028## ##STR01029## P-1641 ##STR01030## ##STR01031##
##STR01032## P-1642 ##STR01033## ##STR01034## ##STR01035## P-1643
##STR01036## ##STR01037## ##STR01038## P-1644 ##STR01039##
##STR01040## ##STR01041## 452.0 P-1645 ##STR01042## ##STR01043##
##STR01044## P-1661 ##STR01045## ##STR01046## ##STR01047## P-1662
##STR01048## ##STR01049## ##STR01050## P-1663 ##STR01051##
##STR01052## ##STR01053## P-1664 ##STR01054## ##STR01055##
##STR01056## P-1665 ##STR01057## ##STR01058## ##STR01059## P-1666
##STR01060## ##STR01061## ##STR01062## P-1667 ##STR01063##
##STR01064## ##STR01065## P-1668 ##STR01066## ##STR01067##
##STR01068## P-1719 ##STR01069## ##STR01070## ##STR01071## P-1720
##STR01072## ##STR01073## ##STR01074## P-1721 ##STR01075##
##STR01076## ##STR01077## P-1722 ##STR01078## ##STR01079##
##STR01080## P-1723 ##STR01081## ##STR01082## ##STR01083## P-1724
##STR01084## ##STR01085## ##STR01086## P-1725 ##STR01087##
##STR01088## ##STR01089## P-1726 ##STR01090## ##STR01091##
##STR01092## P-2018 ##STR01093## ##STR01094## ##STR01095## P-2019
##STR01096## ##STR01097## ##STR01098## 398.4 P-2023 ##STR01099##
##STR01100## ##STR01101## P-2033 ##STR01102## ##STR01103##
##STR01104## 363.5 P-2170 ##STR01105## ##STR01106##
##STR01107##
[1211]
[5-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5--
fluoro-2-methoxy-pyridin-3-ylmethyl)-amine P-2170 is further
reacted to provide
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(4-phenyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine P-2171 following the
protocol of the following step 3.
##STR01108##
Step 3--Preparation of
5-fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(4-phenyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2171)
[1212]
[5-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5--
fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-2170, 1 equivalent),
phenyl boronic acid (157, 1.5 equivalents) and
tetrakis(triphenylposphine)palladium(0) (catalyst) are combined
with 0.33 mL of aqueous potassium carbonate (1.00 M, 3 equivalents)
and 0.34 mL of acetonitrile. The resulting mixture is heated in a
microwave at 120.degree. C. for 10 minutes, followed by 130.degree.
C. for 55 minutes. The mixture is diluted with ethyl acetate and
water and the aqueous layer is separated and extracted with ethyl
acetate. The organic layers are combined and washed with brine,
dried over sodium sulfate, filtered and the filtrate concentrated
under vacuum. The resulting material is purified by silica gel
column chromatography eluting with methanol and dichloromethane.
Appropriate fractions are combined and concentrated under vacuum to
provide the desired compound.
Example 22
Synthesis of
[5-(4-ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine P-1717
[1213]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-
-trifluoromethyl-pyridin-3-ylmethyl)-amine P-1717 was prepared in
three steps from
4-ethynyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 161 and
(5-formyl-pyridin-2-yl)-di-carbamic acid tert-butyl ester 162 as
shown in Scheme 22.
##STR01109##
Step 1--Preparation of
{5-[(4-ethynyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-pyridin-2-y-
l}-di-carbamic acid tert-butyl ester (163)
[1214] In a round bottom flask,
4-ethynyl-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine (161,
0.321 g, 1.08 mmol) was combined with
(5-formyl-pyridin-2-yl)-di-carbamic acid tert-butyl ester (162,
0.416 g, 1.29 mmol), 2.1 mL of methanol, and potassium hydroxide
(0.302 g, 5.38 mmol) and stirred at room temperature for 24 hours.
The reaction was neutralized with aqueous 0.1 N hydrochloric acid,
then extracted 3.times. with ethyl acetate. The combined organic
layer was washed with brine, then dried over sodium sulfate,
filtered and the filtrate concentrated under vacuum. The resulting
material was purified by silica gel column chromatography eluting
with methanol and dichloromethane. Appropriate fractions were
combined and concentrated under vacuum to provide the desired
compound (163, 229 mg). MS (ESI) [M-H.sup.+].sup.-=337.2.
Step 2--Preparation of
5-(4-ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine
(164)
[1215] In a round bottom flask,
{5-[(4-ethynyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-pyridin-2-y-
l}-di-carbamic acid tert-butyl ester (163, 0.225 g, 0.484 mmol) was
combined with trifluoroacetic acid (0.70 mL, 9.1 mmol),
triethylsilane (1.8 mL, 11.0 mmol) and 5.2 mL of acetonitrile and
the reaction was heated to reflux for 6 hours. The reaction was
poured into water and extracted with ethyl acetate. The organic
layer was washed with brine, then dried over sodium sulfate,
filtered and the filtrate concentrated under vacuum. The resulting
material was purified by silica gel column chromatography eluting
with methanol and dichloromethane. Appropriate fractions were
combined and concentrated under vacuum to provide the desired
compound (164, 57 mg). MS (ESI) [M+H.sup.+].sup.+=248.9.
Step 3--Preparation of
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine (P-1717)
[1216] In a round bottom flask,
5-(4-ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine
(164, 0.055 g, 0.22 mmol) was combined with
6-trifluoromethyl-pyridine-3-carbaldehyde (160, 50.4 mg, 0.288
mmol), 0.682 mL of acetonitrile, trifluoroacetic acid (0.0853 mL,
1.11 mmol), and triethylsilane (0.212 mL, 1.33 mmol) and the
reaction heated to reflux for 3 hours. The reaction was poured into
water and extracted with ethyl acetate. The organic layer was
washed with brine, then dried over sodium sulfate, filtered and the
filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography eluting with methanol
and dichloromethane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound (P-1717,
9.3 mg). MS (ESI) [M+H.sup.+].sup.+=408.5.
[1217] Additional compounds are prepared following the protocol of
Scheme 22, where conditions may vary, for example, any of the
solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. Compounds are prepared optionally replacing
6-trifluoromethyl-pyridine-3-carbaldehyde 160 with a suitable
aldehyde in step 3. The following compounds are made using this
procedure. Compounds in the following table were characterized by
.sup.1H and .sup.13C NMR spectroscopy as well as mass spectrometry.
[1218]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluor-
o-6-methoxy-pyridin-3-ylmethyl)-amine (P-1711), [1219]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluor-
o-pyridin-3-ylmethyl)-amine (P-1712), [1220]
(6-Chloro-pyridin-3-ylmethyl)-[5-(4-ethynyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyridin-2-yl]-amine (P-1713), [1221]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluor-
o-2-methoxy-pyridin-3-ylmethyl)-amine (P-1714), [1222]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-trifl-
uoromethyl-pyridin-3-ylmethyl)-amine (P-1715), [1223]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-metho-
xy-pyridin-3-ylmethyl)-amine (P-1716), and [1224]
[5-(4-Ethynyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-metho-
xy-pyridin-3-ylmethyl)-amine (P-1718). The following table
indicates the aldehyde compound (column 2) used in step 3 to afford
the desired compound (column 3). The compound number is provided in
column 1, and the observed mass is in column 4
TABLE-US-00015 [1224] Compound MS (ESI) number Aldehyde Compound [M
+ H.sup.+].sup.+ P-1711 ##STR01110## ##STR01111## P-1712
##STR01112## ##STR01113## P-1713 ##STR01114## ##STR01115## P-1714
##STR01116## ##STR01117## P-1715 ##STR01118## ##STR01119## P-1716
##STR01120## ##STR01121## P-1718 ##STR01122## ##STR01123##
Example 23
Synthesis of
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-{6-fluoro-5-[5-(1-piperidin-4-yl--
1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-yl}-amine
P-1703
[1225]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-{6-fluoro-5-[5-(1-piperidin-
-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-yl}--
amine P-1703 was prepared in five steps from
1-benzenesulfonyl-5-bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine 165 and
(6-fluoro-5-formyl-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester 83 as shown in Scheme 23.
##STR01124## ##STR01125##
Step 1--Preparation of
{5-[(1-benzenesulfonyl-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-met-
hyl]-6-fluoro-pyridin-2-yl}-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester (166)
[1226] To a solution of
1-benzenesulfonyl-5-bromo-3-iodo-1H-pyrrolo[2,3-b]pyridine (165,
1.00 g, 2.16 mmol) in 7 mL of tetrahydrofuran at -50.degree. C.
under nitrogen, isopropylmagnesium chloride (1.18 mL, 2.35 mmol)
was added slowly. The reaction was warmed to 5.degree. C. over 70
minutes, then cooled to -45.degree. C. and
(6-fluoro-5-formyl-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester (83, 0.678 g, 1.88 mmol) in 3.0 mL of
tetrahydrofuran was added. The reaction was allowed to warm to room
temperature over 2-3 hours. The reaction was mixed with aqueous 1 N
citric acid and extracted with ethyl acetate. The organic layer was
washed with water and brine, then dried over magnesium sulfate,
filtered and the filtrate concentrated under vacuum. The resulting
material was purified by silica gel column chromatography eluting
with ethyl acetate and hexane. Appropriate fractions were combined
and concentrated under vacuum to provide the desired compound as a
white solid (166, 1.155 g). MS (ESI) [M+H.sup.+].sup.+=696.4 and
698.3.
Step 2--Preparation of
5-(1-benzenesulfonyl-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluor-
o-pyridin-2-ylamine (167)
[1227] In a round bottom flask,
{5-[(1-benzenesulfonyl-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-met-
hyl]-6-fluoro-pyridin-2-yl}-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester (166, 1.15 g, 1.65 mmol) was combined with 50 mL
of 1,2-dichloroethane, trifluoroacetic acid (0.635 mL, 8.24 mmol),
and triethylsilane (1.32 mL, 8.24 mmol). The reaction was heated at
reflux for 20 hours, then concentrated under vacuum. The residue
was dissolved in 10 mL of trifluoroacetic acid and stirred at room
temperature for 18 hours, then concentrated under vacuum and
combined with aqueous sodium bicarbonate and extracted with ethyl
acetate. The organic layer was washed with sodium bicarbonate,
water and brine, then dried over magnesium sulfate, filtered and
the filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography eluting with ethyl
acetate and hexane. Appropriate fractions were combined and
concentrated under vacuum to provide the desired compound (167, 403
mg). MS (ESI) [M-H.sup.+].sup.-=460.8 and 462.8.
Step 3--Preparation of
[5-(1-benzenesulfonyl-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluo-
ro-pyridin-2-yl]-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine
(168)
[1228] To
5-(1-benzenesulfonyl-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl-
)-6-fluoro-pyridin-2-ylamine (167, 0.342 g, 0.741 mmol) in 10 mL of
acetonitrile, 5-fluoro-2-methoxy-pyridine-3-carbaldehyde (37, 0.118
g, 0.763 mmol), triethylsilane (0.529 mL, 3.71 mmol) and
trifluoroacetic acid (0.286 mL, 3.71 mmol) were added. The reaction
was heated at 80.degree. C. for 4 hours, then concentrated under
vacuum and combined with aqueous potassium carbonate and extracted
with ethyl acetate. The organic layer was washed with water and
brine, then dried over magnesium sulfate, filtered and the filtrate
concentrated under vacuum. The resulting material was purified by
silica gel column chromatography eluting with ethyl acetate and
hexane. Appropriate fractions were combined and concentrated under
vacuum to provide the desired compound as an off-white solid (168,
367 mg). MS (ESI) [M-H.sup.+].sup.-=599.6 and 601.6.
Step 4--Preparation of
4-[4-(1-benzenesulfonyl-3-{2-fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylme-
thyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrazol-1--
yl]-piperidine-1-carboxylic acid tert-butyl ester (170) and
4-[4-(3-{2-fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyrid-
in-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrazol-1-yl]-piperidine-1-c-
arboxylic acid tert-butyl ester (P-1702):
[1229] In a microwave vial,
[5-(1-benzenesulfonyl-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluo-
ro-pyridin-2-yl]-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine
(168, 218 mg, 0.363 mmol) and
4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazol-1-yl]-piperid-
ine-1-carboxylic acid tert-butyl ester (169, 205 mg, 0.545 mmol)
were combined and 2.22 mL of acetonitrile and potassium carbonate
(1.11 mL, 1.0 M in water, 1.11 mmol) were added. Then
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (27 mg,
0.037 mmol) was added to the reaction mixture and heated at
160.degree. C. in a microwave for 5 minutes. Water was added and
the mixture was extracted with ethyl acetate. The organic layer was
washed with water and brine, then dried over magnesium sulfate,
filtered and the filtrate concentrated under vacuum. The resulting
material was purified by silica gel column chromatography eluting
with ethyl acetate and hexane. Appropriate fractions were combined
and concentrated under vacuum to provide the desired compounds
(170, 137 mg) and (P-1702, 66 mg). 170 MS (ESI)
[M+H.sup.+].sup.+=770.7. P-1702 MS (ESI)
[M+H.sup.+].sup.+=631.1.
Step 5--Preparation of
(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-{6-fluoro-5-[5-(1-piperidin-4-yl--
1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-yl}-amine
(P-1703)
[1230] In a vial,
4-[4-(1-benzenesulfonyl-3-{2-fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylme-
thyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrazol-1--
yl]-piperidine-1-carboxylic acid tert-butyl ester (170, 0.137 g,
0.178 mmol) was dissolved in a solution of potassium hydroxide
(0.392 g, 6.99 mmol) in 7.0 mL of methanol and the reaction was
heated at 50.degree. C. for 3 hours. Aqueous 1 M citric acid was
added, then the reaction was extracted with ethyl acetate. The
organic layer was washed with water and brine, then dried over
magnesium sulfate, filtered and the filtrate concentrated under
vacuum.
4-[4-(3-{2-fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyrid-
in-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrazol-1-yl]-piperidine-1-c-
arboxylic acid tert-butyl ester (P-1702, 56 mg, 0.0888 mmol) was
combined with this and 10 mL of dichloromethane and trifluoroacetic
acid (0.50 mL, 6.5 mmol) were added, then stirred at room
temperature for 2 hours. Aqueous saturated sodium bicarbonate was
added to pH.about.8, then concentrated under vacuum and ethyl
acetate and water were added. The organic layer was isolated and
washed with aqueous saturated sodium bicarbonate, then dried with
magnesium sulfate, filtered and the filtrate concentrated under
vacuum to provide the desired compound as a yellow solid (P-1703,
74 mg). MS (ESI) [M+H.sup.+].sup.+=631.1.
[1231] Additional compounds are prepared following the protocol of
Scheme 23, where conditions may vary, for example, any of the
solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. Compounds are prepared optionally replacing
5-fluoro-2-methoxy-pyridine-3-carbaldehyde 37, with a suitable
aldehyde in step 3. The following compounds are made using this
procedure. Compounds in the following table were characterized by
.sup.1H and .sup.13C NMR spectroscopy as well as mass spectrometry.
[1232]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-{6-fluoro-5-[5-(1-piperidin-4-yl--
1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-yl}-amine
(P-1704), [1233]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl]-pyridin-2-yl}-(5-fluoro-pyridin-3-ylmethyl)-amine
(P-1705), [1234]
(6-Chloro-pyridin-3-ylmethyl)-{6-fluoro-5-[5-(1-piperidin-4-yl-1H--
pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-yl}-amine
(P-1706), [1235]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl]-pyridin-2-yl}-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine
(P-1707), [1236]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl]-pyridin-2-yl}-(6-methoxy-pyridin-3-ylmethyl)-amine
(P-1708), [1237]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b-
]pyridin-3-ylmethyl]-pyridin-2-yl}-(6-trifluoromethyl-pyridin-3-ylmethyl)--
amine (P-1709), and [1238]
{6-Fluoro-5-[5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl]-pyridin-2-yl}-(2-methoxy-pyridin-3-ylmethyl)-amine
(P-1710). The following table indicates the aldehyde compound
(column 2) used in step 3 to afford the desired compound (column
3). The compound number is provided in column 1, and the observed
mass is in column 4
TABLE-US-00016 [1238] Compound MS (ESI) number Aldehyde Compound [M
+ H.sup.+].sup.+ P-1704 ##STR01126## ##STR01127## P-1705
##STR01128## ##STR01129## P-1706 ##STR01130## ##STR01131## P-1707
##STR01132## ##STR01133## P-1708 ##STR01134## ##STR01135## P-1709
##STR01136## ##STR01137## P-1710 ##STR01138## ##STR01139##
Example 24
Synthesis of
N-(3-{2-fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin--
3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide P-1669
[1239]
N-(3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-py-
ridin-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide P-1669
is prepared in four steps from
5-bromo-3-iodo-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl
ester 171 and
(6-fluoro-5-formyl-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic acid
tert-butyl ester 83 as shown in Scheme 24.
##STR01140## ##STR01141##
Step 1--Preparation of
5-bromo-3-({6-[tert-butoxycarbonyl-(4-methoxy-benzyl)-amino]-2-fluoro-pyr-
idin-3-yl}-hydroxy-methyl)-pyrrolo[2,3-b]pyridine-1-carboxylic acid
tert-butyl ester (172)
[1240] To 5-bromo-3-iodo-pyrrolo[2,3-b]pyridine-1-carboxylic acid
tert-butyl ester (171, 1 equivalent) in 500 mL of tetrahydrofuran
under nitrogen at -20.degree. C., iso-propylmagnesium chloride (1.2
equivalent) is added. The reaction is allowed to warm to 0.degree.
C. over 30 minutes, then cooled to -40.degree. C., followed by
adding (6-fluoro-5-formyl-pyridin-2-yl)-(4-methoxy-benzyl)-carbamic
acid tert-butyl ester (83, 0.8 equivalent). The reaction is allowed
to warm to 0.degree. C. over an hour, then quenched with brine and
extracted with ethyl acetate. The organic layer is concentrated
under vacuum to provide the desired compound, used in the next step
without further purification.
Step 2--Preparation of
5-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-ylamin-
e (173)
[1241] To
5-bromo-3-({6-[tert-butoxycarbonyl-(4-methoxy-benzyl)-amino]-2-f-
luoro-pyridin-3-yl}-hydroxy-methyl)-pyrrolo[2,3-b]pyridine-1-carboxylic
acid tert-butyl ester (172, 1 equivalent) in 451 mL of
acetonitrile, triethylsilane (10 equivalents) and trifluoroacetic
acid (10 equivalents) are added. The reaction is stirred at
80.degree. C. for several hours, then concentrated under vacuum.
The resulting material is taken up in 250 mL of dichloromethane and
250 mL of trifluoroacetic acid is added, then stirred at reflux for
several hours. The reaction is concentrated under vacuum and the
resulting material is taken up in ethyl acetate and extraction with
the addition of aqueous saturated potassium carbonate. The organic
layer is concentrated under vacuum and the resulting material is
purified by silica gel column chromatography, eluting with 0-5%
methanol in dichloromethane. Appropriate fractions are combined and
concentrated under vacuum to provide the desired compound.
Step 3--Preparation of
[5-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(-
5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1497)
[1242] To
5-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-
-2-ylamine (173, 1 equivalent) and
5-fluoro-2-methoxy-pyridine-3-carbaldehyde (37, 1 equivalent),
triethylsilane (4 equivalents) and trifluoroacetic acid (4
equivalents) are added. The reaction is stirred at 80.degree. C.
for several hours, then concentrated under vacuum. The resulting
material is taken up in ethyl acetate and extracted with addition
of aqueous potassium carbonate. The organic layer is concentrated
under vacuum, then triturated with dichloromethane to provide the
desired compound.
Step 4--Preparation of
N-(3-{2-fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin--
3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1669)
[1243]
[5-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-
-yl]-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1497, 1
equivalent) is dissolved in 25 mL of dioxane in a sealable vial.
Cesium carbonate (2.1 equivalents), copper(I) iodide (1.5
equivalents), acetamide (174, 22 equivalents) and
N,N'-dimethylethylenediamine (17 equivalents) are added. The vial
is sealed and heated at 100.degree. C. overnight. The reaction is
added to ethyl acetate and brine and extracted. The organic layer
is concentrated under vacuum and the resulting material dissolved
in dichloromethane and purified by silica gel column
chromatography, eluting with 0-10% methanol in dichloromethane.
Appropriate fractions are concentrated, and the material dissolved
in tetrahydrofuran for further purification on a C18 reverse phase
column, eluting with 0-100% methanol (with 10%
tetrahydrofuran)/water. Appropriated fractions are combined and
concentrated under vacuum. The resulting material is triturated
with methyl tert-butyl ether and filtered, washing with methyl
tert-butyl ether, then heptane. The solid is dried under vacuum to
provide the desired compound.
[1244] Additional compounds are prepared following the protocol of
Scheme 24, where conditions may vary, for example, any of the
solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. Compounds are prepared optionally replacing
5-fluoro-2-methoxy-pyridine-3-carbaldehyde 37, with a suitable
aldehyde in step 3 and optionally replacing acetamide 174 with
methanesulfonamide in step 4. The following compounds are made
using this procedure. Compounds in the following table were
characterized by .sup.1H and .sup.13C NMR spectroscopy as well as
mass spectrometry. [1245]
N-(3-{2-Fluoro-6-[(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin--
3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1670),
[1246]
N-(3-{2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl-
}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1671), [1247]
N-(3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-fluoro-pyridin-3-ylmethyl-
}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1672), [1248]
N-(3-{2-Fluoro-6-[(4-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-
-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1673),
[1249]
N-(3-{2-Fluoro-6-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethy-
l}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1674), [1250]
N-(3-{2-Fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-
-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1675),
[1251]
N-(3-{2-Fluoro-6-[(2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethy-
l}-1H-pyrrolo[2,3-b]pyridin-5-yl)-acetamide (P-1676), [1252]
N-(3-{2-Fluoro-6-[(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin--
3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1677), [1253]
N-(3-{2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1678), [1254]
N-(3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-fluoro-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1679), [1255]
N-(3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-p-
yridin-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1680), [1256]
N-(3-{2-Fluoro-6-[(4-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-
-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1681), [1257]
N-(3-{2-Fluoro-6-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3--
ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1682), [1258]
N-(3-{2-Fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-py-
ridin-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-methanesulfonamide
(P-1683), and [1259]
N-(3-{2-Fluoro-6-[(2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethy-
l}-1H-pyrrolo[2,3-1)]pyridin-5-yl)-methanesulfonamide (P-1684). The
following table indicates the aldehyde compound (column 2) used in
step 3 and acetamide or methanesulfonamide (column 3) used in step
4 to afford the desired compound (column 4). The compound number is
provided in column 1, and the observed mass is in column 5
TABLE-US-00017 [1259] Compound MS (ESI) number Aldehyde Step 4
Compound [M + H.sup.+].sup.+ P-1670 ##STR01142## ##STR01143##
##STR01144## P-1671 ##STR01145## ##STR01146## ##STR01147## P-1672
##STR01148## ##STR01149## ##STR01150## P-1673 ##STR01151##
##STR01152## ##STR01153## P-1674 ##STR01154## ##STR01155##
##STR01156## P-1675 ##STR01157## ##STR01158## ##STR01159## P-1676
##STR01160## ##STR01161## ##STR01162## P-1677 ##STR01163##
##STR01164## ##STR01165## P-1678 ##STR01166## ##STR01167##
##STR01168## P-1679 ##STR01169## ##STR01170## ##STR01171## P-1680
##STR01172## ##STR01173## ##STR01174## P-1681 ##STR01175##
##STR01176## ##STR01177## P-1682 ##STR01178## ##STR01179##
##STR01180## P-1683 ##STR01181## ##STR01182## ##STR01183## P-1684
##STR01184## ##STR01185## ##STR01186##
[1260]
[6-Fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-
-pyridin-2-yl]-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine P-1688
is prepared from
[5-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(-
5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine P-1497 by the
following step 4a.
##STR01187##
Step 4a--Preparation of
[6-fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1688)
[1261]
[5-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-
-yl]-(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1497, 1
equivalent) is dissolved in 5 mL of dimethyl sulfoxide in a
sealable vial. Copper(I) iodide (0.2 equivalent), L-proline (0.2
equivalent), sodium methanesulfinate (175, 1.2 equivalents), and
sodium hydroxide (0.2 equivalent) are added. The vial is sealed and
heated at 100.degree. C. overnight, then additional copper(I)
iodide (0.2 equivalent), L-proline (0.2 equivalent), sodium
methansulfinate (1.2 equivalent), and sodium hydroxide (0.2
equivalent) are added, and the reaction is sealed and heated at
120.degree. C. overnight. The reaction is added to ethyl acetate
and brine and extracted. The organic layer is concentrated under
vacuum and the resulting material dissolved in tetrahydrofuran for
purification on a C18 reverse phase column, eluting with 0-100%
methanol (with 10% tetrahydrofuran)/water. Appropriate fractions
are combined and concentrated under vacuum. The resulting material
is triturated with methyl tert-butyl ether and filtered, washing
with methyl tert-butyl ether, then heptane. The solid is dried
under vacuum to provide the desired compound.
[1262]
3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyrid-
in-3-ylmethyl}-1H-pyrrolo[2, 3-1)]pyridine-5-carboxylic acid
methylamide P-1696 is prepared from [5-(5-bromo-1H-pyrrolo[2,
3-1)]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(5-fluoro-2-methoxy-pyrid-
in-3-ylmethyl)-amine P-1497 by the following steps 4b and 5.
##STR01188##
Step 4b--Preparation of
3-{2-fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester
(P-1693)
[1263] In a 2 L Parr bomb,
[5-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(-
5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amine (P-1497, 1
equivalent), triethylamine (2 equivalents), and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.03
equivalents) are combined with 300 ml of methanol. The reaction is
heated at 100.degree. C. under 100 psi of carbon monoxide
overnight. The reaction mixture is concentrated under vacuum, taken
up in ethyl acetate and washed with water. The organic layer is
concentrated under vacuum, the residue dissolved in dichloromethane
and purified by silica gel column chromatography, eluting with
0-10% methanol in dichloromethane. Appropriated fractions are
combined and concentrated under vacuum to provide the desired
compound.
Step 5--Preparation of
3-{2-fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide
(P-1696)
[1264]
3-{2-Fluoro-6-[(5-fluoro-2-methoxy-pyridin-3-ylmethyl)-amino]-pyrid-
in-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl
ester (P-1693, 1 equivalent) is slurried with methylamine (2N in
methanol, 15 equivalents) in a sealable vial, sealed and heated at
50.degree. C. overnight. Additional methylamine (2N in methanol, 15
equivalents) is added and heated at 50.degree. C. overnight. The
reaction is concentrated under vacuum, the residue dissolved in
tetrahydrofuran for purification on a C18 reverse phase column,
eluting with 0-100% methanol (with 10% tetrahydrofuran)/water.
Appropriated fractions are combined and concentrated under vacuum.
The resulting material is triturated with ethyl acetate/heptane and
filtered, washing with heptane. The solid is dried under vacuum to
provide the desired compound.
[1265] Additional compounds are prepared following the protocol of
Scheme 24, using steps 4a or steps 4b and step 5, where conditions
may vary, for example, any of the solvents, reaction times,
reagents, temperatures, work up conditions, or other reaction
parameters may be varied employing alternate solvents, reagents,
reaction times, temperatures, work up conditions, and the like, as
are readily available to one skilled in the art. Compounds are
prepared optionally replacing
5-fluoro-2-methoxy-pyridine-3-carbaldehyde 37, with a suitable
aldehyde in step 3. The following compounds are made using this
procedure. Compounds in the following table were characterized by
.sup.1H and .sup.13C NMR spectroscopy as well as mass spectrometry.
[1266]
[6-Fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-1685),
[1267]
[6-Fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine (P-1686), [1268]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2-
,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1687), [1269]
[6-Fluoro-5-(5-methane
sulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-trifluorom-
ethyl-pyridin-3-ylmethyl)-amine (P-1689), [1270]
[6-Fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amine (P-1690), [1271]
[6-Fluoro-5-(5-methane
sulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluorom-
ethyl-pyridin-3-ylmethyl)-amine (P-1691), [1272]
[6-Fluoro-5-(5-methanesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrid-
in-2-yl]-(2-methoxy-pyridin-3-ylmethyl)-amine (P-1692), [1273]
3-{2-Fluoro-6-[(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-y-
lmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide
(P-1694), [1274]
3-{2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylme-
thyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide
(P-1695), [1275]
3-{6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-fluoro-pyridin-3-ylme-
thyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide
(P-1697), [1276]
3-{2-Fluoro-6-[(4-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyrid-
in-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid
methylamide (P-1698), [1277]
3-{2-Fluoro-6-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide (P-1699),
[1278]
3-{2-Fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-
methyl}-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide
(P-1700), and [1279]
3-{2-Fluoro-6-[(2-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}--
1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methylamide (P-1701).
The following table indicates the aldehyde compound (column 2) used
in step 3 and whether step 4a or step 4b/5 is used (column 3) used
in step 4 to afford the desired compound (column 4). The compound
number is provided in column 1, and the observed mass is in column
5
TABLE-US-00018 [1279] Compound Steps MS (ESI) number Aldehyde used
Compound [M + H.sup.+].sup.+ P-1685 ##STR01189## 4a ##STR01190##
P-1686 ##STR01191## 4a ##STR01192## P-1687 ##STR01193## 4a
##STR01194## P-1689 ##STR01195## 4a ##STR01196## P-1690
##STR01197## 4a ##STR01198## P-1691 ##STR01199## 4a ##STR01200##
P-1692 ##STR01201## 4a ##STR01202## P-1694 ##STR01203## 4b/5
##STR01204## P-1695 ##STR01205## 4b/5 ##STR01206## P-1697
##STR01207## 4b/5 ##STR01208## P-1698 ##STR01209## 4b/5
##STR01210## P-1699 ##STR01211## 4b/5 ##STR01212## P-1700
##STR01213## 4b/5 ##STR01214## P-1701 ##STR01215## 4b/5
##STR01216##
Example 25
Synthesis of
(2-chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine P-2034
[1280]
(2-Chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-
-ylmethyl)-pyridin-2-yl]-amine P-2034 was prepared in two steps
from (2-chloro-benzyl)-(6-fluoro-5-formyl-pyridin-2-yl)-carbamic
acid tert-butyl ester 48 and
3-iodo-5-methoxy-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 5
as shown in Scheme 25.
##STR01217##
Step 1--Preparation of
(2-chloro-benzyl)-{6-fluoro-5-[hydroxy-(5-methoxy-1-triisopropylsilanyl-1-
H-pyrrolo[2,3-b]pyridin-3-yl)-methyl]-pyridin-2-yl}-carbamic acid
tert-butyl ester (176)
[1281] To
3-iodo-5-methoxy-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine
(5, 0.49 g, 1.14 mmol) in 6.8 mL of tetrahydrofuran at -50.degree.
C. under nitrogen, isopropylmagnesium chloride (0.569 mL, 2.0 M in
tetrahydrofuran, 1.14 mmol) was added slowly. The reaction was
allowed to warm to 5.degree. C. over 70 minutes, then cooled to
-60.degree. C. and
(2-chloro-benzyl)-(6-fluoro-5-formyl-pyridin-2-yl)-carbamic acid
tert-butyl ester (48, 0.23 g, 0.63 mmol) in 30.0 mL of
tetrahydrofuran was added. The reaction was allowed to warm to room
temperature over 1 hour, then poured into aqueous ammonium chloride
and extracted with ethyl acetate. The organic layer was dried over
sodium sulfate, filtered and the filtrate concentrated under
vacuum. The resulting material was purified by silica gel column
chromatography eluting with 20-100% ethyl acetate in hexane.
Appropriate fractions were combined and the solvents removed under
vacuum to provide the desired compound as a white solid (176, 0.400
g). MS (ESI) [M+H.sup.+].sup.+=669.4.
Step 2--Preparation of
(2-chloro-benzyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2034)
[1282] To
(2-chloro-benzyl)-{6-fluoro-5-[hydroxy-(5-methoxy-1-triisopropyl-
silanyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-methyl]-pyridin-2-yl}-carbamic
acid tert-butyl ester (176, 400 mg, 0.598 mmol) in 20.0 mL of
dichloromethane, triethylsilane (2.00 mL, 12.5 mmol) and
trifluoroacetic acid (1.00 mL, 13.0 mmol) were added. The reaction
was stirred at room temperature for 4 hours, then poured into
aqueous potassium carbonate and extracted with ethyl acetate. The
organic layer was dried over sodium sulfate, filtered and the
filtrate concentrated under vacuum. The resulting material was
purified by silica gel column chromatography eluting with 20-100%
ethyl acetate in hexane. Appropriate fractions were combined and
the solvents removed under vacuum to provide the desired compound
as a white solid (P-2034, 60.7 mg). MS (ESI)
[M+H.sup.+].sup.+=397.1.
[1283] Additional compounds are prepared following the protocol of
Scheme 25, where conditions may vary, for example, any of the
solvents, reaction times, reagents, temperatures, work up
conditions, or other reaction parameters may be varied employing
alternate solvents, reagents, reaction times, temperatures, work up
conditions, and the like, as are readily available to one skilled
in the art. Compounds are prepared using a suitable
3-iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine in place of
3-iodo-5-methoxy-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 5
and suitable aldehyde in place
(2-chloro-benzyl)-(6-fluoro-5-formyl-pyridin-2-yl)-carbamic acid
tert-butyl ester 48 in step 1. The following compounds are made
using this procedure. Compounds in the following table were
characterized by .sup.1H and .sup.13C NMR spectroscopy as well as
mass spectrometry. [1284]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyridi-
n-3-ylmethyl)-pyridin-2-yl]-amine (P-1499), [1285]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1500), [1286]
[6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-1501), [1287]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-1513), [1288]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
rimidin-2-yl]-amine (P-1514), [1289]
(6-Chloro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py-
rimidin-2-yl]-amine (P-1515), [1290]
[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluorometh-
yl-pyridin-3-ylmethyl)-amine (P-1516), [1291]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p-
yrimidin-2-yl]-amine (P-1517), [1292]
[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-trifluorometh-
yl-pyridin-3-ylmethyl)-amine (P-1518), [1293]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p-
yrimidin-2-yl]-amine (P-1519), [1294]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-1520), [1295]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-
-6-methoxy-pyridin-3-ylmethyl)-amine (P-1521), [1296]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-
-pyridin-3-ylmethyl)-amine (P-1522), [1297]
(6-Chloro-pyridin-3-ylmethyl)-[4-chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-thiazol-2-yl]-amine (P-1523), [1298]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-1524), [1299]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-1525), [1300]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-3-ylmethyl)-amine (P-1526), [1301]
[4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-1527), [1302]
(6-Methoxy-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1532), [1303]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1533), [1304]
(5-Fluoro-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1534), [1305]
(6-Chloro-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1535), [1306]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1536), [1307]
[6-Methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1537), [1308]
[6-Methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1538), [1309]
(2-Methoxy-pyridin-3-ylmethyl)-[6-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1539), [1310]
(6-Methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1554), [1311]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1555), [1312]
(5-Fluoro-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1556), [1313]
(6-Chloro-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1557), [1314]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1558), [1315]
[3-Methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1559), [1316]
[3-Methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1560), [1317]
(2-Methoxy-pyridin-3-ylmethyl)-[3-methyl-5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1561), [1318]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-methoxy-pyridin-3-ylmethyl)-amine (P-1562), [1319]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[3-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1563), [1320]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(5-fluoro-pyridin-3-ylmethyl)-amine (P-1564), [1321]
(6-Chloro-pyridin-3-ylmethyl)-[3-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-1565), [1322]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[3-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-1566), [1323]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1567), [1324]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-1568), [1325]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-thiazol-2-yl]-amine (P-1579), [1326]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-thiazol-2-yl]-amine (P-1580), [1327]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-thiazol-2-yl]-amine (P-1581), [1328]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-1582), [1329]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyridin-2-yl]-amine (P-1597), [1330]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1598), [1331]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-6-fluoro-pyridin-2-yl]-amine (P-1607), [1332]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1608), [1333]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-1609), [1334]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-1630), [1335]
(5-Fluoro-pyridin-3-ylmethyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-1631), [1336]
(6-Chloro-pyridin-3-ylmethyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyrimidin-2-yl]-amine (P-1632), [1337]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-1633), [1338]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-1634), [1339]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-meth-
oxy-pyridin-3-ylmethyl)-amine (P-1635), [1340]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-trif-
luoromethyl-pyridin-3-ylmethyl)-amine (P-1636), [1341]
[5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-meth-
oxy-pyridin-3-ylmethyl)-amine (P-1637), [1342]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(5-fluoro-pyridin-3-ylmethyl)-amine (P-1727), [1343]
(6-Chloro-pyridin-3-ylmethyl)-[6-fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyri-
midin-5-ylmethyl)-pyridin-2-yl]-amine (P-1728), [1344]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(4-methyl-7H-pyrrolo[-
2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl]-amine (P-1729), [1345]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1730), [1346]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(6-methoxy-pyridin-3-ylmethyl)-amine (P-1731), [1347]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-1732), [1348]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(4-methyl-7H-pyrrolo[-
2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl]-amine (P-1733), [1349]
[6-Fluoro-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl)-pyridin-2-yl-
]-(2-methoxy-pyridin-3-ylmethyl)-amine (P-1734), [1350]
(2-Chloro-benzyl)-[6-fluoro-5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2035), [1351]
(2-Chloro-benzyl)-[5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyri-
din-2-yl]-amine (P-2036), [1352]
(4-Chloro-benzyl)-[6-fluoro-5-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmet-
hyl)-pyridin-2-yl]-amine (P-2037), [1353]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-meth-
oxy-pyridin-3-ylmethyl)-amine (P-2038), [1354]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2040), [1355]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methoxy-1H-pyrrolo-
[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2042), [1356]
[6-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(2-methoxy-pyridin-3-ylmethyl)-amine (P-2043), [1357]
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylm-
ethyl)-pyridin-2-yl]-amine (P-2044), [1358]
[6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-2045), [1359]
(5-Chloro-pyridin-2-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyri-
din-3-ylmethyl)-pyridin-2-yl]-amine (P-2047), [1360]
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2048), [1361]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2049), [1362]
(4-Chloro-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyridin-2-yl]-amine (P-2050), [1363]
(2-Chloro-benzyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmeth-
yl)-pyridin-2-yl]-amine (P-2051), [1364]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-3-ylmethyl)-amine (P-2052), [1365]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2057), [1366]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
[(S)-1-(4-fluoro-phenyl)-ethyl]-amine (P-2058), [1367]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2061), [1368]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(4-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2062), [1369]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2063), [1370]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluo-
ro-2-methoxy-pyridin-3-ylmethyl)-amine (P-2064), [1371]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methoxy-pyridin-4-ylmethyl)-amine (P-2065), [1372]
[6-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(2-methyl-pyridin-4-ylmethyl)-amine (P-2067), [1373]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2070), [1374]
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[6-fluoro-5-(5-methyl-1H-pyrrolo[-
2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-2071), [1375]
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2072),
(5-Fluoro-6-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2073), [1376]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(2-methyl-pyridin-4-ylmethyl)-amine (P-2075), [1377]
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-pyrimidin-2-yl]-amine (P-2135), [1378]
(5-Fluoro-2-methoxy-pyridin-4-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]py-
ridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-2136), [1379]
[3-Methoxy-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2143), [1380]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2144), [1381]
[5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-triflu-
oromethyl-pyridin-3-ylmethyl)-amine (P-2145), [1382]
[3-Fluoro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2146), [1383]
[3-Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-
-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2147), [1384]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-
-2-methoxy-pyridin-3-ylmethyl)-amine (P-2152), [1385]
(5-Fluoro-2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyr-
idin-3-ylmethyl)-thiazol-2-yl]-amine (P-2153), [1386]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-3-ylmethyl)-amine (P-2154), [1387]
(6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-thiazol-2-yl]-amine (P-2155), [1388]
3-{[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-ylamino]-
-methyl}-5-fluoro-1-methyl-1H-pyridin-2-one (P-2157), [1389]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methox-
y-pyridin-3-ylmethyl)-amine (P-2158), [1390]
(2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-thiazol-2-yl]-amine (P-2159), [1391]
(6-Methoxy-pyridin-2-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl)-thiazol-2-yl]-amine (P-2162), [1392]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methox-
y-pyridin-2-ylmethyl)-amine (P-2163), [1393]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2,6-dime-
thoxy-pyridin-3-ylmethyl)-amine (P-2164), [1394]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]--
(5-fluoro-6-methoxy-pyridin-3-ylmethyl)-amine (P-2165), and [1395]
[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3-fluoro-pyridin-2-yl]--
(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-2172). The
following table indicates the 1H-pyrrolo[2,3-b]pyridine compound
(column 2) and aldehyde compound (column 3) used in step 1 to
afford the desired compound (column 4). The compound number is
provided in column 1, and the observed mass is in column 5
TABLE-US-00019 [1395] 1H- MS Comp. pyrrolo[2,3- (ESI) number
b]pyridine Aldehyde Compound structure [M + H.sup.+].sup.+ P-1499
##STR01218## ##STR01219## ##STR01220## P-1500 ##STR01221##
##STR01222## ##STR01223## P-1501 ##STR01224## ##STR01225##
##STR01226## P-1513 ##STR01227## ##STR01228## ##STR01229## P-1514
##STR01230## ##STR01231## ##STR01232## P-1515 ##STR01233##
##STR01234## ##STR01235## P-1516 ##STR01236## ##STR01237##
##STR01238## P-1517 ##STR01239## ##STR01240## ##STR01241## P-1518
##STR01242## ##STR01243## ##STR01244## P-1519 ##STR01245##
##STR01246## ##STR01247## P-1520 ##STR01248## ##STR01249##
##STR01250## P-1521 ##STR01251## ##STR01252## ##STR01253## P-1522
##STR01254## ##STR01255## ##STR01256## P-1523 ##STR01257##
##STR01258## ##STR01259## P-1524 ##STR01260## ##STR01261##
##STR01262## P-1525 ##STR01263## ##STR01264## ##STR01265## P-1526
##STR01266## ##STR01267## ##STR01268## P-1527 ##STR01269##
##STR01270## ##STR01271## P-1532 ##STR01272## ##STR01273##
##STR01274## P-1533 ##STR01275## ##STR01276## ##STR01277## P-1534
##STR01278## ##STR01279## ##STR01280## P-1535 ##STR01281##
##STR01282## ##STR01283## P-1536 ##STR01284## ##STR01285##
##STR01286## P-1537 ##STR01287## ##STR01288## ##STR01289## P-1538
##STR01290## ##STR01291## ##STR01292## P-1539 ##STR01293##
##STR01294## ##STR01295## P-1554 ##STR01296## ##STR01297##
##STR01298## 374.4 P-1555 ##STR01299## ##STR01300## ##STR01301##
P-1556 ##STR01302## ##STR01303## ##STR01304## P-1557 ##STR01305##
##STR01306## ##STR01307## P-1558 ##STR01308## ##STR01309##
##STR01310## P-1559 ##STR01311## ##STR01312## ##STR01313## P-1560
##STR01314## ##STR01315## ##STR01316## P-1561 ##STR01317##
##STR01318## ##STR01319## P-1562 ##STR01320## ##STR01321##
##STR01322## 378.0 P-1563 ##STR01323## ##STR01324## ##STR01325##
P-1564 ##STR01326## ##STR01327## ##STR01328## P-1565 ##STR01329##
##STR01330## ##STR01331## P-1566 ##STR01332## ##STR01333##
##STR01334## P-1567 ##STR01335## ##STR01336## ##STR01337## P-1568
##STR01338## ##STR01339## ##STR01340## P-1579 ##STR01341##
##STR01342## ##STR01343## P-1580 ##STR01344## ##STR01345##
##STR01346## P-1581 ##STR01347## ##STR01348## ##STR01349## P-1582
##STR01350## ##STR01351## ##STR01352## P-1597 ##STR01353##
##STR01354## ##STR01355## P-1598 ##STR01356## ##STR01357##
##STR01358## P-1607 ##STR01359## ##STR01360## ##STR01361## P-1608
##STR01362## ##STR01363## ##STR01364## P-1609 ##STR01365##
##STR01366## ##STR01367## P-1630 ##STR01368## ##STR01369##
##STR01370## P-1631 ##STR01371## ##STR01372## ##STR01373## P-1632
##STR01374## ##STR01375## ##STR01376## P-1633 ##STR01377##
##STR01378## ##STR01379## P-1634 ##STR01380## ##STR01381##
##STR01382## P-1635 ##STR01383## ##STR01384## ##STR01385## P-1636
##STR01386## ##STR01387## ##STR01388## P-1637 ##STR01389##
##STR01390## ##STR01391## P-1727 ##STR01392## ##STR01393##
##STR01394## P-1728 ##STR01395## ##STR01396## ##STR01397## P-1729
##STR01398## ##STR01399## ##STR01400## P-1730 ##STR01401##
##STR01402## ##STR01403## P-1731 ##STR01404## ##STR01405##
##STR01406## P-1732 ##STR01407## ##STR01408## ##STR01409## P-1733
##STR01410## ##STR01411## ##STR01412## P-1734 ##STR01413##
##STR01414## ##STR01415## P-2035 ##STR01416## ##STR01417##
##STR01418## 397.0 P-2036 ##STR01419## ##STR01420## ##STR01421##
379.1 P-2037 ##STR01422## ##STR01423## ##STR01424## 397.1 P-2038
##STR01425## ##STR01426## ##STR01427## 380.8 P-2040 ##STR01428##
##STR01429## ##STR01430## P-2042 ##STR01431## ##STR01432##
##STR01433## P-2043 ##STR01434## ##STR01435## ##STR01436## 393.4
P-2044 ##STR01437## ##STR01438## ##STR01439## 368.0 P-2045
##STR01440## ##STR01441## ##STR01442## 364.0 P-2047 ##STR01443##
##STR01444## ##STR01445## P-2048 ##STR01446## ##STR01447##
##STR01448## 396.0 P-2049 ##STR01449## ##STR01450## ##STR01451##
396.0 P-2050 ##STR01452## ##STR01453## ##STR01454## P-2051
##STR01455## ##STR01456## ##STR01457## P-2052 ##STR01458##
##STR01459## ##STR01460## 378.0 P-2057 ##STR01461## ##STR01462##
##STR01463## 360.95 P-2058 ##STR01464## ##STR01465## ##STR01466## P
2061 ##STR01467## ##STR01468## ##STR01469## 379.0 P-2062
##STR01470## ##STR01471## ##STR01472## 416.0 P-2063 ##STR01473##
##STR01474## ##STR01475## 418.1 P-2064 ##STR01476## ##STR01477##
##STR01478## 398.9 P-2065 ##STR01479## ##STR01480## ##STR01481##
P-2067 ##STR01482## ##STR01483## ##STR01484## 361.85 P-2070
##STR01485## ##STR01486## ##STR01487## 398.2 P-2071 ##STR01488##
##STR01489## ##STR01490## 396.2 P-2072 ##STR01491## ##STR01492##
##STR01493## 379.0 P-2073 ##STR01494## ##STR01495## ##STR01496##
379.0 P-2075 ##STR01497## ##STR01498## ##STR01499## 381.9 P-2135
##STR01500## ##STR01501## ##STR01502## 365.3 P-2136 ##STR01503##
##STR01504## ##STR01505## 395.3 P-2143 ##STR01506## ##STR01507##
##STR01508## P-2144 ##STR01509## ##STR01510## ##STR01511## P-2145
##STR01512## ##STR01513## ##STR01514## P-2146 ##STR01515##
##STR01516## ##STR01517## 416.0 P-2147 ##STR01518## ##STR01519##
##STR01520## 431.9 P-2152 ##STR01521## ##STR01522## ##STR01523##
P-2153 ##STR01524## ##STR01525## ##STR01526## P-2154 ##STR01527##
##STR01528## ##STR01529## 385.9 P-2155 ##STR01530## ##STR01531##
##STR01532## 365.9 P-2157 ##STR01533## ##STR01534## ##STR01535##
P-2158 ##STR01536## ##STR01537## ##STR01538## 385.9 P-2159
##STR01539## ##STR01540## ##STR01541## 365.9 P-2162 ##STR01542##
##STR01543## ##STR01544## P-2163 ##STR01545## ##STR01546##
##STR01547## 385.9 P-2164 ##STR01548## ##STR01549## ##STR01550##
415.9 P-2165 ##STR01551## ##STR01552## ##STR01553## 416.0 P-2172
##STR01554## ##STR01555## ##STR01556## 435.8
Example 26
Compound Forms and Formulations
[1396] The compounds disclosed herein can be prepared in additional
forms, such as polymorphs, salt forms and complexes. Such solid
forms can further improve the biopharmaceutical properties, and can
be further formulated to enhance biopharmaceutical properties. For
example, compounds of the invention form acid addition salts such
as hydrochloride or tosylate salts or form a complex with
polyprotic acids, such as citric acid, preferably wherein the
complex is substantially amorphous. Such an amorphous complex can
also be processed with addition of a polymer, such as HPMCAS, that
further stabilizes the amorphous form. The process can also include
spray drying of the material. Compound is dissolved in 400-500 mL
of acetone and added with stirring and heat to 1 equivalent of
citric acid dissolved in ethanol. The solution is spray dried to
provide the dried complex. Additional material is formulated with
addition of the compound/citrate complex to polymer in the same
ratio of acetone/ethanol, for example using either HPMCAS or a
mixture of Eudragit.RTM. L100-55 and Poloxamer 407. In one sample,
components are combined in the weight ratios of 40-50% compound,
15-25% citric acid, 25-35% Eudragit.RTM. L100-55 and 1-10%
Poloxamer 407. In one sample, components are combined in the weight
ratios of 40-50% compound, 15-25% citric acid, and 30-40% HPMCAS.
The amorphous nature of the resulting complex or formulation of the
complex can be determined by X-Ray Powder Diffraction (XRPD),
infra-red spectrometry, and differential scanning calorimetry. For
example using a ShimadzuXRD-6000 X-ray powder diffractometer using
Cu K.alpha. radiation. The tube voltage and amperage are set to 40
kV and 40 mA, respectively. The divergence and scattering slits are
set at 1.degree. and the receiving slit was set at 0.15 mm
Diffracted radiation is detected by a NaI scintillation detector. A
.theta.-2.theta. continuous scan at 3.degree./min (0.4
sec/0.02.degree. step) from 2.5.degree. to 40.degree. 2.theta. is
used. A silicon standard is analyzed to check the instrument
alignment. Data are collected and analyzed using XRD-6100/7000
v.5.0. Sample is prepared for analysis by placing it in an aluminum
holder with silicon insert. The DSC is used to demonstrate that the
complexes lack a characteristic transition and have completely
melted before any free base crystalline transition, further
supporting that these complexes are amorphous.
Example 27
Compound Properties
[1397] While the inhibitory activity of the compounds on any of
Fms, Flt-3 and Kit kinase is important to their activity in
treating of disease, the compounds described herein show favorable
properties that provide advantages as a pharmaceutical as well. In
some instances, Fms selectivity relative to Kit and other kinases
provides preferred activity for treating certain diseases, such as
rheumatoid arthritis, Alzheimer's disease, Parkinson's disease,
osteoarthritis, glomerulonephritis, interstitial nephritis, Lupus
nephritis, tubular necrosis, diabetic nephropathy, or renal
hypertrophy. In some instances, Fms selectivity of compounds in
combination with the compounds inability to cross the blood brain
barrier provides preferred activity for treating certain diseases,
such as osteoarthritis, glomerulonephritis, interstitial nephritis,
Lupus nephritis, tubular necrosis, diabetic nephropathy, or renal
hypertrophy. In some instances, Fms selectivity of compounds in
combination with the compounds ability to effectively cross the
blood brain barrier provides preferred activity for treating
certain diseases, such as rheumatoid arthritis, Alzheimer's
disease, or Parkinson's disease. In some instances, dual Fms/Kit
activity provides preferred activity for treating certain diseases,
such as metastatic breast cancer, prostate cancer, multiple
myeloma, melanoma, acute myeloid leukemia, brain metastases,
neurofibromatosis, gastrointestinal stromal tumors, rheumatoid
arthritis, or multiple sclerosis. In some instances, dual Fms/Flt-3
activity provides preferred activity for treating certain diseases,
such as acute myeloid leukemia. In addition to demonstrating kinase
inhibitory activity against Fms, Kit, Flt-3 or at least both Fms
and Kit or at least both Fms and Flt-3 in both biochemical and cell
based assays, compounds have improved solubility, improved
pharmacokinetic properties, and low Cyp inhibition. The compounds
are assessed in the following assays or similar assays available to
one skilled in the art.
[1398] Assays for biochemical and cell based activity are known in
the art, for example, U.S. Patent Application Publication Number
2009/0076046, the disclosure of which is hereby incorporated by
reference as it relates to such assays. In one assay the
biochemical activity IC.sub.50 values are determined with respect
to inhibition of c-Kit kinase activity, where inhibition of
phosphorylation of a peptide substrate is measured as a function of
compound concentration. Compounds to be tested are dissolved in
DMSO to a concentration of 20 mM. These are diluted 30 .mu.L into
120 .mu.L of DMSO (4 mM) and 1 .mu.L is added to an assay plate.
These are then serially diluted 1:2 (50 .mu.L to 100 .mu.L DMSO)
for a total of 8 points. Plates are prepared such that each kinase
reaction is 20 .mu.L in 1.times. kinase buffer (25 mM HEPES, pH
7.5, 2 mM MgCl.sub.2, 2 mM MnCl.sub.2, 0.01% Tween-20, 1 mM DTT,
0.01% BSA), 5% DMSO and 100 .mu.M ATP. Substrate is 30 nM
biotin-(E4Y) 10 (Millipore). C-kit kinase (obtained from Millipore
(#14-559) or is prepared as described in U.S. Patent Application
Publication Number 2009/0076046, the disclosure of which is hereby
incorporated by reference as it relates to this assay) is at 0.75
ng per sample. After incubation of the kinase reaction for 1 hour
at room temperature, 5 .mu.L of donor beads (Streptavidin coated
beads (Perkin Elmer Life Science) final concentration 10 .mu.g/mL)
in stop buffer (25 mM Hepes pH 7.5, 100 mM EDTA, 0.01% BSA) is
added, the sample is mixed and incubated for 20 minutes at room
temperature before adding 5 .mu.L of acceptor beads (PY20 coated
beads (Perkin Elmer Life Science) final concentration 10 .mu.g/mL)
in stop buffer. The samples are incubated for 60 minutes at room
temperature and the signal per well is read on Envision reader.
Phosphorylated substrate results in binding of the PY20 antibody
and association of the donor and acceptor beads such that signal
correlates with kinase activity. The signal vs. compound
concentration is used to determine the IC.sub.50.
[1399] In one assay the biochemical activity IC.sub.50 values are
determined with respect to inhibition of Fms kinase activity, where
inhibition of phosphorylation of a peptide substrate is measured as
a function of compound concentration. Compounds to be tested,
dissolved in DMSO (1 .mu.L), are added to a white 384-well plate
(Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249),
biotin-(E4Y).sub.10 substrate (Upstate Biotech, Cat#12-440), and
ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM
MgCl.sub.2, 2 mM MnCl.sub.2, 2 mM DTT, 0.01% BSA, and 0.01%
Tween-20. All components are added to the 384-well plate for a
final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y).sub.10
(Upstate Biotechnology) and 100 .mu.M ATP in a volume of 20 .mu.L.
Each sample is at 5% DMSO. The plate is then incubated for 20
minutes at 30.degree. C. Just before use, working stocks of donor
and acceptor beads from the AlphaScreen PY20 Detection Kit
(PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5, pH
7.4, 100 mM EDTA, 0.01% BSA. To stop the reaction, the plate is
uncovered in the dark and 5 .mu.L of Donor Beads solution
(Streptavidin beads) is added to each well. The plate is incubated
at room temperature for 20 minutes. Five microliters of Acceptor
Beads solution (PY20 coated beads) are then added to each well. The
final concentration of each bead is 10 .mu.g/mL. The plates are
incubated at room temperature for 60 minutes. Fluorescence signal
is recorded on the Envision reader. Phosphorylated substrate
results in binding of the PY20 antibody and association of the
donor and acceptor beads such that signal correlates with kinase
activity. The signal vs. compound concentration is used to
determine the IC.sub.50.
[1400] In one assay the biochemical activity IC.sub.50 values are
determined with respect to inhibition of Flt-3 kinase activity,
where inhibition of phosphorylation of a peptide substrate is
measured as a function of compound concentration. Compounds to be
tested, dissolved in DMSO (1 .mu.L), are added to a white 384-well
plate (Costar #3705). Working stocks of Flt-3 kinase (Invitrogen),
biotin-(E4Y).sub.10 substrate (Upstate Biotech, Cat#12-440), and
ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 5 mM
MgCl.sub.2, 5 mM MnCl.sub.2, 1 mM DTT, and 0.01% Tween-20. All
components are added to the 384-well plate for a final
concentration of 1 ng/well Flt-3, 30 nM biotin-(E4Y).sub.10 and 100
.mu.M ATP in a volume of 20 .mu.L. Each sample is at 5% DMSO. The
plate is then incubated for 1 hour at room temperature. Just before
use, working stocks of donor and acceptor beads from the
AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are
prepared in 25 mM Hepes pH 7.5, pH 7.4, 100 mM EDTA. 0.3% BSA. To
stop the reaction, the plate is uncovered in the dark and 5 .mu.L
of Donor Beads solution (Streptavidin beads) is added to each well.
The plate is incubated at room temperature for 20 minutes. Five
microliters of Acceptor Beads solution (PY20 coated beads) are then
added to each well. The final concentration of each bead is 10
.mu.g/mL. The plates are incubated at room temperature for 60
minutes. Fluorescence signal is recorded on the Envision reader.
Phosphorylated substrate results in binding of the PY20 antibody
and association of the donor and acceptor beads such that signal
correlates with kinase activity. The signal vs. compound
concentration is used to determine the IC.sub.50.
[1401] Compounds are assessed in a variety of cell based assays.
For example BCR-FMS/BaF3, BCR-KIT/BaF3, M-NFS-60, M-07e, and
BAC1.2F5 cell proliferation assays are used to assess inhibitory
activity of Fms or Kit and MV-4-11 cell proliferation assay is used
to assess inhibitory activity in Flt-3. Reagent and assay
conditions are as follows: [1402] BCR-FMS/BaF3 and BCR-KIT/BaF3
cells: [1403] Maintained in RPMI containing 10% FBS, 1% PenStrep,
1% NEAA, and 1% L-Glutamine, supplemented with 1 mg/mL G418 and 5%
WEHI-CM (or recombinant murine IL-3). [1404] Confluent cells are
split 1:50 to 1:100 every 3-4 days. [1405] M-NFS-60 cells (ATCC
#CRL-1838): [1406] Maintained in RPMI containing 10% FBS, 1% Hepes,
1% NaPyruvate, and 0.45% Glucose, supplemented with 62 ng/mL murine
M-CSF. [1407] Confluent cells are split 1:20 every 3-4 days. [1408]
M-07e cells (DSMZ #ACC 104): [1409] Maintained in IMDM containing
10% FBS, supplemented with either 200 ng/mL human SCF or 75
ng/.mu.L SCF (R&D Systems 255-SC). [1410] Confluent cells are
split 1:5 to 1:10 every 3-4 days. [1411] BAC1.2F5 cells: [1412]
Maintained in Alpha-MEM containing 10% Newborn Calf Serum
(Invitrogen #26010-074) supplemented with 36 ng/mL murine M-CSF.
[1413] Confluent cells are split 1:4 every 3-4 days. [1414] MV-4-11
cells: [1415] Maintained in Iscove's Modified Dulbecco's Medium
containing 10% FBS. [1416] Confluent cells are split 1:4 every 3-4
days. On day 1, cells are counted, then centrifuged in a conical
tube for 5 minutes at 1000 rpm. The supernatant is removed and
cells are re-suspended as follows: [1417] BCR-FMS/BaF3 and
BCR-KIT/BaF3: resuspend in growth media+1 mg/mL G418 (without
WEHFIL-3) to 2.times.10.sup.5 cells/mL. [1418] M-NFS-60: resuspend
in growth media+62 ng/mL murine M-CSF to 5.times.10.sup.5 cells/mL.
[1419] M-07e: resuspend in growth media+200 ng/mL human SCF to
5.times.10.sup.5 cells/mL. [1420] BAC1.2F5: resuspend in growth
media+36 ng/mL murine M-CSF to 1.4.times.10.sup.5 cells/mL. [1421]
MV-4-11: resuspend in growth media+10% FBS to 5.times.10.sup.5
cells/mL. The cells are plated (50 .mu.L) in each well of a 96-well
dish (Corning 3610) and incubated at 37.degree. C. in 5% CO.sub.2
overnight, cells plated to a final concentration of cells as
follows: [1422] BCR-FMS/BaF3 and BCR-KIT/BaF3: 10,000 cells per
well. [1423] M-NFS-60: 25,000 cells per well. [1424] M-07e: 25,000
cells per well. [1425] BAC1.2F5: 7,000 cells per well. [1426]
MV-4-11: 25,000 cells per well. On day 2, compound at a maximum
concentration of 5 mM is serially diluted 1:3 for a total of 8
point titration with DMSO as a control. A 1 .mu.L aliquot of each
dilution point is added to 249 .mu.L growth media and 50 .mu.L is
added to a well containing cells, providing 10 .mu.M compound for
the maximum concentration point. The cells are incubated for 3 days
at 37.degree. C. in 5% CO.sub.2.
[1427] On day 5, ATPlite 1 step Luminescence Assay System (Perkin
Elmer #6016739) is brought to room temperature along with the cell
cultures. ATPlite is added to each well as follows: [1428]
BCR-FMS/BaF3 and BCR-KIT/BaF3: 25 .mu.g., per well. [1429]
M-NFS-60: 25 .mu.L per well. [1430] M-07e: 40 .mu.L per well.
[1431] BAC1.2F5: 50 .mu.L per well. [1432] MV-4-11: 40 .mu.L per
well. The cells are incubated at room temperature for 10 minutes,
then luminescence is read on Safire reader. The measured
luminescence correlates directly with cell number, such that the
reading as a function of compound concentration is used to
determine the IC.sub.50 value.
[1433] Further, an osteoclast differentiation assay is used to
assess the efficacy of Fms inhibitors for treating bone disease
such as osteoarthritis. On day 0, Osteoclast Medium BulletKit
(Lonza catalog #PT-8001, containing Media, FBS, L-Glutamine,
PenStrep, RANKL, and M-CSF) media is thawed and the FBS,
L-glutamine and PenStrep from the kit is added to 100 mL of
Osteoclast Precursor Basal medium to provide the Osteoclast
Precursor Growth Medium (OPGM). This is warmed to 37.degree. C.
Osteoclast precursor cells (Lonza catalog #2T-110) frozen in
cryovial are warmed to 37.degree. C. and transferred to a 50 mL
conical tube. The cryovial is rinsed with OPGM and added dropwise
to the conical tube of cells with swirling, then the volume is
adjusted to 20-30 mL with addition of OPGM. The cells are
centrifuged at 200.times.g for 15 minutes at room temperature and
all but approximately 3 mL of supernatant is removed to a new
conical tube. The cells are suspended in the remaining supernatant
and the volume is adjusted to 10-15 mL with OPGM added dropwise
with swirling. The cells are centrifuged at 200.times.g for 15
minutes at room temperature and all but approximately 1 mL of
supernatant is removed. The cells are resuspended in the remaining
supernatant, counted, and the volume adjusted with an appropriate
amount of OPGM to provide approximately 1.times.10.sup.5 cells/mL.
A 0.1 mL aliquot of cells is added to each well of a 96-well plate.
Compound to be tested is prepared in DMSO for plating at a high
concentration of 2.5 mM, with 8 point 1:3 serial dilutions. A 1
.mu.L aliquot of each compound dilution is added to a 96 well
v-bottom polypropylene plate and 0.124 mL of OPGM is added to the
compound. Then 50 .mu.L of the compound in OPGM is added to the
osteoclast precursor cells in 96-well plate (providing highest test
concentration of 5 .mu.M). RANKL (2 .mu.g) from the BulletKit is
reconstituted in 1 mL of OPGM, then vortexed and centrifuged
briefly. A 792 .mu.L aliquot of RANKL is added to 6 mL of OPGM and
50 .mu.L is added to low control wells. Then 76.6 .mu.L M-CSF (10
.mu.g/mL) from the BulletKit is added to the remaining 5.8 mL of
OPGM/RANKL solution (4.times.RANKL/M-CSF/OPGM). A 50 .mu.L aliquot
of this is added to the remaining wells, and the remainder is
stored at 4.degree. C. for later use. The plate is incubated at
37.degree. C. for 6 days, then the remaining OPGM/RANKL/M-CSF
solution is warmed to 37.degree. C. The remaining approximately 198
.mu.L is combined with 6 mL of OPGM. The media is aspirated from
the osteoclast wells and 100 .mu.L of RANKL/OPGM is added to the
low controls. The remaining RANKL/OPGM is combined with the
approximately 18.5 .mu.L of remaining M-CSF. The remaining
4.times.RANKL/M-CSF/OPGM from day 0 is diluted to 1.times. and
combined with the freshly prepared solution. A 0.1 mL aliquot of
this is added to each osteoclast well and incubated for 37.degree.
C. for 1 day. The Acid Phosphatase kit (Cayman Chemical catalog
#10008051) is warmed to room temperature. The assay buffer is
diluted 5 mL with 45 mL of water. For each plate, two substrate
tablets are dissolved in 4.5 mL of the assay buffer, mixing by
vortex to break up the tablet. Stop solution is diluted 12 mL with
36 mL of water. In a tissue culture hood, 20 .mu.L of each
osteoclast well supernatant is transferred to a 96 well plate. A 30
.mu.L aliquot of the substrate solution is added to each well and
incubated at 37.degree. C. for 20 minutes, then added 100 .mu.L
stop solution to each well. The absorbance of each well is read at
405 nM on Safire plate reader. The absorbance reading is plotted
vs. concentration to provide the IC.sub.50 for each compound.
[1434] The following table indicates the Fms and Kit biochemical
inhibitory activity and selectivity (Kit IC.sub.50/FmsIC.sub.50)
and the BCR-FMS/BaF3 and BCR-KIT/BaF3 cell based inhibitory
activity selectivity (Kit IC.sub.50/FmsIC.sub.50) for exemplary
compounds according to the invention as indicated:
TABLE-US-00020 Compound Biochemical activity (IC.sub.50 .mu.M)
BCR/BaF3 (IC.sub.50 .mu.M) number Fms Kit selectivity Fms Kit
selectivity P-1496 <0.1 <0.1 >0.1 >20 P-1554 <0.1
<0.1 <20 <0.1 >0.1 <20 P-1562 <0.1 <0.1 <20
<0.1 >0.1 <20 P-1622 <0.1 >0.1 >20 <0.1
>0.1 >20 P-1669 <0.1 >0.1 >20 P-1679 <0.1 >0.1
>20 <0.1 >0.1 >20 P-2001 <0.1 >0.1 >20 <0.1
>0.1 >20 P-2003 <0.1 <0.1 <20 <0.1 <0.1 <20
P-2004 <0.1 <0.1 <20 <0.1 <0.1 <20 P-2008 <0.1
<0.1 <20 <0.1 >0.1 <20 P-2013 <0.1 <0.1 <20
<0.1 >0.1 <20 P-2019 <0.1 <0.1 <20 <0.1
<0.1 <20 P-2028 <0.1 >0.1 >20 <0.1 >0.1 >20
P-2029 <0.1 >0.1 >20 <0.1 >0.1 >20 P-2030 <0.1
>0.1 <20 <0.1 >0.1 >20 P-2031 <0.1 >0.1 <20
<0.1 >0.1 >20 P-2032 <0.1 <0.1 <20 <0.1
<0.1 <20 P-2037 <0.1 >0.1 <20 <0.1 >0.1 <20
P-2038 <0.1 >0.1 <20 <0.1 >0.1 >20 P-2043 <0.1
>0.1 >20 <0.1 >0.1 >20 P-2045 <0.1 >0.1 >20
<0.1 >0.1 >20 P-2048 <0.1 >0.1 >20 <0.1
>0.1 >20 P-2049 <0.1 >0.1 >20 <0.1 >0.1 >20
P-2052 <0.1 >0.1 >20 <0.1 >0.1 >20 P-2057 <0.1
>0.1 <20 <0.1 >0.1 >20 P-2061 <0.1 >0.1 >20
<0.1 >0.1 >20 P-2062 <0.1 >0.1 >20 <0.1
>0.1 >20 P-2063 <0.1 <0.1 <20 <0.1 >0.1 >20
P-2064 <0.1 >0.1 >20 <0.1 >0.1 >20 P-2067 <0.1
>0.1 >20 P-2070 <0.1 <0.1 <20 <0.1 >0.1 >20
P-2071 <0.1 >0.1 >20 >0.1 >0.1 >20 P-2073 <0.1
>0.1 >20 <0.1 >0.1 >20 P-2075 <0.1 >0.1 >20
P-2078 <0.1 >0.1 >20 <0.1 >0.1 >20 P-2079 <0.1
<0.1 <20 <0.1 >0.1 <20 P-2081 <0.1 <0.1 <20
>0.1 >0.1 <20 P-2082 <0.1 <0.1 <20 <0.1
>0.1 <20 P-2088 <0.1 >0.1 >20 <0.1 >0.1 >20
P-2097 <0.1 >0.1 >20 <0.1 >0.1 >20 P-2103 <0.1
>0.1 >20 <0.1 >0.1 >20 P-2118 <0.1 >0.1 >20
<0.1 >0.1 >20 P-2131 <0.1 >0.1 <20 <0.1
>0.1 <20 P-2139 <0.1 >0.1 >20 >0.1 >0.1 <20
P-2146 <0.1 <0.1 <20 <0.1 >0.1 <20 P-2147 <0.1
<0.1 <20 <0.1 <0.1 <20 P-2148 <0.1 >0.1 <20
<0.1 >0.1 <20 P-2154 <0.1 <0.1 <20 <0.1
>0.1 <20 P-2157 >0.1 >0.1 <20 <0.1 >0.1 >20
P-2163 <0.1 >0.1 <20 <0.1 >0.1 <20 P-2165 <0.1
>0.1 >20 <0.1 >0.1 >20 P-2172 <0.1 <0.1 <20
<0.1 <0.1 <20 P-2176 <0.1 >0.1 >20 <0.1
>0.1 >20 P-2193 <0.1 >0.1 >20 <0.1 >0.1 >20
P-2198 <0.1 >0.1 <20 <0.1 >0.1 <20 P-2202 <0.1
>0.1 <20 <0.1 >0.1 <20
[1435] The following table indicates the Fms and Flt-3 biochemical
inhibitory activity and the BCR-FMS/BaF3 and MV-4-11 cell based
inhibitory activity for exemplary compounds according to the
invention that are approximately equipotent inhibitors of Fms/Flt-3
as indicated:
TABLE-US-00021 Cell based (IC.sub.50 .mu.M) Compound Biochemical
(IC.sub.50 .mu.M) BCR/BaF3 MV-4-11 number Fms Flt-3 (Fms) (Flt-3)
P-1644 <0.1 <0.1 <0.1 P-1646 <0.1 <0.1 <0.1
P-2003 <0.1 <0.1 <0.1 >0.1 P-2004 <0.1 <0.1
<0.1 P-2009 <0.1 <0.1 <0.1 P-2019 <0.1 <0.1
<0.1 P-2029 <0.1 <0.1 <0.1 <0.1 P-2030 <0.1
<0.1 <0.1 <0.1 P-2031 <0.1 <0.1 <0.1 <0.1
P-2032 <0.1 <0.1 <0.1 <0.1 P-2034 <0.1 <0.1
<0.1 >0.1 P-2037 <0.1 <0.1 <0.1 >0.1 P-2038
<0.1 <0.1 <0.1 <0.1 P-2044 <0.1 >0.1 <0.1
<0.1 P-2048 <0.1 <0.1 <0.1 >0.1 P-2057 <0.1
<0.1 <0.1 <0.1 P-2165 <0.1 <0.1 <0.1 >0.1
[1436] Compounds P-1554, P-2001, P-2003, P-2004, P-2019, P-2028,
P-2029, P-2030, P-2031, P-2032, P-2037, P-2038, P-2045, P-2048,
P-2049, P-2052, P-2057, P-2061, P-2063, P-2064, P-2070, P-2146,
P-2147, P-2157, P-2165, P-2176, and P-2193 demonstrated an
IC.sub.50 below 0.1 .mu.M in the osteoclast differentiation
assay.
[1437] As an indication of relative solubility, the turbidity of
compounds in aqueous solutions is assessed. To assess possible
compound properties in different physiological compartments, such
as stomach, intestine, and blood, a series of aqueous buffers with
varying pH is used. Thus each compound is diluted into four
different physiologically relevant buffers and solution turbidity
is measured by spectrophotometry. The concentration of compound
that demonstrates turbidity by forming enough insoluble suspension
to raise the average optical density above 0.01 at three
wavelengths (490, 535, and 650 nm) is used to define the limit of
the compound solubility in that buffer.
[1438] Compounds are dissolved at a concentration of 25 mM in
dimethyl sulfoxide, then serially diluted 1:1 into a 96 well plate,
diluting 10 times in pure dimethyl sulfoxide, with the final well
of each row a dimethyl sulfoxide blank. In an assay plate, 99 .mu.L
of appropriate buffer is added to each well, and 1 .mu.L of each
sample dilution is added to the buffer, achieving a range of final
total concentrations in aqueous solutions having different pH. The
buffers used are Simulated Gastric Fluid (SGF-pH 1.5) 0.5M NaCl, pH
1.5; Simulated Intestinal fluid (SIF-pH 4.5 and pH 6.8) 0.05M
NaH.sub.2PO.sub.4, pH 4.5 and 6.8; and Hepes Buffer (HEPES-pH 7.4)
10 mM HEPES, 150 mM NaCl, pH 7.4. Control compounds pyrene, estriol
and propranolol HCl are also assessed. Plates are spun and then
mixed for 1 minute, and the absorbance is read using a Tecan Safire
II to read wavelengths in the visible range (490, 535, and 650 nm)
at four locations per well, reflecting the degree of turbidity
present. The average optical density for each wavelength in each
well is graphed vs. compound concentration, and the concentration
at which the curve crosses a threshold O.D. of 0.01 for each
wavelength is reported as the endpoint turbidity assay result. The
average of the three wavelengths is used to compare turbidity of
compounds. Compounds are considered to have low solubility if the
threshold concentration is <31.3 .mu.M, moderate solubility if
the threshold concentration is 31.3 .mu.M to 250 .mu.M, and high
solubility if the threshold concentration is >250 .mu.M.
[1439] The following table indicates the relative solubility
(L=low, M=moderate, H=high) based on turbidity threshold
concentration at each pH for exemplary compounds according to the
invention as indicated:
TABLE-US-00022 Compound turbidity threshold (L, M, H) number 1.4
4.5 6.8 7.4 P-1554 H H M M P-1562 H H M M P-1622 H M M M P-1669 M M
M M P-1679 M L L L P-2001 M L L L P-2003 H M L L P-2004 H M M M
P-2019 H M M L P-2028 H M M M P-2029 H M M M P-2030 H M M L P-2031
M L L L P-2032 M L L L P-2037 M L L L P-2038 H L L L P-2043 H M M M
P-2045 H M M M P-2048 M L L L P-2049 M L L L P-2052 H L L L P-2057
H L L M P-2061 H M M L P-2062 H L L L P-2064 H M L L P-2067 H H H H
P-2071 M L L L P-2073 H M M M P-2075 H M L M P-2146 H M M L P-2165
L L L L P-2172 H L L L P-2193 L P-2198 M L L L
[1440] CYP (Cytochrome P450) enzymes are the major drug
metabolizing enzymes present in the liver. The inhibition of CYP
enzyme activity (IC.sub.50) for each of CYP1A2, CYP2C19, CYP2C9,
CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds,
where inhibition of metabolism of a known substrate leads to a
decrease in the fluorescence of the metabolized product. The
fluorescence of the product is monitored as a function of compound
concentration.
[1441] Compounds are dissolved in DMSO to a concentration of 100
mM. These are diluted 1 .mu.L into 82 .mu.L of acetonitrile. An 11
.mu.L aliquot of this solution is then added to 204 .mu.L of
cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04%
NADPH Regeneration system Solution B from BD Biosciences, 5%
acetonitrile and 0.05% DMSO). These are then serially diluted 1:1
(160 .mu.L to 160 .mu.L co-factor mix) for a total of 10 points. A
10 .mu.L aliquot of this final mixture is dispensed into 384 well
assay plates and incubated for 10 minutes at 37.degree. C. Enzyme
and substrate mix (10 .mu.L; 0.5 pmol CYP1A2/5 .mu.M CEC; 1.0 pmol
CYP2C9/75 .mu.M MFC; 0.5 pmol CYP2C19/25 .mu.M CEC; 1.5 pmol
CYP2D6/1.5 .mu.M AMMC; 1.0 pmol CYP3A4/50 .mu.M BFC; or 1.0 pmol
CYP3A4/40 .mu.M BQ) is added to these assay plates. Assay plates
are incubated at 37.degree. C. (CYP1A2-15 min; CYP2C9-45 min;
CYP2C19, 2D6 and 3A4-30 min) and read in a Tecan Safire 2 plate
reader (CYP1A2, 2C19 and 3A4 409 ex/460 em; CYP2C9 and 2D6.409
ex/530 em). The signal versus compound concentration is used to
determine the IC.sub.50. The enzymes and substrates for this assay
are obtained from BD Biosciences. While other factors are involved
in determining CYP effects in vivo, compounds preferably have
IC.sub.50 values of >5 .mu.M, more preferably IC.sub.50 values
of >10 .mu.M.
[1442] The following table indicates the Cyp inhibition for
exemplary compounds according to the invention as indicated:
TABLE-US-00023 Compound Cyp IC.sub.50 (.mu.M) number 1A2 2C19 2C9
2D6 3A4(BFC) 3A4(BQ) P-1562 >10 >10 <5 >10 5-10 5-10
P-1622 >10 <5 5-10 >10 5-10 5-10 P-1669 >10 >10
<5 >10 5-10 P-1679 >10 <5 <5 >10 >10 P-2001
>10 <5 5-10 >10 5-10 5-10 P-2003 >10 5-10 <5 >10
5-10 >10 P-2004 >10 5-10 <5 5-10 <5 5-10 P-2019 >10
5-10 <5 <5 <5 >10 P-2028 >10 >10 <5 >10
<5 <5 P-2029 >10 <5 <5 >10 5-10 5-10 P-2030
>10 <5 <5 >10 5-10 >10 P-2031 >10 <5 <5
>10 5-10 5-10 P-2032 5-10 <5 <5 >10 >10 >10
P-2037 >10 <5 <5 >10 5-10 >10 P-2038 >10 >10
5-10 >10 >10 >10 P-2043 >10 >10 5-10 >10 >10
5-10 P-2045 >10 5-10 >10 >10 5-10 >10 P-2048 >10
>10 >10 >10 >10 >10 P-2049 >10 5-10 5-10 >10
5-10 >10 P-2052 >10 >10 5-10 >10 5-10 5-10 P-2057
>10 5-10 5-10 >10 >10 >10 P-2061 >10 >10 5-10
>10 >10 5-10 P-2062 >10 <5 <5 >10 5-10 5-10
P-2063 >10 5-10 >10 >10 5-10 5-10 P-2064 >10 >10
5-10 >10 >10 >10 P-2067 >10 <5 <5 >10 <5
>10 P-2071 >10 >10 5-10 >10 5-10 5-10 P-2073 >10
>10 <5 >10 5-10 >10 P-2075 5-10 <5 <5 >10
<5 5-10 P-2078 >10 >10 <5 >10 <5 >10 P-2079
>10 5-10 5-10 >10 <5 5-10 P-2081 >10 <5 <5 >10
<5 5-10 P-2082 >10 <5 <5 >10 <5 <5 P-2088
>10 <5 <5 >10 5-10 5-10 P-2097 >10 <5 <5
>10 5-10 5-10 P-2103 >10 <5 <5 >10 5-10 5-10 P-2118
>10 <5 5-10 >10 5-10 >10 P-2131 >10 5-10 <5
>10 <5 >10 P-2139 >10 >10 5-10 >10 5-10 >10
P-2146 >10 <5 5-10 >10 >10 >10 P-2147 >10 <5
>10 >10 5-10 5-10 P-2157 >10 >10 >10 >10 5-10
>10 P-2165 >10 >10 >10 >10 >10 >10 P-2172
>10 <5 5-10 >10 >10 P-2193 >10 >10 >10 >10
>10 >10 P-2198 >10 <5 5-10 >10 <5
[1443] Pharmacokinetic properties of compounds (including any solid
forms or formulations thereof) are assessed in male Sprague Dawley
rats or male Beagle dogs. Rats are dosed daily with compound either
by IV injections via surgically implanted jugular catheters or by
oral gavage (PO). Each compound is prepared as a 20 mg/mL stock
solution in dimethyl sulfoxide, which is further diluted to provide
the dosing stock at the desired concentration for the IV or PO
formulations. For IV dosing, the dosing stock is diluted into a
1:1:8 mixture of Solutol.RTM.:ethanol:water. For PO dosing, the
dosing stock is diluted into 1% methylcellulose. In a cassette
format (or each compound, solid form thereof or formulation thereof
is done individually), compounds are diluted to 0.5 mg/mL each for
IV dosing and 0.4 mg/mL each for PO dosing and dosed at 1 mg/kg (2
mL/kg) or 2 mg/kg (5 mL/kg), respectively. For IV dosed animals,
tail vein blood samples are collected with lithium heparin
anticoagulant at 5, 15, 30, and 60 minutes and 4, 8, and 24 hours
post dosing each day. For PO dosed animals, tail vein blood samples
are collected with lithium heparin anticoagulant at 30 minutes, 1,
2, 4, 8 and 24 hours post dosing each day. Dogs are dosed daily by
oral capsules in a suitable formulation at 50 mg/mL. Cephalic vein
blood samples are collected with lithium heparin anticoagulant at
30 minutes, 1, 2, 4, 8 and 24 hours post dosing each day. All
samples are processed to plasma and frozen for later analysis of
each compound by LC/MS/MS. Plasma levels as a function of time are
plotted to assess the AUC (ng*hr/mL). Compounds according to the
present invention preferably show improved pharmacokinetic
properties relative to previously described compounds, i.e. they
have substantially higher values for one or more of AUC, Cmax and
half-life relative to previously described compounds.
[1444] Analysis of penetration of compound into the brain can be
assessed similarly. Each compound is prepared as a 100 mg/mL stock
solution in dimethyl sulfoxide, as well as control compounds
atenolol at 100 mg/mL and antipyrine at 50 mg/mL. In a cassette
format, up to three test compounds, along with atenolol and
antipyrine, are combined, 180 .mu.L each, and added to 17.1 mL of
1% methylcellulose. The compounds are in a suspension that is
administered in a single dose (10 mL per kg body weight) to 2
groups of CD rats (8-9 weeks, n=3 per group) by oral gavage, an
additional group of rats dosed with vehicle only. One group of
compound treated rats is sacrificed at 2 hours post dosing, the
other group at 6 hours. Plasma is collected in Li-heparin and the
brains are collected, cut into right and left hemispheres, weighed
and flash frozen. Brain homogenate (30%) and plasma samples are
assessed by equilibrium dialysis using a 96 well equilibrium
dialysis apparatus with a 5K MW cut off membrane (The Nest Group,
Inc.) as per the vendor's protocol with the samples on one side of
the dialysis membrane and an equal volume of 1.times.PBS on the
other side. The apparatus is incubated overnight at 37.degree. C.
on a plate rotator (The Nest Group, Inc.). The compound
concentrations on both sides are analyzed by LC/MS/MS to calculate
the mass balance recovery. The concentration in the PBS side is
calculated using a standard curve generated for each compound. The
PBS concentration is the free compound concentration, while the
side with the biological sample provides the concentration in
plasma or brain.
[1445] Additional features of the complex can be used to
demonstrate improved properties, such as comparison of the
intrinsic dissolution rate of a similarly prepared substantially
amorphous citrate complex or formulation thereof as compared to
that of a crystalline form of the compound or similar formulation
thereof in simulated gastric fluid (SGF) without enzyme and in
simulated intestinal fluid (SIF). A pellet of test sample is
dissolved in the appropriate fluid, and the UV absorbance as a
function of time is measured at 254 nm (SGF) or 310 nm (SIF) and
plotted.
Example 28
In Vivo Model System Testing
[1446] For in vivo testing, a suitable animal model system can be
selected for use. For example, for multiple sclerosis, the rodent
experimental allergic encephalomyelitis (EAE) system is commonly
used. This system is described, for example, in Steinman, 1996,
Cell 85:299-302 and Secor et al., 2000, J. Exp. Med. 5:813-821,
which are incorporated herein by reference in their entireties. For
rheumatoid arthritis (RA), the type II collagen-induced arthritis
(CIA) small animal model of rheumatoid arthritis (RA) can be used
for testing. This model is described, for example, in Wooley, et
al. Current Rheumatology Reviews, 2008, 4: 277-287, which is
incorporated herein by reference in its entirety.
[1447] Similarly, other model systems can be used to evaluate
compounds described herein. Numerous compounds described herein,
including compounds of Formulas I, I', II, II', IIa, III, and III'
(e.g., P-1496, P-1622, P-1669, P-1679, P-2001, P-2028, P-2029,
P-2030, P-2038, P-2043, P-2045, P-2048, P-2049, P-2052, P-2057,
P-2061, P-2062, P-2063, P-2064, P-2067, P-2070, P-2071, P-2073,
P-2075, P-2078, P-2088, P-2097, P-2103, P-2118, P-2139, P-2157,
P-2165, P-2176, P-2193, P-1554, P-1562, P-2003, P-2004, P-2008,
P-2013, P-2019, P-2031, P-2032, P-2037, P-2079, P-2081, P-2082,
P-2131, P-2146, P-2147, P-2148, P-2154, P-2163, P-2172, P-2198,
P-2202, P-1644, P-1646, P-1667, P-2003, P-2004, P-2009, P-2019,
P-2029, P-2030, P-2031, P-2032, P-2034, P-2037, P-2038, P-2040,
P-2041, P-2044, P-2047, P-2048, P-2050, P-2057 and P-2065; the
compounds disclosed in paragraphs [0038], [0079], [0094], [0102],
[0103], and [0104]; and the compounds described in the Examples),
or compositions thereof, hydrates or solvates thereof, are tested
in mice for the treatment of various diseases and conditions as
described herein.
Collagen Induced Rheumatoid Arthritis (RA) Mouse Model.
[1448] Methods: Intradermal injections with collagen-CFA, followed
by a collagen boost by intraperitoneal (ip) injection on day 21
induces rheumatoid arthritis in a variety of mouse strains,
especially the DBA/1 genotype used in this study (Brand et al.,
2004; Wooley et al., 1981). Disease is quantified and recorded by
clinical scores using a scale of 0-4 per paw. The score records the
degree and extent of swelling and redness in each digit and joint
and culminates in the absence of use of individual front or rear
paws. Scores are accumulated per animal resulting in a maximum
score of 16, which indicates that animals avoid the use of all
paws. Groups were balanced for disease score at day 21 after the
initial immunization when the average clinical score was 2.5 for
all animals. Treatment was for 21 days with daily oral dosing with
the following dosing groups: vehicle, and 10 mg/kg, 20 mg/kg and 50
mg/kg the compounds of the invention.
Results
[1449] Oral administration of the compounds of the invention
inhibited the clinical disease development in the murine CIA model
in a dose dependent fashion with significant responses at all doses
tested (10, 20 and 50 mg/kg qd). Histopathological analysis of the
joints showed inhibition of inflammation, bone resorption,
cartilage damage and pannus formation by compounds of the invention
treatment. The mechanism of action of compounds of the invention
was confirmed by the decreased scores for macrophage and
osteoclast-cells in the joints.
[1450] Daily oral administration of Fms kinase inhibitors described
herein showed at all dose levels tested (10, 20 and 50 mg/kg) a
rapid benefit as compared to the vehicle control, as evidenced by
decreased clinical scores, reflecting less swelling and redness of
limbs. This clinical benefit was confirmed by decreased
histopathological scores for inflammation, cartilage damage, pannus
formation and bone destruction. Scores for both macrophage and
osteoclast-cells were decreased in the joint tissues confirming
that the mode of action of the compounds described herein is by
inhibiting the Fms receptor tyrosine kinase, which is crucial for
the proliferation and differentiation of these cell lineages.
Plasma concentrations of the dose groups drawn at the 2 hr time
point after dosing showed a clear dose proportional response.
[1451] All patents and other references cited in the specification
are indicative of the level of skill of those skilled in the art to
which the invention pertains, and are incorporated by reference in
their entireties, including any tables and figures, to the same
extent as if each reference had been incorporated by reference in
its entirety individually.
[1452] One skilled in the art would readily appreciate that the
present invention is well adapted to obtain the ends and advantages
mentioned, as well as those inherent therein. The methods,
variances, and compositions described herein as presently
representative of preferred embodiments are exemplary and are not
intended as limitations on the scope of the invention. Changes
therein and other uses will occur to those skilled in the art,
which are encompassed within the spirit of the invention, are
defined by the scope of the claims.
[1453] The invention illustratively described herein suitably may
be practiced in the absence of any element or elements, limitation
or limitations which is not specifically disclosed herein. Thus,
for example, in each instance herein any of the terms "comprising",
"consisting essentially of" and "consisting of" may be replaced
with either of the other two terms. Thus, for an embodiment of the
invention using one of the terms, the invention also includes
another embodiment wherein one of these terms is replaced with
another of these terms. In each embodiment, the terms have their
established meaning. Thus, for example, one embodiment may
encompass a method "comprising" a series of steps, another
embodiment would encompass a method "consisting essentially of" the
same steps, and a third embodiment would encompass a method
"consisting of" the same steps. The terms and expressions which
have been employed are used as terms of description and not of
limitation, and there is no intention that in the use of such terms
and expressions of excluding any equivalents of the features shown
and described or portions thereof, but it is recognized that
various modifications are possible within the scope of the
invention claimed. Thus, it should be understood that although the
present invention has been specifically disclosed by preferred
embodiments and optional features, modification and variation of
the concepts herein disclosed may be resorted to by those skilled
in the art, and that such modifications and variations are
considered to be within the scope of this invention as defined by
the appended claims.
[1454] In addition, where features or aspects of the invention are
described in terms of Markush groups or other grouping of
alternatives, those skilled in the art will recognize that the
invention is also thereby described in terms of any individual
member or subgroup of members of the Markush group or other
group.
[1455] Also, unless indicated to the contrary, where various
numerical values are provided for embodiments, additional
embodiments are described by taking any 2 different values as the
endpoints of a range. Such ranges are also within the scope of the
described invention.
[1456] Thus, additional embodiments are within the scope of the
invention and within the following claims.
* * * * *